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1 Summary 
 
Colorectal cancers (CRCs) show extensive genetic and epigenetic aberrations, including DNA 
sequence changes, chromosomal alterations and abnormal epigenetic chromatin 
modifications. These alterations often reflect defects in molecular mechanisms establishing 
and maintaining (epi-) genome integrity. Central to the maintenance of genetic stability is the 
cellular DNA damage response, including various systems of DNA repair, the malfunction of 
which increases the rate of mutation and, hence, drives tumor evolution. Epigenetic alterations 
in CRC are as prominent as genetic alterations and well documented, both, at the levels of 
histone modifications and DNA methylation (Kondo and Issa, 2004). Epigenetic mechanisms 
play critical roles in the regulation of DNA-templated processes such as transcription, DNA 
repair but also replication. Shaping higher order chromatin structure, they regulate DNA 
accessibility and, thereby, assure proper genome function. Epigenetic aberrations deregulate 
genomes and thus contribute to cell transformation in different ways. Although many epigenetic 
alterations in CRC and other cancers are described and, in specific cases, their role in 
carcinogenesis established, the origin of and the molecular mechanisms underlying epigenetic 
instability in CRC remained elusive (Goel and Boland, 2012). 
The aims of my thesis were to elucidate the molecular basis of DNA methylation aberrations 
in CRC in a first part, and to investigate mechanisms by which CRC-associated DNA 
methylation alterations contribute to colorectal carcinogenesis in a second part. 
A subset of human CRCs is characterized by genome-wide hypermethylation of promoter CpG 
islands (CGIs) and therefore referred to as displaying a CGI-methylator phenotype (CIMP). 
Although, overexpression of DNA methyltransferases (DNMTs) has been associated with 
CRC-CIMP, it has remained uncertain to what extent this is causal for CGI hypermethylation 
(Kanai et al., 2001; Nosho et al., 2009). Mutational inactivation and metabolic inhibition of the 
Ten Eleven Translocation (TET) DNA dioxgenases, key factors of active DNA demethylation, 
have been reported to be causal for DNA hypermethylation phenotypes in leukemias and 
gliomas (Figueroa et al., 2010; Letouze et al., 2013; Turcan et al., 2012). We investigated 
whether deregulated, TET-mediated DNA demethylation can account for CIMP in CRC. We 
discovered that TET1 is significantly downregulated, both at the mRNA and protein level, in 
CIMP-displaying CRCs. Knock-down of TET1 in the non-CIMP CRC cell line SW620 confirmed 
that the loss of TET1 results in genome-wide CGI hyper- and hypomethylation in cell culture, 
which, upon xenograft tumor formation, converted into a hypermethylation phenotype. Notably, 
the loss of TET1 in the CRC cell line resulted in increased promoter methylation and 
concomitant transcriptional downregulation of MLH1 and CDH1, a characteristic feature of 
CRC-CIMP. These results thus showed that depletion of TET1 and selection during tumor 
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growth can recapitulate features of CIMP in non-CIMP cancer cells. Thus, TET1 activity in 
colon epithelial cells contributes to maintenance of cell type specific CGI-methylation patterns 
and prevents the development of CRC through the CIMP-pathway. 
Beside cancer-specific defects in the maintenance of CpG methylation, aging constitutes a 
major source of methylation alterations associated with CRC (Issa, 2014; Menigatti et al., 2009; 
Toyota et al., 1999). Lifestyle-related factors including overweight, aspirin use, hormone 
replacement therapy (HRT) and smoking have been reported to influence the risk of CRC over 
long periods of time. (Chan et al., 2007; Long et al., 2010; Parajuli et al., 2013; Robsahm et 
al., 2013). I contributed to a collaborative project, in which we investigated whether these 
factors exert their effects on cancer risk via modulation of age-related DNA methylation 
changes. Genome-wide and detailed target-wise methylation analysis in a cohort of 546 
healthy women revealed that promoter-associated DNA methylation increases over age in 
specific patterns. We were able to determine and compare for the first time rates of age-
dependent DNA methylation change and thereby observed that smoking and obesity promote 
whereas aspirin use and HRT reduce the genome-wide methylation drift. A significant fraction 
of promoter-associated CpG sites, whose age-related hypermethylation was modified by 
lifestyle factors, also occurred hypermethylated in CRC. Lifestyle factors affected the 
methylation drift of CRC-related CpGs concordant with the effects of these factors on CRC 
risk. These and further results suggested that the effect of the investigated lifestyle factors on 
CRC-risk can be accounted for by the modulation of age-related DNA methylation changes. 
The promoter methylation of cancer-relevant genes detectable in the healthy colorectal 
mucosa, as reported for instance for the two DNA repair genes MLH1 and MGMT, allows the 
definition and monitoring of early epigenetic events in colorectal carcinogenesis (Menigatti et 
al., 2009). To explore this possibility, we selected five genes downregulated in colorectal 
adenomas (precancerous, benign tumors of the colorectum) and quantified their promoter 
methylation levels in CRC tissue as well as in the matched healthy appearing colonic mucosa. 
We included MLH1 and MGMT, two genes with established roles in colorectal carcinogenesis, 
in this analysis. The five marker genes; FOXF1, CA4, NPY1R, GREM1 and IFITM1 were 
previously not described as targets of aberrant hypermethylation in CRC. With different 
incidence all seven markers were found hypermethylated in 106 CRC samples tested. 
Interestingly, methylation of the two novel markers CA4 and GREM1 associated with CRC-
CIMP. We found that these two markers are methylated at low levels also in cancer-associated 
mucosa as well as in colonic mucosa from healthy individuals, as it was reported previously 
for the CIMP marker MLH1 (Menigatti et al., 2009). The results of this collaborative efforts thus 
suggest that features of CIMP-specific DNA methylation are present and, hence, detectable 
already in the mucosa of healthy individuals.  
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DNA hypermethylation in gene promoters often interferes with transcription of the associated 
gene. Promoter methylation can exert its repressive function due to compaction of the 
chromatin structure but also by interfering with transcription factor binding (Kulis and Esteller, 
2010). In a collaborative project, we identified SHOCA-2 as a regulator of Epidermal Growth 
Factor Receptor (EGFR) signaling and observed its loss of expression in advanced CRCs. The 
loss of SHOC-2 expression was associated with different genetic and epigenetic alterations. 
We detected chromosomal deletions affecting the SH2D4A gene (encoding for SHOCA-2) as 
well as mutations in the coding region of the gene. Finally, we found the cancer-specific 
hypermethylation of two CpG sites in the 5´-untranslated region of SH2D4A, one of which 
overlapped with a binding site for the transcription factor Sp1. I was able to show that 
methylation of this CpG site in the SH2D4A sequence context interferes with Sp1 binding in 
vitro and therefore might be responsible for SHOCA-2 expression loss in some CRCs.  
Taken together, in collaboration with many colleagues from different laboratories, I was able 
to elucidate different mechanisms involved in the generation of CRC-related DNA methylation 
aberrations. First, I could show that impaired TET-mediated DNA demethylation contributes in 
the acquisition of methylation aberrations in CRCs characterized by a methylator phenotype. 
Second, together with colleagues I was able to provide new and fundamental insight into the 
relationships between aging and lifestyle and cancer-relevant DNA methylation change in a 
cohort of healthy individuals. Finally, by investigating promoter methylation of the newly 
established tumor suppressor SHOCA-2, I was able to describe a molecular mechanism by 
which site-specific DNA methylation may contributes to cancerous transformation.  
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2 Introduction 
2.1 The Instable Cancer Genome 
Human cancers show a large variety of genetic and epigenetic alterations when compared to 
the respective healthy tissue. These aberrations form the genetic basis of the malignant cell 
phenotype (Hanahan and Weinberg, 2011). Genomic changes range from subtle point 
mutations in the primary DNA sequence to chromosomal aberrations with structural and 
numerical changes of huge DNA sections. Cancer-associated changes in the epigenome 
include all layers of epigenetic information: DNA-methylation, histone modifications as well as 
the expression and function of regulatory RNA molecules (Esteller, 2011; Ting et al., 2006). In 
healthy human cells the genome integrity is maintained by a number of control and repair 
mechanisms which keep the rate and extent of mutations very low. However, as the normally 
low spontaneous mutation rate cannot account for the large number of mutations accumulating 
in human cancers, Loeb proposed that pre-cancerous cells elevate their mutation rate and 
acquire a so-called mutator phenotype (Loeb, 1991). Increased mutation can, for instance, 
result from replication stress induced by oncogene activation or by defects in processes 
responsible for the maintenance of genome integrity. This mutability of the cancer genome 
together with an epigenetic instability provides for a high genetic plasticity of cancer cells that 
facilitates fast diversification and high potential for adaptation to environmental changes like 
increased hypoxia and challenges by the immune system. The following chapters introduce 
the main forms of genetic and epigenetic instabilities found in human cancers as well as their 
underlying causes. 
 
2.1.1 Chromosomal Instability (CIN) 
Chromosomal aberrations have long been described as a hallmark of human cancers (Baudis, 
2007; Beroukhim et al., 2010). These abnormalities can include large parts of chromosomes 
like chromosome arms or even whole chromosomes and were therefore originally identified as 
alterations in the karyotype. The occurrence of intra-tumor variations in chromosomal 
aberrations was referred to as chromosomal instability (CIN). The increased chromosomal 
plasticity in CIN cancers contributes to the phenotypic variation within the tumor and might 
facilitates adaption to environmental changes (D. J. Gordon et al., 2012). In line with this, CIN 
appears to influence cancer sensitivity to chemotherapy (McClelland et al., 2009). 
Chromosomal aberrations can affect genome functionality either by structural or numerical 
effects. Structural aberrations exert their effect due to the rearrangement of genetic information 
whereas numerical changes alter the abundance of genetic information. Translocations are 
most prominent type of structural aberrations in cancer (Nambiar et al., 2008). Chromosomal 
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translocation is an exchange of genetic material between two non-homologous chromosomes. 
This can happen either in a balanced manner with even exchange of material or unbalanced 
when the exchange is unequal resulting in gain or loss of chromosome regions. When involving 
two separate gene locations translocations can give rise to fusion genes which are commonly 
found in human cancers. Fusion genes can be oncogenic due to the deregulation of the original 
function or acquisition of a new function. The fusion between the histone methyltransferase 
MLL and the DNA hydroxylase TET1, for instance, which is frequent and causal in acute 
myeloid leukemia (AML) results from a translocation between chromosome 10q22 and 
chromosome 11q23 (Lorsbach et al., 2003). Translocations represent a form of gross 
chromosomal rearrangements (GCR), the origin of which is generally the misrepair of DNA 
double strand-breaks (DSB). Two major pathways are involved in the repair of DSBs: the 
homology dependent repair or homologous recombination (HR) system and the non-
homologous end joining (NHEJ) pathway. Repair by the NHEJ-pathway, which directly re-joins 
two double-stranded DNA ends of a DSB has been linked to the formation of structural 
aberrations. This mechanism is error-prone because it uses only small sequence homologies 
at the single stranded ends of the DSB and can potentially link any two available chromosome 
ends (Kasparek and Humphrey, 2011; Natarajan et al., 2008). NHEJ represents the 
predominant DSB-repair mechanism in the cell cycle stage G1 before DNA is replicated and 
no sister chromatid is available for HR, which uses the homologous sister duplex as a template 
for DSB repair and, therefore, operates with higher fidelity. The tumor suppressors BRCA1 and 
BRCA2 are essential for DSB repair by HR. The functional loss of these or other HR factors 
due to mutation or transcriptional inactivation leads to a bias in DSB repair towards the error-
prone NHEJ (Thompson et al., 2010). DSBs are relatively rare but deleterious lesions and 
originate from exposure of cells to ionizing radiation but also oxidative stress by reactive 
oxygen species (ROS). In most human cancers, however, replication-associated DSBs appear 
to be the major source of GCRs. They occur in response to “replication stress” when the DNA 
replication fork encounters DNA lesions or DNA secondary structures and becomes stalled. If 
unrepaired or uncorrected the stalled replication fork may collapse (the replication complex 
falls apart) and potentially generate a DSB (Zeman and Cimprich, 2014). Some DNA regions 
are intrinsically capable to produce replication stress and tend to break during replication, 
particularly under replication inhibitory conditions. Such fragile sites are characterized by the 
potential to form DNA secondary structures which interfere with replication fork progression 
and represent places of chromosome breakage and rearrangement in human cancers (Durkin 
and Glover, 2007). An example are G-quadruplexes (G4), intramolecular four-stranded 
structures which arise from guanine-rich sequences (G3N1-7G3N1-7G3N1-7G3) capable to 
obstruct polymerase movement. Many potential G4 sequences contain CpG sites in which 
cytosine can be methylated (see chapter 2.2.2 DNA methylation). Interestingly, it was shown 
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that G4 sequences, associated with chromosomal breakpoints are cancer-specifically 
hypomethylated (De and Michor, 2011). In addition to DSBs also telomere dysfunction can 
induce GCRs. In highly proliferative cancer cells the repetitive telomere-region at the 
chromosome ends becomes rapidly shortened due to the so-called “end-replication problem”- 
the incomplete synthesis of the 3´end of the DNA strand. When the telomere end protection is 
compromised chromosome ends are seen by the cells as DSBs and subsequent NHEJ can 
result in the fusion of two different chromosomes, generating a dicentric chromosome (two 
centromeres) (Gisselsson et al., 2000). In mitosis, the two chromatids involved may end up 
being attached to microtubules from opposite spindle poles, thus forming chromatin bridges in 
telophase. Breakage of these bridges that occurs not necessarily at the site where the 
chromosomes were fused can be the start of another round of breakage-fusion-bridge (BFB). 
Repeating BFB cycles contribute strongly to the intra-tumoral chromosomal instability and 
diversification (Gisselsson et al., 2000).  
In addition to the structural changes, numerical chromosome aberrations, termed aneuploidy, 
are ubiquitous in human cancers. Aneuploidy usually includes either very short DNA segments 
whose length ranges from 1 kb (kilobase pair) to a few Mb (megabase pairs) (focal) or affects 
chromosome arms or whole chromosomes (arm-level). Small focal copy number variations are 
present in all humans and contribute to human evolution and genetic diversity. They may 
account for 13% of the human genome (Stankiewicz and Lupski, 2010). Accordingly, cancer 
cells are characterized by larger, arm-level somatic copy number alterations (SCNAs). It was 
shown that 25% of a typical human cancer genome is affected by arm-level SCNAs (Beroukhim 
et al., 2010). Aneuploidy can contribute differently to cancerous transformation depending on 
the genes affected. Aneuploidy can result in the deletion of tumor suppressor genes or the 
amplification of oncogenes. Linked to that SCNAs can cause loss of heterozygosity (LOH) 
which means the loss of the wildtype allele in heterozygous loss-of-function mutations. 
Eventually, aneuploidy could affect levels of DNA repair genes and thereby promote genomic 
instability (Janssen and Medema, 2013). However, aneuploidy has also potentially detrimental 
effects on cell viability and proliferation due to gene dosage effects. Cancer cells can adapt to 
tolerate an aneuploid genotype in several ways: they can increase the protein degradation to 
compensate for increased protein amounts, or they can buffer the effects of aneuploidy by 
facilitating further numerical whole-chromosome alterations. The gain or loss of a single 
chromosome is expected to have a larger impact in a diploid than in a polyploidy cancer cell. 
Finally, cancer cells often have an impaired p53 signaling pathway, which limits the 
proliferation of aneuploid cells (Ganem and Pellman, 2007; D. J. Gordon et al., 2012; 
Thompson et al., 2010). Chromosome arm and whole chromosome numerical alterations 
originate from different underlying mechanisms. Whereas arm-sized deletions and 
amplifications are the result of DSB-initiated GCRs, the mechanisms underlying whole-
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chromosome aneuploidy are more diverse. One mechanism includes the aberrant attachment 
of a single kinetochore to microtubules from both spindle poles, termed merotelic attachments. 
Merotelic attachments are common during mitosis due to stochastic interactions between the 
kinetochore and the spindle microtubules. The incidence of merotelic attachments is basically 
determined by the rate of their formation and the rate of their correction. An increased number 
of centrosomes often associated with an aberrant overexpression of the Aurora A kinase, 
elevates the rate of merotely. Defects in several kinetochore proteins like CENP-E can 
hyperstabilize kinetochore-microtubule attachments and thereby lower the correction rate of 
erroneous merotelic attachments (D. J. Gordon et al., 2012; Thompson et al., 2010) . The 
second pathway of whole chromosome aneuploidy is characterized by defects in the spindle 
assembly checkpoint (SAC). SAC signaling arrests cells in metaphase until all chromosomes 
form proper bipolar attachments to the spindle microtubules. Yeast and mouse models have 
shown that impaired SAC increases the rate of chromosomal missegregation and can cause 
CIN. However, the role of SAC defects in human cancers is not clear. Mutations in SAC 
proteins appear extremely rare, but there is evidence of epigenetic inactivation of SAC genes 
(Cahill et al., 1999; Haruki et al., 2001; Myrie et al., 2000; Park et al., 2007; R. H. Wang et al., 
2004). Finally, defects in chromosome cohesion were found to be associated with whole 
chromosome aberrations in cancer. Chromosome cohesion, mediated by the cohesin protein 
complex, prevents premature separation of sister chromatids during mitosis. Mutations in 
cohesin subunits were shown to cause aneuploidy in cancer (Solomon et al., 2011). Further, 
overexpression of separase, a protease which cleaves the cohesin complex during the onset 
of anaphase (before sister chromatids become separated) was found in breast cancer cells (N. 
Zhang et al., 2008). Excessive separase expression can result in premature sister chromatid 
dissociation and chromosome missegregation. 
A special form of cancer-associated GCRs is characterized by massive structural and 
numerical (mostly deletions) aberrations occurring clustered in discrete sub-chromosomal 
regions. This phenomenon, termed chromothripsis, is most evident in a small fraction of solid 
tumors. The molecular mechanisms underlying chromothripsis are not clear, although some 
evidence links its occurrence to replication stress. Based on in silico simulations, 
chromothripsis and concomitant complex rearrangements were originally described as a result 
of a single catastrophic event. However, revision of initially applied statistical approaches 
indicates that they could also result from progressive chromosomal alterations (M. J. Jones 
and Jallepalli, 2012; Kinsella et al., 2014; Stephens et al., 2011).  
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Figure 2-1: The spectrum of genomic instabilities in cancer. Genetic alterations in cancer can 
basically subdivided into three main classes. At the smallest scale, subtle sequence changes may affect 
single or a few adjacent nucleotides (left). Examples include changes in the length of microsatellites as 
a result of MMR deficiency or C to T transition mutations deriving from deregulation of DNA deaminases. 
At the intermediate scale, gross chromosomal rearrangements (GCRs) including translocations, 
deletions and amplifications arise mainly from double strand breaks and telomeric dysfunction (middle). 
At the largest scale, whole chromosome instability is the major cause of aneuploidy in cancer and can 
result from errors in virtually any aspect of mitosis (right). The depicted example shows the merotelic 
kitetochor-microtuble attachment (adapted from Jones and Jallepalli, 2012). 
 
2.1.2 Microsatellite Instability (MSI) 
Microsatellite instability (MSI) is a hallmark of a restricted group of human malignancies 
including colorectal, gastric and endometrial cancers. MSI is characterized by variability of the 
length of microsatellite repetitive DNA sequences. Microsatellites, also referred to as short 
tandem repeats (STR) or short sequence repeats (SSR), are sequences of 1-5 nucleotides 
repeated from ten to thousand times in tandem. Microsatellites account for about 3% of the 
human genome and are usually located in non-coding DNA regions. They can overlap with 
gene regulatory regions and MSI can therefore lead to downregulation of gene expression 
(Kim et al., 2013). A fraction of microsatellites resides within gene exons and the instability in 
the length of these microsatellites may induce frame shift mutations (Duval and Hamelin, 
2002). For instance, TGFR2 contains a microsatellite of ten consecutive adenines (A10) in 
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exon 3. Single nucleotide deletions in this microsatellite are common in MSI colorectal cancers 
and render the gene product – a transforming growth factor receptor – non-functional 
(Markowitz et al., 1995).  
Instability in the length of DNA microsatellites is caused by defects in the replication-coupled 
DNA mismatch repair system (MMR). Single nucleotide insertion- or deletion loops (IDL) occur 
occasionally during replication due to DNA polymerase slippage on templates with repetitive 
sequences. Microsatellite sequences may form secondary DNA structures like DNA hairpins 
or small stem-loop structures, which can pause the encountering DNA polymerase during 
replication. The stalled polymerase possibly dissociates and the newly synthesized DNA 
strand can separate from the template. Shifted re-annealing with another tandem repeat 
generates small loops either in the template or in the daughter strand (IDL). If unrepaired by 
MMR, subsequent reassembly of the polymerase and further replication would result in 
insertions or deletions in the daughter strand depending in which strand the IDLs occurred 
(Viguera et al., 2001). According to the role of MMR in correcting mis-incorporated single 
nucleotides and IDLs, the loss of functional MMR results in the accumulation of microsatellite-
associated frameshift mutation but also in nucleotide substitutions and therefore generates a 
strong mutator phenotype. MMR deficient colorectal cancers, for instance, are characterized 
by their hypermutated genomes compared to microsatellite stable cancers (Cancer Genome 
Atlas, 2012). The core MMR machinery in mammals consists of seven proteins named 
according to their homology to the bacterial and yeast mutS, mutL and pms proteins, 
respectively. MutS homologes, including MSH2, MSH3 and MSH6 function as heterodimers in 
the recognition and binding to single nucleotide mismatches and IDLs. Upon MutS dimer 
binding to a DNA mismatch a MutL heterodimer is recruited. In mammals there are four MutL 
homologs: MLH1, MLH3, PMS1 and PMS2. All mutL heterodimers include MLH1, which 
therefore possesses a central role in mammalian mismatch repair. The MLH1-PMS2 dimer 
was shown to have an endonuclease activity which cleaves the newly synthesised DNA strand 
close to the lesion. The subsequently recruited exonuclease EXO1 and DNA polymerase  
remove the incised DNA strand and resynthesize it. DNA ligase 1 seals the newly synthesized 
fragment and completes the repair process (Kadyrov et al., 2006; Pena-Diaz and Jiricny, 
2012). Germline point mutations or deletions affecting mismatch repair genes, mainly MSH2 
and MLH1, are associated with a severe hereditary predisposition to cancer, called Lynch 
syndrome (Boland and Goel, 2010; van der Klift et al., 2005). Lynch syndrome associated 
tumors, which predominantly develop in the colon but also in endometrium and stomach, are 
all characterized by MSI. Sporadic forms of MSI colon and endometrial cancers often show 
epigenetic inactivation of MLH1. 
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2.1.3 DNA Sequence Mutability  
Genomes of cancer cells can harbor hundreds and thousands of DNA sequence mutations 
(Alexandrov et al., 2013). These include nucleotide substitutions as well as small insertions 
and deletions (indels). The prevalence of somatic mutations is the highest in cancers 
associated with chronic mutagen exposure like skin (melanoma, UV light) and lung cancers 
(tobacco smoking). This indicates an important role of exogenous mutagenic agents in the 
generation of somatic mutations in cancer (Alexandrov et al., 2013). Only in MMR deficient 
colorectal cancers the incidence of mutations is higher than in melanomas and lung cancers 
(Vogelstein et al., 2013). The most common form of mutations found in human cancers are C 
to T (C>T) substitutions in a cytosine-guanine (CpG) sequence context. Cytosines in a CpG 
dinucleotide can become methylated at the C-5 position (5mC). This modification does not 
alter base pairing but, in plants and vertebrates it serves as an epigenetic mark involved in the 
regulation of transcriptional activity. Methylated cytosines are hotspots of mutations in human 
cancers. Compared to unmethylated cytosines, 5mCs are more susceptible to spontaneous 
deamination resulting in the conversion of 5mC into thymine (C>T). Methylated CpGs also 
appear to be a preferential target for alkylation of guanine to generate 6-methyl-G, which then 
mispairs with T during replication, resulting in G>A mutations (Chen et al., 1998). Further, the 
apparently inefficient repair of T/G mismatches compared to U/T mismatches (resulting from 
cytosine deamination) and the higher vulnerability to UV light induced pyrimidine dimer 
formation may contribute to increased mutagenic potential of 5mC (Pfeifer et al., 2005). 
Interestingly, the extent of C>T mutations in a cancer genome correlates significantly with the 
age of the patient, indicating that these mutations are acquired continuously during life time 
rather than being the result of an increased cancer-associated mutability. However, other types 
of mutations appear to be associated with defects in DNA repair. As mentioned above small 
indels (mostly of 1bp) in short sequence repeats are characteristic for MSI cancers with 
defective MMR. Larger indels of up to 50bp with overlapping microhomology at the breakpoint 
junctions are likely to result from the functional loss of BRCA1 and BRCA2 and the concomitant 
bias towards NHEJ-mediated DSB repair (Alexandrov et al., 2013). Imperfect re-ligation of the 
overhanging DNA single strands at the sites of DSB during NHEJ is a plausible scenario 
explaining the generation of indels in this context. Also abnormalities in DNA modifying proteins 
contribute to DNA mutability. Members of the APOBEC protein family of cytidine deaminases, 
for instance, are highly expressed in several human cancers. APOBEC deaminase activity is 
involved in mRNA editing and contributes to innate immunity against retroviruses (Burns et al., 
2013; Harris and Liddament, 2004; Roberts et al., 2013). Their overexpression gives rise to 
C>T substitutions in different genomic locations. Finally also aberrations in DNA polymerases 
can act as mutators. Mutational disruption of the proofreading exonuclease activity in the 
replicative DNA polymerases POLE and POLD1 has been associated with hypermutated, 
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MMR-proficient colorectal and endometrial cancers (Alexandrov et al., 2013; Cancer Genome 
Atlas, 2012; Palles et al., 2013).  
Genetic mutations can be classified according to their contribution to cancer initiation and 
progression. Driver mutations are causally implicated in carcinogenesis and provide a selective 
advantage to a (pre-) cancerous cell. It is estimated that most human cancers have acquired 
2-8 driver mutations. They can generate a gain of function in oncogenes, or they can inactivate 
a tumor suppressor gene, and therefore passively initiate or promote tumor formation. Very 
frequently mutated driver genes are the tumor suppressors TP53 and APC and the oncogene 
KRAS. p53 acts as a transcription factor, central in the transduction of a variety of stress 
induced signals to different anti-proliferative cellular endpoints. The DNA binding domain of 
p53 represents a hotspot of somatic mutations in human cancers. A significant fraction of these 
are C>T substitutions in a CpG sequence context, which probably derive from deamination of 
5mC (Olivier et al., 2010; Zilfou and Lowe, 2009). Substitution mutations, which are not directly 
involved in carcinogenesis are called passengers. Compared to neutral mutations, passengers 
confer a selective advantage during cancer development. Classification into drivers and 
passengers requires detailed knowledge about the function of the affected gene, the genomic 
region or the precise mutation site and therefore proves to be difficult – also due to the fact 
that mutations not only affect protein functionality but also gene regulation. Such mutations are 
located in gene regulatory elements like the promoter region and alter the gene expression 
level. Promoter mutations are responsible for aberrant upregulation of TERT, the catalytic 
subunit of the telomerase, and a loss of SDHD (subunit D of the succinate dehydrogenase 
complex) expression in melanomas (F. W. Huang et al., 2013; Weinhold et al., 2014). 
 
2.2 Epigenetic Instability 
In addition to genomic aberrations human cancer cells also display extensive alterations in the 
“epigenetic code”. The epigenetic code represents a second layer of genetic information that 
is clonally heritable and greatly contributes to the regulation of gene transcription and other 
DNA-templated processes including DNA repair and replication. Epigenetic mechanisms 
determine the accessibility of discrete chromosomal regions to enzymatic activities by 
regulating the structural compaction of the chromatin. Epigenetic information is laid down in 
the form of covalent chemical modifications at DNA bases and histone proteins. The 
epigenome represents a landscape of chromatin that shaped in response to intrinsic and 
extrinsic cues during embryonic development and cell differentiation to program cell-type 
specific gene expression and thus determine cell fate. Non-coding RNAs, including micro-
RNAs (miRNAs), represent an additional epigenetic system with gene regulatory functions but 
are not subject of my PhD theses. Aberrations in all layers of epigenetic information are 
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widespread in human cancers and appear to occur already during early phases of 
carcinogenesis. The underlying molecular causes are diverse and often include transcriptional 
deregulation or mutational inactivation of enzymes involved in (i) the deposition or removal of 
epigenetic marks, (ii) “reading” of epigenetic marks or (iii) chromatin remodeling. 
 
2.2.1 Epigenetic Mechanisms 
Chromatin Structure 
In the nucleus of eukaryotic cells, DNA exists in the form of a protein-DNA composite termed 
chromatin (Figure 2-2). The basic units of chromatin are the nucleosomes which consist of 145 
base pairs of DNA wrapped around a histone octamer and the DNA linking these structures. 
The histone octamers are composed of two H3-H4 and two H2A-H2B histone dimers. The 
linker DNA is associated with the histone protein H1. The resulting chromatin fiber with a 
diameter of about 10nm, resembling “beads on a string”, can be further compacted. Results 
from mainly in vitro assays have suggested that the 10nm fiber becomes assembled in a 
regular helical structure containing 6-11 nucleosomes per turn generating a 30nm fiber. 
However, several observations made in vivo, using the chromosome conformation capture 
(3C) method, do not support the presence of a 30nm fiber but rather suggest that interphase 
chromatin exists in a dynamic, disordered and intertwined state with rather irregular spacing 
of nucleosomes (Hubner et al., 2013; Maeshima et al., 2010; Nishino et al., 2012). This form 
of chromatin organization is characterized by open and closed chromatin sections which 
appear as fractal globules at the chromosome level (see Figure 2-2). It enables dense 
chromatin compaction but still allows rapid conformational changes. In addition, the fractal 
globule chromatin structure describes interactions between genomic sites that are distant 
within a chromosome or located on different chromosomes. Interestingly, such interaction sites 
investigated by 3C were shown to be associated with chromosomal breakpoints in cancer 
(Fudenberg et al., 2011).  
Closed and compacted chromatin regions are referred to as heterochromatin, in contrast to 
the open structure of the euchromatin. Heterochromatin is concentrated to centric, pericentric 
and telomeric regions and is enriched for repetitive DNA elements. It is usually highly DNA 
methylated and largely transcriptionally silent. Heterochromatic regions play an essential role 
in centromere function and chromosome end protection by telomeres and therefore contribute 
significantly to genome stability. Cancer cells are commonly characterized by the partial loss 
of heterochromatic structures. Aberrant opening of the chromatin structure results in the 
exposure of repetitive sequences, promoting erroneous recombination events, and thereby 
facilitating the accumulation of chromosomal aberrations. Furthermore, the loss of 
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heterochromatin can lead to the activation of transposons, mobile DNA elements that are 
capable to invade the genome and generate insertion mutations and chromosomal aberrations 
(Oberdoerffer and Sinclair, 2007; J. C. Peng and Karpen, 2008). Centric and telomeric 
heterochromatin is present throughout the cell cycle and in all cell types and is therefore termed 
constitutive heterochromatin. In contrast, facultative heterochromatin is established during 
embryonic development in a cell-type or gender specific manner, an example being the 
inactivated X chromosome in female genomes. Heterochromatic and euchromatic regions 
occupy different compartments in the nucleus. Heterochromatin clusters around the nuclear 
periphery and is associated with the nuclear lamina whereas euchromatin fills most of the 
internal nucleoplasm. Repressive heterochromatic and active euchromatic domains are 
demarcated by CTCF, an insulator protein that binds specific DNA sequences and prevents 
spreading of heterochromatin into neighboring euchromatic regions. Mutations and deletions 
affecting CTCF were found in breast and prostate cancers (Cuddapah et al., 2009; H. Shen 
and Laird, 2013).  
The transition from a transcriptionally inactive and condensed chromatin state to an active and 
open chromatin state or vice versa requires the ATP-dependent activity of chromatin 
remodeling protein complexes. These enzyme complexes gate or close the access to the 
underlying DNA for transcription, replication and repair by reposition or eviction of 
nucleosomes or by replacement of canonical histones with histone variants (Petty and Pillus, 
2013). In mammals, four major families of chromatin remodeling complexes can be 
distinguished according to their biochemical activity and subunit composition: SWI/SNF 
(switching defective/sucrose nonfermenting), ISWI (imitation SWI), NURD/Mi-2/CHD 
(nucleosome remodeling and deacethylation/chromodomain helicase DNA-binding) and the 
INO80 (inositol requiring 80) family. Mutations in chromatin remodeling proteins, especially in 
members of the SWI/SNF family, are frequently found in human cancers (Kadoch et al., 2013; 
Narlikar et al., 2013). However, little is known about the mechanisms by which these 
aberrations contribute to carcinogenesis (Dawson and Kouzarides, 2012).  
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Figure 2-2: Chromatin organization in the mammalian nucleus according to the fractal globules 
model. The 10nm chromatin fiber can form a dynamic and disordered fiber-shaped structure. This fiber 
is further organized as fractal globules at the chromosome scale. Fractal globules can intertwine and 
regions of chromosomal synapsis appear to present chromosomal breakpoints often observed in cancer. 
Individual chromosomes occupy different territories within the nucleus (Hubner et al., 2013). 
 
Histone Modifications 
Histones are largely globular proteins except for their unstructured N-termini which protrude 
outward from the nucleosomes and are available for interactions with other neighboring 
histones or non-histone proteins. Select amino acid residues within these N-terminal tails are 
subject to a variety of posttranslational modifications. These modifications can alter higher 
chromatin architecture either (i) by changing the charge of the modified amino acids in a way 
that affects the contacts between adjacent nucleosomes or the interaction between histones 
and DNA or (ii) by modulating the affinity of chromatin-associated proteins including chromatin 
remodeling proteins. Hence, histone modifications exert strong influence on the grade of 
chromatin condensation and transcriptional activity. Accordingly, hetero- and euchromatic 
regions are marked by different histone modifications. At least five different modifications are 
found in histones: lysine methylation and acetylation, serine, threonine and tyrosine 
phosphorylation, lysine ubiquitination and lysine sumoylation. (Kouzarides, 2007). Most 
prominent and best studied are modifications in the N-termini of the canonical histones H3 and 
H4. Acetylation of lysine residues, e.g. at H3K9 and H3K14, is dynamic and generally 
associated with an open chromatin structure and transcriptional activity. The role of lysine 
methylation appears to be more diverse. Methylation of H3K4 is associated with active 
transcription in euchromatic domains whereas H3K9 and H3K27 methylation is found in 
transcriptionally silenced regions. Lysine methylation can occur in mono-, di-, and tri-
methylated forms, which are associated with different chromatin states (Barski et al., 2007; 
Shilatifard, 2008). Histone acetylation and methylation are tightly controlled by the concerted 
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activity of histone acetyl/methyl transferases (HATs and HMTs) and histone 
deacetylases/demethylases (HDACs and HDMs). Histone modifications do occur and exert 
their effects on chromatin structure in combinations. For instance, phosphorylation of H3 serine 
10 can be a marker for chromosomal condensation but, in combination with H3K14 acetylation 
it is found at actively transcribed gene loci (Prigent and Dimitrov, 2003; Strahl and Allis, 2000). 
Figure 2-3 summarizes well-established H3 modifications and their association with different 
chromatin states. 
The combinatorial nature of histone modifications constitutes a “histone code”, which 
determines the final chromatin structural read-out. Chromatin remodeling complexes and 
chromatin architecture proteins like HP1 belong to the readers of this code (Yun et al., 2011). 
The heterochromatin protein HP1 recognizes and binds to methylated H3K9 in 
heterochromatic regions but can also be found in euchromatin where it contributes to gene 
regulation. HP1 contributes to the stability and functioning of telomeres and centromeres. 
Down regulation of HP1 expression is found in several human malignancies including leukemia 
and thyroid carcinomas and correlates with cancer progression, probably due to an increased 
chromosomal instability and alterations in gene expression (Dialynas et al., 2008). Similarly, 
histone modifying enzymes themselves are targeted to specific chromatin loci via specific pre-
established histone modifications, further demonstrating the functional cooperation of different 
histone modifications. Polycomb group (PcG) and trithorax group (trxG) proteins are central to 
the maintenance of facultative hetero- and euchromatic domains, established during 
development. They form multimeric protein complexes which can contain histone readers and 
writers. The polycomb repressive complexes PRC1 and PRC2 recognize and deposit the 
repressive H3K27 trimethylation mark and remove activating H3K4 methylation (Lanzuolo and 
Orlando, 2012). On the opposite side, trxG proteins comprise H3K4 methyltransferases like 
MLL and chromatin remodeling factors (Schuettengruber et al., 2007). EZH2, the H3K27 
methyltransferase component of PRC2 was originally thought to be oncogenic because both 
gain-of function mutations and overexpression were found in several human cancers. 
However, EZH2 loss-of-function mutations found in predominantly myeloid malignancies 
suggest that PRC2 can also act as a tumor suppressor (Gibbons, 2005; H. Shen and Laird, 
2013).  
In addition to mutation and transcriptional deregulation of histone modifying enzymes, 
translocation-generated gene fusions involving transcription factors, nuclear receptors or other 
histone writers can be found in cancers. Such alterations can result in mistargeting of the 
histone writing activity and, thus, in aberrant chromatin changes. The fusion between DNA-
binding domain of the trithorax H3K4 methyltransferase MLL and histone acetyltransferase 
CBP, for instance, results in the aberrant activation of developmental HOX genes and thereby 
imparts stem cell-like properties (Gibbons, 2005; H. Shen and Laird, 2013). 
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Figure 2-3: Activating and repressive histone marks in histone H3. The N-terminus of histone H3 
is subject to various post-translational modifications. a) Lysine acetylation generally marks active and 
open chromatin structure. Whereas, lysine methylation at K4 is associated with the active state, K9 and 
K27 methylation is present in transcriptionally silenced regions. b) Summarizing graph, illustrating well-
established H3 modifications, their target amino acid residue and their function in transcription 
regulation. 
 
Regulatory Non-coding RNAs 
Recent whole transcriptome sequencing approaches revealed that mammalian genomes are 
almost fully transcribed although only a very small proportion is in fact protein encoding (about 
2%) and subsequently translated. The remaining “non-coding” RNAs (ncRNAs) are involved 
in numerous genomic processes including gene regulation, formation of heterochromatin and 
the maintenance of genomic stability (Amaral et al., 2008). Regulatory ncRNAs include the 
micro-RNAs (miRNAs) and the long non-coding RNAs (lncRNAs). The normally 22 nucleotides 
long miRNAs mediate post-transcriptional silencing by controlling the translation of mRNA. 
They are estimated to regulate the translation of more than 60% of the human genes. 
Accordingly, miRNAs are involved in the regulation of many biological processes like cell 
proliferation, differentiation and development. Some miRNAs regulate individual target genes, 
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whereas others act as master regulators implicated in expression regulation of hundreds of 
genes. miRNAs emerge either from separate transcriptional units or embedded within the 
introns of protein coding genes. Their biogenesis is multistep process in which the primary 
transcript becomes trimmed to eventually form the RNA-induced silencing complex (RISC) 
together with members of the Argonaut protein family which harbor an endonuclease activity. 
RISC is targeted to miRNA-complementary sequences in mRNAs usually located in their 
3´UTR. Translation of the targeted mRNA is repressed either by mRNA degradation or 
inhibition of translation initiation (Jansson and Lund, 2012). A multitude of miRNAs are 
transcriptionally deregulated in human cancers due to promoter DNA methylation, mutation, 
aneuploidy or secondary to transcription factor dysregulation. Depending on their target genes 
miRNAs can function as tumor suppressors or oncogenes (Croce, 2009). The transcriptional 
silencing of miR-200 miRNA family members observed in lung, breast and bladder cancers 
results in a down-regulation of the cell adhesion molecule E-cadherin and consequently in 
epithelial-to-mesenchymal transition, a process which is essential for metastasis formation 
(Davalos et al., 2012). lncRNAs form a heterogeneous group of transcripts more than 200 
nucleotides long. lncRNAs are involved in the regulation of chromatin state by the recruitment 
of chromatin remodelers and histone modification writers (Esteller, 2011). Hundreds of 
lncRNAs are expressed from the human HOX loci in a temporally and spatially concerted 
manner. HOTAIR is one of the best studied lncRNAs and emerges from the mammalian HOXC 
cluster. HOTAIR recruits PRC2 and the histone H3K4 demethylase LSD1 to the HOXD locus, 
resulting in its transcriptional repression. Overexpression of HOTAIR was observed in breast 
cancer leading to a genomewide re-targeting of PRC2 and altered H3K27 methylation and 
gene expression (R. A. Gupta et al., 2010). 
 
2.2.2 DNA methylation 
The covalent modification of DNA by methylation of the C5 in cytosine bases (5mC) is the best 
studied mechanism of epigenetic chromatin regulation. Mammalian DNA methylation occurs 
almost exclusively in the CpG sequence context. Non-CpG methylation is common in plants 
but is found only in pluripotent stem cells in mammals. Due to the increased spontaneous 
deamination and mutation rate of methylated cytosine, evolution has depleted CpG 
dinucleotides from large parts of the mammalian genome (Colot and Rossignol, 1999). They 
are 5-10 fold underrepresented compared to what would be expected from the frequency of C 
and G nucleotides. The vast majority of CpG dinucleotides in mammals are methylated (~70% 
in humans) and associated with heterochromatic chromatin domains (Ehrlich et al., 1982). A 
small fraction of CpG sites (~7% in humans) occurs clustered forming CpG islands (CGI; 
observed versus expected ratio>0.6). CGIs are found in promoters of about 60% of the human 
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genes including virtually all ubiquitously expressed housekeeping genes (Jeltsch, 2002). 
Although the great majority of CGIs appear to be unmethylated at all developmental stages 
and in all tissue types, methylation of a small but substantial fraction of CGIs associated with 
gene regulatory regions occurs in a tissue specific manner and effects downregulation of gene 
expression (Bird, 2002). Methylation of cytosine at the C5 position is catalyzed by DNA 
methyltransferases (DNMTs). In mammals there are three catalytically active DNMTs: DNMT1, 
DNMT3A and DNMT3B. All of them use the co-facor S-adenosylmethionin (SAM) as a donor 
for the methyl group. DNMT1 constitutes the key maintenance DNMT with a preference for 
hemimethylated CpG substrates. During DNA replication, the nascent newly synthesized DNA 
double-helix exists in a hemimethylated state, in which only the parental strand carries the 
methylation marks. DNMT1 faithfully copies the methylation pattern from the parental- to the 
daughter-strand to generate symmetrically methylated DNA strand, hence providing for the 
genetic inheritance of the parental methylation pattern. Interestingly, both biochemical and 
genetic data indicate that DNMT1 is activated to methylate unmodified CpG sites in the 
presence of fully methylated DNA and therefore might also play a role in de novo methylation 
(Fatemi et al., 2001). The stimulation of DNMT1 by methylated DNA indicates that heavily 
methylated regions might activate DNMT1 to promote spreading of methylation into 
neighboring unmethylated sequences (Turker, 1999). DNMT3A and DNMT3B exhibit no 
preference for hemimethylated DNA and are highly expressed during early embryonic 
development in the course of which they establish cell-type specific methylation patterns de 
novo but also may contribute to the maintenance of these patterns (P. A. Jones and Liang, 
2009). The catalytically inactive DNMT3L interacts with DNMT3A and DNMT3B and might play 
a regulatory role in genomic imprinting (Hata et al., 2002).  
 
Sites of DNA Methylation 
DNA methylation is generally associated with transcriptional repression and condensed 
chromatin sates. In this capacity, DNA methylation contributes to the establishment and 
maintenance of tissue-specific gene expression, X-chromosome inactivation, suppression of 
transposable elements and the general landscape of heterochromatic structures. Accurate 
DNA methylation is thus essential for normal development and chromatin organization (Bird, 
2002). Two mechanisms have been described by which DNA methylation mediates 
transcriptional repression. First, DNA methylation was proposed to generate a physical barrier 
for the binding of transcription factors such as E2F and CREB or the insulator protein CTCF, 
the DNA target sequence of which contain a CpG site (Bell and Felsenfeld, 2000; Griswold 
and Kim, 2001; Mancini et al., 1998). However, not all transcription factors prefer the 
unmethylated sequences for binding (Kulis and Esteller, 2010). The second mechanism 
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features the recruitment of methyl-CpG binding proteins (MBPs), DNA methylation readers that 
associate with several histone modifying enzymes. Five MBD proteins, characterized by the 
presence of methyl-CpG binding domain (MBD), have been identified: MeCP2, MBD1, MBD2, 
MBD3 and MBD4. Whereas MBD4 also has an active thymine DNA glycosylase domain and, 
thus, acts in the base excision repair (BER), MeCP2, MBD2 and MBD3 are associated with 
repressive histone modifying proteins like HDACs and H3K9 methyltransferases. Further, 
MBD2 and MBD3 are components of NURD/Mi-2 chromatin remodeling complexes which 
eventually mediate the repressive effect of underlying DNA methylation (Bogdanovic and 
Veenstra, 2009). Interestingly, it was found that HDAC1 and HDAC2 (components of the 
NURD/Mi-2 complex) and EZH2 (H3K27 methyltransferase in the polycomb repressive 
complex PRC2) interact with DNMTs. This bidirectional interdependence of histone 
modifications and DNA methylation is thought to assure transcriptional repression of a certain 
DNA region through replication and mitosis (D'Alessio and Szyf, 2006).  
DNA methylation in the intergenic space can influence gene expression through enhancer 
regulation as for example in the context of genomic imprinting. Imprinted genes are expressed 
only from one parental allele. They usually reside within clusters that allow their organization 
by common imprinting control regions (ICRs). These ICRs have a high CpG density and their 
methylation state differs according to the parent-of-origin of the respective allele. At the 
H19/IGF2 imprinted locus, for instance, methylation of the ICR in the paternal allele which is 
located in between the non-coding RNA H19 and the growth factor IGF2, prevents binding of 
the insulator CTCF. In consequence, a downstream enhancer element can associate with the 
IGF2 promoter and drive its expression while H19 is silenced. In the maternal allele, however, 
the ICR is unmethylated and the bound CTCF blocks interaction between the enhancer and 
IGF2, allowing it to associate with the H19 promoter instead (Lim and Maher, 2010).  
Finally, DNA methylation occurs within gene bodies where it has variable effects on gene 
expression and alternative splicing (Jjingo et al., 2012; Maunakea et al., 2013). Particularly 
interesting seems to be the effect on splicing as it involved the recruitment of MeCP2 and 
HDACs to sites of alternative splicing (Maunakea et al., 2013). The functions of intragenic 
methylation remains only poorly understood. 
 
DNA Methylation and Aging 
It is well-documented for specific genomic loci that DNA methylation gradually changes over 
age (methylation drift). In general, methylation at promoter CGIs increases whereas intergenic 
methylation, including repetitive genomic elements declines with age. These age-dependent 
methylation changes are likely to reflect imperfect maintenance of methylation marks during 
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DNA replication (Issa, 2014). Accordingly, the highly proliferative population of tissue stem 
cells display an epigenetic mosaicism with some aged stem cells showing minor methylation 
changes while others having the highest methylation drift (Shibata, 2009). The stem cell-
related methylation changes in aging tissues may affect the differentiation potential and 
epigenetic plasticity of these cells (Issa, 2014). It was shown that target regions of polycomb 
repressive complexes are prone to become hypermethylated over age (Rakyan et al., 2010). 
Interestingly, PRC2 target genes which include several tumorsuppressors are also 
predisposed to aberrant hypermethylation in cancer (Ohm et al., 2007; Schlesinger et al., 2007; 
Widschwendter et al., 2007). These observations indicate that methylation abnormalities in 
cancer may partially be targeted and that they occur in an age-dependent manner. Indeed, a 
large proportion of DNA methylation abnormalities in cancer can be traced to aging effects 
(Toyota et al., 1999). Furthermore, age represents the major risk factor for cancer. 
Remarkably, it was reported that lifestyle-related risk factors for colorectal cancer like smoking 
and overweight can influence the rate of methylation drift in the colon (Noreen et al., 2014). 
Chronic inflammation was found to be associated with substantial methylation drift in normal 
tissues from colon, stomach, lung and liver. Possibly, this is due to stimulation of stem cell 
proliferation for tissue regeneration and thereby acceleration of the drift (Issa, 2014). 
 
Aberrant DNA Methylation and CIMP in Cancer 
Aberrant DNA hypermethylation of gene promoter associated CGIs is common in human 
cancers. Affected genes are usually downregulated, which can be of direct relevance for 
tumorigenesis if tumor suppressors are involved. For instance, CDKN2A (p16) and CDKN2B 
(p15), both encoding regulators of cell cycle progression, undergo aberrant methylation in 
several cancer types. Other cancer-specifically methylated genes control cell adhesion, cell 
survival or DNA repair. Most prominent are MLH1, essential for mismatch repair, BRCA1, 
involved in DSB repair and MGMT (O-6-methylguanine methyltransferase), which removes the 
methyl moiety from naturally occurring or mutagen-induced (alkylating agents) O6-methylated 
guanine (Kulis and Esteller, 2010). The functional loss of DNA repair enzymes can promote 
genetic instabilities like MSI, in the case of MLH1, or G:C to A:T mutability when MGMT is 
inactivated. Also promoter regions of ncRNAs can be target of cancer specific 
hypermethylation and transcriptional silencing. For instance members of the miR-200 family of 
miRNAs are frequently hypermethylated in colon, breast and lung cancers. Investigation of 
genome-wide methylation patterns revealed that a significant proportion of cancer-specifically 
hypermethylated CpG sites reside within regions adjacent to CGIs called CGI-shores (<2kb 
around CGIs). Cancer-specific methylation changes in these CGI-shores also affect 
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expression of associated genes and may result from the loss or shift of CGI-methylation 
boundaries (Hansen et al., 2011; Irizarry et al., 2009).  
Subgroups of colon, liver, gastric, ovarian and lung cancers but also leukemias and gliomas 
feature an exceptionally high degree of gene promoter hypermethylation, and were therefore 
referred to as displaying a CGI-methylator phenotype (CIMP). CIMP accounts for about 10-
20% of the respective cancers (Noushmehr et al., 2010; Teodoridis et al., 2008). The molecular 
mechanisms underlying this particular epigenetic phenotype are not fully understood and 
probably differ between types of CIMP cancers. For gliomas and leukemias, there is good 
evidence that the loss or inhibition of DNA-demethylation activity (see chapter 2.2.3 DNA 
demethylation) is causal for the hypermethylation phenotype (Figueroa et al., 2010; Turcan et 
al., 2012). The CGI methylator phenotype in colorectal cancer usually implicates the 
hypermethylation and transcriptional silencing of the MLH1 promoter. The functional loss of 
MLH1 leads to MSI and a concomitant characteristic mutator phenotype. This represents an 
illustrative example for the coincidence of cancer-related genetic instabilities. The different 
forms of genetic and epigenetic instabilities introduced in this chapter exist not mutually 
exclusive but rather appear to cooperate to increase the selectable variability.  
In addition to focal CGI hypermethylation a global loss of DNA methylation is observed in a 
large variety of human cancers. This loss of methylation affects highly methylated and silenced 
heterochromatic regions in which satellite sequences, repetitive genomic sequences and 
transposable elements reside. Hypomethylation and increased accessibility of these elements 
have potential impact on chromosomal stability due to an increased rate of transposon-related 
mutagenesis and recombination events. DNMT1 knockdown experiments in animal models 
and studies of the molecular phenotype of ICF (Immunodeficiency, Centromere instability and 
Facial anomalies syndrome), a genetic syndrome caused by mutation of DNMT3B clearly show 
that the loss of DNMT activity is accompanied by the global loss of methylation, associated 
with increased chromosomal instability. However, deregulation of catalytically active DNMTs 
appears not to be causal for hypomethylation in cancer (Wilson et al., 2007). Still, catalytically 
inactive splice variants of DNMT3B, which negatively regulate methyltransferase activity have 
been linked to hypomethylation in leukemia and liver cancer (C. A. Gordon et al., 2013; Kulis 
and Esteller, 2010). There is evidence supporting that hypomethylation occurs secondary to 
altered histone modifications (e.g. H3K9 methylation) caused by deregulated histone modifying 
enzymes. Unlike global loss of methylation, hypomethylation of individual gene promoter CGIs 
is rather uncommon. Only few genes, some of which are oncogenes, are reported to be 
reactivated by aberrant hypomethylation of their promoter. For example, the CDH3 (P-
cadherin) gene was reported to be overexpressed in colon and breast cancers leading to 
decreased of cell polarity, promoting cell mobility and invasion. Focal hypomethylation in CGI-
shores appeared to be more frequent in a series of human cancers. Genes overexpressed due 
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to CGI shore hypomethylation include several mitosis and cell-cycle-related genes (Hansen et 
al., 2011).  
Aberrant hypo- and hypermethylation in cancer can be related to imprinting control regions 
(ICRs). Loss of imprinting (LOI) i.e. the biallelic expression or repression of imprinted genes is 
considered a hallmark of human cancers. A well-studied example is the H19/IGF2 locus where 
hypermethylation of the ICR results in the overexpression of IGF2 (see paragraph Sites of 
DNA methylation), which functions as an autocrine and paracrine growth factor in many 
cancers, and thereby promotes cell proliferation (Lim and Maher, 2010). Figure 2-4 
summarizes the different forms of cancer-related aberrant methylation events. 
 
 
Figure 2-4: DNA methylation patterns in normal and cancer cells. Repetitive sequences residing in 
heterochromatic regions are generally methylated in normal cells. Global loss of methylation in cancer 
cells leads to chromosomal instability and activation of transposable elements. Promoter CpG islands 
typically are unmethylated in normal cells whereas they can become hypermethylated in cancer cells, 
leading to transcriptional repression. Examples of genes affected are shown on the right. Similar 
patterns are seen in CpG island shores, located upstream of promoters. Loss of imprinting (LOI) due to 
aberrant methylation of imprinting control regions can block binding of the insulator CTCF which can 
result in the overexpression of oncogenes. A prominent example is LOI of the IGF2/H19 locus (Adapted 
from Varela-Rey et al., 2013). 
 
2.2.3 DNA Demethylation 
In terminally differentiated somatic cells, the cell type-specific methylation patterns established 
during embryogenesis are largely stable. Indeed, DNA methylation is thought to primarily 
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provide stability to the epigenome and thereby the somatic cell identity. However, particularly 
during early embryonic development genome-wide methylation patterns change profoundly 
and this includes the erasure of existent methylation marks. The methylation of the 5´ position 
of cytosine has long been thought to be irreversible due to the strength of the established C-C 
bond. Methylation dilution by inhibition of methylation maintenance during DNA replication was 
considered the only way of demethylation (passive DNA demethylation). However, 
investigation of DNA methylation in the preimplantation mouse embryo suggested the 
existence of an active demethylation mechanism. Both the maternal as well as the paternal 
genome undergo global erasure of DNA methylation after fertilization in the context of restoring 
totipotency, the ability to generate any cell type. Whereas methylation levels of the maternal 
DNA decline gradually in a replication dependent manner (dilution), the paternal pronucleus 
loses global methylation rapidly within the first round of DNA replication (Jenkins and Carrell, 
2012). This indicates the involvement of an enzymatic component actively removing the methyl 
mark. Numerous DNA repair pathways, DNA editing enzymes and even DNMTs were 
proposed to be involved in active DNA demethylation (Ooi and Bestor, 2008). However, for 
many mechanisms their role in demethylation seemed limited to the specific biological systems 
investigated. Eventually, the discovery of the TET family of DNA dioxygenases shed light on 
methylation dynamics during early development. TET proteins (TET1, TET2 and TET3) can 
oxidize 5mC to 5-hydroxymethyl cytosine (5hmC) which was shown to function as an 
intermediate of DNA demethylation (J. U. Guo, Su, et al., 2011; Ito et al., 2011; Tahiliani et al., 
2009). 5hmC is not maintained by DNMT1 and lost with ongoing DNA replication (Valinluck 
and Sowers, 2007). Indeed, recent studies confirmed that such a semiactive mechanism 
mediated by TET3 contributes to the rapid loss of 5mC in the male pronucleus (Gu et al., 2011; 
Inoue and Zhang, 2011; Wossidlo et al., 2011). However, the observation that extensive 
demethylation occurs also in post-mitotic neurons suggests the existence of a truly active 
mechanism which completely restores the unmodified cytosine independent of replication (J. 
U. Guo, Su, et al., 2011). Two major pathways for the active replacement of 5hmC with 
unmodified C were proposed, both postulating the further chemical modification of 5hmC and 
the subsequent replacement of this modified base by the base excision repair (BER) pathway. 
The first pathway suggests deamination of 5hmC by AID/APOBEC cytidine deaminases, which 
results in the generation of 5-hydroxymethyl uracil (5hmU) (Cortellino et al., 2011). 5hmU-G 
base pairs are substrate for the DNA glycosylases TDG and SMUG which excise the base 
from the DNA by cleavage of its N-glycosidic bond, thus producing an abasic site (AP-site, 
apurinic/apyrimidinic site). This represents the initial step of the BER pathway in the course of 
which the excised base becomes replaced with unmodified C. Several lines of evidence, 
however, challenge the concept of deamination-mediated active demethylation and favor a 
second pathway of active demethylation (Nabel et al., 2012; Rangam et al., 2012). This 
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pathway bases on the observation that TET proteins are capable to further oxidize 5hmC 
iteratively to 5-formyl cytosine (5fC) and 5-carboxy cytosine (5caC), two bases efficiently 
processed by TDG but apparently no other DNA glycosylase (Ito et al., 2011; Maiti and Drohat, 
2011). Indeed, the loss of TDG leads to the accumulation of 5caC in embryonic stem cells (He 
et al., 2011). TDG was originally identified as an enzyme releasing thymine from G-T 
mismatches and thereby proposed to counteract CT transition mutation by 5mC deamination 
(Cortazar et al., 2007). But in contrast to other DNA glycosylases and consistent with a non-
redundant function in TET1 mediated active DNA demethylation, TDG is essential for 
embryonic development and mutant embryos feature epigenetic abnormalities including 
aberrations in DNA methylation (Cortazar et al., 2011; Cortellino et al., 2011). The oxidative 
pathway in which TDG acts on TET-generated 5hmC derivatives is currently the only 
biologically and biochemically validated mechanism for active DNA demethylation (Kohli and 
Zhang, 2013).  
 
DNA Demethylation and Epigenetic Plasticity 
5hmC is enriched in embryonic stem cells (ESC) in which TET1 and TET2 are highly expressed 
and active. 5hmC in mouse ESCs is present mainly at transcription start sites (TSS) and in 
gene bodies. Whereas, TET2 appears to be associated with 5hmC in gene bodies, TET1 is 
rather related to hydroxymethylation at the TSS (Y. Huang et al., 2014; Williams et al., 2011). 
TET1 seems to bind preferentially near the TSS of CpG-rich gene promoters, including a 
significant fraction of polycomb target genes. During ESC differentiation the global 5mC 
content decreases concomitantly with a decline in TET1 and TET2 expression (Szwagierczak 
et al., 2010). It was reported that TET1 and TET2 transcription is regulated by the master 
regulator of ESC self-renewal, OCT4, and that they are themselves directly involved in the 
regulation of key ESC transcription factors like NANOG (Ito et al., 2010; Koh et al., 2011). 
These results suggest a major function of TET proteins in the ESC state. Koh and colleagues 
showed that TET1 depleted ESC display an altered differentiation potential in vitro, indicating 
a role of TET1 in maintenance of ESC pluripotency (Koh et al., 2011). However, TET1 and 
TET2 knockout mice develop normal and are fertile, an observation that is difficult to reconcile 
with a premature loss of pluripotency (Dawlaty et al., 2011). Although, the exact function of 
TET proteins in ESCs is poorly understood and requires further investigation, several studies 
with induced pluripotent stem cells (iPSCs, see Apostolou and Hochedlinger, 2013 for review) 
indicate a central role of TET proteins during cell reprogramming and suggest that TET function 
is associated with cell state plasticity (Gao et al., 2013). Interestingly, TET2 depletion in mice 
results in an augmented hematopoietic stem cell (HSC) population which, however, displays a 
skewed differentiation potential indicating that TET proteins exert important functions in 
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somatic stem cells as well (Ko and Rao, 2011; Nakajima and Kunimoto, 2014). Unlike most 
differentiated and post-mitotic somatic cells, neuronal cells in the adult hippocampus show a 
remarkable level of DNA methylation plasticity. Synaptic connections between neurons in the 
hippocampus are reorganized in the context of memory generation. Activity in these neurons 
can alter their DNA methylation profile in vivo including gain and loss of methylation. This 
activation-induced demethylation is likely to be active (independent of replication) and TET1-
dependent (J. U. Guo, Ma, et al., 2011). In summary, TET-mediated active DNA demethylation 
appears to be associated with an increased epigenetic and phenotypic plasticity required 
during early embryonic development, in tissue homeostasis as well as in neuronal activity.  
 
Defective DNA Demethylation in Cancer 
The first identified, cancer-related alteration involving TET proteins was the gene fusion 
between TET1 and the H3K4 methyltransferase MLL present in a subset of leukemias (Ono et 
al., 2002). Indeed, TET1 and the subsequently identified other members of the protein family 
were named with reference to this gene fusion which resulting from translocation between 
chromosome 10 q22 (TET1 locus) and chromosome 11 q23 (TET for Ten-Eleven-
Translocation). Later, mutations and deletions affecting TET2 were found in ~25% of myeloid 
leukemia patients as well as in one third of patients with lymphomas (Delhommeau et al., 2009; 
Langemeijer et al., 2009; Quivoron et al., 2011). The functional loss of TET2 in leukemias is 
accompanied by decreased global 5hmC and the accumulation of 5mC, thus reflecting a 
hypermethylation phenotype (Figueroa et al., 2010; Ko et al., 2010). Interestingly, TET2 
mutations in leukemia occur mutually exclusively with mutations in IDH1 and IDH2 (Isocitrate 
dehydrogenases). IDH enzymes normally catalyze the oxidative decarboxylation of isocitrate 
to -ketoglutarate (-KG) which, along with Fe(II), represents a cofactor for TET enzymes. 
Mutant IDH1/2 acquire a neomorphic enzymatic activity catalyzing the reduction of -KG to 2-
hydroxyglutarate (2-HG) which directly inhibits TET2 (Figueroa et al., 2010; W. Xu et al., 2011). 
Similar to TET2-mutant leukemias, IDH-mutant leukemias are also characterized by 
genomewide hypermethylation, impaired hematopoietic differentiation and an enlarged stem 
cell compartment (Figueroa et al., 2010). Subsequently, it was shown that the same 
neomorphic mutation in IDH1 represents the molecular basis for the CGI-methylator phenotype 
in gliomas (G-CIMP) (Turcan et al., 2012). The TET2 and IDH1/2 mutation-related pathways 
of CGI-hypermethylation are illustrated in Figure 2-5. Irrespective of the association with 
specific hypermethylation phenotypes, reduced TET protein expression and the concomitant 
global loss of 5hmC appears to be a common feature of several human solid tumors (Yang et 
al., 2013).  
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Similar to impaired TET activity, the loss of TDG has potential impact on DNA methylation 
patterns. However, cancer-related aberrations affecting TDG are rare. Somatic mutation of 
TDG have so far only been described in a single rectal cancer which featured a CT mutator 
phenotype (Vasovcak et al., 2012). Loss of TDG expression was reported in pancreatic 
cancers and myelomas and was associated with deletion of the TDG locus or the aberrant 
hypermethylation of its promoter, respectively (B. Peng et al., 2006; Yatsuoka et al., 1999).  
 
 
Figure 2-5: Defects in TET–mediated DNA demethylation in cancer. (Left) In normal cells the IDH1 
and IDH2 enzymes catalyze the oxidative decarboxylation of Isocitrate to α-ketoglutatrate (αKG) which 
serves as a cofactor for TET DNA dioxygensases. TET proteins prevent aberrant methylation events by 
hydroxylation of 5mC to 5hmC which represents a demethylation intermediate. (Middle) Mutations in 
IDH1/2 result in a neomorphic catalytic activity reducing αKG to 2-hydroxyglutatrate (2HG) which inhibits 
TET activity. This leads to an accumulation of 5mC and genomewide hypermethylation. (Right) Loss-of-
function mutations in TET2 found in myeloid leukemia and in lymphoma similarly generate a methylator 
phenotype. (Adapted from Cimmino et al., 2011) 
 
2.3 Colorectal Cancer 
Colorectal cancer (CRC) is the third most common form of cancer, accounting for 
approximately 10% of all cancer cases (World Cancer Report 2014. World Health 
Organization., 2014). CRCs are usually adenocarcinomas with glandular origin. Numerous 
factors have been shown to be associated with increased risk of CRC. These include heritable 
predisposition, age, chronic inflammation, and several lifestyle factors like diet, smoking and 
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alcohol intake. Most CRCs arise sporadically without any familial background. Only 10-15% of 
all CRCs are etiologically linked to a hereditary predisposition. The most significant forms of 
familial CRCs are the hereditary non-polyposis colorectal cancer (HNPCC, Lynch-syndrome) 
and the familial adenomatous polyposis (FAP) which together account for 3-5% of all CRCs. 
Most HNPCC patients harbor heterozygous germline mutations in mismatch repair genes 
including MLH1 (33%), MSH2 (31%), MSH6, PMS1 and PMS2. Accordingly, HNPCC related 
tumors are usually characterized by MSI. A hallmark of FAP is the development of myriad 
adenomatous polyps in the colon from which some will inevitably progress and form 
carcinomas. FAP is caused by germline mutations in the APC tumor suppressor gene. APC 
(adenomatous polyposis coli) is a negative regulator of the canonical Wnt signaling pathway.  
Wnt-signaling is one of the fundamental pathways regulating cell proliferation, cell polarity and 
cell fate determination in embryonic development and tissue homeostasis. Canonical Wnt-
signaling functions by regulating the amount of the transcriptional coactivator -catenin, which 
controls developmental gene expression programs. In this pathway secreted Wnt ligands bind 
to a frizzled family receptor and its coreceptor LRP5 or LRP6 resulting in the activation of 
Dishevelled (DVL). In its active form DVL inhibits the -catenin destruction protein complex 
consisting of APC, Axin, protein phosphatase 2A (PP2A), glycogen synthase kinase 3 (GSK3) 
and casein kinase 1α (CK1α). -catenin, normally targeted to ubiquitination by the destruction 
complex and consequently degraded by proteasomes, accumulates and translocates to the 
nucleus where it interacts with transcription factors of the TCF/LEF family. The TCF/-catenin 
complex regulates the expression of a multitude of Wnt-responsive genes by recruiting further 
co-activators or co-repressors, respectively (MacDonald et al., 2009). TCF/-catenin promotes 
the expression of several oncogenes including MYC and genes involved in cell cycle regulation 
like Cyclin D. Also expression of the pluripotency factors NANOG and OCT4 can be induced 
by canonical Wnt signaling (Cole et al., 2008). Activity of the Wnt/-catenin pathway is highly 
associated with the adult colonic stem cell compartment and is essential for its maintenance 
also in colorectal cancer. LGR5, a target gene of TCF/-catenin is widely used as a reliable 
marker for intestinal stem cells (Becker et al., 2008; Schepers and Clevers, 2012; van de 
Wetering et al., 2002). 
The molecular mechanisms underlying HNPCC and FAP demonstrate the central roles of 
mismatch repair and the Wnt-signaling pathway in the carcinogenesis of human CRC. In 
sporadic CRCs both pathways are commonly affected also in consequence of (epi-) genomic 
instabilities.  
Another significant cellular signaling pathway in colorectal carcinogenesis is the extracellular 
signal-regulated kinase (ERK) pathway involved in the regulation of fundamental cellular 
processes such as growth, proliferation, differentiation, migration and apoptosis. The ERK 
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pathway belongs to the mitogen-activated protein kinase (MAPK) pathways and constitutes 
the best studied member of this extracellular signal-regulated kinase pathways. The ERK 
signaling pathway can be triggered by activation of transmembrane receptors tyrosine kinases 
(RTKs) which include growth factor receptors like EGFR (epidermal growth factor receptor) 
and FGFR (fibroblast growth factor receptor). Binding of the growth factors to the extracellular 
domain of their receptors results in the phosphorylation of the intracellular domains. The 
activated RTKs trigger the GTP-loading to Ras GTPases, which phosphorylate the Raf 
kinases. Activated Raf proteins in turn induce the phosphorylation of Mek kinases which 
eventually phosphorylate the ERK kinase (Katz et al., 2007). ERK phosphorylates a multitude 
of cytoplasmic proteins and after its translocation to the nucleus it also activates various 
transcription factors including the oncogenes MYC, FOS and JUN. The aberrant activation of 
the ERK pathway can be considered as a hallmark of human cancers and cancer-related 
abnormalities occur across the whole signaling cascade. Activating mutations in Ras genes 
(KRAS and NRAS), which impair their GTPase activity and render Ras in active, GTP bound 
state are found in a large variety of human cancers with an exceptionally high frequency. 
Mutations of Raf genes are mainly found in melanomas and CRCs and affect almost 
exclusively the B-RAF family member (Dhillon et al., 2007). The most common mutation of 
BRAF is a V600E change that implicates the constitutive activation of its kinase activity. KRAS 
mutations are more common in CRC than BRAF mutations and they occur mutually exclusive 
which is indicative of their common function in activating ERK signaling during cancer 
development. However, the BRAF V600E mutation in CRC is highly associated with the CGI-
methylator phenotype (see chapter 2.3.1), whereas KRAS is not significantly correlated with 
epigenetic aberrations. This suggests that the oncogenic potential of BRAF and KRAS 
mutations is not exclusively related to activation of ERK. The over-activation of the ERK 
pathway by BRAF and KRAS mutations and the consequent hyper-proliferation trigger a 
cellular tumor suppressive response mechanism resulting in the senescence of the cells, the 
ceasing of cell division. The mechanism of oncogene-induced senescence (OIS) depends on 
the activation of p53. (Epi-) genetic aberrations affecting p53 function itself or affecting 
cofactors of p53 confer resistance to OIS and are common in CRC. 
In 1990, Fearon and Vogelstein proposed a multistep molecular model for colorectal 
tumorigenesis. According to this model, different genetic driver aberrations accompany the 
development of discrete intermediates in the progression to cancer (Fearon and Vogelstein, 
1990). These precancerous lesions include the aberrant crypt foci (ACF), the earliest 
detectable tissue anomalies, and different stages of adenomas, benign tumors of colon 
epithelium. Mutations and LOH of APC occur early in this ACF-adenoma-carcinoma sequence 
followed by mutations in KRAS (Haigis et al., 2008). Subsequent malignant transformation is 
driven by additional aberrations affecting the p53 tumor suppressor, the transforming growth 
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factor (TGF)-β pathway and the phosphatidylinositol bisphosphate kinase (PIK3CA). PIK3CA 
acts in the PI3K/AKT signaling pathway mediating cell growth and proliferation signals from 
several growth factors including insulin-like growth factors (IGFs). Activating mutations in 
PIK3CA lead to the constitutive activation of this pathway and increased cell proliferation, 
survival and motility (Karakas et al., 2006). TGF-β signaling exerts a dual role in tumorigenesis 
and cancer progression. As a potent inhibitor of cell proliferation TGF-β signaling activity is 
blocked in early phases of colorectal tumorigenesis, for instance due to mutation of TGF-β 
receptor II (TGFβ2R) in MSI tumors or mutation of the SMAD TGF-β signaling molecules. In 
later stages when tumor cells became resistant to TGF-β-mediated growth inhibition they often 
upregulate their TGF-β expression and secretion, which triggers increased tumor cell mobility 
and invasiveness and promotes angiogenesis (Blobe et al., 2000). Due to TGFβ2R mutations, 
MSI tumors are less susceptible to the late metastasis promoting effects of TGF-β and thus 
have usually a better prognosis (Pino et al., 2010). The multistep model for colorectal 
carcinogenesis, even with ongoing refinements due to the identification of other carcinogenic 
pathways, became a paradigm for solid tumor progression. It indicates that only a relatively 
small number of (epi-) genetic aberrations are required for cancerous transformation. Genomic 
and epigenomic instabilities are likely to be involved in the acquisition of these driver events. 
 
2.3.1 (Epi-) Genetic Instabilities in Colorectal Carcinogenesis 
Based on the integrative analysis of genetic and epigenetic aberrations two molecular 
pathways of colorectal carcinogenesis can be distinguished: The CIN pathway and the 
CIMP/MSI pathway. Besides the different underlying genetic instabilities, tumors arising from 
these pathways are characterized by a different set of associated somatic mutations, by 
different degree of malignancy and also by different precursor lesions.  
CIN is the most frequent form of genomic instability in CRC and is observed in 65%-70% of 
sporadic cancers. CIN occurs at very early stages of tumorigenesis. More than 90% of 
adenomas show allelic imbalances of individual chromosomes (Shih et al., 2001). However, 
the molecular basis of CRC-CIN is not well understood, yet. To identify gene mutations 
underlying colorectal CIN, Wang and colleagues searched for CRC-related mutations in 
human gene homologues corresponding to genes involved in CIN in drosophila melanogaster 
and in budding yeast. They identified mutations in MRE11, an important factor of DSB repair 
by NHEJ, in DING, required for proper chromosome disjunction in yeast, and in a number of 
factors of a kinotochor-associated protein complex. Together, these mutations accounted for 
~10% of the analyzed CIN cancers (Z. Wang et al., 2004). However, functional prove of the 
causal relationship between these mutations and CIN is still missing. Interestingly, mutations 
in APC and concomitant activation of the Wnt/-catenin signaling pathway were reported to 
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induce CIN in vivo, maybe due to upregulation of Axin, a component of the -catenin 
destruction complex. Transcription of Axin is induced by TCF/-catenin in the context of a 
negative regulatory circuit. Overexpression of Axin compromises the mitotic spindle assembly 
checkpoint and is thereby capable to induce CIN (Aoki et al., 2007; Hadjihannas et al., 2006). 
A characteristic set of chromosomal aberrations was recurrently observed in CRC-CIN. It 
includes several armlevel-deletions like chromosome 5q encompassing the APC and the 
Mutated in Colorectal Cancer (MCC) gene loci. MCC is a cell cycle regulatory protein that 
induces cell cycle arrest in response to DNA damage and also acts as a repressor of -catenin-
dependent transcription (Fukuyama et al., 2008). Deletions of chromosome 17p segment 
which includes the p53 locus and chromosome 18q containing many candidate tumor 
suppressors are found in approximately 70% of CIN CRCs. These examples again illustrate 
the potential of CIN in inducing LOH, the loss of the functional allele in heterozygous mutations. 
On the other hand amplifications of genomic loci containing oncogenes like MYC at 
chromosome 8q are frequent in colorectal cancer (Sheffer et al., 2009). Although, CIN-CRCs 
are primarily characterized by genomic instability, it is important to note that epigenetic 
alterations are not absent in CIN-CRCs and include, for instance, focal hyper- and 
hypomethylation events (Sakai et al., 2014).  
Microsatellite instability in sporadic CRCs is basically caused by aberrant hypermethylation 
and transcriptional silencing of the MLH1 promoter in the context of a genomewide CGI 
methylator phenotype (CIMP). Therefore, MSI and CIMP are mechanistically linked in CRC 
and form the second major pathway of sporadic colorectal carcinogenesis, accounting for 10%-
15% of the cancers. The functional loss of MLH1 generates a characteristic mutator phenotype. 
TGF2R as well as the mismatch repair genes MSH3 and MSH6 harbor single nucleotide 
repeats in their coding regions which are targets of MSI induced mutations. CRC-CIMP was 
first described 1999 by Toyota and colleagues, who found that a subgroup of CRCs shows 
simultaneous cancer-specific methylation of a small set of promoter-associated CGIs (Toyota 
et al., 1999). Since their initial marker panel included MLH1, they concluded that CIMP may 
be causal for MSI in CRC. Recent genome-wide methylation studies, however, revealed that 
CIMP is not restricted to a small number of CGIs but rather represents a genomewide 
phenomenon with a multitude of aberrantly hypermethylated CGIs (Ang et al., 2010; Hinoue et 
al., 2012; L. Shen et al., 2007; Yagi et al., 2010). These studies also introduced a third DNA 
methylation-related phenotype characterized by an intermediate degree of CGI methylation 
referred to as CIMP-low (CIMP-L) or CIMP2 in contrast to CIMP-high (CIMP-H) or CIMP1, 
respectively. Whereas, CIMP-H tumors were found to be highly associated with V600E BRAF 
mutations and MSI, the intermediate CIMP state was characterized by mutations in KRAS and 
rare MSI. In contrast to the CIMP-negative condition, both CIMP forms correlated negatively 
with p53 mutations. Since, CIMP-L methylation profiles occur also in CIN tumors, this 
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methylation phenotype appears not as distinctive as the CIMP-H/MSI pathway. It is currently 
unclear whether CIMP-L represents a discrete pathway of carcinogenesis, although its unique 
association with KRAS mutations suggests a separate underlying oncogenic mechanism. The 
molecular processes leading to the aberrant hypermethylation in CRC-CIMP are largely 
ambiguous. Overexpression of DNMT1 and DNMT3B was proposed to be involved in the 
generation of CIMP (Kanai et al., 2001; Nosho et al., 2009). However, a causal link between 
DNMT expression and CIMP-related hypermethyation has not been shown, yet. It was found 
that BRAF V600E mutations can induce MSI in vitro and in vivo indicating a mechanistic link 
between the BRAF V600E mutation and CIMP/MSI (Oikonomou et al., 2009; Rad et al., 2013). 
Results from our group indicate that a loss of TET1 expression is involved in aberrant CGI 
methylation in CRC-CIMP (see 4. Results). The observation that the BRAF V600E-induced 
transformation of mouse fibroblast cells leads to the downregulation of Tet1 expression 
substantiates the hypothesis that impaired demethylation rather than aberrantly active 
methylation is responsible for 5mC accumulation in CRC-CIMP (Kudo et al., 2012). This would 
coincide with different reports indicating that mutation or inhibition of TET proteins is causal for 
methylator phenotypes in leukemias and gliomas.  
By and large, CIN and CIMP/MSI features of genomic instability arise in a mutually exclusive 
manner in CRC (Cancer Genome Atlas, 2012; Cheng et al., 2008), implicating separate 
underlying pathways of carcinogenesis, differing in specific molecular, clinical and histological 
aspects. For instance, due to MMR-deficiency CIMP/MSI tumors appear hypermutated 
compared to CIN cancers. Moreover, both pathways are associated with different driver 
mutation profiles: KRAS and p53 mutations are hardly found in tumors derived from CIMP/MSI 
which often harbor BRAF mutations, instead. However, in accordance to the critical role of the 
Wnt-signaling pathways in colorectal carcinogenesis, APC mutations are found in tumors from 
both pathways with a high frequency. Patients diagnosed for CIMP/MSI derived cancers are 
usually older than patients with CIN cancers. In addition, CIMP/MSI tumors are associated with 
the female gender and are mainly located at the right side of the colon (proximal colon). Finally, 
CIN- and CIMP/MSI-related tumors arise from different precursor lesions. CIN tumors develop 
from conventional adenomatous polyps and ACFs in which mutations in APC, KRAS and p53 
can be already found. Tumors from the CIMP/MSI pathway arise from serrated adenomas, 
referring to the sawtooth-shaped infoldings of the surface of these polyps. Mutation of BRAF 
has been observed in serrated adenomas and even serrated ACFs and therefore represents 
a very early event in the CIMP/MSI pathway. Aberrant hypermethylation events can also be 
detected in serrated polyps such as methylation of CDKN2A (p16), a p53 stabilizing factor, and 
MCC (Leggett and Whitehall, 2010). Figure 2-6 illustrates the different molecular events 
associated with the CIN and CIMP/MSI oncogenic pathways. 
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In early stages of tumorigenesis genetic and epigenetic instabilities of both pathways 
contribute to the generation of a persistent hyper-proliferative phenotype. Further tumor 
progression and the transition to malignant stages i.e. the capability to invade other organs to 
establish metastasis require the induction of angiogenesis and acquisition of a reversible 
migratory cell behavior. 
 
 
 
Figure 2-6: The CIN and the CIMP/MSI pathway of colorectal carcinogenesis. The two oncogenic 
pathways of colorectal cancer differ regarding the key (epi-) genetic driver aberrations. The CIN pathway 
(top) is initialized by mutations in APC and the concomitant over-activation of the Wnt/β-catenin 
signaling. Also in the CIMP/MSI pathway (bottom) activation of canonical Wnt signaling represents an 
early event and is associated with mutations in APC and AXIN. Whereas, further cancer development 
in the CIN pathway is related to mutations in KRAS, p53 and the SMAD TGFβ signaling mediators, the 
CIMP/MSI pathway is characterized by the BRAF V600E mutation which might be causally linked to the 
CGI-methylator phenotype. Hypermethylation of the MLH1 promoter results in MSI which induces 
frameshift mutations in TGFβ2R and IGF2R (Adapted from Walther et al., 2009). 
 
2.3.2 (Epi-) Genomic Instabilities in Colorectal Cancer Progression 
CRCs derive from the adenomatous epithelium in colon and rectum. Normal colonic epithelial 
cells typically show an apical (facing the colonic lumen) versus basolateral (attached to the 
subjacent basal lamina) polarity. In addition, cells of an epithelial layer are strongly attached 
to each other due to tight junctions and adherence junctions anchoring epithelial cells in this 
structure. However, in the course of cancer progression tumor cells break out of the epithelial 
cell layer and invade other organs leading to the establishment of distant metastases. For this 
purpose cancer cells use a mechanism which is normally functions during embryonic 
development where certain differentiated epithelial cells lose their polarity and cell-cell 
junctions and acquire a migratory mesenchymal phenotype. Upon this epithelial-to-
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mesenchymal transition (EMT) the cells become recruited to specific sites in the developing 
embryo wherein they can undergo the reverse process of mesenchymal-to-epithelial transition 
(MET) to form epithelial tissues at distal locations. Accordingly, cancer cells which underwent 
EMT possess migratory and invasive properties which are lost again by MET after initiation of 
secondary tumor growth (Ocana et al., 2012; Tsai et al., 2012). TGF- signaling is a potent 
inducer of EMT. In consequence to TGF- signaling, the E-cadherin repressors SNAI1, SNAI2, 
ZEB1 and TWIST are upregulated. Reduced of E-cadherin expression leads to the breakdown 
of adherence junctions and, along with other signaling events, loss of cell polarity ensues. In 
addition to its function in the canonical Wnt-pathway, cytoplasmic -catenin is a component of 
adherence junctions. The collapse of these cell adhesion complexes results in the 
accumulation of -catenin and in its nuclear translocation triggering expression of Wnt target 
genes. These include several E-cadherin repressors like SNAI1/2, ZEB1 and TWIST 
(Heuberger and Birchmeier, 2010; Sanchez-Tillo et al., 2011). Hence, also the canonical Wnt-
signaling pathway can induce EMT and, moreover, can reinforce the mesenchymal phenotype. 
It was shown that EMT generates cells with stem cell properties e.g. expression of the stem 
cell marker CD44, a TCF/-catenin target (Fan et al., 2013; Mani et al., 2008). Vermeulen and 
colleagues reported that the hepatocyte growth factor (HGF), a potent inducer of EMT secreted 
by the tumor-associated stroma, can activate stem cell-related Wnt/β-catenin signaling also in 
vivo (Vermeulen et al., 2010). Together these findings indicate that cancer cells can 
dedifferentiate to acquire stem cell-like features in a process resembling developmental EMT. 
Such stem cell features are the capacity of self-renewal (maintain the undifferentiated state 
over cell division) and the potential to differentiate to other cell types. In numerous human 
cancers, including CRC, a small cell population was identified, which is capable to give rise to 
tumors when xenografted into immunosuppressed mice. In contrast, most of tumor cells were 
not able to induce tumor growth (Ricci-Vitiani et al., 2007). The tumors derived from these 
tumor-initiating cells (TICs) resembled the cellular heterogeneity of the original human cancer 
and contained again a small TIC population. This suggested that TICs are able to differentiate 
and to self-renew and thus have stem cell character, a reason why they were also referred to 
as cancer stem cells (CSCs). Compared to normal colonic stem cells in healthy mucosa TICs 
occurred with much higher frequency in cancers. Several protein markers were proposed for 
the identification of TICs in CRC such as the surface proteins CD133, CD166, CD44 and as 
well as LGR5. The expression of CD44 and LGR5 is induced by Wnt/-catenin signaling, 
suggesting that the Wnt-pathway also plays a role generation of CRC-TICs. In vitro data 
suggest that TICs and non-TICs don´t follow a hierarchical model in which the stem-like TICs 
could differentiate to non-TIC cells but not vice versa. Rather, they appear to be linked by 
dynamic and stochastic inter-conversions. For instance, LGR5 negative cells can reversible 
convert into LGR positive under selective pressure (Kobayashi et al., 2012). Separation and 
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subsequent culturing of the differentiated cell fraction from two breast cancer cell lines re-
established the original heterogeneous population including stem-like cells (P. B. Gupta et al., 
2011). Whether these dynamic state transitions are linked to EMT and MET processes remains 
elusive, particularly in the light of reports showing that different types of TICs, possibly 
associated with different mesenchymal and epithelial features, are likely to co-exist in the same 
tumor (Liu et al., 2014).  
EMT and MET are related to extensive gene expression reprogramming accompanied by 
reversible epigenetic changes at the levels of histone modifications and DNA methylation 
(Carmona et al., 2014; Ke et al., 2010). The EMT-inducing factors SNAI1 and SNAI2 were also 
shown to be regulated by DNA methylation during EMT (Y. Chen et al., 2013). The reversible 
nature of EMT and MET in cancer indicates therefore that underlying epigenetic mechanisms 
exhibit a certain plasticity or instability, respectively. However, it is currently not known, whether 
and how CRC-related deregulation of epigenetic mechanisms, which is particularly 
pronounced in cancers from the CIMP/MSI type, is involved in the generation of the implicated 
epigenetic plasticity. 
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3 Aims of the Thesis 
 
DNA methylation aberrations are a hallmark of human CRCs. Focal hypermethylation of 
promoter CpG islands results in the transcriptional silencing of tumor suppressor genes, 
whereas the global loss of methylation may trigger chromosomal instability. Although, CRC-
specific methylation changes are well documented (Goel and Boland, 2012), the underlying 
molecular mechanisms are poorly understood.  
The first aim of my PhD thesis was to elucidate causes of aberrant hypermethylation in 
CRC.  
Towards this aim, I first investigated the effect of aging on the accumulation of methylation 
aberrations associated with CRC. To this end, I – in collaboration with others determined DNA 
methylation changes in the aging colon in a cohort of 546 healthy women by analyzing target-
wise and genome-scale CpG methylation (Appendix II). 
In a second project, I addressed the molecular basis of the CpG island methylator phenotype 
(CIMP) in CRC. Together with colleagues, I identified DNA methylation-regulating enzymes 
which are transcriptionally deregulated in CRC-CIMP, and investigated the effect of their 
deregulation on genome-wide CGI methylation and the cell phenotype (Appendix I). 
 
DNA methylation modulates the accessibility of DNA for transcription, recombination and, 
presumably, replication. Accordingly, methylation aberrations in cancer contribute to 
cancerous transformation in different ways. Although, a multitude of methylation alterations 
and their function in colorectal carcinogenesis have been described, many aspects of CRC-
related aberrant methylation remain undiscovered (Goel and Boland, 2012).  
The second aim of my PhD thesis was to explore consequences of aberrant methylation 
in CRC.  
Towards this aim, I investigated the role of aberrant methylation in the formation of numerical 
chromosomal aberrations during tumor development. In this pilot approach, I in collaboration 
with colleagues from different laboratories, characterized and correlated chromosomal 
breakpoint patterns and genome-wide DNA methylation patterns in a model system for 
secondary tumor formation (Supplementary Results 4.5.1).  
In a second collaborative project, I addressed the role of aberrant methylation in 
downregulation of the tumor suppressor SHOCA-2. To this end, I analyzed DNA methylation 
in the promoter CGI of SHOCA-2 and investigated the mechanisms by which DNA methylation 
regulates SHOCA-2 expression (Appendix III).  
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4 Results 
 
The following section summarizes the results presented in the manuscripts provided in the 
appendix as well as supplementary results not included in the manuscripts. 
 
4.1 Loss of TET1 explains a CpG island methylator phenotype and altered cell 
plasticity in a subset of colorectal cancers (Appendix I) 
 
The CIMP pathway of colorectal carcinogenesis is characterized by extensive 
hypermethylation of promoter-associated CGIs. Although, CRC-CIMP has been associated 
with overexpression of DNMT1 and DNMT3B, a direct link between overabundant DNA 
methyltransferase activity and CGI hypermethylation has not been established and the 
molecular basis of the aberrant methylation remains elusive (Kanai et al., 2001; Nosho et al., 
2009). Recent studies showed that the glioma- and paraganglioma-associated competitive 
inhibition of α-KG-dependent dioxygenases, which include the TET family of DNA 
dioxygenases, is sufficient to generate hypermethylation phenotypes in cell culture in vitro 
(Letouze et al., 2013; Turcan et al., 2012). These studies therefore suggest a plausible 
scenario whereby impaired TET-mediated DNA demethylation is involved in the development 
of hypermethylated tumors. To elucidate the role of impaired DNA demethylation in CRC-CIMP 
we analyzed mRNA expression levels of the three TET family members, TET1, TET2 and 
TET3 in CIMP and non-CIMP CRC cell lines. We found that TET1 is significantly 
downregulated in CIMP cell lines compared to non-CIMP cell lines (Appendix I, Figure 1a-c). 
Reduced TET1 expression coincides with reduced hydroxymethylation in the promoter CGIs 
of several CIMP marker genes, already indicating that TET proteins are involved in methylation 
regulation of these loci (Appendix I, Figure 1d). To test the association between CRC-CIMP 
and TET1 loss in primary human CRCs, we analyzed mRNA expression of TET1-3 in a series 
of 23 CIMP and non-CIMP cancers as well as in 143 primary colon cancers for which TET1 
expression data and genome-wide methylation data were available from the The Cancer 
Genome Atlas (TCGA) database. In both cancer cohorts, TET1 expression was significantly 
downregulated in CIMP-associated cancers compared to non-CIMP cancers (Appendix I, 
Figure 2a and 2b). Remarkably, we observed that the loss of TET1 is frequently associated 
with hypermethylation of its own promoter region. Treatment of the CIMP cell line SW48 with 
the demethylating agent 5-Aza-cytidine then indeed confirmed that TET1 promoter methylation 
causes its transcriptional repression and hence that TET1 loss in CIMP can be explained by 
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epigenetic silencing (Appendix Figure 2c and 2d). This raised the question whether TET1 
downregulation is cause or consequence of genome-wide hypermethylation in CIMP cancers. 
To address this question, we performed a sh-RNA mediated knockdown of TET1 in the non-
CIMP cell line SW620 (TET1-kd) and analyzed the genome-wide CGI methylation patterns in 
two most efficient TET1-kd clones using the Illumina Infinium human methylation (HM) 450 
platform. In these clones TET1 depletion resulted in hyper- and hypomethylation of CGI-
associated CpG sites (Appendix I, Supplementary Figure 3d). Promoter hypermethylation was 
observed in MLH1 and targets included in the CIMP five-marker panel (Weisenberger et al., 
2006). Increased levels of MLH1 promoter methylation were accompanied by reduction of its 
mRNA expression (Appendix I, Supplementary Figure 4a-c). Eventually, individual CpG sites 
in the TET1 promoter also became hypermethylated upon TET1-kd demonstrating that TET1 
promoter methylation can result from its transcriptional repression (Appendix I, Figure 3d). We 
then wondered how altered methylation pattern in TET1-kd cells would further evolve in the 
course of tumor formation. To address this question, we engrafted cells from the two TET1-kd 
clones subcutaneously into immunosuppressed mice (NOD/SCID) and analyzed CGI 
methylation at genome-scale (HM 450) in the emerged tumors. Xenograft methylation patterns 
from both TET1-kd clones showed a significant shift towards hypermethylation compared to 
the engrafted cells (Appendix I, Figure 3c).  
Tet1 expression has been shown to be critical for embryonic stem cell identity in mouse 
(Freudenberg et al., 2012; Ito et al., 2010). To address the role of TET1 in stem cell phenotype 
in CRC cells, we investigated the expression of LGR5, which has been previously identified as 
a marker of CRC-TICs but also of normal epithelial stem cells of the colon (Dame et al., 2014; 
Forster et al., 2014; Hirsch et al., 2014). TET1-kd cells showed significantly reduced TET1 
expression and the respective xenografts reduced numbers of LGR5 expressing cells in 
flowcytometric analyses when compared to the relevant controls. Similarly, the number of cells 
expressing CD44 and CD166, two additional putative markers for CRC-TICs was also reduced 
in TET1-kd xenografts (Appendix I, Figure 4).  
Cancer cell lines and primary tumors represent a heterogeneous cell population regarding the 
degree of differentiation. They contain cells which appear fully differentiated and cells 
exhibiting stem cell character. It has been previously shown that these cell states are inter-
convertible in cell lines (P. B. Gupta et al., 2011). Since, such a cell state plasticity corresponds 
to and requires epigenetic plasticity we wondered how TET1 depletion would affect the 
behavior of cancer cell populations. We found that populations of TET1-kd cells have an 
altered cell composition regarding the expression of the two putative CRC-TIC markers CD24 
and CD44 (Appendix I, Figure 5a). This composition was either shifted to the CD24/CD44 
double positive state or the CD24/CD44 double negative state. We then isolated CD24/CD44 
double-positive and CD24/CD44 double-negative cell subpopulations from TET1-kd and 
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control cells and expanded them in culture. We found that sorted TET1-kd cells remained in 
their cell state whereas control cells re-established the original cellular heterogeneity 
(Appendix I, Figure 5b). We concluded that TET1 depletion results in a reduced DNA 
methylation plasticity and TET1 depleted cells are locked in the cell state at the time of TET1 
depletion. 
Analysis of mRNA expression data from TCGA revealed that CIMP-CRCs feature a significant 
loss of the epithelial cell marker E-cadherin (Appendix I, Figure 6c). We wondered whether the 
loss of E-cadherin in CIMP cancers can be attributed to TET1 depletion and the ensuing 
methylation aberrations. We found that E-cadherin is downregulated also in TET1-kd cells and 
that this is indeed associated with increased promoter methylation (Appendix I, Figure 6b). In 
addition, TET1-kd cells showed elevated expression of the mesenchymal markers fibronectin 
and vimentin, and acquired a migratory cell behavior (Appendix I, Figure 6d and 6e). Therefore, 
the loss of E-cadherin, associated with hypermethylation of its promoter generates a 
mesenchymal cell behavior, a process which resembles an epithelial-to-mesenchymal (EMT) 
in some aspects. 
 
In conclusion, we show that the CIMP pathway of colorectal carcinogenesis is characterized 
by the loss of TET1 expression. Further, we show that TET1 depletion results in genome-wide 
methylation aberrations which are associated with the acquisition of CRC-CIMP-specific 
features, including the transcriptional repression of MLH1 and E-cadherin. Whereas TET1-
depleted cells showed both, CpG hyper- and hypomethylation, mouse xenograft tumors 
derived from these cells displayed a significant shift towards hypermethylation, suggesting that 
the selection associated with tumor formation shapes cancer specific CpG hypermethylation 
patterns. Furthermore, our results show that the loss of TET1 expression results in a decreased 
cell plasticity, most likely due to the loss of an essential pathway providing DNA methylation 
dynamics and, hence, epigenetic plasticity. Eventually, we showed that TET1 depletion is 
associated with a loss of epithelial cell character and the acquisition of mesenchymal cell 
features, resembling an EMT. This has potential clinical implications. 
 
Contribution: I characterized CRC cell lines as well as the tester set of primary CRCs 
regarding their CIMP status by analyzing the methylation status of the five marker panel. I 
further investigated mRNA and protein expression levels of TETs, DNMTs and TDG in CRC 
cell lines and in the tester set of primary CRCs. Moreover, I established and validated the sh-
RNA mediated knockdown of TET1 in the SW620 cell line. In TET1 knockdown cells I 
performed all methylation analysis (except for the pre-processing of Illumina Infinium HM 450 
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data) and hydroxymethylation analysis by 5hmC dot blot and I analyzed mRNA or protein 
expression of TET1, TET2, TET3, FN1, VIM and MLH1. I initiated and coordinated 
collaborations with colleagues from different laboratories. Eventually, I designed and wrote the 
manuscript provided in Appendix I. 
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4.2 Modulation of Age- and Cancer-Associated DNA Methylation Change in 
Healthy Colon by Aspirin and Lifestyle (Appendix II) 
 
DNA methylation patterns change over age (methylation drift) in various human tissues 
including the colonic mucosa (Issa, 2014). Age-related de novo methylation arises also in 
promoter CGIs of cancer-relevant genes like MLH1 and MGMT (Menigatti et al., 2009). We 
addressed the question to what extend epidemiologically implicated, lifestyle-related CRC-risk 
factors, like smoking and overweight, but also protective factors, including hormone 
replacement therapy (HRT) and aspirin use, influence the methylation drift of these two genes 
(Chan et al., 2007; Long et al., 2010; Parajuli et al., 2013; Robsahm et al., 2013). Using the 
very sensitive locus-normalized quantitative methylation specific PCR method (ln-qMSP) we 
quantified methylation levels of the promoter-associated CGIs of MLH1 and MGMT in a total 
of 1092 biopsies obtained from the cecum (proximal, right colon) and the sigmoid (distal, left) 
colon of 546 healthy women. Multivariable regression analysis showed that MLH1 promoter 
methylation increases significantly with age in the proximal colon (Appendix II, Figure 1A). 
MGMT promoter methylation levels were not significantly age-related unless lifestyle factors 
were taken into account: Long-term aspirin use, defined as two or more tablets per week for 
more than 2 years, significantly lowered the methylation rate of MGMT (Appendix II, Figure 
1B). Log-term aspirin use also reduced the risk of developing serrated polyps (hyperplastic 
polyps and sessile serrated adenomas) and consistently, women with no polyps had a 
significantly lower rate of MGMT methylation compared to women with serrated polyps 
(Appendix II Figure 1C and 1D). In contrast to the protective effect of aspirin, long-term 
smoking, defined as 1 or more cigarettes per day for more than 20 years increased the risk of 
serrated polyps (Appendix II Figure 1D).  
To extend our investigation to a genome-wide level we further analyzed DNA methylation in 
178 normal colon samples from our cohort, using the Illumina Infinium human methylation (HM) 
27 platform. We analyzed methylation of 20,025 promoter-associated CpG sites with 
multivariable regression adjusted for colonic location, smoking, aspirin use and also for 
received HRT and the body mass index (BMI). We found that methylation of promoter-
associated CpG sites mainly increases over age (1713 CpGs gaining and 343 CpGs loosing 
methylation). Further, we found that age-related methylation changes are predominantly 
associated with the distal part of the colon (Appendix II, Figure 2A). Regarding the lifestyle 
factors, HRT and aspirin use reduced the number of age-dependent differentially methylated 
CpG sites. However, a high BMI (>30) promoted an age-related hypermethylation (Appendix 
II, Figure 2B). Smoking promoted age-related hypermethylation in proximal colon but 
suppressed age-dependent methylation changes in the distal colon (Appendix II, 
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Supplementary Figure 2A and 2B). Next, we investigated the rate of age-dependent 
hypermethylation regarding the colonic location and lifestyle factors. The rate of methylation 
changes was significantly higher in the distal colon compared to the proximal colon but it was 
significantly lower in long-term aspirin users (compared to non-users) and women who 
reported HRT (compared to no-HRT) (Appendix II, Figure 2C and D). Long-term smoking was 
associated with an increased rate of hypermethylation in the proximal colon but a decreased 
rate in the distal colon (Appendix II, Supplementary Figure 2A and B).  
It has been shown previously, that sites of age-dependent methylation changes in blood are 
associated with the H3K27 trimethylation (H3K27me3) mark estabilished by polycomb-group 
proteins (PcG) during embryonic development (Rakyan et al., 2010). We wondered whether 
sites of age-related methylation changes in the colon are also associated with polycomb 
targets and classified HM27 CpG sites according to coincidence of H3K27me3 in human 
embryonic stem cells (GSE13084; (Ku et al., 2008). Regions (500bp) around age-dependent 
hypermethylated CpG sites were significantly enriched for H3K27me3 compared to total 
H3K27me3-marked CpG on the HM27 array. In addition, the rate of hypermethylation at 
H3K27me3-associated CpG sites was significantly higher compared to the median rate of 
hypermethylation. Aspirin use suppressed the hypermethylation of PcG target regions, 
whereas long-term smoking and a high BMI promoted methylation of these sites (Appendix II, 
Figure 2F).  
To address the cancer relevance of the age-related and lifestyle-modulated methylation 
changes in the healthy colon, we compared genome-wide methylation data of 59 primary 
CRCs (female patients) with those from our healthy colonic mucosa samples (Hinoue et al., 
2012). Half of the CpG sites hypermethylated in cancer samples showed age-dependent 
hypermethylation. These sites were enriched for H3K27me3 compared to sites only age-
dependent or only cancer-related. In addition, CpG sites methylated also in cancer displayed 
a higher rate of age-related methylation change than sites showing age-dependent methylation 
change only (Appendix II, Figure 3B). We used gene expression data available for colonic 
adenomas (GSE8671; (Sabates-Bellver et al., 2007) and found a significant overlap between 
CpG sites associated with age-dependent hypermethylation and transcriptional repression of 
the corresponding genes in adenomas (Appendix II, Figure 3C). Cancer-relevant methylation 
changes in the normal colonic mucosa were influenced by lifestyle factors. A statistically 
significant fraction of promoters showing either aspirin- or HRT-suppressed methylation or high 
BMI- or smoking-promoted methylation in the aging colon coincided with CpG sites 
hypermethylated in CRC (Appendix II, Figure 4A). These included several genes with 
established roles in carcinogenesis like CDKN2A and CDH1. In this context, we further 
investigated the effect of lifestyle factors on the age-dependent methylation of CpG sites 
located in the promoter regions of 664 annotated tumor-associated genes (J. S. Chen et al., 
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2013). The rate of methylation change at these loci was significantly reduced in long-term 
aspirin users compared to non-users and women reporting HRT compared to no-HRT but 
increased in women with high BMI vs normal BMI and long-term smokers vs non-smokers 
(Appendix II, Figure 4B).  
In conclusion, we were able to show that lifestyle factors which have been reported as 
modulators of CRC risk have genome-wide influence on DNA methylation stability in the 
colonic mucosa. Age-associated gene promoter methylation increase was suppressed by HRT 
and regular long-term aspirin use but was promoted by long-term smoking and obesity, which 
is concordant with the effects of these factors on CRC risk (Appendix II, Figure 4C). Together 
with the finding that a significant fraction of targets of age- and cancer-related hypermethylation 
coincided, our results provide a functional link between age-related hypermethylation, CRC 
and lifestyle-related CRC risk factors.  
 
Contribution: I established the methods for quantitation of MGMT promoter methylation by 
ln-qMSP. Further, I analysed MGMT promoter methylation in the genomic DNA from 510 
healthy colonic mucosa samples. 
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4.3 The 8p21.3 encoded SHOCA-2 acts as a tumor suppressor in colorectal 
cancer via repression of STAT3 activation (Appendix III) 
 
Allelic loss in short arm of chromosome 8 (8p) is a frequent chromosomal abnormality in CRC 
and linked to chromosome breakage at fragile sites located at 8p12 and 8p22 (Chughtai et al., 
1999; Emi et al., 1992). However, a tumor suppressor gene at this locus has not been 
identified. We found, that the SH2D4A gene which encodes for a SH2-domain containing 
protein named SHOCA-2 (SH2-domain containing adaptor protein), maps to human 
chromosome 8p21.3. SH2D4A was originally identified as a paralogue to SH2D4B (encoding 
SHOCA-1) which is differentially expressed during maturation of epithelial cells in the embryo. 
Both genes are evolutionary conserved and their gene products display a 65% amino acid 
sequence identity (Appendix III, Figure 1A), neither of them has been functionally 
characterized. We analysed SHOCA-2 expression in 400 sporadic CRCs by 
immunohistochemistry and found significant differences in detectable SHOCA-2, correlating 
with clinical tumor stage (I-IV). SHOCA-2 expression was reduced in advanced CRC stages 
(Appendix III, Figure 1B and 1C). Patients with low or absent SHOCA-2 had a significantly 
poorer clinical outcome compared to patients with the highest measured SHOCA-2 expression 
(Appendix III, Figure 1D). We found that SHOCA-1 mRNA expression is concurrently lost in 
half of the samples showing low or no SHOCA-2 expression (Appendix III, Figure S1F).  
To determine the molecular basis of SHOCA-2 loss we selected 27 CRCs from a cohort of 70 
CRC patients, in which SH2D4A alleles could be distinguished by 3 microsatellite markers and 
6 gene specific single nucleotide polymorphisms (SNPs). 17 of these primary tumors had lost 
or diminished SHOCA-2 expression. We detected LOH of SH2D4A in 7 of the 17 tumors. Gene 
dosage quantification of chromosome 8p indicated mono- and biallelic loss in 6 and 1 of the 
LOH tumors, respectively (Appendix III, Figure 2A). In the matched healthy mucosa, 4 of the 6 
patients with a monoallelic loss of SH2D4A were heterozygous for an intronic SNP 
(rs17128221, c.342-5T>C) existing in a T (wildtype) or C allele. The C mutated allele leads to 
exon 4 skipping causing a frame shift mutation and premature translation termination in exon 
5 (Appendix III, Figure 2B). The corresponding cancer samples of heterozygote patients 
uniformly demonstrated the selective loss of the T allele whereas homozygosity for the C allele 
was never observed in 83 normal mucosa samples. In 3 of the 10 primary tumors in which loss 
of SH2D4A expression was not associated with LOH we found missense mutations and 
deletions. These alterations either produced amino acid changes or frame shift mutations 
(Appendix III, Figure 2C). To further elucidate the causes for SH2D4A loss in CRC we 
investigated the promoter methylation status of SH2D4A by pyrosequencing of bisulfite 
converted genomic DNA. Two neighboring CpG sites, located downstream of the transcription 
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start site, were hypermethylated compared to the matched healthy mucosa in 4 patients with 
SH2D4A loss, that did not show LOH or mutations (Appendix III, Figure 2D). One of these CpG 
sites coincided with a canonical Sp1 transcription factor binding motif and its methylation 
significantly reduced Sp1 affinity (Appendix III, Figure S2B). Hence, we found that distinct 
genetic but also epigenetic abnormalities contribute the loss of SH2D4A expression in CRC. 
The function of SHOCA-2 was uncharacterized so far. A proteomic study of EGFR-driven 
phosphor-tyrosine signaling in lung cancer cells identified a target peptide with sequence 
homology to SHOCA-2 (A. Guo et al., 2008). We confirmed that EGFR activation triggers 
tyrosine phosphorylation of SHOCA-2 in HeLa cells (Appendix III, Figure 3A). EGF stimulation 
of HeLa cells overexpressing SHOCA-2 decreased phosphorylation of the transducer and 
activator of transcription 3 (STAT3) at tyrosine (Tyr) 705. Two other EGFR signal transition 
pathways, PI3K/Akt and MAPK/ERK were activated or unaffected, respectively, in response to 
SHOCA-2 overexpression (Appendix III, Figure S3A). To further investigate the function of 
SHOCA-2 in EGFR signaling we performed a sh-RNA mediated knockdown (kd) of SHOCA-2 
in HeLa cells which reduced SHOCA-2 levels by 90%. When stimulating kd-cells with EGF, 
STAT3 Tyr 705 phosphorylation was increased compared to control cells (Appendix III, Figure 
3C). In contrast, phosphorylation of Akt was decreased while that of ERK1/2 was unchanged 
(Appendix III, Figure S3C). These results suggest an involvement of SHOCA-2 in the regulation 
of STAT3-mediated EGFR-signaling. To prove this hypothesis, we used a STAT3-driven 
reporter construct in SHOCA-2 overexpressing and SHOCA-2-kd HeLa cells. EGF treatment 
in overexpressing cells reduced reporter expression, however, in kd-cells it resulted in a robust 
transcriptional activity (Appendix III, Figure 3D). Using immunoprecipitation assays we found 
that SHOCA-2 binds to EGFR as well as STAT3 independent of its SH2 domain (Appendix III, 
Figure 3E and Figure S3F). These results suggest that SHOCA-2 functions as an inhibitor of 
EGF-induced STAT3 activation. 
Using tandem affinity purification (TAP) we identified the serine/threonine protein 
phosphatase-1 beta (PP1β) as an additional interaction partner of SHOCA-1 and SHOCA-2 
(Appendix III, Figure 4A). The interaction between SHOCA-2, STAT3 and PP1β increased 
upon EGF treatment in HeLa cells (Appendix III, Figure 4D). We wondered whether the EGFR-
mediated phosphorylation of SHOCA-2 is important for the formation of the SHOCA-
2/EGFR/STAT3/PP1β complex and mutated the SHOCA-2 phosphorylation site (Tyr 131). 
Although, the point mutation (Y131A) did not disturb the ability to interact with EGFR, STAT3 
and PP1β, it resulted in a constitutive phosphorylation of other SHOCA-2 tyrosine residues 
and in the abolishment of SHOCA-2-mediated inhibition of STAT3 phosphorylation (Appendix 
III, Figure S4H and S4I). These results show that the STAT3-inhibitory function of SHOCA-2 
depends on its phosphorylation by EGFR. In addition, it depends on the association of SHOCA-
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2 with PP1β as mutation of the PP1β-binding motif in SHOCA-2 abolishes its ability to inhibit 
STAT3 activation upon EGF stimulation (Appendix III, Figure 4E).  
To address the contribution of SHOCA-2 to the regulation of cell proliferation we assessed the 
expression of STAT3-controlled genes in SHOCA-2-kd HeLa cells. Upon stimulation with EGF, 
protein expression of c-Myc, Cyclin D1 and Jun B was increased in SHOCA-2-kd cells 
compared to control cells. Consistently, the fraction of cells in G2/M stage of the cell cycle was 
significantly higher in EGF-stimulated and unstimulated SHOCA-2-kd cells (Appendix III, 
Figure 5A). Increased cell proliferation marked by Ki-67 inversely correlated with SHOCA-2 
expression also in tissue sections from primary CRCs (Appendix III, Figure 5B). To address 
whether the inhibition of STAT3 signaling by SHOCA-2 is responsible for the increased cell 
proliferation in kd-cells we overexpressed STAT3 in the CRC cell line SW480 and co-
expressed either wildtype or mutant SHOCA-2. Overexpression of STAT3 resulted in an 
increased potential of colony formation coinciding with high levels of STAT3 phosphorylation. 
Co-transfection with wildtype SHOCA-2 significantly reduced the colony forming potential of 
SW480 cells as well as STAT3 phosphorylation. This growth suppressive effect was less 
pronounced when cells were co-transfected with either the SHOCA-2 Y131A (phosphorylation 
site) mutant or the PP1β-binding site mutated form of SHOCA-2 (Appendix III, Figure 5C and 
5D). Furthermore, SHOCA-2 overexpression in the CRC cell line SW620 in which STAT3 is 
constitutively phosphorylated suppressed cell growth (Appendix III, Figure 5 E).  
Further, we found that the sh-RNA-mediated knockdown of SHOCA-2 in SW480 cells changes 
the cell shape towards a spindle-like appearance. This was accompanied by the loss of E-
cadherin expression and the increased expression of mesenchymal markers including N-
cadherin, vimentin, ZEB-1 and SNAI1; features characteristic for an epithelial-to-mesenchymal 
transition (EMT) (Appendix III, Figure 6A and 6B). 
To investigate the potential tumor-suppressive role of SHOCA-2 in vivo we engrafted SW480 
cells and SW480 SHOCA-2-kd cells into nude mice. The tumor forming potential of SHOCA-
2-depleted cells was higher compared to normal SW480 cell, in terms of tumor incidence as 
well as tumor growth rate (Appendix III, Figure 6 E). In addition, higher levels of phosphorylated 
nuclear STAT3 were detected in tumors derived from SHOCA-2-kd cells.  
In conclusion, our results establish SHOCA-2 as a tumor suppressor due to the inhibition of 
STAT3-mediated EGFR signaling which impedes apoptosis and promotes cell proliferation. 
Inactivation of SHOCA-2 in colorectal cancers included genetic (chromosomal aberrations and 
mutations) and epigenetic mechanisms. Further, our data indicate that the tumor-suppressive 
role of SHOCA-2 takes effect primarily during cancer progression (advanced cancer stages) 
as the loss of SHOCA-2 is particularly pronounced at later cancer stages and induces EMT 
which is essential for metastasis formation. Eventually, SH2D4A represents the first identified 
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tumor suppressor located within chromosome 8p21-23, the deletion of which constitutes a 
characteristic of CRCs but its contribution to CRC development has remained unclear until 
now. 
 
Contribution: I quantified mRNA expression levels of SHOCA-1 in cancer-associated 
matched mucosa samples as well as in primary CRCs using qRT-PCR. Furthermore, I 
quantified SH2D4A promoter methylation levels by pyrosequencing of bisulfite converted 
genomic DNA. This included the assay design as well as data analysis. In addition, I 
determined the affinity of the Sp1 transcription factor to the methylated and unmethylated 
SH2D4A-associated Sp1 binding site using an electrophoretic mobility shift assay. This 
included the assay design, execution and data analysis. 
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4.4 Colorectal mucosa of healthy individuals displays part of the CpG island 
methylator phenotype signature (Appendix IV) 
 
Aberrant promoter hypermethylation is a hallmark of human CRCs and is particularly 
pronounced in cancers of the CIMP oncogenic pathway. However, little is known about the 
precise timing of CIMP during tumor development. We had previously shown that promoter 
methylation of MLH1, which is associated with CIMP, can be detected at low levels in colonic 
mucosa from healthy individuals (Menigatti et al., 2009). This observation suggested that CIMP 
cancer-related methylation signatures are partially reflected in the healthy colon. To further 
investigate the extent of cancer-specific methylation in normal colonic tissues, we identified 
gene promoters affected by aberrant DNA methylation early in colorectal carcinogenesis. To 
this end, we explored gene expression data from adenomas and matched normal mucosa 
samples (GSE8671, (Sabates-Bellver et al., 2007)) and selected five gene candidates, 
showing reduced mRNA expression compared to normal mucosa and harboring a promoter 
CpG island; Forkhead box F1 (FOXF1), Carbonic anhydrase IV (CA4), Neuropeptide Y 
receptor Y1 (NPY1R), Gremlin 1 (GREM1) and Interferon-induced transmembrane protein 1 
(IFITM1). We quantified promoter methylation levels of these genes as well as MLH1 and 
MGMT in genomic DNA of matched primary colorectal cancer tissue (CRC), CRC-associated 
normal mucosa (CAM) and blood samples from 106 unselected patients, using a highly 
sensitive, locus-normalized methylation-specific quantitative PCR assay (ln-qMSP). By 
comparing methylation levels in these three different tissues, we established a methylation 
threshold for each target gene, allowing us to discriminate CRC from CAM with ≥ 99% 
specificity. These thresholds ranged from 4% (FOXF1) to 7% (IFITM1). Tumor samples 
showing methylation levels above the threshold were classified as hypermethylated. (Appendix 
IV, Figure 1A). FOXF1 represented the most frequently hypermethylated target gene (66% of 
all cancer samples), whereas GREM1 was only hypermethylated in 13% of the cancer 
samples. When applying the criterion that at least one of the target genes must be 
hypermethylated, our seven-marker panel separated CRC from CAM in 82% of the patients 
(87/106) with a specificity of 99%. The coverage reached 94% (30/32) when the panel was 
applied to CRCs located at the proximal (right) colon (Appendix IV, Figure 1B and 1C). 
Treatment of CRC cell lines, in which the seven marker panel was highly methylated and 
transcriptional repressed, with the demethylating agent 5-Aza-Cytidine and/or the histone 
deacetylase inhibitor Trichostatin A partially restored mRNA expression of the genes and 
showed that promoter methylation of the genes is directly involved in their transcription 
regulation (Appendix IV, Supplementary Figure 3). We correlated the methylation patterns of 
our seven-marker panel with clinical features including gender, tumor location, and cancer 
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stage. Tumors hypermethylated in IFITM1 occurred more frequently in men whereas FOXF1, 
MGMT, NPY1R, GREM1, and MLH1 were more frequently hypermethylated in women. All 
markers, except IFITM1, were more frequently hypermethylated in proximal than in distal (left) 
CRCs. Further, MGMT was found hypermethylated more frequently at advanced cancer 
stages (Appendix IV, Figure 1B and 2A and Supplementary Figure 4A and 4B).  
To address whether methylation of our seven-marker panel is associated with an overall 
methylator phenotype as proposed for CIMP, we correlated the methylation status of all 
markers in 106 CRCs. We observed concomitant hypermethylation of CA4, NPY1R and 
GREM1 with the CIMP associated marker MLH1 (Appendix IV, Figure 2B and 3C). To 
ascertain the possible association of CA4, NPY1R and GREM1 hypermethylation with CIMP, 
we analyzed genome methylation patterns of 3 CIMP and 4 non-CIMP (classified according to 
the BRAF V600E mutation status) CRCs as well as 8 healthy colonic biopsies (HM) and 1 
blood sample using the Illumina Infinium human methylation 27 platform. Methylation levels of 
CA4, GREM1 and MLH1 were significantly higher in CIMP-associated CRCs compared to non-
CIMP cancers. For NPY1R this trend did not reach statistical significance (Appendix IV, Figure 
4). Hence, our results suggest that GREM1 and CA4 represent novel markers for CRC-CIMP. 
All CRCs hypermethylated for CA4, GREM1, MLH1 but also NPY1R located to the proximal 
colon coinciding with the high incidence of CIMP cancers in this colonic region (Appendix IV, 
Figure 2A).  
Finally, we asked whether methylation of our seven-marker panel is detectable in healthy 
colonic mucosa as it has already been reported for MLH1 (Menigatti et al., 2009). Therefore, 
we quantified their methylation levels in 106 CAM samples and in tissue samples from 32 
healthy subjects (HM). We found concomitant low-level (below cancer-specific thresholds) 
methylation of CA4, NPY1R and GREM1 in CAM and HM samples (Appendix IV, Figure 3A 
and 3B). Genome-wide methylation data from 8 HM samples substantiated this observation 
(Appendix IV, Figure 4). Hence, in addition to MLH1, also for the novel CIMP markers CA4 and 
GREM1 low levels of methylation are detectable in healthy colonic mucosa. 
In conclusion, our data show that CRC-specific methylation aberrations occur in a cancer 
stage, gender and tumor location specific manner, suggesting different roles in colorectal 
carcinogenesis. A subset (CA4, GREM1 and NPY1R) of investigated methylation target genes 
displayed association with CRC-CIMP and, as previously reported for the CIMP marker MLH1, 
showed low levels of methylation in healthy colonic mucosa. These observations suggest that 
CIMP arises very early in colorectal carcinogenesis and then progress throughout tumor 
development. The extended CIMP marker panel represents a potential diagnostic tool for 
cancer-risk assessment with 99% specificity and a sensitivity of 83% (94% for proximal CRCs). 
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Contribution: I quantified promoter methylation of CA4, NPY1R and IFITM1 in 106 CRC 
samples, 106 CAM samples as well as in 32 healthy mucosa samples using ln-qMSP. Further, 
I quantified promoter methylation of CA4, NPY1R and IFITM1 as well as the mRNA expression 
levels in 5-Aza-cytidine and Trichostatin A-treated CRC cell lines CO115 and SW48. 
Eventually, I analyzed promoter methylation of FOXF1, GREM1, CA4, NPY1R and IFITM1 by 
sequencing of bisulfite-converted genomic DNA from two CRCs each, using a TA-cloning 
approach. My contribution included design and execution of experiments such as qPCR, 
cloning, DNA sequencing and data analysis.  
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4.5 Supplementary Results 
 
4.5.1 Association of Chromosomal and Epigenetic Alterations During Tumor 
Development 
 
Chromosomal instability (CIN) constitutes a frequent form of genetic instability in CRC and is 
present in 65%-70% of sporadic CRCs. CIN is characterized by structural and numerical 
(aneuploidy) chromosome alterations and is therefore a major source of gains or losses of 
genetic information, including Loss of Heterozygosity (LOH). Interestingly, somatic DNA Copy 
number alterations (SCNAs) in CRC-CIN preferentially affect a certain genomic loci. Large 
(chromosome-arm level) amplifications are mainly found at 7p and q, 8q, 13q and 20q whereas 
arm-level deletions primarily affect 1p, 5q, 8p, 15q, 17p, 18p and q (Al-Sohaily et al., 2012; 
Cancer Genome Atlas, 2012). Sites of chromosomal breakage and rearrangements, also 
referred to as fragile sites, are often capable to obstruct DNA polymerase progression during 
replication due to the formation of secondary structures. Stalled replication forks represent a 
potential source of DNA double strand breaks (DSBs), which are believed to give rise to 
chromosomal rearrangements (Zeman and Cimprich, 2014). Guanine-rich G4 sequences can 
form intramolecular four-stranded structures (G4 quadruplexes) that interfere with DNA 
polymerase movement, and the formation of which is negatively affected by CpG methylation. 
It has been shown that G4 sequences associated with chromosomal breakpoints are cancer-
specifically hypomethylated in colorectal cancer (De and Michor, 2011). This observation 
suggests a mechanistic relationship between epigenetic aberrations and the emergence of 
chromosomal instability. It was reported that patterns of SCNAs change during metastasis 
formation in colorectal cancer and we wondered whether these changes are triggered or 
accompanied by epigenetic alterations (Xie et al., 2014).  
To address this question we used mouse xenograft tumors derived from stem cell-like tumor-
initiating cells (TICs) as a model for secondary tumor formation. We investigated genome-wide 
patterns of SCNAs and DNA methylation in 5 pairs of TICs and xenografts. TIC cell lines were 
established from primary colorectal tumor tissues on the basis of their self-renewal capacity 
and expression of the putative stem cell markers CD133 and LGR5. These cells were shown 
to have potential to differentiate and to be tumorigenic in immunosuppressed mice (Ricci-
Vitiani et al., 2007). Samples of TICs and xenograft tissues, which were generated by 
subcutaneous inoculation of TICs into SCID mice, were kindly provided by Lucia Ricci-Vitiani 
from the Istituto Superiore di Sanità in Rome, Italy. Clinical characteristics of the cancer 
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patients and the molecular features of TICs (analyszed in the lab of Ricci-Vitiani) are given in 
Table 4-1. 
Genome-wide SCNA-patterns in TICs and xenografts were analyzed in collaboration with 
Tobias Heckel at Roche, Basel, Switzerland, using a comparative genome hybridization (CGH) 
microarray from NimbleGen in the 2.1M format. Two human ES cell lines and a healthy 
peripheral blood sample served as normal controls. Using the segMNT algorithm with the 
conservative criteria of a +/- 0.5 shift in fluorescence signal log2 ratio (sample vs. reference), 
we identified high confidence SCNA-segments. TIC2, TIC4 and TIC5 showed a high number 
of SCNAs, spanning entire chromosomes and chromosome arms. TIC1 and TIC3 displayed a 
lower level of copy number alterations with segments usually smaller than 50kb (Figure 4-1a 
and 4-1b). Such small numerical aberrations with a size below 100kb commonly present in 
human cells and also observed in our normal controls (Figure 4-1a) (Conrad et al., 2010). 
Several chromosomal aberrations observed were previously described in CRC, including 
deletions of 1p, 8p and 18q and amplifications of 13q and 20q. Hierarchical clustering and 
principal component analysis revealed that SCNA-patterns of TICs and corresponding 
xenografts are highly correlated, except for TIC2. TIC2 showed unstable SCNA-pattern with 
clear changes occurring during xenograft formation (Figure 4-1a and 4-1c). Notably, in the 
TIC2 derived xenograft, short chromosomal aberrations appeared to be merged into or 
superimposed by larger (>5Mb) numerical alterations, affecting chromosome arms and even 
whole chromosomes, e.g. 3p, 14q and chromosome 12 (Figure 4-1a and 4-1d). Similar to the 
TIC2 xenograft also the TIC5 xenograft displayed increased occurrence of very large SCNAs 
(>5Mb) and a concomitant loss of shorter alterations (Figure 4-1a and 4-1d). Xenografts from 
TIC1, TIC3 and TIC4 acquired additional, relatively short copy number alterations shorter than 
50kb (TIC1 and TIC3) and 500kb (TIC4), respectively. According to the extent of SNCAs and 
their stability during xenograft formation, we distinguished three classes of TICs: Chromosomal 
stable (TIC1, TIC3), chromosomal degenerated (TIC4, TIC5) and chromosomal instable 
(TIC2). Chromosomal stable TICs displayed the lowest level of chromosomal aberrations 
which appeared stable during xenograft formation (Figure 4-1b and 4-1d). Chromosmal 
degenerated and chromosomal instable TICs featured a high number of chromosomal 
aberrations which appeared largely stable during xenograft formation in degenerated TICs, but 
changed drastically in instable TIC (Figure 4-1b and 4-1c). 
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Figure 4-1: SCNA profiles of CRC-TICs and derived mouse xenografts. a) Hierarchical clustering of 
SCNA profiles of TICs and xenografts (Xeno). Log2 converted ratios of fluorescence signals from 
samples compared to reference genome is indicated by the color key from purple (deletion) to green 
(amplification). Autosome number is indicated at the bottom. b) Number of numerical aberrations in TICs 
and xenografts (Xeno). Total number of SCNAs, number of copy number losses and number of copy 
number amplifications are depicted. c) Principle component analysis (PCA) of SCNA-profiles in TICs 
and xenografts (Xeno). Corresponding TIC-xenograft pairs are depicted in the same color. Control 
samples are depicted in white color. d) Changes in the number of SCNAs in mouse xenografts (Xeno) 
compared to corresponding TICs, according to the size of aberrations. 
 
Genome-wide DNA methylation profiles of TICs and Xenografts were analyzed using the 
Illumina Infinium human methylation (HM) 450 platform. The CIMP CRC cell line CO115 and 
the non-CIMP cell line SW620 were included in this analysis as references for methylator and 
non-methylator phenotype CRC samples. RPMM-based unsupervised clustering using the 
25% most variably methylated CpG sites (6571 CpG sites) revealed that genome-wide 
methylation patterns of TICs and corresponding xenografts are closely related (Figure 4-2a). 
In contrast to the SCNA patterns, methylation profiles of TIC2 were largely stable during 
xenograft formation. Methylation pattern of TIC3 was closely related to that of the CIMP cell 
line CO115. TIC3 harbors an activating KRAS G12V mutation (Table 4-1), which has been 
shown to be associated with an intermediate methylator phenotype referred to as CIMP-low or 
CIMP-2 (Hinoue et al., 2012). In addition, TIC3 displayed microsatellite instability (MSI; Table 
4-1) associated with CRC-CIMP as well. We analyzed promoter methylation levels of the CIMP 
marker MLH1 and the CIMP-associated marker genes CA4, NPY1R and GREM1 (see chapter 
4.4) using the sensitive ln-qMSP assay. Promoter regions of MLH1, GREM1 and NPY1R were 
highly methylated in TIC3, further indicating that TIC3 derived from a tumor which arose by a 
CIMP-related oncogenic pathway (Figure 4-2b). In accordance with previous studies, showing 
that CIN and CIMP occur mutually exclusive in CRC, TIC3 showed the lowest level of 
chromosomal aberrations (Cheng et al., 2008). Interestingly, TIC3 showed a monoallelic 
amplification of a 3.6 Mb segment in chromosome 7, containing the BRAF gene. Activating 
mutations of BRAF are highly associated with CRC-CIMP. A link between CIMP and the 
amplification of the BRAF locus has not been described but may possible, as indicated by this 
observation.  
To perform an initial analysis into the relationship between DNA methylation and 
chromosomal(in)stability, we examined the correlation between CpG methylation levels and 
the presence of chromosomal breakpoints. To this end, we defined sections of 1kb in size 
(according to the median probe spacing of 1169bp in CGH array) around identified 
chromosome breakpoints (500bp upstream and downstream). Chromosome breakpoints were 
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determined by the segMNT algorithm as endpoints and startpoints of SCNA segments. 
Subsequently, we identified CpG sites in the breakpoint sections that were represented on the 
HM450 array. 9% of the breakpoint-sections in TICs and xenografts did overlay with CpG sites 
represented on the HM 450 array. Breakpoint-associated CpG sites were usually highly 
methylated (medien methylation β-values in TICs and xenografts ranging from 0.63 to 0.84). 
To correlate xenograft-specific changes in the SCNA-profiles with possible changes in CpG 
methylation, we compared methylation β-values of CpG sites located within breakpoint-
sections specific for xenografts to the methylation value of corresponding section in the TICs.  
 
 
 
Figure 4-2: Characterization of TICs and xenografts by genome-wide and target-wise methylation 
analysis. a) Illumina Infinium HumanMethylation450 data of TIC and xenografts. Heat map illustrating 
methylation levels (β-values) of the 25% most variable CpG sites (6571 sites; blue, low methylation; red, 
high methylation). Unsupervised clustering is indicated at the top. b) Methylation analysis of the CIMP 
markers MLH1, GREM1, NPY1R and CA4 in 5 TICs using ln-qMSP. PMA, percentage methylated 
alleles. 
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Xenografts from TIC2 and TIC3 showed a trend of reduced methylation levels at xenograft-
specific breakpoint sections (Figure 4-3). However, this trend did not reach statistical 
significance (xenograft 2: p=0.113; xenograft 3: p=0.233; Wilcoxon matched-pairs test). Other 
TIC/xenograft pairs did not show a correlation between the occurrence of chromosomal 
breakpoints and methylation levels. 
 
 
 
Figure 4-3: Methylation changes of breakpoint-associated CpG during xenograft formation. 
Depicted are the methylation β-values of CpGs in chromosome sections associated with breakpoints 
specific for xenografts (Xeno). Methylation β-values of the corresponding chromosome section in TICs 
(TIC) are also depicted. Box plots indicate the median value and the first and third quartile. Whiskers 
indicate the minimum and maximum values. 
 
In summary, our preliminary analysis of SCNA-profiles in TICs and mouse xenografts derived 
from them, distinguishes cancer cells not only according to the extent of chromosomal 
aberrations but also with regard to the inherent chromosomal instability. TIC2, TIC4 and TIC5 
displayed a high level of numerical chromosomal alterations but only in TIC2 the copy number 
profile was unstable and changed during xenograft formation. This reflects different molecular 
mechanisms and deficiencies associated with the generation of chromosomal aberrations. 
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Further, the currently existing results show that in some TIC/xenograft pairs (TIC2 and TIC3) 
the loss of CpG methylation at breakpoint regions might be associated with emerging 
chromosomal aberrations. However, only for a small fraction of chromosomal breakpoint 
regions were covered by methylation data from the HM450 array and further investigation will 
require a higher density of methylation data (genome-wide bisulfite DNA sequencing) and a 
detailed high resolution analysis of methylation changes between TICs and xenografts. 
Interestingly, the indication for an association between DNA hypomethylation and the 
emergence of chromosome breakage was strongest for TIC2, which displayed the highest 
instability of SCNA patterns during xenograft formation, and for TIC3, which is associated with 
a methylator phenotype.  
 
 
Methods 
 
Colorectal Cancer Initiating Cells 
Established cell lines from colorectal cancer initiating cells (CR-CICs) were kindly provided by 
Lucia Ricci-Vitiani from the Istituto Superiore di Sanità in Rome, Italy. CIC cell lines were 
established as described in (Cammareri et al., 2008). Briefly, surgical specimens were washed 
in PBS and incubated overnight in DMEM/F12 medium containing antibiotica and antimycotica 
at high concentrations. Afterwards, tissues were mechanically and enzymatically disrupted, 
filtered and seeded onto ultra-low adhesion flasks with serumfree DMEM/F12 medium 
containing EGF and FGF. Under these conditions self-renewing stem like cells could be 
continuously cultured whereas differentiated cells progressively died out. The propagating cell 
population had cancer-initiating potential in immunosuppressed mice and showed expression 
of putative colorectal cancer stem cell markers including CD133. Genomic DNA from CR-CICs 
was extracted with the QIAamp DNA mini kit (Qiagen) according to the manufacturer´s 
instructions including the RNase-treatment step.  
 
Mouse Xenografts 
Cancer initiating cells were resuspended in a 1:1 mixture of phosphate-buffered saline and 
growth factor-reduced Matrigel matrix (BD Biosciences) and inoculated subcutaneously into 
the flank of recipient mice. After 8-10 weeks mice were sacrificed, tumors were removed and 
genomic DNA was extracted as described for CR-CICs. 
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Copy Number Variation Analysis  
Genomic DNA from CICs, xenograft tissues, two human embryonic stem cell lines (SA001 and 
SA167) and a normal human colonic epithelium specimen (HT2010) was isolated as described 
above. DNA quality and fragmentation assessment was performed using 50 ng of genomic 
DNA loaded onto a microfluidic Agilent DNA 12000 chip in combination with an Agilent 2100 
bioanalyzer. 0.5 μg of DNA samples were labeled with random-nonamer Cy3 primer and 
Promega reference DNA samples (Blood DNA, Promega) were labeled with random-nonamer 
Cy5 primer using isothermal PCR according to the manufacturer’s instructions (Roche-
Nimblegen, Madison, Wisconsin, USA). Cy3 and Cy5 labeled DNA was co-hybridized for ~70 
h at 42°C to the NimbleGen human Whole Genome Tiling Array (design ID: 
100718_HG18_WG_CGH_v2D_HX1) that contains 2.1 million isothermal ~60mer 
oligonucleotide probes with a median probe spacing of 1169 bp (Roche-Nimblegen, Madison, 
Wisconsin, USA). After washing and drying microarray data was collected by confocal 
scanning using the Roche NimbleGen MS200 Microarray Scanner at 2 μm pixel resolution 
(Roche NimbleGen). Using the software NimbleScan version 2.6 (Roche NimbleGen), 
microarray probe intensities were subjected LOESS Spatial Correction to adjust signal 
intensities based on probe position (Smyth and Speed, 2003), qspline fit normalization to 
compensate for inherent differences in signal between the Cy3 and Cy5 dyes (Workman et al., 
2002) and copy number variation analysis to detect log2 (test/reference) values that deviate 
significantly from baseline using the SegMNT algorithim. A set of conservative criteria (five or 
more probes in a segment, mean amplitude of log2 shift across segment +/- 0.5) were used to 
define the final set of high confidence CNV calls. 
 
Genomewide methylation analysis 
Array-based gene-specific DNA methylation analysis was performed using Infinium 
HumanMethylation450 bead chip technology (Illumina, San Diego, CA, USA). Genomic DNA 
(500 ng) from each sample was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo 
Research Corporation). Bisulfite treated genomic DNA was whole-genome amplified and 
hybridized to HumanMethylation450 BeadChips. The methylation status of a specific cytosine 
was indicated by average beta (AVB) values where 1 corresponds to full methylation and 0 to 
no methylation. Raw array data were quantile normalised as described previously (Touleimat 
and Tost, 2012) and p-values for comparisons between different datasets were statistically 
adjusted using the Benjamini-Hochberg correction. For the data analysis we masked data point 
as “NA” for the following conditions 1) Probes containing single-nucleotide polymorphisms 
(SNPs), 2) those that overlap with a repetitive element that covers the targeted CpG 
dinucleotide, 3) those that overlap with regions of insertions and deletions in the human 
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genome, 4) probes that are targeting X or Y chromosome. Beta values with detection p value 
greater than 0.05 were also replaced as "NA". Furthermore, probes containing at least one 
“NA” across any sample were also masked as “NA”. Methylation analysis was performed using 
R package limma.  
 
Locus-normalized quantitative methylation-specific PCR 
All qMSP reactions were carried out on the Rotor-Gene 3000 real time thermal cycler (Qiagen) 
using the QuantiTect SYBR Green Kit (Qiagen) according to the manufacturer´s instructions. 
15µl reactions were performed containing 0.5µM of each primer as well as 1.5µl bisulfite-
converted DNA. DNA from a peripheral blood sample was treated with M.SSSI 
methyltransferase to obtain full methylation within the promoter regions of all target genes 
(methylation positive control). For each target gene standard curves for the M- (specific for 
bisulfite-unconverted sequence) and S- (standardizer; methylation independent) primers were 
established by amplifying serial 1:10 dilutions (100% - 0.1%) of the bisulphite treated positive 
control DNA. Methylation of target genes (expressed as percentage of methylatated alleles 
[PMA]) in sample DNA was quantified by relating M-amplification rate to the S-amplification 
rate both of which were previously determined using the recorded standard curves. DNA from 
peripheral blood showed no or only minor fractions of methylated alleles for the target genes 
and was therefore used as a methylation negative control. For ln-qMSP primer sequences see 
Table 4-2. 
 
Table 4-1: Clinical characteristics of patients and molecular features of TICs 
TIC Gender Age 
Tumor 
grade 
APC TP53 KRAS PIK3CA 
Micro-
satellite 
1 m 68 G3 mut mut wt mut stable 
2 m 68 G2 mut wt wt mut stable 
3 f 51 G2 mut mut mut wt instable 
4 f 63 G2 mut mut wt wt stable 
5 m n/a G3 mut mut wt wt stable 
wt, wiltype; mut, mutated 
 
Table 4-2: ln-qMSP primers 
Name Orientation Sequence (5´-3´) 
MLH1 M F ACGCAGACGCTCCACCAGGGCCGC 
MLH1 M R TCCGGAGGGCGATGGGGCCCTGTGC 
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MLH1 S F AGTTTGGAGTGGTAGGTTTTTAGAGG 
MLH1 S R CATCCCCAAATTCTTACTCCTTCTTTC 
CA4 M F TTTCGGGTTGCGTGTGCGTC 
CA4 M R CTCGTCTCGCCGAACCACG 
CA4 S F GGGTATTGGTTGAAGATAAAGGGGAAT 
CA4 S R TTCTCCCACTCTTACAATACACCCTACC 
NPY1R  M F GCGCGTCGTTTAGCGTCGTAC 
NPY1R  M R CGCGACTCGATTACAACCGAAAAACG 
NPY1R  S F GGATAATTTTTAGGTTTTGGTTTGAGGGAG 
NPY1R  S R TTACATATACCCAACCCTCAATCTTTACC 
GREM1 M F CGTCGGTATTTAAACGGGAGACG 
GREM1 M R CAAAACCGCCGAAACTCGACG 
GREM1 S F GTGTGAATATGGTGGTTTGTGGTATG 
GREM1 S R CACAACTAAATAACAAACATCCACTCCTAC 
M, Methylation-specific primer; S, Standardizer primer; F, forward; R, reverse 
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5 Concluding Discussion and Outlook 
 
Colorectal cancer features a multitude of epigenetic aberrations, and although these 
aberrations are well documented at the histone and DNA modification levels, little is known 
about their origin and the underlying molecular defects. During my PhD studies, I addressed, 
on the one hand, the molecular processes underlying the wide-spread changes of DNA 
methylation in CRC and, on the other hand, the consequences of malfunction of these 
mechanisms in colorectal carcinogenesis. 
Methylation alterations in CRC are particularly pronounced in cancers developing through the 
CIMP pathway, which is characterized by the hypermethylation of multiple gene promoters. 
Previous studies linked hypermethylation phenotypes in glioma and leukemia with impaired 
TET-mediated DNA demethylation (Figueroa et al., 2010; Letouze et al., 2013; Turcan et al., 
2012). Together my colleagues, I discovered that the loss of TET1 expression is characteristic 
of CIMP-associated CRCs (Appendix I). We showed that TET1 depletion in the non-CIMP 
CRC cell line SW620 results in genome-wide CpG island-associated methylation changes 
which included hyper- as well as hypomethylation events. These initial results indicate that the 
loss of TET protein function does not primarily generate a hypermethylation phenotype. This 
is in line with previous studies showing that Tet1 loss in mouse embryonic stem cells results 
in hyper- and hypomethylation (Y. Xu et al., 2011). Tumors derived from engrafting of TET1 
depleted cells into immunosuppressed mice then displayed a shift in the methylation patterns 
towards hypermethylation. This may indicate the genetic consequences of CGI 
hypermethylation are directly relevant for cancer development and thus provide a selective 
advantage in tumor evolution. Indeed, we observed transcriptional repression and 
hypermethylation of MLH1 in TET1 depleted cells, a hallmark of CRC-CIMP. Further, we found 
that TET1 depletion results in the downregulation of LGR5, an established marker of epithelial 
intestinal stem cells as well as of colorectal cancer initiating cells (Koo and Clevers, 2014). E-
cadherin (CDH1) is an essential component of intercellular adherence junctions and therefore 
an important marker for epithelial cells. CDH1 expression was downregulated in TET1 
depleted cells whereas the mesenchymal markers vimentin and fibronectin were upregulated. 
In addition TET1 depleted cells showed an increased migratory behavior. These are features 
of an epithelial-to-mesenchymal transition (EMT), which has been associated a poor cancer 
prognosis as increased cell migration and reduced cell-to-cell contacts are linked to metastasis 
formation (Findlay et al., 2014). Together, these results show that the loss of TET1 not only 
generates a DNA hypermethylation phenotype and a loss of tissue specific stem cell features, 
but also to the concomitant acquisition of mesenchymal cell properties. The latter might 
suggest that the loss of TET1 is associated with poor cancer prognosis. In line with, this a 
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recently published study indicates that CIMP-CRCs have a worse prognosis compared to non-
CIMP cancers (Juo et al., 2014). Impaired DNA demethylation due TET1 depletion and the 
ensuing restriction of DNA methylation plasticity is likely to affect cell state plasticity. We 
isolated and expanded differentially CD24/CD44–marked subpopulations of TET1 depleted 
cells and control cells and found that TET1 depleted cells can hardly re-establish the original 
heterogeneity. We propose that TET1 depleted cells are locked in the cell state at the time 
TET1 was lost and fail to memorize differentiation cues from the environment. Notably, it has 
been recently reported that the BRAF V600E mutation, which is highly associated with CRC-
CIMP, results in the downregulation of TET1 (Kudo et al., 2012). This makes oncogenic BRAF 
a promising upstream factor of TET1 downregulation in CRC-CIMP. Overall my results provide 
novel insight into the molecular mechanisms underlying the CIMP oncogenic pathway in CRC. 
In future studies it will be interesting to address the molecular processes by which oncogenic 
BRAF affects the expression of TET1. 
A significant fraction of methylation aberrations described in CRC can be linked to aging 
(Toyota et al., 1999). It has been reported previously that environmental factors may influence 
age-dependent methylation changes in the colorectum (Tapp et al., 2013). To further 
investigate the effect of lifestyle-related factors in the dynamics of methylation changes in the 
aging colon we quantified promoter methylation levels target-wise and genome-wide in colonic 
mucosa specimens from a large cohort of 546 healthy women (Appendix II). We correlated 
methylation data with CRC-risk modulating lifestyle factors smoking, overweight, hormone 
replacement therapy (HRT) and aspirin use (Chan et al., 2007; Long et al., 2010; Parajuli et 
al., 2013; Robsahm et al., 2013). The regular use of aspirin and HRT reduced the number of 
age-hypermethylated CpG sites as well as the rate of their methylation increase. Obesity, 
however, promoted age-related hypermethylation. Interestingly, long-term smoking was 
associated with increased methylation changes in the proximal (right) colon but suppressed 
age-dependent hypermethylation at the distal (left) colonic side. A significant fraction of CpGs, 
the age-related hypermethylation of which was modulated by lifestyle factors, is 
hypermethylated in CRC. The identification of this age- and cancer-related subgroup is of 
particular interest. First, it provides insight into the molecular mechanisms by which lifestyle-
related factors may exert their effect on CRC risk and, second, the hypermethylation at these 
CpG sites implies a risk for CRC. Hence, the identification and discrimination of a full spectrum 
of age- and cancer-related hypermethylation targets allows the establishment of biomarkers 
for subtype specific CRC prediction, i.e. risk assessment, diagnosis and monitoring of 
treatment response. Since, our studies focused on women for technical reasons, the findings 
will have to be validated by studies including men. 
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DNA methylation is involved in the regulation of numerous cellular processes including 
transcription, DNA repair and replication. Therefore the consequences of methylation 
aberrations in cancer are multifaceted. I contributed to an original study, which identified 
SHOCA-2 as a tumor suppressor in CRC. We were able to show that SHOCA-2 inhibits EGFR 
signaling by suppressing STAT3 activation (Appendix III). The loss of SHOCA-2 expression 
correlated with advanced CRC stages, a poor clinical outcome and was associated with 
different genetic and epigenetic alterations. In a large fraction of SHOCA-2-depleted cancers 
the expression loss was associated with chromosomal deletion affecting the SH2D4A locus 
(encoding for SHOCA-2) resulting in a loss of heterozygosity (LOH) for a point mutation 
causing premature termination. Additional DNA sequence alterations, resulting in frame shift 
or missense mutations, were not associated with LOH. In addition, within the scope of this 
collaboration, I showed that cancer-specific hypermethylation of two CpG sites, part of a CGI 
located in the 5´-UTR of the SH2D4A gene, is associated with SHOCA-2 downregulation in a 
small fraction of SHOCA-2-depleted cancers. Interestingly, other CpGs in the CGI did not show 
cancer-specific methylation changes. The specific hypermethylation of these two CpG sites 
suggests an underlying selective process, which promotes and preserves accumulation of 
methylation at these sites. One of the two hypermethylated CpG sites overlapped with a 
consensus binding motif for the transcription factor Sp1. In an electrophoretic mobility shift 
assay (EMSA) I could show that methylation at this CpG significantly reduced the affinity of 
Sp1 to its binding motif in vitro. This could indeed be sufficient to explain a loss of SHOCA-2 
expression. However, different aspects need further investigation. For instance, it is unknown 
whether or to what extent Sp1 indeed contributes to transcriptional activation of SHOCA-2. 
Furthermore, my findings do not imply that methylation of the respective CpG site does also 
interfere with Sp1 binding in vivo. There is some disagreement in the literature over the effect 
of methylation on Sp1 binding to its consensus sequence, although several recent studies 
confirm the methylation sensitivity of Sp1 binding (Harrington et al., 1988; Reynard et al., 2014; 
X. Zhang et al., 2014). Despite these uncertainties, our results introduce a pathway by which 
well-defined, aberrant methylation events can contribute to colorectal carcinogenesis.  
It has been reported that hypomethylation of fragile sites in the genome is associated 
chromosome breakage (De and Michor, 2011). However, it is unknown whether 
hypomethylation is causally linked to the emergence of chromosome breakage. To address 
this question, I and colleagues from different laboratories at Roche, Basel, analyzed somatic 
copy number alterations (SCNAs) profiles and genome-wide CpG methylation patterns in five 
pairs of tumor-initiating cells (TICs) and mouse xenografts derived from these cells 
(Supplementary Results 4.5.1). SCNA analysis revealed that cancer cells differed in the 
extent of numerical chromosomal aberrations as well as in the stability of these aberrations. 
Whereas for most TICs SCNA patterns remained largely unchanged in the course of xenograft 
70 
 
formation, in one TIC the patterns were unstable and xenografts acquired additional arm-level 
SCNAs. The difference in the stability of SCNA profiles among different CRC samples have 
not been reported, yet, and could reflect different molecular mechanisms underlying 
chromosomal aberrations. Consistent with previous findings we found that cancer cells 
featuring a CGI hypermethylation phenotype show a lower level of chromosomal aberrations 
(Cancer Genome Atlas, 2012; Cheng et al., 2008). To address whether SCNA changes during 
xenograft formation are associated with methylation changes, we correlated methylation levels 
of CpG sites located in regions of chromosomal breakpoints specific for xenografts and 
compared them to the levels in corresponding region in TICs, where these sites were not 
associated with breakpoints. Two TIC/xenograft pairs indeed displayed a trend for reduced 
methylation levels at chromosomal breakpoints. The differences in the association of 
differential methylation and chromosomal breakage may again reflect different mechanisms 
underlying the accumulation of SCNAs. Notably, the TICs in which we observed an association 
between hypomethylation and the emergence of chromosomal breakpoints displayed 
continuous instability of SCNAs or were associated with a hypermethylation phenotype, 
respectively. Although, the preliminary results from our TIC/xenograft model introduce several 
interesting aspects regarding the development of genetic and epigenetic profiles during tumor 
formation, the validity of our findings is limited due to the small number of TIC/xenograft pairs. 
Further detailed analysis of TICs and xenografts will be required to address mechanistic 
aspects of SCNA-profile instability which, furthermore, needs to be addressed in primary CRCs 
by future studies. 
Aberrant methylation occurs early in colorectal carcinogenesis and is partially related to the 
aging process as discussed before (Menigatti et al., 2009; Noreen et al., 2014). This allows for 
the establishment of specific biomarkers for diagnosis and CRC risk assessment. In 
collaboration with my colleagues, I contributed to the identification of seven genes (CA4, 
NPY1R, IFITM1, GREM1, FOXF1, MLH1 and MGMT) downregulated in precancerous benign 
adenomas compared to matched normal colonic mucosa and to the analysis of their promoter 
methylation in matched samples from primary human CRCs, healthy mucosa and peripheral 
blood (Appendix IV). This marker panel could discriminate between CRC and matched normal 
mucosa with a sensitivity of 82% and a specificity of 99%, when the criterion of at least one 
methylated marker was applied. The sensitivity was even higher when the panel was applied 
to CRC located at the proximal side of the colon. The seven marker panel therefore provides 
a potential tool for cancer diagnosis and CRC risk assessment with a high specificity and 
sensitivity. As it was reported previously for MLH1, we detected low levels of CA4, NPY1R, 
GREM1 promoter methylation also the mucosa from healthy individuals suggesting that the 
level rather than the presence of methylation in the promoter of the marker genes distinguishes 
healthy from cancerous tissues (Menigatti et al., 2009). This has implications for the clinical 
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utilization of methylation biomarkers, as quantitative rather than qualitative approaches are 
required to determine pathologic DNA methylation changes. 
In the course of my PhD thesis I produced data that may contribute to the understanding of 
how DNA methylation aberrations in human CRC occur and how they can promote cancerous 
transformation. 
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Abstract 
 
Colorectal cancers and other human malignancies displaying a CpG island methylator 
phenotype (CIMP) constitute a well-defined subtype of tumors characterized by extensive 
epigenetic aberrations and a distinct etiology. Although, epigenetic as well as genetic 
alterations specific for colorectal cancer CIMP (CRC-CIMP) are well described its molecular 
basis remains unresolved. Here we report that expression of the DNA hydroxylase TET1 is 
significantly reduced in CRC-CIMP, associated with an aberrant hypermethylation of the TET1 
promoter. Accordingly, in CIMP cell lines levels of 5-hydroxymethylcytosine (5hmC) were 
reduced at CIMP-specifically hypermethylated loci. The sh-RNA mediated depletion of TET1 
in colorectal cancer (CRC) cells generated genomewide CpG island-associated methylation 
aberrations with equal dimensions of hyper- and hypomethylation. TET1-depleted cells 
acquired CRC-CIMP specific characteristics including promoter hypermethylation and 
transcriptional repression of MLH1 and E-cadherin. Furthermore, the loss of TET1 was 
accompanied by the loss of cell phenotype plasticity and reduced expression of stem cell 
markers. The altered methylome of TET1 depleted cells evolved towards a methylator 
phenotype in mouse xenograft tumors. Together, our data therefore provide evidence that the 
loss of TET1 expression is causal for genomewide hypermethylation observed in CRC-CIMP 
and involved in changes in the cellular behavior with potential clinical implications. 
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Introduction 
 
Aberrant hypermethylation of promoter-associated CpG islands (CGIs) is prevalent in many 
human cancers and is usually associated with transcriptional repression of the respective 
genes (Ting et al., 2006). The phenomenon was first described in colorectal cancers (CRC), 
based on the finding that a subgroup of tumors showed strong and widespread CGI 
methylation, a feature that was named CpG island methylator phenotype (CIMP) (Toyota et 
al., 1999). Subsequent studies identified similar methylator subgroups also in other human 
cancers including gastric, lung, liver, ovarian and also in gliomas and leukemias (Noushmehr 
et al., 2010; Teodoridis et al., 2008). The existence of distinct methylation phenotypes indicates 
that aberrant methylation does not occur randomly in the genomes of cancer cells but rather 
is associated with a specific pathway of carcinogenesis, characterized by epigenetic instability. 
CRCs showing CIMP are associated with BRAF V600E mutation and are often microsatellite 
instable (MSI), due to hypermethylation and concomitant silencing of the MLH1 promoter (Ang 
et al., 2010; Shen et al., 2007; Yagi et al., 2010). In addition, CIMP CRCs are mainly found in 
women and on the right side of the colon. Patients with CIMP-associated CRC are older at 
diagnosis and several studies indicate that they have worse prognosis compared to those with 
non-CIMP cancers. Histologically, CIMP CRCs are characterized by poor cellular 
differentiation (Nazemalhosseini Mojarad et al., 2013). Recently, it has been shown that CIMP-
CRCs also arise from a distinct class of precursor lesions described as the serrated pathway 
of colorectal carcinogenesis. The significant association of the defined group of serrated 
adenomas with MSI, BRAF V600E mutation and with CRC-CIMP further substantiates the 
evidence for a discrete CIMP-associated pathway of colorectal carcinogenesis (Leggett and 
Whitehall, 2010).  
The molecular mechanisms underlying CGI hypermethylation in CIMP cancers are poorly 
understood and remain speculative. Overexpression of DNA methyltransferases (DNMTs), 
enzymes that establish and maintain CpG methylation, has been implicated in CGI 
hypermethylation in cancer. Increased levels of DNMT1, the maintenance DNA 
methyltransferase, have been associated with CGI hypermethylation in colorectal, pancreatic 
and gastric human cancers (Etoh et al., 2004; Kanai et al., 2001; Peng et al., 2006), while 
overexpression of the de novo methyltransferase DNMT3B has been described in breast and 
colorectal cancers with a hypermethylator phenotype (Nosho et al., 2009; Van der Auwera et 
al., 2010). However, no study has directly shown that DNMT overexpression is sufficient to 
generate a CGI hypermethylation phenotype. More recently, several studies have implicated 
impaired DNA demethylation in the development of CIMP cancers, through inhibition or genetic 
inactivation of ten-eleven-translocation 5-methylcytosine dioxygenases family of enzymes. 
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The three family members, TET1, TET2 and TET3 catalyze the iterative oxidation of 5-
methylcytosine (5mC) to 5-hydroxymethyl cytosine (5hmC), 5-formylcytosine (5fC) and 
5carboxycytosien (5caC) (Ito et al., 2010; Tahiliani et al., 2009). 5fC and 5caC are substrates 
for the Thymine DNA glycosylase (TDG), which excises these bases to give way for the de 
novo incorporation of an unmethylated cytosine by DNA repair. (He et al., 2011; Maiti and 
Drohat, 2011).  
Loss-of-function mutations of TET2 are associated with a hypermethylation phenotype in acute 
myeloid leukemia (AML) (Nakajima and Kunimoto, 2014). These occur in a mutually exclusive 
manner with mutations in isocitrate dehydrogenases (IDH1 and IDH2), which give rise similar 
methylation aberrations (Figueroa et al., 2010). This is rationalized by the neomorphic nature 
of the respective IDH1 and IDH2 mutations, conferring an α-KG reducing activity to these 
enzymes, which then generate the oncometabolite 2-Hydroxyglutarate (2-HG), a competitive 
inhibitor of α-KG-dependend dioxygenases like TET proteins (W. Xu et al., 2011). Such a 
neomorphic mutation in IDH1 was also suggested to constitute the molecular basis for glioma-
CIMP (Turcan et al., 2012). IDH1 mutations, however, are rare in most other solid cancers 
including CRC and appear to play a role only in a small group of CIMP cancers (Bleeker et al., 
2009; Borger et al., 2012; Kang et al., 2009). Similarly, loss-of-function mutations in Succinate 
dehydrogenase (SDH) were associated with a hypermethylation phenotype in paragangliomas 
and gastrointestinal stromal tumors. These mutations result in an accumulation of succinate 
(Killian et al., 2013; Letouze et al., 2013), an intermediate of the Krebs cycle and, the same as 
fumarate, a competitive inhibitor of α-KG-dependend dioxygenases including histone 
demethylases and TET family proteins (Xiao et al., 2012). These studies implicate a central 
role to impaired TET-mediated DNA demethylation in the development of CIMP cancers in 
humans.  
In this study, we addressed to what extent deregulation of TET activity may explain the origin, 
phenotype and biology of CIMP cancers in the colon. We report the consistent loss of TET1 
expression in CIMP CRC cell lines and primary tumors and describe epigenetic and cellular 
changes upon the knockdown of TET1 in the non-CIMP CRC cell line SW620 which mirror 
characteristics of CIMP-CRCs. Thereby, our results also provide insight into molecular 
mechanisms which are associated with cancer progression. 
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Results 
 
Promoter hypermethylation in CRC cell lines is associated with low TET1 expression 
 
We first used a set of eight CRC cell lines (SW48, SW620, COLO320, COLO205, HCT-116, 
CACO2, LOVO and DLD-1) to investigate the role of the oxidative DNA demethylation pathway 
in the CRC associated methylator phenotype. To arrange the cell lines according to their 
methylation patterns in an unbiased manner, we performed unsupervised cluster analysis on 
publicly available genome-wide CGI methylation data from Illumina Infinium 
HumanMethylation27 (HM27) arrays; GEO accession number GSE35573 (Easwaran et al., 
2012). We then validated the CIMP relevance in the resulting clusters by examining the 
methylation status of conventional CIMP markers (5 marker panel; CACNA1G, NEUROG1, 
RUNX3, IGF2 and SOCS2 (Weisenberger et al., 2006) as well as the microsatellite instability 
(MSI) status. The methylation levels of the CIMP marker panel were quantified by ln-qMSP; 
cell lines showing methylation of at least three of these markers were considered to reflect 
CIMP positivity. The MSI status in these cell lines was previously determined (Ahmed et al., 
2013). 
In the analysis of the CpG methylation array data, we excluded probes that are overlapping 
with repetitive elements, regions of insertions and deletions and single-nucleotide 
polymorphisms and probes designed for sequences on sex chromosomes (Hinoue et al., 
2012). In the remaining 19,773 probes, we then identified CpG sites showing top 25% highest 
variation in methylation, from which we further extracted those associated with promoter CpG 
islands (3713 CpG sites) for an unsupervised clustering analysis (Figure 1a). This grouped cell 
lines along a gradient of increasing methylation ranging from low methylation in COLO320 to 
high levels of gene promoter methylation in HCT116 and SW48. Higher levels of promoter 
methylation by genome-wide analysis correlated with the presence of hypermethylation at the 
CIMP five marker panel as well as MSI. Based on this associations, we classified COLO205, 
LOVO, DLD-1, HCT116 and SW48 as CIMP cell lines and COLO320, SW620 and CACO2 as 
non-CIMP cell lines. We then quantified the mRNA expression of TET1, TET2 and TET3 by 
RT-qPCR in all cell lines. Averaged methylation levels of the 3713 differentially methylated 
CGI-associated CpG sites were inversely associated with the mRNA expression of TET1 but 
not with the expression levels of TET2 or TET3 (Figure 1b). The correlation applied also for 
TET1 protein levels (Figure 1c).  
Next, we asked whether TETs expression correlates with the occurrence of 5hmC, the product 
of TET catalyzed oxidation of 5mC, in the cell line genomes. Global levels of 5hmC were 
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quantified by LC-MS/MS. We did not find any correlation between expression of TET1, TET2 
or TET3 and global 5hmC levels (Supplementary Figure 1). In addition, we assessed levels of 
locus-specific 5hmC and 5mC modifications at nine CGI containing gene promoters (PROK2, 
NPPC, DLX5, LHX6, POU3F2, WNT10A, SLC30A, TRIM9, CDK5R2) by immunoprecipitation 
of modified DNA (MeDIP and GLIP) and subsequent quantification by qPCR. It has been 
previously shown that these genes are specifically hypermethylated in CRC-CIMP (Hinoue et 
al., 2012; Y. Xu et al., 2012) and targeted by TET1 in mouse ESCs (Williams et al., 2011). We 
found significantly higher levels of promoter methylation at all nine targets in CIMP cell lines 
(SW48 and HCT116) compared to non-CIMP cell lines (CACO2 and SW620) (Figure 1d). 
Since, 5mC constitutes the substrate for TET proteins in the generation of 5hmC, and 5mC-
rich regions are therefore more likely to possess higher levels of 5hmC, we normalized the 
levels of 5hmC against the levels of 5mC in the respective promoter. Normalized 5hmC levels 
were significantly lower in CIMP cell lines versus non-CIMP cell lines (Figure 1d).  
We thus conclude that CRC cell lines displaying a methylator phenotype have low levels of 
TET1 expression, which coincides with lower 5hmC levels at promoter regions known to be 
hypermethylated in CRC-CIMP. 
 
 
TET1 expression correlates with methylation profiles in primary human colorectal 
cancers 
 
To test relevance of these findings for primary CRCs, we examined methylation levels of the 
CIMP five-marker panel in a consecutively collected set of 23 primary CRCs, 18 matched 
cancer-associated normal mucosa samples (CAM) and 8 colonic mucosa biopsies from 
healthy individuals (HM). Cancers were classified as CIMP (n=7) when ≥ 3 markers were 
methylated, or else as non-CIMP (n=15). TET1 mRNA expression was significantly lower in 
CIMP compared to non-CIMP cancers, HM and CAM. No difference was apparent in TET2 
and TET3 expression between CIMP and non-CIMP cancers (Figure 2a). 
We validated these results in a larger set of colon adenocarcinoma samples (n=143) using 
genome-wide DNA methylation and mRNA expression data available from The Cancer 
Genome Atlas (TCGA). 25 colon cancers were classified previously as CIMP using Recursively 
Portioned Mixture Model (RPMM) (Cancer Genome Atlas, 2012). We observed significantly 
lower TET1 and TET3 expression in CIMP cancers compared to non-CIMP (Figure 2b). In 
contrast to the findings in our test set of CRCs, TET2 expression was significantly higher in 
CIMP cancers from the validation set (Figure 2b). We also investigated the expression of other 
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factors involved in regulation of CpG methylation. Expression of DNMT3A and DNMT3B was 
significantly lower in CIMP cancers compared to non-CIMP (Supplementary Figure 2a). No 
significant difference was found in the expression of DNMT1, TDG, IDH1 and IDH2 between 
CIMP and non-CIMP tumors (Supplementary Figure 2).  
To investigate whether the loss of TET1 expression in CIMP-CRCs is associated itself with 
hypermethylation of the TET1 promoter, we quantified the promoter methylation levels of TET1 
in 22 primary CRCs from our test set as well as in 8 CRC cell lines. Using ln-qMSP, we found 
TET1 promoter hypermethylated in several CIMP tumors (5/7) and CIMP cell lines (3/4) (Figure 
2c). In accordance with this, when we treated CIMP CRC cell line SW48 with the demethylating 
agent 5-azacytidine (5-aza-C) TET1 mRNA was re-expressed upon the reduction of promoter 
methylation levels (Figure 2d). This observation raised the question whether the loss of TET1 
expression occurs before genome-wide CGI methylation in CIMP or as a result of it. 
 
 
TET1 knockdown cells generate hypermethylated tumors 
 
To address the causal relationship between reduced TET1 expression and promoter 
hypermethylation, we depleted TET1 in the non-CIMP cell line SW620 by transduction of a 
lentiviral short-hairpin-RNA (sh-RNA) expression construct. A non-targeting sh-RNA (sh-ctrl) 
was included as a control. The two most efficient knockdown (kd) clones shTET1-1 (60% 
knockdown) and shTET1-2 (68% knockdown) derived from two different sh-RNAs were 
subjected to further analysis (Figure 3a). Notably, although sh-RNA sequences were 
specifically designed for TET1, we also found reduced TET2 mRNA levels in both knockdown 
clones (Figure 3a). We cultured shTET1 knockdown clones for 6 passages after viral 
transduction before assessing global levels of 5mC and 5hmC by dot blot analysis with specific 
antibodies and LC-MS/MS. 5hmC was clearly reduced in both knockdown clones whereas total 
5mC levels were unaffected, as expected (Figure 3b, Supplementary Figure 3a/b). To address 
whether and how the loss of TET1 affects CpG methylation we performed genome-scale 
methylation analysis using the Illumina Infinium HumanMethylation450 (HM450) platform. 
Focusing the analysis on CGI-associated CpG sites (252,129 CpGs), we found both 
hypermethylation and hypomethylation resulting from TET1 depletion (Supplementary Figure 
3d). A total of 1698 CpG sites were differentially methylated (FDR-adjusted p < 0.0001, Fold 
change in methylation M-values > 4), commonly in both TET1 kd-clones compared to sh-ctrl, 
comprising 859 hypermethylated and 839 hypomethylated CpG sites (Figure 3d). To follow up 
knockdown methylation patterns in the process of tumor development in vivo, sh-ctrl and 
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shTET1 kd cells were xeno-transplanted subcutaneously into NOD/SCID mice. Genome-wide 
methylation patterns (HM450) were analysed when tumors reached a diameter of 10 mm (5-7 
weeks). We verified TET1 knockdown in mouse xenografts (Supplementary Figure 3c). A total 
of 1674 CpG sites were differentially methylated, commonly in xenogrqafts from both TET1-kd 
clones, 1069 of which were hypermethylated and 605 were hypomethylated (Figure 3d, 
Supplementary Figure 3d). Hence, in the process of xenograft-tumor formation the ratio of 
hyper- to hypomethylated sites increased significantly (p<0.0001, Chi-square), with CpGs 
showing hyper- and hypomethylation overlapping significantly between cell lines and 
xenografts (each with p<0.0001, Chi-square) (Figure 3d). To characterize the CGI-associated 
CpGs, differentially methylated upon the depletion of TET1, we further subdivided them into 
island, shore (0-2kb from island) and shelf (2-4kb from island). In TET depleted cells, hyper- 
and hypomethylated CpGs ranked randomly among the three subcategories. However, in 
xenografts hypermethylated CpGs were enriched in the island category compared to 
hypomethylated CpGs (p=0.036, fisher´s extact). 
To address whether methylation changes upon TET1 depletion mirror to some extent 
methylation patterns of CIMP CRCs, we assessed methylation levels of the CIMP five-marker 
panel and hMLH1 by ln-qMSP. For several marker genes (IGF2, NEUROG1 and RUNX3) 
methylation levels in promoter CGIs increased (Supplementary Figure 4a/b). The increase of 
MLH1 promoter methylation in TET1-kd cells was accompanied by reduced MLH1 mRNA 
expression (Supplementary Figure 4c). We also asked whether loss of TET1 expression 
affects methylation of its own promoter and investigated the TET1 promoter CGI methylation 
in shTET1-kd cells by pyrosequencing of bisulfite-converted genomic DNA. This identified 
three CpG located at the 3´end of the CGI as highly methylated in shTET1-1 but not in shTET1-
2 cells. Data from the HM450 confirmed the increased methylation of individual CpG sites 
within the TET1 promoter in shTET1-kd cells and mouse xenografts compared to control 
samples (data not shown). 
From these results we conclude that TET1 depletion in SW620 CRC cells gives rise to both 
hyper- and hypomethylation at CGIs, including known CIMP targets as well as the TET1 
promoter itself. Xenograft tumor formation from these TET1 knockdown cells, however, is 
accompanied with a significant increase in the fraction of hypermethylated CpGs compared to 
the respective knockdown cell line, indicating that tumor growth generates a bias towards 
hypermethylation in CIMP. 
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TET1 knockdown cells and xenografts show a reduced expression of the colon cancer 
initiating cell marker LGR5 
 
In mouse embryonic stem cells Tet1 is critical for stem cell identity (Freudenberg et al., 2012; 
Ito et al., 2010). To address the role of TET1 in the stem cell phenotype of CRC cells we 
quantified mRNA levels of LGR5, a generally accepted marker for CRC-initiating cells but also 
normal epithelial intestinal stem cells (Dame et al., 2014; Forster et al., 2014; Hirsch et al., 
2014). LGR5 mRNA expression was consistently reduced in shTET1-kd cells compared to sh-
ctrl cells (Figure 4a). Similarly, xenografts derived from shTET1-kd cells showed significantly 
reduced number of LGR5-positive cells. Also the fraction of xenograft cells positive for CD44 
and CD166, two additional putative markers for colon cancer initiating cells was reduced in 
TET1-kd tumors compared to sh-ctrl (Dalerba et al., 2007) (Figure 4b). We therefore conclude 
that TET1 expression is associated with a stem cell-like phenotype in human CRC cells. 
 
 
TET1 knockdown cells display reduced cell state plasticity 
 
In cultures, the SW620 CRC cell line constitutes a heterogeneous population of cells showing 
stem-like cells features or a more differentiated phenotype, as inferred from the heterogeneous 
expression of putative cancer-initiating cell markers CD24 and CD44 (Muraro et al., 2012). It 
was reported previously that such cell states are interconvertible, most likely as a result of 
epigenetic plasticity involving DNA demethylation (Carmona et al., 2014; Gupta et al., 2011). 
We thus wondered whether the loss of TET1 would affect the cell-state plasticity. 
Flowcytometric analysis showed that the two shTET1-kd clones behave differently regarding 
the expression of CD24 and CD44. Whereas, shTET1-1 displayed a higher fraction of cells 
negative for both markers (double negative) compared to sh-ctrl, shTET1-2 was enriched for 
cells positive for both markers (double positive) (Figure 5a and 5b). Using fluorescence-
activated cell sorting (FACS), we isolated cells positive for CD24 and CD44 (CD24hiCD44hi, 
double positive) and negative for both (CD24negCD44neg, double negative) from sh-ctrl and 
shTET1-kd cells (resulting in subpopulations which were at least 96% pure based on reanalysis 
immediately after sorting). We then allowed the separated cells to expand in culture for eight 
days before we analysed phenotypic composition again by flow cytometry. Sh-ctrl cells from 
both subpopulations showed progression towards establishing the original population 
heterogeneity. However, the double negative subpopulation of shTET1-1 cells largely 
remained in their cell state, whereas the double positive cells showed an enhanced transition 
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to the double negative state compared to sh-ctrl (Figure 5b). The behaviour of shTET1-2 
diametrically opposite: Double positive cells remained largely in this state whereas double 
negative cells showed a more efficient conversion to double positive state compared to sh-ctrl 
(Figure 5b). Since we did not observe any difference in cell proliferation, the differences in the 
progression rate were unlikely the result from different growth rates. 
From these results we conclude that depletion of TET1 in SW620 cells reduced their capacity 
to change cell states and establish a stable heterogeneity in the population. Cells appear to be 
blocked in their differentiation state at the time of TET1 depletion and fail to memorize 
differentiation cues from the environment. 
 
 
TET1-knockdown cells lose epithelial cell characteristics and acquire mesenchymal 
features 
 
shTET1-kd cell cultures showed morphological changes, they formed colonies larger than 
control cells (sh-ctrl) with a dispersed composition in which individual cells were identifiable 
(Figure 6a). This as well as the observed loss of LGR5 expression could be interpreted as a 
loss of the epithelial phenotype. Therefore, we quantified mRNA expression of E-cadherin 
(CDH1) which constitutes an essential component of adherence junctions mediating cell-to-
cell contacts and which expression is characteristic of epithelial cells (van Roy and Berx, 2008). 
CDH1 mRNA levels were drastically reduced in both shTET1-kd clones and this was 
accompanied with increased methylation in the CDH1 promoter (Figure 6b). Consistent with 
this observation, CDH1 mRNA levels are reduced in CIMP-CRCs from the TCGA validation 
set (Figure 6c; Cancer Genome Atlas; 2012). By contrast, mRNA levels of vimentin (VIM) and 
fibronectin (FN1), two markers of mesenchymal cells, were increased in TET1-kd cells (Figure 
6c). Consistently with the acquisition of a mesenchymal phenotype, both SW620 TET1-kd 
clones showed an increased level of cell migration compared to sh-ctrl cells (Figure 6e). 
ZEB1, SNAI1 and SNAI2 are EMT-promoting transcription factors which directly inhibit 
expression of E-cadherin (J. Xu et al., 2009). Although mRNA levels of these factors were 
affected by depletion of TET1, only ZEB1 was consistently up-regulated in both kd-clones 
(Supplementary Figure 5a). We thus conclude that the loss of TET1 induces a change in cell 
phenotype that shows aspects of but does not fully recapitulate EMT.  
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Discussion 
 
The molecular pathway resulting in the CpG island methylator phenotype (CIMP) in human 
CRC has remained elusive. This work shows that CRC-CIMP is associated with a 
downregulation of the DNA hydroxylase TET1. Reduced TET1 expression results in CGI-
methylation alterations, which evolve to a methylator phenotype during tumor growth, 
accompanied by the acquisition of molecular characteristics of CRC-CIMP, including the 
transcriptional repression of MLH1 and CDH1. These findings are in line with recent reports 
suggesting that impaired TET-mediated DNA demethylation is causal for the development of 
hypermethylation phenotypes in several other human cancers (Figueroa et al., 2010; Letouze 
et al., 2013; Turcan et al., 2012). Furthermore, we provide evidence that reduced TET1 
expression affects the cell phenotype and the cell state plasticity of CRC cells with potential 
clinical implications. 
In contrast to previous reports, which associated CRC-CIMP with elevated expression of DNA 
methyltransferases, we observed significantly lower DNMT expression levels in CIMP-
associated CRCs (Kanai et al., 2001; Nosho et al., 2009). These discrepancies can be 
explained by (i) the different methods used for DNMT expression quantitation (IHC versus 
mRNA based methods), (ii) the different sample sizes but also (iii) the large variety of DNMT 
transcripts and enzyme isoforms. Several DNMT isoforms display no methyltransferase activity 
but have regulatory functions which can even interfere with DNA methylation (Gordon et al., 
2013; Weisenberger et al., 2004). The observation that 5hmC levels are significantly reduced 
in CGIs of CIMP marker genes further indicate that the molecular basis of CRC-CIMP is rather 
related to TET function than to a deregulation of DNMTs. 
The sh-RNA mediated TET1 knockdown in the CRC cell line SW620 resulted in genome-wide 
CGI methylation changes with almost equal dimensions of hyper- and hypo-methylation. 
Previous studies showed that the loss of Tet1 expression in mESCs does also lead to CpG 
hyper- and hypomethylation (Y. Xu et al., 2011). Based on its function in DNA demethylation 
the loss of TET1 is expected to result exclusively in de novo methylation at its target regions. 
The possible causes for hypomethylation linked to TET1 depletion remain elusive, and may be 
related to the dynamics of methylation regulation (Shen et al., 2013) or occur secondary to 
hypermethylation-associated transcriptional deregulation of TET1 target genes. We 
investigated the further development of the aberrant methylation in the context of tumor 
formation by engrafting TET1-kd cells into immunosuppressed mice, thus allowing the effects 
of more physiological tumor growth conditions (nutrient supply, tumor-stroma interactions, 
hypoxia) on the shaping of DNA methylation patterns to be examined. Compared to the TET1-
kd cells, which displayed a general perturbance of DNA methylation in both directions, 
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hypermethylation was clearly predominant in their xenografts. Interestingly, several known 
CIMP marker genes became consistently hypermethylated upon the knockdown of TET1 and 
might thus represent a distinct subset of TET1 targets. One of these genes is the DNA 
mismatch repair gene MLH1 the hypermethylation of which and concomitant transcriptional 
silencing are hallmarks of CIMP-associated CRCs (Weisenberger et al., 2006). The resulting 
mismatch repair deficiency leads to instability in the length of microsatellite DNA sequences 
(MSI) due to a failure to correct polymerase slippage events at those repetitive elements. We 
found that MLH1 hypermethylation in TET1-kd cells is accompanied by transcriptional 
repression of MLH1. However, the only moderate loss of MLH1 mRNA expression in TET1-kd 
cells and xenografts was not sufficient to cause microsatellite instability (data not shown). 
In addition, we present evidence that the transcriptional repression of TET1 and the 
hypermethylation of its promoter can generate a negative feedback loop. We found that the 
loss of TET1 expression results in an accumulation of 5mC in its own promoter region, which 
then reinforces and presumably stabilizes its transcriptional repression. In consequence, 
transcriptional repression of the TET1 promoter followed by its hypermethylation could 
constitute an epigenetic driver event, which promotes subsequent accumulation of 5mC in 
TET1 targeted promoter CGIs resulting in a methylator phenotype. Interestingly, induced 
BRAF V600E expression in the mouse fibroblast cell line NIH3T3 has been shown to reduce 
expression of all three TETs most prominently TET1. This effect was apparently independent 
from MAPK-signaling activation (Kudo et al., 2012). The BRAF V600E mutation, which is highly 
associated with CIMP in colorectal cancer, might therefore be a promising candidate for an 
upstream factor.  
Furthermore, we showed that reduced TET1 expression in the SW620 cell line results in the 
loss of LGR5, an marker for epithelial colonic stem cells, and the putative CRC-initiating cell 
markers CD44 and CD166 (Dalerba et al., 2007; Koo and Clevers, 2014). Together with the 
loss of stem cell markers, we found that the depletion of TET1 results in a reduction of cell 
state plasticity. TET1 depletion shifted the cell population equilibrium state regarding the 
expression of the cancer-initiating cell markers CD24 and CD44. Isolated subpopulations of 
CD24hi/CD44hi and CD24low/CD44low TET1-kd cells reverted more efficiently to the initial 
cellular heterogeneity than control cells. We propose, that impaired DNA demethylation due to 
the loss of TET1, restricts epigenetic plasticity and locks the cells in the current cell state. 
External signals may modulate the phenotype of TET1 deficient cells, but the cells cannot 
epigenetically memorize these changes and preferentially revert to their locked state in the 
absence of these signals.  
Finally, we showed that the loss of TET1 expression promotes EMT-like processes and 
enhances cellular migration. This coincides with promoter hypermethylation and concomitant 
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downregulation of E-cadherin (CDH1) and the upregulation of the mesenchymal markers 
fibronectin (FN1) and vimentin (VIM). EMT and the associated migratory and invasive cell 
behavior are involved in metastasis formation (Ocana et al., 2012; Thiery et al., 2009; Tsai et 
al., 2012). Both, the loss of E-cadherin as well as CIMP have been previously associated with 
a poor prognosis in colorectal cancer (Bruun et al., 2014; Juo et al., 2014). Our results provide 
a mechanistic link between the prognostic features of CIMP and loss of E-cadherin in CRC. 
Notably, in hepatocellular and gastric cancers the loss of TET1 expression was reported to be 
associated with an unfavorable prognosis (Liu et al., 2013; Yang et al., 2013).  
Overall our study provides novel insight into the molecular mechanisms involved in the 
development of CIMP-associated CRC and identifies TET1 as a factor involved in the 
maintenance of CGI methylation patterns in colonic epithelial cells. 
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Methods 
 
Patients, Tissue Samples and Cell Lines 
 
Tissue specimens from colorectal cancer patients were obtained from the Department of 
Surgery of the Kantonsspital Aarau, Switzerland and the Department of Gastroenterology of 
the Inselspital in Berne, Switzerland and were randomly collected on the occasion of surgical 
therapy. From each patient two biopsies were taken, one from the primary tumor and one from 
the adjacent healthy appearing mucosa (excised approximately 7cm aside the primary tumor). 
Tissue samples from healthy individuals were randomly collected by the Department of 
Gastroenterology of the Spital Region Oberaargau in Langenthal, Switzerland during routinely 
performed colonoscopy examinations. All patients gave their informed consent for the use of 
their tissue specimens for research purposes. Immediately after removal all tissue samples 
were submerged in RNAlater (Sigma) and stored at -80°C until further usage. For patients 
clinical data see Supplementary Table 1. 
Cell lines used in this study and the composition of their culture media are given in 
Supplementary Table 2. All cell lines were cultured at 37°C with 100% humidity and 5% CO2. 
 
 
DNA extraction and Bisulfite Conversion 
 
For the preparation of genomic DNA from cell lines 106-107cells were collected in 300µl Tris-
EDTA buffer (10mM Tris-HCl pH 8.0, 1mM EDTA) and 300µl lysis buffer (20mM Tris-HCl pH 
8.0, 4mM EDTA, 20mM NaCl, 1% SDS, 1mg/ml proteinase K) were added. After incubation at 
55°C for 5h and subsequent phenol/cholorform extraction DNA was Na-acetate/ethanol 
precipitated. DNA pellets were resuspended in 10mM Tris-HCl pH 8.0. RNA was removed by 
incubation with 20µg/ml RNase A (Qiagen) at 37°C for 30min followed by phenol/chloroform 
extraction and Na-acetate/ethanol precipitation. DNA pellets were resuspended in 10mM Tris-
HCl pH 8.0 and concentration was measured by absorbance at 260nm. 
Genomic DNA from RNAlater-preserved colorectal cancer tissues was extracted with the 
QIAamp DNA mini kit (Qiagen) according to the manufacturer´s instructions including the 
RNase-treatment step.  
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1µg of genomic DNA was treated with sodium bisulfite using the EZ DNA Methylation Kit (Zymo 
Research) according to manufacturer´s instructions.  
 
Locus-normalized Quantitative Methylation Specific PCR (ln-qMSP) 
 
ln-qMSP was performed as described previously (Noreen et al., 2014). Reactions were carried 
out on the Rotor-Gene 3000 real time thermal cycler (Qiagen) using the QuantiTect SYBR 
Green Kit (Qiagen) according to the manufacturer´s instructions. Each reaction was carried 
out in duplicates in a final volume of 15µl containing 0.5µM of each primer and 1.5µl of bisulfite-
converted DNA. DNA from a peripheral blood sample was treated with M.SssI 
methyltransferase to obtain full methylation within the promoter regions of all target genes 
(methylation positive control). For each target gene standard curves for the M- (specific for 
bisulfite-unconverted sequence) and S- (standardizer; methylation independent) primers were 
established by amplifying serial 1:10 dilutions (100% - 0.1%) of the bisulphite-treated positive 
control DNA. Methylation of target genes (expressed as percentage of methylatated alleles 
[PMA]) in sample DNA was quantified by relating M-amplification rate to the S-amplification 
rate both of which were previously determined using the recorded standard curves. DNA from 
peripheral blood showed no or only minor fractions of methylated alleles for the target genes 
and was therefore used as a methylation negative control. For ln-qMSP primer sequences see 
Supplementary Table 3. 
 
 
Pyrosequencing of Bisulfite-Converted DNA 
 
Gene promotor regions were PCR amplified using primers annealing methylation-
independently to the (oxidative) bisulfite-converted sequence. Reverse primers were either 
directly Biotin-labeled (5´-end of reverse primer) or extended at the 5´-end by an 11 nucleotide 
long universal primer target sequence. In the latter case PCR amplifications were performed 
in 20µl reaction volume, PCR products were diluted 1:105 with 10mM Tris-HCl pH 8.0 and 
again PCR amplified with a universal biotin-labeled reverse primer in 50µl reactions. The biotin-
labeled PCR products were purified using the NucleoSpin Gel and PCR clean-up kit 
(Macherey-Nagel). In case of direct biotin-labeling PCR reactions were performed in 50µl and 
were used for pyrosequencing without further processing. All PCR reactions were performed 
with 0.03units TrueStart Hot Start Taq DNA polymerase (Thermo) per µl reaction volume, 
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0.5µM primers and 2mM MgCl2. Biotin-labeled PCR products were immobilized on 
streptavidin-coated sepharose beads (GE Healthcare) and sequenced with a PyroMark Q24 
pyrosequencing system (Qiagen) using methylation independent sequencing primers 
according to manufacturer´s instructions. Sequence of PCR and sequencing primers are given 
in Supplementary Table 4. 
 
 
hmC Dot Blot 
 
3µl of Rnase-treated genomic DNA was blotted onto an H-bond N+ nylon membrane 
(Amsherham) and dryed for 15min. Membrane-bound DNA was denatured in 400mM NaOH 
for 4h. Membane was washed twice with SSC buffer pH7 (300mM NaCl, 34mM Na-citrate) and 
blocked with 10% milk in TBST (20mM Tris-HCl pH7.5, 150mM NaCl, 0.1% Tween 20) for 1hr 
at RT. After incubation membrane was washed three times with TBST. Anti-5hmC antibody 
(Active Motif) was diluted 1:104. Primary antibody was incubated overnight at 4°C. After 
washing three times for 10min in TBST HRP-linked -rabbit secondary antibody (GE 
Healthcare) was diluted 1:104 in 10% milk (in TBST) and incubated for 1hr at RT. After again 
washing three times with TBST for 10min 5hmC signals were detected on Amersham Hyperfilm 
ECL (GE Healthcare) using the Pierce ECL Western Blotting Substrate (Thermo). In order to 
prove equal sample loading the membrane was subsequently stained with 0.02% methylene 
blue in 300mM Na-citrate pH5.2 for 3min. 
 
 
MeDIP (Methylated DNA Immunoprecipitation) and GLIP (glucosylation, periodate 
oxidation and biotinylation) 
 
MeDIP detection of 5-mC was performed essentially as described in (Weber et al., 2005). DNA 
was sonicated to yield fragments of 100-500bp followed by NaCl/ethanol precipitation in the 
presence of glycogen-carrier. 1µg fragmented DNA in TE buffer (10mM Tris-HCl pH 8.0, 1mM 
EDTA) was denatured (95°C for 10min) and incubated with 0,3µg of monoclonal anti-5-
methylcytidine (Diagenode, clone 33D3) at 4°C for 2 h in 1x immunoprecipitation (IP) buffer 
(10mM sodium phosphate pH 7.0, 140 mM NaCl, 0.05% Triton X-100). Immuno-complexes 
were precipitated by the addition of 20 µl M-280 sheep anti-mouse IgG antibody coupled 
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Dynabeads (Invitrogen) and incubation at 4°C for 2 h followed by three washes in IP buffer. 
Bound material was treated with 250 µl proteinase K digestion buffer (50 mM Tris-HCl pH 8.0, 
10 mM EDTA, 0.5% SDS and 0.25mg/ml proteinase K) at 50°C for 3 h. Immunoprecipitated 
methylated DNA was purified by phenol/chloroform extraction followed by NaCl/ethanol 
precipitation and re-suspended in 10 mM Tris-HCl pH 8.0. 5-hmC containing DNA fragments 
were captured with the Hydroxymethyl Collector kit from Active Motif as described in the 
manufacturer’s instructions. qPCR analysis of sonicated genomic input DNA and MeDIP/GLIB 
DNA with target specific primers was performed using Quantitect SYBR Green (Qiagen) with 
a Rotor-Gene 3000 thermocycler (Qiagen). Sequences of primers used in MeDIP and GLIB 
are given in Supplementary Table 5. 
 
 
LC-MS/MS (High Performance Liquid Chromatography Coupled with Tandem Mass 
Spectrometry)  
 
Genomic DNA was enzymatically hydrolyzed to nucleosides as described (Crain, 1990), 
followed by addition of 3 volumes of methanol and centrifugation (16,000g, 30 min, 4°C). The 
supernatants were dried and dissolved in 50 µl 5% methanol in water (v/v) for LCMSMS 
analysis of the deoxynucleosides 5-hm(dC), 5-f(dC), 5-ca(dC), and 5-hm(dU). A portion of 
each sample was diluted for the quantification of 5-m(dC) and unmodified deoxynucleosides 
(dA, dC, dG, and dT). Chromatographic separation was performed on a Shimadzu Prominence 
HPLC system with a Zorbax SB-C18 2.1x150 mm i.d. (3.5 µm) column equipped with an 
Eclipse XDB-C8 2.1x12.5 mm i.d. (5 µm) guard column (Agilent Technologies). The mobile 
phase consisted of water and methanol (both supplemented with 0.1% formic acid), for 5-
m(dC) and 5-hm(dC) starting with a 5 min gradient of 5-60% methanol, followed by 6 min re-
equilibration with 5% methanol, and for unmodified nucleosides maintained isocratically with 
85% methanol. Mass spectrometry detection was performed using an MDS Sciex API5000 
triple quadrupole (Applied Biosystems) operating in positive electrospray ionization mode for 
the mass transitions 258.1/ 142.1 (5-hm(dC)), 242.1/ 126.1 (5-m(dC)), 252.1/136.1 (dA), 
228.1/112.1 (dC), 268.1/152.1 (dG), and 243.1/127.1 (dT). 
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Array-based DNA Methylation Profiling and Data Analysis 
 
Array-based gene-specific DNA methylation analysis was performed using Infinium 
HumanMethylation450 bead chip technology (Illumina, San Diego, CA, USA). Genomic DNA 
(500 ng) from each sample was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo 
Research Corporation). Bisulfite treated genomic DNA was whole-genome amplified and 
hybridized to HumanMethylation450 BeadChips. The methylation status of a specific cytosine 
was indicated by average beta (AVB) values where 1 corresponds to full methylation and 0 to 
no methylation. Raw array data were quantile normalised as described previously (Nizar 
Touleimat 2012) and p-values for comparisons between different datasets were statistically 
adjusted using the Benjamini-Hochberg correction. For the data analysis we masked data point 
as “NA” for the following conditions 1) Probes containing single-nucleotide polymorphisms 
(SNPs), 2) those that overlap with a repetitive element that covers the targeted CpG 
dinucleotide, 3) those that overlap with regions of insertions and deletions in the human 
genome, 4) probes that are targeting X or Y chromosome. Beta values with detection p value 
greater than 0.05 were also replaced as "NA". Furthermore, probes containing at least one 
“NA” across any sample were also masked as “NA”. After data filtering, total of 413,594 probes 
were kept for differential methylation analysis using R package limma. Individual loci were 
scored as differentially methylated if fold change difference was more than 4 (FC>4) and p 
value <0.001.  
Genome-wide methylation data of 8 CRC cell lines was obtained from GEO (GSE35573), 
which was done on Infinium HumanMethylation27 Beadchip arrays interrogating methylation 
at 27,578 CpGs distributed in the promoters of 14,475 coding genes. Data was normalized 
using lumi and methylumi packages in R/Bioconductor as described previously (Du P 2008). 
After quality control and data filtering, a total of 19,773 probes were further analysed. 
 
 
5-Azacytidine Treatment 
 
SW48 CRC cells were cultured in standard medium containing 1µM 5-Azacytidine (5-AzaC, 
Sigma) for 5 days. Medium containing fresh 5-AzaC was renewed every 24 h. Genomic DNA 
(see DNA extraction paragraph) and total RNA (see qRT-PCR paragraph) were extracted from 
treated and untreated cells. 
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Quantitative Reverse Transcription PCR (qRT-PCR) 
 
Total RNA was extracted from tissue specimens and CRC cell lines using the Tri-Reagent 
(Sigma #93289) according to manufacturer´s instructions. For tissue sampels, 50-80mg of 
tissues were homogenized directly in 1ml Tri-Reagent with the MP-FastPrep-24 system 
together with Zirconia beads (BioSpec). For cell lines, 106-107 cultured cells were resuspended 
in 1ml Tri-Reagent. Extracted RNA was Dnase treated (New England Biolabs) and cDNA was 
synthesized using either the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo 
Scientific) or the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to manufacturer´s manuals. All qRT-PCR reactions were carried out on the Rotor-
Gene 3000 real time thermal cycler (Qiagen) using the QuantiTect SYBR Green Kit 
(Qiagen). 15µl reactions were performed containing 0.5µM of each primer as well as 1µl cDNA 
template. mRNA levels of target genes were expressed as the averaged expression relative 
to ACTB and GAPDH. For qRT-PCR primer sequences see Supplementary Table 5. 
 
 
Western Blot 
 
Cells lysed (50mM Na-P buffer pH 8, 125mM NaCl, 1% NP-40, 500µM EDTA, 1mM PMSF, 1x 
cOmplete EDTA free [Roche], 1mM DTT) on ice for 30min. After centrifugation at 21,000g for 
15min at 4°C, supernatant was collected, aliquoted and snap-freezed in liquid nitrogen prior 
use. Total protein concentration in lysate was determined using the Protein Assay Dye 
Reagent Concentrate (Bio-Rad). 50µg total protein were boiled in SDS loading buffer (45mM 
Tris-HCl pH 8, 10% glycerol, 1% SDS, 0.01% bromphenol blue, 50mM DTT) at 95°C for 2min 
and afterwards loaded onto 7% and 10% PAA (amresco) gels, respectively, together with 5µl 
of Precision Plus Dual Color protein standard (Bio-Rad). Proteins were separated at 100V and 
transfered onto a nictrocellulose membrane (Whatman, GE Healthcare) in transfer buffer 
(25mM Tris, 192mM glycine, 10% methanol, 0.005% SDS) at 30V and 4°C o/n. Unspecific 
binding sites were blocked by incubation with 10% milk in TBST (20mM Tris-HCl pH7.5, 
150mM NaCl, 0.1% Tween 20) for 1hr at RT and then sequentially probed with 1:1000 (5% 
milk in TBST) anti-Tet1 antibody (polyclonal rabbit, Abiocode #R1084-4) for 4h at RT and HRP-
linked anti-rabbit antibody (GE Healthcare). For loading control blots were probed with 
1:10,000 (5% milk in TBST) anti-Actin antibody (polyclonal mouse, Abcam) and HRP-linked 
20 
 
anti-mouse antibody (GE Healthcare). Blots were washed with TBST and subsequently 
incubated with Pierce ECL Western Blotting Substrate (Thermo) for 1min at RT. 
Chemiluminescence signals were detected on an Amersham Hyperfilm ECL (GE Healthcare). 
 
 
Generation of TET1 knockdown cell line 
 
A set of five pLKO.1-puro vectors encoding for short hairpin RNA constructs against TET1 
mRNA (TRCN0000075023, TRCN0000075024, TRCN0000075025, TRCN0000075026, 
TRCN0000075027) as well as a pLKO.1-puro non-mammalian target shRNA control vector 
were obtained from Sigma-Aldrich as bacterial glycerol stocks (#SHCLNG-NM_030625 and 
#SHC002). Sh-vectors were purified from o/n cultures in LB medium containing 100µg/ml 
Ampicillin using the QIAfilter Plasmid Midi Kit (Qiagen) together with the EndoFree Plasmid 
Buffer Set (Qiagen). Identity of purified sh-vectors was checked by restriction digest with 
BamHI and XhoI. Using the JetPEI transfection reagent (Polyplus transfection) with a N/P ratio 
of 5 HEK293T cells were cotransfected with 0.5µg sh-vector and 5µl packaging mix (Sigma-
Aldrich) containing the two lentiviral packaging vectors. Lentivirus-containing supernatant 
medium was collected 48h and 96h after transfection, pooled and concentrated using the Lenti-
X Concentrator (Clontech). Lentiviral particles (LPs) were quantified by means of the Lenti-X 
p24 Rapid Titer ELISA Kit (Clontech # 632200). Aliquots of LPs were frozen at -80°C before 
use. 
1.2-1.4x105 cells of SW620 were transduced with lentiviral partices in 48-well plates at MOI´s 
(multiplicity of infection) ranging from 0.5 to 8 using 8µg/ml Hexadimethrine bromide. Medium 
was replaced 24h post-transduction and 48h post-transduction with standard medium 
containing 5µg/ml Puromycin (Sigma). Cells were passaged three times in selective medium 
before individual cell clones were picked. Knockdown efficiency was analysed in monoclonal 
knockdown cells by qRT-PCR. 
 
 
Mouse xenografts 
 
In vivo experiments were approved by the Basel Cantonal Veterinary Office. NOD/SCID mice, 
that were initially obtained from Charles River Laboratories (Germany), and bred and 
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maintained under pathogen free conditions in the animal facility of the Department of 
Biomedicine of the University of Basel. Eight to ten week old mice were used for xenografting 
experiments.  
105 TET1-knockdown SW620 cells were resuspended in a 1:1 mixture of phosphate-buffered 
saline and growth factor-reduced Matrigel matrix (BD Biosciences) and inoculated 
subcutaneously into the flank of recipient mice. Tumor development was monitored by 
palpation. Time to onset of a palpable tumor was recorded and the tumor size was measured 
weekly by a dial caliper. Mice were sacrificed when tumors reached a maximum diameter of 
10 mm. 
 
 
Flow cytometric analysis and fluorescence activated cell sorting (FACS) 
 
Xenograft tissues were enzymatically digested in serum-free DMEM (GIBCO), containing 
1mg/ml Collagenase IV (Sigma Aldrich) and 50mg/ml DNAse I (Sigma-Aldrich), as well as 
several antibiotics, including Kanamycin (GIBCO), Amphotericin B (Sigma-Aldrich), 200mg/ml 
Metronidazol (Sigma-Aldrich) and 6mg/ml Cefuroxim (Sigma-Aldrich). After digestion, 
xenograft tissues were ground inside a 100 μm sterile cell filter with the blunt end of a Luer 
syringe while continually rinsing with DMEM medium. The filtrate was filtered again through a 
70 µm sterile cell filter and then centrifuged at 300g for 5min. The supernatant was removed 
and cells were resuspended in 1 mL of DMEM medium.  
For flow cytometric analysis the following antibodies were used: AlexaFluor488 (AF488) 
labeled anti-EpCAM (1:200, clone 9C4, Biolegend), Phycoerythrin (PE) labeled anti-CD166 
(1:25, clone 3A6, BD Biosciences), Peridinin Chlorophyll Protein Complex- (PerCP) labeled 
anti-CD24 (1:100, clone ML5, BD Biosciences), Allophycocyanin (APC) labeled anti-CD133 
(1:25, clone AC133/1, MiltenyiBiotec), Allophycocyanin cyanine 7 analog (APC-H7) labeled 
anti-CD44 (1:200, clone G44-26, BD Biosciences), Briliant Violet 421 (BV421) labeled anti-
Lgr5 (1:200, clone 8F2, BD Biosciences). LIVE/DEAD Fixable Yellow Dead Cell Stain Kit 
(Molecular Probes) was used according to manufacturer’s specifications. Relative 
fluorescence intensities were measured using a BD LSRFortessa cell analyzer (BD 
Biosciences), following exclusion of dead cells based on high Yellow Dead signal. Analysis 
was performed using FlowJo software (Tree Star). 
SW620 TET1-kd cells and sh-ctrl. cells were sorted using the above specified anti-CD24 and 
anti-CD44 antibodies. FACS was performed using a BD FACSAria Ilu (BD Biosciences).  
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Cell migration / invasion assay 
 
The migratory behavior and the invasive potential of SW620 TET1 knock down cells was 
assessed by an in vitro chemoinvasion assay as previously described (Albini and Benelli, 
2007). Briefly, SW620 cells were seeded into upper chambers of transwell plates onto 
uncoated (cell migration) or matrigel-coated (invasiveness) membranes (8µm pore size, BD 
Biocoat Tumor invasion assay, BD Biosciences). Lower chambers contained standard culture 
medium supplemented with 5% FBS. Plates were incubated at 37°C for 20 h. Inserts were 
then removed and the cell numbers in the lower chambers were quantified by CyQUANT Cell 
Proliferation Assay Kit (Invitrogen).  
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Figure legends 
 
Figure 1: Correlation of TET expression with genomewide promoter methylation in CRC 
cell lines. a) Illumina Infinium HumanMethylation27 data of eight human CRC cell lines. 
Shown is the unsupervised clustering based on the 25% of the probes with the highest 
methylation variability across the eight cancer cell lines (4945 CpG sites). Methylation M-
values are represented in a colour scale from green (low methylation) to red (high methylation). 
Black bars indicate microsatellite instable (MSI) and CIMP-positive cell lines, respectively. 
CIMP status was determined by methylation analysis (ln-qMSP) of the five marker panel. b) 
Linear correlation of log2 converted TET1, TET2 and TET3 mRNA expression levels (relative 
to the averaged expression of ACTB and GAPDH) in eight CRC cell lines with methylation M-
value means of the 3713 most variable CpG-island-associated Infinium methylation probes. 
Correlation coefficients (R) and p-values (p) are specified for each correlation. c) TET1 and β-
Actin protein expression analysis by western blotting in eight human CRC cell lines. d) 5mC 
and 5hmC levels quantified by MeDIP and GLIP in the promoter regions of PROK2, NPPC, 
DLX5, LHX6, POU3F2, WNT10A, SLC30A, TRIM9, CDK5R2 in the CRC cell lines CACO2, 
SW620, HCT116 and SW48. 5mC and 5hmC levels are given as enrichment relative to ACTB 
(RE vs. ACTB). **, p  0.01; n.s., not statistical significant (Wilcoxon matched pairs signed rank 
test) 
 
 
Figure 2: TET expression in CIMP and non-CIMP primary colorectal cancers. a) mRNA 
expression (analysed by qRT-PCR) of TET1, TET2 and TET3 in CIMP (n=7, colored),non-
CIMP- (n=15) primary human colorectal cancers (CIMP status according to the five marker 
panel), 18 matched cancer-associated normal mucosa samples (CAM) and 8 colonic mucosa 
biopsies from healthy individuals (HM). Expression was normalized against expression of 
ACTB and GAPDH (mean). Boxplots indicate the first and the third quartile plus the median, 
Whiskers indicate the minimum and maximum values. b) mRNA expression (Agilent 
expression array G4502A) of TET1, TET2 and TET3 in CIMP colorectal cancers (n=25) 
compared to non-CIMP cancers (n=118) (Cancer Genome Atlas, 2012). Expression levels are 
given as log2 converted fold-change relative to reference (log2 FC). Boxplots indicate the first 
and the third quartile plus the median, Whiskers indicate the minimum and maximum values. 
*, p  0.05; **, p  0.01 (Mann-Whitney test). c) TET1 promoter methylation analysis by ln-
qMSP in 22 primary colorectal cancers, classified in CIMP and non-CIMP according to the 
methylation status of the five marker panel, and in 8 CRC cell lines. PMA, percentage 
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methylated alleles. d) 5-AzaC treatment of CRC cell line SW48. TET1 mRNA expression 
quantified by qRT-PCR (left panel) and promoter methylation analysed by ln-MSP (right panel) 
in untreated cells and 5-AzaC treated cells. TET1 mRNA expression is relative to expression 
of GAPDH and ACTB (mean). PMA, percentage methylated alleles. 
 
 
Figure 3: Knockdown of TET1 in non-CIMP CRC cell line SW620. a) TET1 knockdown 
(TET1-kd) efficiency determined by qRT-PCR and western blotting and TET2 and TET3 mRNA 
expression in SW620 TET1-kd cells. TET1, TET2 and TET3 mRNA expression levels 
(normalized to ACTB and GAPDH) in TET1-kd cell clones (shTET1-1 and shTET1-2) are 
depicted relative to control vector-transduced cells (sh-ctrl.). Error bars show the standard 
deviation from two cDNA replicates. b) Dot Blot analysis of global 5hmC levels in SW620 sh-
ctrl and knockdown clones shTET1-1 and shTET1-2. Left panel: Chemiluminescence signals 
of 5hmC-antibody-incubated membrane. Loaded amount of genomic DNA is indicated at the 
top. Right panel: Loading control by Bromophenol blue staining. c) Venn diagram illustrating 
number of commonly hyper- and hypo-methylated Infinium HM450 array probes in shTET1-1 
and shTET1-2 cells compared to sh-ctrl (clear circles) as well as array probes commonly hyper- 
or hypo-methylated in shTET1-1 and shTET1-2 derived xenografts compared to sh-ctrl derived 
xenografts (grey circles). Circle size is proportional to number of probes. Overlaps indicate 
commonly hyper- or hypo-methylated probes in cells and xenografts. These overlaps were 
statistical significant (each with p<0.0001, Chi square). The increase in the fraction of 
hypermethylated probes from cell lines to xenografts is statistical significant, p<0.0001 (Chi-
square). d) TET1 promoter methylation levels in shTET1-1 and shTET1-2 (relative to sh-ctrl.) 
analysed by pyrosequencing of bisulfite-converted genomic DNA (from position +603 to +728 
relative to transcription start site). Each bar represents a single CpG site within the TET1 
promoter CGI ordered in 3´-5´ direction. PMA, percentage methylated alleles. 
 
 
Figure 4: TET1 depletion results in the loss of cancer-initiating cell markers. a) LGR5 
mRNA expression in SW620 sh-ctrl and TET1-kd clones shTET1-1 and shTET1-2 analysed 
by qRT-PCR. LGR5 expression is given relative to the expression of GAPDH and ACTB 
(mean). Error bars indicate the standard deviation from three RNA preparations.**, p  0.01; 
***, p  0.005, t-test. b) The fraction of LGR-, CD44- and CD166-positive cells in mouse 
xenografts derived from sh-ctrl and TET1-kd clones shTET1-1 and shTET1-2 determined by 
flow-cytometry. Fraction of marker-positive cells is represented as the mean percentage of 
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viable cells. Error bars indicate the standard deviation from four xenografts. *, p  0.05; **, p  
0.01; ***, p  0.005, t-test 
 
 
Figure 5: TET1 depletion decreases cell state plasticity. a) Dot blots showing viable 
CD24hiCD44hi and CD24negCD44neg cells in sh-ctrl and the TET1-kd clones shTET1-1 and 
shTET1-2 analysed by flow-cytometry. Dot plots indicate the gates used for quantitation. b) 
Dot plots illustrating the cell population distribution of sh-ctrl, shTET1-1 and shTET1-2 cells 
after sorting and expansion of CD24hiCD44hi (CD24+/CD44+) and CD24negCD44neg (CD24-
/CD44-) subpopulations. Staining for CD24 and CD44 was analysed by flow-cytometry. Bar 
graphs indicate the fraction of CD24+/CD44+ and CD24-/CD44- in sh-ctrl, shTET1-1 and 
shTET1-2 cells, before sorting (US, unsorted), after sorting (t0) and 8 days after expansion in 
culture (t8), normalized to the total number of cells comprised in the gates depicted in a). Error 
bars indicate the range of values from two experiments.  
 
 
Figure 6: TET1 depletion induces EMT-like process. a) Light microscopy pictures of cell 
colonies from sh-ctrl and TET1 knockdown clones shTET1-1 and shTET1-2 scale bar = 
200µm). b) CDH1 (E-cadherin) mRNA expression (left panel) and promoter methylation (right 
panel) in sh-ctrl cells and TET1 knockdown clones shTET1-1 and shTET1-2 analysed by qRT-
PCR and pyrosequencing of bisulfite converted genomic DNA, respectively. CDH1 expression 
is given relative to the expression of ACTB and GAPDH (mean). Error bars indicate the 
standard deviation from three RNA preparations. *, p  0.05, t-test. Blue bars indicate the 
median methylation value. PMA, percentage methylated alleles; *, p  0.05, Wilcoxon 
matched-pairs test. c) CDH1 mRNA expression data from TCGA (Cancer Genome Atlas, 
2012). Expression levels are shown as log2 converted fold change relative to reference (log2 
FC). Boxplots indicate the first and the third quartile plus the median, Whiskers indicate the 
minimum and maximum values. ****, p < 0.0001, Mann-Whitney test. d) FN1 (Fibronectin) and 
VIM (Vimentin) mRNA expression in sh-ctrl and theTET1-kd clones shTET1-1 and shTET1-2 
analysed by qRT-PCR. Expression levels are normalized to the expression of GAPDH and 
ACTB (mean). Error bars indicate the standard deviation from three RNA preparations. *, p  
0.05; ***, p  0.005, t-test. e) Cell migration assay with SW620 sh-ctrl cells and TET1 kd clones 
shTET1-1 and shTET1-2. Illustrated is the mean fluorescence signal from five experiments. 
Error bars indicate the standard deviation. **, p  0.01, t-test.  
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Supplementary Figure Legends 
 
Figure S1: Correlation of DNMTs and TDG with genomewide methylation and TETs with 
global hydroxymethylation in CRC cell lines. Linear correlation of log2 converted TET1, 
TET2 and TET3 mRNA expression levels in eight CRC cell lines with log2 converted global 
5hmC levels analysed by LC-MS/MS. mRNA expression values were determined by qRT-PCR 
relative to the combined expression of GAPDH and ACTB. Correlation coefficients (R) and p-
values (p) are specified for each correlation. 
 
 
Figure S2: DNMT and TDG expression in CIMP and non-CIMP primary CRCs. mRNA 
expression (Agilent expression array G4502A) of DNMT1, DNMT3A, DNMT3B, TDG, IDH1 
and IDH2 in colorectal cancers from the CIMP-H cluster (n=25) compared to non-CIMP-H 
clusters (CIMP-L, 3, 4; n=118) (Cancer Genome Atlas, 2012). Expression levels are given as 
log2 converted fold-change relative to reference (log2 FC). Boxplots indicate the first and the 
third quartile plus the median, Whiskers indicate the minimum and maximum values. *, p  
0.05; **, p  0.01; ***, p  0.005; n.s., not statistical significant (Mann-Whitney test). 
 
 
Figure S3: Global 5hmC levels and genome-wide methylation in TET1 knockdown cells 
a) Specificity test for hmC-antibody. Shown are the chemiluminescence signals of the 5hmC-
antibody incubated membrane. Loaded amounts of hmC- and mC-containing control oligomers 
are indicated at the top. b) Global 5mC and 5hmC levels in TET1 knockdown cells quantified 
by LC-MS/MS and shown as number of modified cytosines in one million nucleotides. Depicted 
are two sh-controls (sh-ctrl) and four monoclonal TET1 knockdown cell lines (shTET1). Blue 
bars indicate the median value. c) TET1 mRNA expression in mouse xenografts derived from 
sh-ctrl and TET1-kd clones shTET1-1 and shTET1-2. Shown is the mean expression value 
from four xenografts together with the standard deviation. Expression was determined relative 
to the expression of GAPDH and ACTB (mean). d) Volcano blots depicting differential 
methylation of TET1-kd cells and xenografts shTET1-1 (shTET1-xeno1) and shTET1-2 
(shTET1-xeno2) compared to sh-ctrl cells and xenografts analysed using the Illumina Infinium 
450k methylation platform. Plotted are the log2 fold changes (FC) in methylation with the 
negative log10 of false discovery rate (FDR)-adjusted p-values. Numbers indicate the fraction 
of significantly (log2FC>2, p-value<0.0001) differently methylated CpG methylation probes. 
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Figure S4: CIMP five marker panel in TET1-kd cells a) Methylation levels of CIMP five-
marker panel (Weisenberger et al. 2006) quantified by ln-qMSP in sh-ctrl and TET1-kd clones 
shTET1-1 and shTET1-2. Shown is the mean value plus standard deviation of two PCR 
replicates. PMA, percentage methylated alleles. b) Agarose gel electrophoresis of ln-qMSP 
products (after 45 PCR cycles) from methylation quantitation of the five-marker panel. 
Genomic DNA from human peripheral blood treated with the CpG-methyltransferase M.SssI 
served as positive control (Pb SSSI). c) Left panel: Promoter methylation level of MLH1 
analysed by pyrosequencing of bisulfite-converted genomic DNA from sh-ctrl and the TET1-
kd clones shTET1-1 and shTET1-2. Each dot represents a single CpG site, blue bars indicate 
the median methylation value. *, p  0.05; **, p  0.01 (Wilcoxon matched-pairs test). Right 
panel: MLH1 mRNA expression in sh-ctrl and TET1-kd clones shTET1-1 and shTET1-2 
analysed by qRT-PCR. Error bars indicate the standard deviation from three RNA 
preparations. Expression values are shown relative to the expression of GAPDH and ACTB 
(mean). *, p  0.05 (t-test). 
 
 
Figure S5: EMT marker expression in TET1-kd cells. SNAI1, SNAI2 and ZEB1 mRNA 
expression quantified by qRT-PCR in sh-ctrl and the TET1-kd clones shTET1-1 and shTET1-
2. Expression levels are shown relative to the expression levels of GAPDH. 
 
 
Figure S6: TET1 Western Blots. a) TET1 Western Blot with whole cell extracts from human 
CRC cell lines. Chemiluminescence signals of anti-Tet1 antibody (α-TET1, left panel) and anti-
ACTB antibody (α-ACTB) incubated membranes. Molecular weights are shown in kilo Daltons 
(kDa) on the left. b) TET1 Western Blot with whole cell extracts from monoclonal SW620 TET1-
kd cell lines (clone1 and clone2) and sh-control cells. Chemiluminescence signals of anti-Tet1 
antibody (α-TET1, left panel) and anti-ACTB antibody (α-ACTB) incubated membranes. 
Molecular weights are shown in kilo Daltons (kDa) on the left. c) TET1 Western Blot with whole 
cell extracts from CACO2 TET1-kd cell lines (vec1 and vec2) and sh-control cells. 
Chemiluminescence signals of anti-Tet1 antibody (α-TET1, left panel) and anti-ACTB antibody 
(α-ACTB) incubated membranes. Molecular weights are shown in kilo Daltons (kDa) on the 
left.  
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Supplementary Table 1: Clinical data of CRC patients 
Patient # Gender Age Tumor location Colonic site Tumor stage CIMP CAM 
1 f 65 Caecum Right T3 N0 M1 negative no 
2 f 67 Rectosigmoid Left T2 N0 MX negative no 
3 f 75 Rectum Left T3 N2 M1 negative yes 
4 m 61 Rectum Left T3 N1 M0 negative yes 
5 m 53 C. sigmoideum Left T4 N1 M1 negative yes 
6 f 46 Rectum Left T3 N2 M0 negative yes 
7 m 76 C. ascendens Right T4 N1 M1 negative yes 
8 m 75 C. sigmoideum Left T3 N0 M0 negative yes 
9 f 66 C. sigmoideum Left T3 N1 M1 negative yes 
10 m 82 C. sigmoideum Left T3 N0 MX negative yes 
11 m 67 Rectum Left T2 N0 M0 negative yes 
12 f 85 C. transversum Right T4 N1 M0 negative no 
13 f 57 Rectum Left T1 N0 MX negative yes 
14 m 69 Rectum Left T3 N0 M0 negative yes 
15 m 81 Rectosigmoid Left T4 N2 M1 negative yes 
16 m 65 C. ascendens Right T3 N2 MX positive yes 
17 m 70 C. sigmoideum Left T3 N0 M0 positive yes 
18 m 74 C. ascendens Right T2 N0 M1 positive yes 
19 f 82 C. ascendens Right T3 N0 M0 positive yes 
20 f 85 n/a n/a T3 N0 M0 positive no 
21 f 80 C. ascendens Right T3 N0 MX positive no 
22 m 73 C. ascendens Right T3 N0 M0 positive yes 
23 f 70 C. ascendens Right T3 N2 M0 positive yes 
 
 
Supplementary Table 2: Cell lines used in this study 
Name Species Source Standard medium 
HEK293T human Embryonic kidney DMEM + 10% FCS + 2mM L-Glutamin  
CACO2 human Colon adenocarcinoma EMEM + 20% FCS 
CO115 human Colon adenocarcinoma DMEM + 10% FCS + 2mM L-Glut 
COLO205 human Colon adenocarcinoma RPMI 1640 + 10% FCS + 2mM L-Glut 
COLO320 human Colon adenocarcinoma RPMI 1640 + 10% FCS 
COLO741 human Colon adenocarcinoma RPMI 1640 + 10% FCS + 2mM L-Glut 
DLD-1 human Colon adenocarcinoma RPMI 1640 + 10% FCS 
GP5-d human Colon adenocarcinoma DMEM + 10% FCS + 2mM L-Glutamin  
HCT116 human Colon McCoy 5a + 10% FCS 
LOVO human Colon adenocarcinoma F-12 + 10% FCS + 2mM L-Glut 
SW48 human Colon adenocarcinoma DMEM + 10% FCS + 2mM L-Glut 
SW620 human Colon adenocarcinoma DMEM + 10% FCS + 2mM L-Glut 
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Supplementary Table 3: Primers used for ln-qMSP 
Name Orientation Sequence (5´- 3´) Length 
MLH1 qMSP M-primer F ACGCAGACGCTCCACCAGGGCCGC 24 
MLH1 qMSP M-primer R TCCGGAGGGCGATGGGGCCCTGTGC 25 
MLH1 qMSP S-primer F AGTTTGGAGTGGTAGGTTTTTAGAGG 26 
MLH1 qMSP S-primer R CATCCCCAAATTCTTACTCCTTCTTTC 27 
TET1 qMSP M-primer F TATTTCGGGACGTTCGGGAC  20 
TET1 qMSP M-primer R CGCTATAACGAAACCTCCGAAACG  24 
TET1 qMSP S-primer F TGTAGAGGGAATTTGAGTTAGGTTTGG  27 
TET1 qMSP S-primer R CCCCATTTTCTTCCCCAAATAACAAC  26 
NEUROG1 qMSP M-primer F GGGGCGTTTATTGTTGCGTC 20 
NEUROG1 qMSP M-primer R CGATCTCCTAAATAATATCGCCGACG 26 
NEUROG1 qMSP S-primer F GATGTTTGGGTTTTTGTGGTTTTTGG 26 
NEUROG1 qMSP S-primer R CCTATTCCAACAAATCTTCCCTCTACATATC 31 
CACNA1G qMSP M-primer F GATTCGGTTTTAGTTGCGTCGC 22 
CACNA1G qMSP M-primer R AATTCGACGCTACCTTCGACG 21 
CACNA1G qMSP S-primer F GGTTGTGAGGGAGGGGTAAAG 21 
CACNA1G qMSP S-primer R ACCTCAATTTCTCAACAAAAACACTAAACC 30 
RUNX3 qMSP M-primer F GATTACGTAGGCGAGTTCGTGC 22 
RUNX3 qMSP M-primer R CTCACCTTAAAAACGACGAACAACG 25 
RUNX3 qMSP S-primer F GATTGTGGTTTTGGGAGATGTAAGAGG 27 
RUNX3 qMSP S-primer R TCCTCCTCAAATCACTTCCTACCTC 25 
SOCS1 qMSP M-primer F CGTGGTTATCGTGGGTCGC 19 
SOCS1 qMSP M-primer R GTACACGACGAACGCTACCG 20 
SOCS1 qMSP S-primer F TATTAGGGGGTGAGGTGAGGTTTG 24 
SOCS1 qMSP S-primer R CTACCCCAACCCAAAACCACTAC 23 
IGF2 qMSP M-primer F GTAGTTCGGTTCGTAGGTCGTC 22 
IGF2 qMSP M-primer R ACGATAACGACACCGAAACCG 21 
IGF2 qMSP S-primer F GGGAGGTTGTAGAAGGTTGGTG 22 
IGF2 qMSP S-primer R ATCTACATCAATCACCCCCATATCCC 26 
 
 
Supplementary Table 4: Primers used for Pyrosequencing 
Name Orientation Sequence (5´- 3´) Length 
MLH1 Pyro amp F TTTTGTGATATTTGGAGATAAG  22 
MLH1 Pyro amp R BIO-ATAAAACCCTATACCTAATCTAT 23 
MLH1 Pyro seq 1   GTAATATTTTTATGTATTGGTATATAAAG  29 
MLH1 Pyro seq 2   TAGGAGTGAAGGAGGT  16 
CDH1 Pyro amp F GAATTGTAAAGTATTTGTGAGTTTG 25 
CDH1 Pyro amp R GCCCCCGCCCGCCCACTCCCATCACTAA 28 
CDH1 Pyro seq 1   GTTGTTGTTGTAGGTAT 17 
CDH1 Pyro seq 2   TTTTTTTTTTTTAAGAAAG 19 
Pyro Biotin universal F BIO-GCCCCCGCCCG 11 
Target sequences for the Biotin-labeled universal primer are marked in red 
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Supplementary Table 5: Primers used for MeDIP and GLIP 
Name Orientation Sequence (5´- 3´) Length 
DLX5 F GGAGGAAGAGGAGGAGGAGA 20 
DLX5 R GGCCAATAGAACCAGATCCA 20 
NPPC F GAGGGAGAGCAGCGTGAG 18 
NPPC R TATAAAGGCGCGAGCAGAG 19 
PROK2 F CCTCTAGCCTGCCCTTCAG 19 
PROK2 R CCCACTCCTGCTCCTCTTG 19 
LHX6 F GCGTTCTCATGCTTCCAGTA 20 
LHX6 R AGCCTCTGCTCCCACTGC 18 
POU3F2 F GCAGCGTCTAACCACTACAGC 21 
POU3F2 R GGGTGTCCGTTGCTCTGC 18 
WNT10A F AAAGGGAAGGCGGCAGAG 18 
WNT10A R GGTGCCTCTCAAGGGTAAGG 20 
SLC30A F TCTGTCCTACCTCTTCAAACG 21 
SLC30A R CAGTTCGCTCCACTCTGGT 19 
TRIM9 F CCTACCTGCCCTCCTAGTCC 20 
TRIM9 R CGAAGACTGCCCTATCCTCA 20 
CDK5R2 F CGCAGCTCAGGATTAGAGCA 20 
CDK5R2 R CAGGCGAAAGAGACAGCAC 19 
 
 
Supplementary Table 6: Primers used for qRT-PCR 
Name Orientation Sequence (5´- 3´) Length 
TET1 RT-primer F GTTGTTGTGCCTCTGGAGGTTATAAAGG  28 
TET1 RT-primer R TCTGACTTGGGGCCATTTACTGG 23 
TET2 RT-primer F GAAGAGCAGTAAGGGACTGAGC 22 
TET2 RT-primer R GGACTTAGTCTGTTGCCCTCAAC 23 
TET3 RT-primer F CCCACCTGCGATTGCGTC 18 
TET3 RT-primer R CTCTCCATACCGCTCCTCCATG 22 
DNMT1 RT-primer F CCAGAGAACGAGTTGCTAGACC 22 
DNMT1 RT-primer R TTCTTTGGTTTGACTTCGGAGTCTC 25 
DNMT3A RT-primer F CAGTGGAAAATGGCTGCTGC 20 
DNMT3A RT-primer R AGCCCTCCATTTTCATGGATTCG 23 
DNMT3B RT-primer F GCTACACACAGGACTTGACAGG 22 
DNMT3B RT-primer R GGCTGGAGACACTGTTGTTATTTCG 25 
TDG RT-primer F CGGAAGTGCAGCACAGAAAG 20 
TDG RT-primer R CTGAAGGGAATAGCTGCCCG 20 
LGR5 RT-primer F GCTGCCTTCCAACCTCAGC 19 
LGR5 RT-primer R CCGCAAGACGTAACTCCTCCAG 22 
ACTB RT-primer F AGCCTCGCCTTTGCCGA 17 
ACTB RT-primer R CTGGTGCCTGGGGCG 15 
GAPDH RT-primer F ATCTTCTTTTGCGTCGCCAG 20 
GAPDH RT-primer R AATCCGTTGACTCCGACCTTC 21 
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 Background Aberrant DNA methylation in gene promoters is associated with aging and cancer, but the circumstances deter-
mining methylation change are unknown. We investigated the impact of lifestyle modulators of colorectal cancer 
(CRC) risk on the stability of gene promoter methylation in the colonic mucosa.
 Methods We measured genome-wide promoter CpG methylation in normal colon biopsies (n = 1092) from a female screening 
cohort, investigated the interaction of lifestyle factors with age-dependent increase in methylation with log-linear mul-
tivariable regression, and related their modifying effect to hypermethylation in CRC. All statistical tests were two-sided.
 Results Of 20 025 promoter-associated CpGs analyzed, 1713 showed statistically significant age-dependent methylation 
gains. Fewer CpGs acquired methylation in users of aspirin (≥2 years) and hormonal replacement therapy (HRT 
age ≥50 years) compared with nonusers (43 vs 1355; 1 vs1377, respectively), whereas more CpGs were affected in 
smokers (≥20 years) and individuals with a body mass index (BMI) of 25 kg/m2 and greater compared with control 
groups (180 vs 39; 554 vs 144, respectively). Fifty percent of the CpGs showing age-dependent methylation were 
found hypermethylated in CRC (odds ratio [OR] = 20; 95% confidence interval [CI] = 18 to 23; P < 2 × 10–16). These 
loci gained methylation with a higher median rate compared with age-only methylated sites (P = 2 × 10–76) and 
were enriched for polycomb regions (OR = 3.67). Importantly, aspirin (P < .001) and HRT use (P < .001) reduced the 
methylation rate at these cancer-related genes, whereas smoking (P < .001) and high BMI (P = .004) increased it.
 Conclusions Lifestyle, including aspirin use, modulates age-associated DNA methylation change in the colonic epithelium and 
thereby impacts the evolution of cancer methylomes.
  JNCI J Natl Cancer Inst (2014) 106(7): dju161 doi:10.1093/jnci/dju161
Aberrations in DNA methylation deregulate the genome and 
contribute to the loss of tissue homeostasis observed in aging and 
diseases such as cancer (1,2). They can constitute both driver and 
passenger events of tumorigenesis, as evident from widespread 
changes in CpG methylation observed in cancers. Among those, 
the hypermethylation of promoter-associated CpG islands is a 
well-documented phenomenon (3), often associated with the loss 
of expression of the respective gene (4). Exactly why and how such 
epigenetic change arises is currently unknown.
Hypermethylation at promoters of tumor suppressor genes is a 
hallmark of colorectal cancer (CRC), for which age is a major risk fac-
tor (5,6). An increasing body of evidence indicates that aging is, at the 
same time, associated with an accumulation of aberrations in DNA 
methylation in human tissues, including colon (7–10). We and others 
have shown that de novo methylation at CpG island promoters of 
cancer-relevant genes arise in the aging mucosa of healthy individuals 
with no evidence of intestinal disease (11,12). Notably, these meth-
ylation changes appeared in patterns implicating a contribution of 
physiological and environmental factors (11,13,14). Understanding 
what controls the stability of DNA methylation in aging tissue is of 
both biological and clinical importance. Herein we address to what 
extent age-associated methylation change in the human colon is 
influenced by lifestyle and whether the ensuing epigenetic aberrations 
have relevance for neoplastic transformation. For this purpose, we 
determined CpG methylation levels in normal colon biopsies from 
a large female screening cohort and related these to the exposure of 
well-accepted CRC risk modulators (15–19): aspirin use, hormone 
replacement therapy (HRT), BMI, and smoking habits.
Methods
Study Participants and Data Collection
The study included 546 healthy women randomly recruited from 
a national colonoscopy screening for CRC in Poland (20). Ethical 
approval was obtained for all samples. From each participant, biop-
sies of normal mucosa from the cecum and sigmoid colon were 
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collected in RNAlater (Applied Biosystems, Lucerne, Switzerland) 
and stored at −80°C. Information on the use of aspirin, HRT, and 
cigarette smoking was collected using a self-administered question-
naire under the assistance of a study nurse (Table 1; Supplementary 
Materials, available online).
Quantification of DNA Methylation
Locus-Specific DNA Methylation. Bisulfite-converted genomic 
DNA of 1092 samples was used to measure human MutL homolog 
1 (hMLH1) and O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation levels (percentage of methylated 
alleles) by locus normalized quantitative methylation specific poly-
merase chain reaction (ln-qMSP). Full details are available in the 
Supplementary Materials (available online). Primer sequences are 
provided in the Supplementary Table 1.
Genome-Wide DNA Methylation. Genome-wide assessment of 
DNA methylation was done on Infinium HumanMethylation27 
Beadchip arrays (Illumina, San Diego, CA), interrogating methyla-
tion at 27 578 CpGs distributed in the promoters of 14 475 coding 
genes. Details on quantitation of methylation levels are available 
in the Supplementary Materials (available online). Microarray 
data were validated by bisulfite pyrosequencing (Supplementary 
Materials, available online).
All primary data generated in the study were deposited in the 
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/; accession No. GSE48988. Methylation data of 59 
female CRC samples were obtained from GEO (accession No. 
GSE25062) (21).
Gene Expression Analysis
Expression data for 32 colon adenomas/normal tissues were 
obtained from GEO (accession No. GSE8671) (22). The data were 
median normalized, log2 transformed, and analyzed using the R/
Bioconductor limma package.
H3K27me3 Status in Human Embryonic Stem Cells
H3K27me3 is a polycomb repressive mark of interest because 
its presence in stem cells has been shown to predispose genomic 
sequences to aberrant DNA methylation during aging and carcino-
genesis (8,23,24). An H3K27me3 profile in human embryonic stem 
cells was obtained from GSE13084 (25). Five hundred base-pair win-
dows symmetrically positioned around the Illumina Infinium human-
Methylation27 CpGs were analyzed for enrichment of H3K27me3.
Statistical Analyses
Locus-Specific DNA Methylation Analysis. Log-linear multivari-
able regression models were applied to investigate the interaction of 
age-related DNA methylation changes with lifestyle factors by con-
sidering age as a linear predictor and the four lifestyle factors of aspi-
rin use, HRT use, BMI, and smoking as categorical predictors. To 
analyze methylation interaction with age, corresponding interaction 
terms were introduced in the model. To investigate the interaction of 
age with polyps, separate multivariable regression models (adjusted 
for the interaction of the four lifestyle factors with age) were done by 
considering age as a linear predictor and polyps as categorical predic-
tors (either as one group [any polyp] or classified as tubular adenomas 
Table 1. Clinical characteristics of the study population
Characteristic
No. of 
subjects (%)
Age, y
 <60 275 (50)
 ≥ 60 271 (50)
Aspirin regular use*
 Nonuser† 391 (71)
 Short-term user (< 2y)‡ 86 (16)
 Long-term user (≥ 2y)§ 69 (19)
Hormone replacement therapy||
 Nonuser¶ 245 (45)
 Aged <50 y# 175 (32)
 Aged ≥ 50 y** 126 (23)
Body mass index, kg/m2††
 Normal, 18.5–25 227 (42)
 Overweight, 26–30 224 (41)
 Obese, >30 95 (17)
Cigarette smoking‡‡
 Nonsmoker§§ 272 (50)
 Short-term smoker, <20 y|||| 122 (22)
 Long-term smoker, ≥20 y¶¶ 152 (28)
Polyps
 No polyps 350 (64)
 Yes 196 (36)
  Proximal colon##
  Tubular adenoma 49 (25)
  Serrated lesion*** 25 (13)
   Hyperplastic polys 22 (11)
   Sessile serrated adenoma 3 (2)
  Distal colon†††
  Tubular adenoma 41 (21)
  Serrated lesion 81 (41)
   Hyperplastic polyps 69 (35)
   Sessile serrated adenoma 12 (6)
* Regular use defined as two or more tablets per week for 1 or more months.
† Non-user: women who indicated that they did not use two or more aspirin 
tablets per week for 1 or more months (minimum level).
‡ Short-term user: women who indicated that they used two or more aspirin 
tablets per week for less than 2 years.
§ Long-term user: women who indicated that they used two or more aspirin 
tablets per week for 2 or more years.
|| Hormone replacement therapy defined as estrogen therapy and/or oral 
contraceptive for 1 or more years.
¶ Non-user: women who indicated that they did not have hormone 
replacement therapy for 1 or more years (minimum level).
# Aged <50: women who indicated that they did had hormone replacement 
therapy for 1 or more years before age 50 years.
** Aged ≥50 years: women who indicated that they did have hormone 
replacement therapy for 1 or more years after the age of 50 years.
†† Body mass index: height (cm) and weight (kg) were self-reported, and body 
mass index was calculated (kg/m2) from these variables.
‡‡ Cigarette smoking was defined as one or more cigarettes per day for one or 
more years.
§§ Nonsmoker: women who indicated that they did not smoke one or more 
cigarettes per day for 1 or more years (minimum level).
|||| Short-term smoker: women who indicated that they smoked one or more 
cigarettes per day for less than 20 years.
¶¶ Long-term smoker: women who indicated that they smoked one or more 
cigarettes per day for 20 or more years.
## Proximal colon: cecum.
*** Serrated lesion: any serrated polyp including hyperplastic and sessile 
serrated adenoma.
††† Distal colon: sigmoid.
 at U
niversity of Basel/ A
284 U
PK
 on N
ovem
ber 13, 2014
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
JNCI | Article 3 of 9jnci.oxfordjournals.org
and serrated lesions, including both hyperplastic polyps and sessile 
serrated adenomas). Separate calculations were done for each colonic 
location (proximal and distal colon) and gene. For data presentation, 
log-linear regression coefficients were back transformed and used 
to calculate rates of change in methylation per 10-year increase in 
age in respective lifestyle strata. The fold difference in the rate of 
change in methylation between two categories was defined as the 
methylation rate ratio (MRR). Full details and analyses are given in 
the Supplementary Materials (available online) and Supplementary 
Tables 2–4 (available online). The association between lifestyle factors 
and occurrence of polyps was examined by means of logistic multivar-
iable regression models adjusted for age, aspirin use, HRT use, BMI, 
and smoking but without age interaction (Supplementary Table  5, 
available online). Regression coefficients are expressed as odds ratios 
(ORs). Median regression analysis was conducted as supplementary 
analysis to evaluate the impact of extreme values on the results. The 
impact of methylation values below the detection limit was tested 
with tobit regression. Neither supplementary analysis changed the 
results, and thus they are not reported.
Genome-Wide DNA Methylation Analysis. The differential anal-
ysis of methylation data was performed on the M value (log2 ratios 
of methylated and unmethylated probes) using routines implemented 
in the R/Bioconductor limma package (26). Full details are given in 
the Supplementary Materials (available online). False-discovery rate 
(FDR)–adjusted P values for multiple comparison were calculated 
using the Benjamini and Hochberg approach. CpGs were considered 
statistically significantly differentially methylated with age when dis-
playing an FDR-adjusted P value less than .05. CpGs were considered 
statistically significantly hypermethylated in colorectal cancer vs nor-
mal when displaying FDR-adjusted P value less than .0001 and fold 
change difference in M values greater than 2. P values for the differ-
ence in median rate of DNA methylation change were calculated by 
Wilcoxon rank sum test. P values and ORs for overlap were calculated 
using Fisher exact test. Cancer relevance of identified age-related 
hypermethylation targets was addressed using the tumor-associated 
genes (TAG) database (27). Pathway analyses were performed with 
KEGGprofile in R/Bioconductor. All statistical tests were two-sided.
results
We investigated a cohort of 546 healthy women aged 50 to 80 years 
for relationships between gene promoter methylation in the colonic 
mucosa and the reported use of aspirin, reported HRT, BMI, and 
smoking (Table 1).
Age-Related DNA Methylation and Association With 
Lifestyle and Polyp Occurrence
We first measured hMLH1 and MGMT promoter methylation as per-
centage of methylated alleles by ln-qMSP in a total of 1092 normal 
biopsies obtained from cecum (proximal) and sigmoid (distal) colon. 
Log-linear multivariable regression analysis showed that methyla-
tion at the hMLH1 promoter statistically increased with age in the 
proximal colon (rate per 10 years of age = 2.1%; P < .001) (Figure 1A; 
Supplementary Table 2, available online). By contrast, the MGMT 
promoter did not show an overall age-dependent methylation change 
(Figure 1A; Supplementary Table 3, available online) unless lifestyle 
factors were taken into account (Figure 1B; Supplementary Table 3, 
available online); long-term aspirin use was associated with a more 
than 50% suppressed rate of methylation when compared with non-
use (proximal colon: MRR = 0.44, 95% CI = 0.27 to 0.70, P = .004; 
distal colon: MRR = 0.47, 95% CI = 0.31 to 0.73, P = .005), whereas 
HRT after the age of 50 years and long-term smoking slightly stimu-
lated MGMT methylation in the proximal colon (HRT: MRR = 1.63, 
95% CI = 1.05 to 2.53, P = .07; smoking: MRR = 1.51, 95% CI = 1.01 
to 2.26, P = .09). Notably, women with serrated lesions had a 48% 
higher rate of MGMT promoter methylation in the distal colon com-
pared with women with no polyps (MRR = 1.48; 95% CI = 1.12 to 
1.95; P = .02) (Figure 1C; Supplementary Table 4, available online), 
and the risk of serrated lesions was reduced in long-term aspirin 
users (OR = 0.36; 95% CI = 0.16 to 0.74; P = .03) but increased in 
long-term smokers (OR = 2.67; 95% CI = 1.72 to 4.15; P < .001) 
(Figure 1D; Supplementary Table 5, available online). No association 
with lifestyle and/or the occurrence of polyps was found for hMLH1 
promoter methylation (Supplementary Table 2, available online).
Next, we analyzed genome-wide DNA methylation in 178 
normal colon samples from our cohort (Illumina Infinium 
HumanMethylation27 BeadChip). We analyzed 20 025 promoter-
associated CpGs with multivariable regression adjusted for colonic 
location, aspirin use, HRT, BMI, and smoking and identified 1713 
CpGs gaining and 343 losing methylation with age; 219 CpGs 
acquired methylation exclusively in the proximal, and 416 acquired 
methylation exclusively in the distal colon (Figure  2A). When 
stratified for lifestyle factors, age-dependent hypermethylation was 
suppressed in aspirin users (43 CpGs in users vs 1355 in nonus-
ers) and/or in women reporting HRT (1 CpG in users vs 1377 in 
nonusers) but promoted in individuals with a high BMI (554 CpGs 
in high BMI vs 144 in normal BMI) (Figure 2B). Whereas aspirin 
use, HRT, and BMI modulated age-dependent DNA methylation 
changes along the entire colon, the effect of smoking was confined 
to the proximal colon (180 CpGs in smokers vs 39 in nonsmok-
ers) (Supplementary Figure  2, A  and B, available online). The 
median rate of age-dependent methylation change at hypermeth-
ylated CpGs (median rate = 1.6%; range = 0.07%–6.97%) was 56% 
higher in the distal colon than in the proximal colon (MRR = 1.56; 
P  =  9 × 10–18) (Figure  2C). The rate was 48% lower in aspirin 
users and 47% lower in women reporting HRT compared with 
non-users (aspirin: MRR = 0.52, P = 1 × 10–94; HRT: MRR = 0.53; 
P = 5 × 10–57) (Figure 2D), whereas a high BMI was associated with 
a 27% increased methylation rate in the distal colon (MRR = 1.27; 
P  = 5 × 10–9), and smoking was associated with a 400% increased 
rate in the proximal colon (MRR = 4.67; P = 1 × 10–28) but a 33% 
decreased rate in the distal colon (MRR  =  0.66; P  =  8 × 10–46) 
(Supplementary Figure 2, A and B, available online).
Examining potential interactions between these lifestyle effects, 
we found statistically significant overlaps between CpGs show-
ing suppression of age-related methylation by aspirin use or HRT 
(OR = 72; 95% CI = 62 to 83; P < 2 × 10–16) (Figure 2E) and, less 
pronounced, between CpGs showing BMI- or smoking-stimulated 
hypermethylation (OR  =  14; 95% CI  =  11 to 19; P  =  2 × 10–63). 
Although the methylation-retarding effect of aspirin use was appar-
ent in the entire study population, it appeared more effective in indi-
viduals with a high BMI (52%; MRR = 0.48; P = 2 × 10–31) compared 
with individuals with a normal BMI (22%; MRR = 0.78; P = .0001) 
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Figure  1. Association of human MutL homolog 1 (hMLH1) and O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation 
with lifestyle factors and polyps. A) hMLH1 and MGMT promoter meth-
ylation in proximal (cecum) and distal (sigmoid) colon as percentages 
of methylated alleles (PMAs) determined by locus normalized quanti-
tative methylation specific polymerase chain reaction (ln-qMSP). For 
presentation only, age is shown in two groups as indicated. Shown are 
median (lines) and mean (black circles) PMAs with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme 
values (gray lines). B) Association between age-dependent MGMT 
promoter methylation and lifestyle factors. Each point represents one 
biopsy. P values are derived from log-linear multivariable regression 
analysis (Supplementary Table 3, available online) representing signifi-
cance of the difference in two regression lines. C) Association of MGMT 
promoter methylation with the occurrence of polyps. Methylation rate 
ratios (MRRs) and P values are derived from log-linear multivariable 
regression (Supplementary Table 4, available online). D) Association of 
lifestyle parameters with the occurrence of polyps. Odds ratios (ORs) 
and P values are derived from logistic multivariable regression analy-
sis (Supplementary Table 5, available online). BMI = body mass index; 
CI = confidence interval; HRT = hormone replacement therapy. All statis-
tical tests were two-sided.
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Figure  2. Genome-wide DNA methylation and its association with 
lifestyle factors. A and B) Numbers of age-associated differentially 
methylated CpGs in all samples or when stratified by colon location 
(proximal [cecum] vs distal [sigmoid]) and lifestyle factors (aspirin: 
nonuser vs user [long-term]; hormone replacement therapy [HRT]: 
nonuser vs user [aged ≥50  years]; body mass index [BMI]: normal 
vs high [>25 kg/m2]; smoking: nonsmoker vs smoker [long-term]). 
Numbers of samples tested in each category are indicated at the bot-
tom of each bar. C and D) Ten-year rates of DNA methylation change 
for CpGs showing age-associated hypermethylation in all samples 
or when stratified by colon location and lifestyle factors. Shown are 
median (lines) and mean (black circles) rates with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme val-
ues (gray lines). P values according to the Wilcoxon rank sum test. 
E) Concordance of probes showing suppression of age-associated 
methylation by aspirin-use and HRT or promotion of age-associated 
methylation by a high BMI and long-term smoking. P values and odds 
ratios (ORs) according to the Fisher exact test. F) Enrichment of age-
associated differentially methylated sites marked by histone 3 lysine 27 
tri-methylation (H3K27me3) in human embryonic stem cells (hESCs). 
Barplots indicate percentages of age-associated hypermethylated 
(Age-hyperM) and hypomethylated (Age-hypoM) CpGs either marked 
by H3K27me3 (positive) or not (negative), or the enrichment of CpGs 
marked by H3K27me3 in lifestyle modulated age-related hypermeth-
ylation (bottom). Odds ratios and P values according to Fisher exact 
test. Density plots on the right show the rate of change in Age-hyperM 
and Age-hypoM probes at H3K27me3 positive (gray line) and negative 
(black, dashed line) CpGs. Dashed vertical lines indicate median rate 
of change per 10 years of age. PcG = polycomb group. All statistical 
tests were two-sided.
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or in smokers (79%; MRR = 0.21; P = 3 × 10–20) compared with non-
smokers (31%; MRR = 0.69; P = 2 × 10–84) (Supplementary Figure 2C, 
available online). HRT use retarded methylation in individuals with 
a high BMI only (70%; MRR = 0.30; P = 9 × 10–44), whereas its effect 
on smoking remained unclear because of limited statistical power.
Association of Lifestyle-Modulated DNA Methylation 
With Genomic Regions Disposed to Hypermethylation 
in Cancer
To investigate whether CpGs prone to age-dependent methylation 
are distinguished by specific genomic features, we classified array 
CpG probes with regard to coincidence of H3K27me3 in human 
embryonic stem cells. Regions surrounding age-hypermethylated 
CpGs were statistically significantly enriched for domains marked 
by H3K27me3 in stem cells compared with total H3K27me3 
marked CpGs on the array (OR = 4.84; 95% CI = 4 to 5; P = 4 × 10–175) 
(Figure  2F), and the median rate of age-dependent methylation 
was 53% higher at these sites compared with sites depleted for 
H3K27me3 (MRR  =  1.53; P  =  4 × 10–27). Aspirin use suppressed 
hypermethylation selectively at H3K27me3 marked sequences 
(user vs nonuser: OR  =  0.37; 95% CI  =  0.2 to 0.8; P  =  .004), 
whereas a high BMI promoted methylation at these sites (high vs 
normal BMI: OR = 1.6; 95% CI = 1.1 to 2.5; P = .02). The associa-
tion of hypermethylation with H3K27me3 modification was less in 
smokers (smoker vs nonsmokers: OR = 0.59; 95% CI = 0.5 to 0.8; 
P = .0003), indicating that smoking promotes methylation in CpG-
rich regions other than the typical polycomb targets.
Association of Lifestyle-Modulated DNA Methylation 
with CRC
To address the cancer relevance of these age- and lifestyle-
modulated DNA methylation changes in the healthy colon, 
we compared methylation data of 59 CRCs (female patients) 
included in a genome-wide methylation study (21) with those of 
our healthy mucosa samples. We identified 1709 CpGs statistically 
significantly hypermethylated and 1441 CpGs hypomethylated in 
the CRCs (Figure  3A). Half of the CpGs showing age-depend-
ent hypermethylation in the healthy mucosa (n  =  856 of 1713; 
OR = 20; 95% CI = 18 to 23; P  < 2 × 10–16) coincided with sites 
hypermethylated in CRC (Figure 3B; Age–Cancer). At these loci, 
the median rate of methylation gain per 10  years was doubled 
(MRR  =  2.21; P  =  2 × 10–76) compared with age-methylated sites 
only (Figure 3B; Age-only), and they were most highly enriched for 
polycomb regions (OR = 3.67; 95% CI = 3.0 to 4.5; P = 1 × 10–38). 
Age-hypermethylated CpGs also coincided partially with genes 
transcriptionally downregulated (n = 296 of 1287) (Figure 3C) in 
colonic adenomas (22), and 174 genes showed all features (ie, age- 
and CRC-dependent hypermethylation and transcriptional down-
regulation in adenomas) (Figure 3D).
Importantly, cancer-relevant methylation change in the normal 
colonic mucosa was influenced by lifestyle. A statistically significant 
fraction of promoters showing either aspirin- or HRT-suppressed 
methylation (aspirin: n = 549 of 1080, OR = 15, 95% CI = 13 to 
17, P  = 1 × 10–284; HRT: n = 612 of 996, OR = 25, 95% CI = 22 
to 30, P < 2.2 × 10–16) or BMI- or smoking-promoted methylation 
(high BMI: n = 209 of 510, OR = 6.8, 95% CI = 6 to 8, P = 9 × 10–76; 
smoking in proximal colon: n = 49 of 177, OR = 3.3, 95% CI = 2 
to 7, P = 1 × 10-10) in the aging colon coincided with sites hyper-
methylated in CRC (Figure  4A). These included genes control-
ling key aspects of carcinogenesis (Supplementary Figures 3–6, 
available online) such as cell cycle regulation (CDKN2A), DNA 
repair (MGMT), apoptosis (DAPK1), cell invasion (CDH1), and 
Wnt (WNT16) and RAS signaling (RASSF1) (2,28–30). Moreover, 
the rates of methylation change at promoters of established 
Figure  3. Enrichment of colorectal cancer (CRC)–associated hyper-
methylation in age-related methylated genes. A) Differences in DNA 
methylation between 59 CRC samples (21) of female patients and 178 
normal biopsies. Plotted are difference in log2-fold change (FC) in DNA 
methylation on the x-axis with false discovery rate (FDR)–adjusted P 
values (calculated by moderated t statistics; -1  × log10 scale) on the 
y-axis. CpGs statistically significantly hypermethylated in CRC are high-
lighted in red (n = 1709; FDR-adjusted P < .0001; FC > 2). B) Intersection 
between age-related hypermethylated CpGs in healthy mucosa and 
CpGs hypermethylated in tumor samples. Barplots indicate percent-
ages of CpGs marked by histone 3 lysine 27 tri-methylation (H3K27me3) 
in each intersection (Age-only Age–Cancer, Age-only, Cancer-only). The 
boxplot shows median rates of DNA methylation change per 10 years 
for age–tumor vs age-only hypermethylated loci. Shown are median 
(lines) and mean (black circles) rates with interquartile ranges (boxes), 
1.5 times the interquartile ranges (whiskers), and extreme values (gray 
lines). C) Intersection between 1287 age-related hypermethylated genes 
(n = 1713 CpGs) in the normal colon mucosa and genes downregulated 
(FDR-adjusted P ≤ .05) in colon adenomas (22). D) Intersection between 
genes statistically significantly hypermethylated over age in the nor-
mal colon mucosa, genes hypermethylated in CRC samples, and genes 
downregulated in colon adenomas. Odds ratios (ORs) and associated 
P values were calculated according to the Fisher exact test. P values 
for the difference in median rates of DNA methylation change were 
calculated according to the Wilcoxon rank sum test. All statistical tests 
were two-sided.
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tumor-associated genes (27) were statistically significantly reduced 
in aspirin users or in women reporting HRT compared with non-
users (aspirin: MRR = 0.53, P < .001; HRT: MRR = 0.54, P < .001) 
(Figure  4B) but increased in smokers vs nonsmokers or in indi-
viduals with high BMI vs normal BMI (smoking in proximal colon: 
MRR = 4.0, P < .001; high BMI: MRR = 1.57, P = .004).
Discussion
We report that lifestyle factors that are known modulators of CRC 
risk have widespread effects on the stability of gene promoter 
methylation in the aging colonic mucosa. We found age-associated 
DNA hypermethylation to be suppressed by regular aspirin use 
and HRT use but accelerated by long-term smoking and a high 
BMI, which is concordant with the effects of these factors on CRC 
risk. Statistically significant subsets of affected promoters were 
associated with genes controlling key aspects of carcinogenesis and 
with chromatin features known to predispose to hypermethylation 
in cancer, accentuating the cancer relevance of the lifestyle-mod-
ulated DNA methylation change in the normal colon. These find-
ings provide an important resource for understanding the interplay 
between lifestyle exposure and aging in the modulation of epige-
netic (in)stability in colonic epithelial cells and, thereby, in the evo-
lution of CRC methylomes.
Our data extend the well-established relationships between 
aging and gene promoter hypermethylation (9,31,32) by providing 
a functional link to cancer. Comparing genome-wide methylation 
data of CRC (21) with those of normal aging mucosa allowed us to 
discriminate between age-only, cancer-only and age–cancer hyper-
methylation. Importantly, the rate of methylation change at age–
cancer hypermethylated sites was statistically significantly higher 
than at loci showing age-only methylation, and aspirin use and 
Figure 4. Modulation of cancer-associated hypermethylation by lifestyle 
factors. A) Concordance between genes showing modulation of age-
associated methylation by lifestyle parameters and hypermethylation in 
colorectal cancer (CRC). Enrichment in each category is calculated over 
the percentage of 11 872 genes (n = 20 025 CpGs) present on the Illumina 
array (Total). Odds ratios (ORs) and P values were calculated according 
to the Fisher exact test. n = number of genes. B) Median rates of DNA 
methylation on 664 annotated tumor-associated genes (TAG database) 
(27). n = number of tumor-associated genes hypermethylated in each 
category. P values are calculated by Wilcoxon rank sum test. Shown are 
median (lines) and mean (black circles) rates with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme val-
ues (gray lines). C) Mode for the modulation of CRC risk by lifestyle 
factors (41). Inherent DNA methylation instability generates epigenetic 
mosaicism (gray cells) in the aging colonic epithelium. Some methyla-
tion changes will affect transcription of genes controlling carcinogen-
esis, eventually contributing to the evolution of premalignant (gray cell 
cluster) and cancer cells (red cell cluster). Lifestyle factors are capable 
of negatively (blue arrow) or positively (green arrow) influencing pro-
gressive age-related methylation change, thereby connecting lifestyle 
with cancer risk. BMI = body mass index; HRT = hormone replacement 
therapy; OR = odds ratio. All statistical tests were two-sided.
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HRT use suppressed whereas high BMI and smoking promoted 
methylation in a large fraction of these promoters. The identifica-
tion of this specific subgroup of gene promoters, displaying age-
associated and cancer-associated hypermethylation modulated by 
lifestyle factors, is important for several reasons. First, the targets 
provide insight into molecular pathogenesis of CRC and how 
lifestyle factors may exert their effects on CRC risk. Second, age-
associated hypermethylation at such targets in the normal colonic 
mucosa implies a risk for CRC. Hence, age–cancer hypermethyl-
ated CpGs may serve as biomarkers for risk prediction and dis-
ease progression because their methylation can be monitored in 
the healthy mucosa. Third, unlike genetic mutations, epigenetic 
alterations are reversible and the identification of gene promoters 
at which hypermethylation can be modulated by lifestyle will help 
develop tailored methylation and thus cancer-preventive strategies. 
Future investigations will thus have to be directed toward estab-
lishing biomarker panels with methylation thresholds predicting 
cancer risk in healthy individuals and to evaluate the clinical poten-
tial of methylation-suppressive medication.
Numerous studies have shown that aspirin use is associated with 
a lower incidence of colonic neoplasia, metastatic CRC, and death 
due to CRC (33–36). Although the genetic makeup of a tumor is 
likely to play a role in this context (37), our methylation profiling 
of the normal colonic mucosa adds to the understanding of this 
cancer protective effect, showing that regular aspirin use stabilizes 
DNA methylation at promoters of genes controlling critical cancer 
pathways. This is likely to retard carcinogenesis at different stages, 
including metastasis, in the colon and other tissues. This insight 
will thus be instrumental in identifying both patients and healthy 
individuals who will benefit from aspirin use.
Our study has several strengths. First, we collected normal 
mucosa samples from an unselected screening cohort, providing 
for an unbiased analysis of methylation profiles. Second, the age-
related and lifestyle-modulated methylation changes observed in 
the promoters of the two DNA-repair and tumor-suppressor genes 
hMLH1 and MGMT are an important proof of concept because the 
pathogenic consequence of their epigenetic silencing is well known. 
Third, the comparison of our genome-wide methylation data in 
normal mucosa of a female screening cohort with those of women 
with CRC enabled us not only to exclude sex-associated methyla-
tion variance but also to identify the gene promoters at which age-
related hypermethylation is relevant for CRC development.
There are also limitations to our study. Residual confounding 
by measured or unmeasured additional factors cannot be excluded. 
To limit biological variation, we investigated only women and, 
therefore, our findings will have to be validated by independent 
studies including men. Genome-wide methylation array is largely 
restricted to CpG islands, thereby limiting the detection of meth-
ylation globally.
We conclude that the aging colonic mucosa undergoes changes 
in gene promoter methylation with rates modulated by lifestyle. 
The highly variable methylation rates at individual CpGs are con-
sistent with an underlying inherent instability of DNA methyla-
tion rather than an outgrowth of subpopulations of tissue cells; a 
concept supported by many other studies (38–40). We propose that 
this epigenetic instability contributes to the aging of the colonic 
epithelium (41), generating opportunities for the evolution of early 
cancer-initiating cells (Figure  4C) showing patterns of aberrant 
DNA methylation typically observed in malignant tissues (2). The 
finding that lifestyle factors specifically modulate the rate of the 
underlying DNA methylation change provides a novel paradigm 
for how the environment modulates cancer risk.
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 Supplementary Materials 
Supplementary Methods 
DNA Isolation and bisulfite conversion 
Genomic DNA was extracted from freshly collected biopsies of normal mucosa stored in 
RNAlater using QIAamp DNA mini kit (Qiagen, Hilden, Germany) including RNAse A 
treatment according to the manufacturer protocol. 2 µg genomic DNA from each sample 
was bisulfite-treated using the EZ DNA Methylation kit (Zymo Research, Orange, CA), 
according to the manufacturer's protocol and stored at -80°C until for quantitative 
methylation-specific PCR. 
 
Study participants and data collection  
Aspirin use was determined as never versus (vs.) ever ( twice per week for >1 month) 
and medication duration was scaled as short-term (< 2 years) vs. long-term ( 2 years). 
Hormonal medication use (estrogen therapy and/or oral contraceptives) was determined 
as never vs. ever ( one year) and whether hormone replacement therapy (HRT) was 
started before or after age 50 years. Height (cm) and weight (kg) were self-reported and 
BMI was calculated (kg/m2) from these variables. Smoking status was determined as 
never vs. ever ( one cigarette daily for  1 year), while smoking duration was 
determined as short-term (< 20 years) vs. long-term ( 20 years). Polyp status was 
determined as no polyps vs. yes (any type), while polyp type was classified as tubular 
adenoma vs. serrated lesion (hyperplastic, sessile serrated adenoma). Subjects with 
missing information in each category were coded as not being exposed to these factors. 
 
Quantification of DNA methylation 
Locus-specific DNA methylation: hMLH1 and MGMT promoter methylation was 
measured by locus normalized quantitative methylation specific PCR (ln-qMSP). 
Bisulfite-modified DNA was used as a template using primers pair specific for either 
methylated (M) or modified unmethylated (U) sequence. Amplification was normalized 
for total DNA input using a set of standardized primers (S). Primer sequences are 
provided in Supplementary Table 2. These primers were located in areas without CpG 
 nucleotides, thus amplifying the modified DNA independently of methylation status of 
CpG nucleotides. In order to ensure product specificity, a melting point analysis was 
performed after each run. PCR reactions were performed with QuantiTect SYBR Green 
PCR Kit (Qiagen, Hilden, Germany) using Rotor-Gene 3000 real time thermo cycler 
(Corbett life science, Sydney, Australia). Each reaction was carried out in duplicates in a 
final volume of 15µl containing 1.5µl of bisulfite-modified DNA and 0.5µM concentration 
of each forward and reverse primer. PCR conditions were as followed: activation of 
polymerase at 95°C for 10 sec; primer annealing at 58° for 25 sec and extension at 
62°C for 20 sec. To quantify methylation, blood DNA from healthy individual was in vitro 
methylated with SssI methyltransferase (New England Biolabs, Hitching, UK) and 
further bisulfite-modified to generate positive-control for each PCR reaction. Serial 
dilutions (from 100 to 0.1%) of positive-control DNA were used to generate standard 
curves for each gene using M- and S-primers. The quality of positive-control DNA was 
proven by unsuccessful amplification with U-primers under optimized conditions. To 
determine the methylation levels in each sample, the value of amplification with M-
primers was compared to the value of amplification with S-primers and this ratio was 
then multiplied by 100 to give percentage of methylated alleles (PMA) ([M-primers 
amplification levels/S-primers amplification level]x100. A sample was considered 
methylation positive, if the assay performed in duplicate resulted in a PMA above 
0.0001% (reflecting the detection limit for reproducible measurements). At this 
threshold, the frequency of individuals showing methylation positivity ranged from 85% 
to 98%. To conduct log transformation of the methylation results for data analysis, all 
non-detects were replaced by half of the lowest observed value. This was 0.00015% for 
right colon hMLH1 and 0.00035% left colon hMLH1, 0.0023% for right colon MGMT and 
0.005% left colon MGMT. 
 
Genome-wide DNA methylation: 
Quality control and data normalization: Total of 184 normal colon biopsies from our 
female cohort were processed on 16 chips (12 samples per chip). Samples were run 
together in a randomized order to avoid confounding batch effects within the population. 
Mean non-background corrected signal intensities of the methylated (M) and 
 unmethylated (U) probes were extracted using the Illumina BeadStudio software v3.2 
and then exported to lumi and methylumi packages (1) using R/Bioconductor 
(htpp://www.bioconductor.org). Samples were filtered according to CpG coverage, using 
P values of detection of signal above background, demanding at least 95% coverage 
per sample. After this quality control step, 178 samples remained. Using same formula 
applied in GenomeStudio, Beta (β) values (M/[M+U+100] and M-value (log2 ratios of 
methylated and unmethylated probes) were calculated after performing 
smoothQuantileNrmalization for color balance adjustment followed by background level 
correction and quantile based probe level normalization according to the routine 
implemented in lumi and methylumi packages in R/Bioconductor (2).   
Data Filtering: For the data analysis we masked data point as “NA” for the following 
conditions as described previously;[3] 1) Probes containing single-nucleotide 
polymorphisms (SNPs), 2) those that overlap with a repetitive element that covers the 
targeted CpG dinucleotide, 3) those that overlap with regions of insertions and deletions 
in the human genome, 4) probes that are targeting X or Y chromosome. Beta values 
with detection p value greater than 0.01 were also replaced as "NA". Furthermore, 
probes containing at least one “NA” across the normal sample set were masked as 
“NA”. In total, 20,025 probes corresponding to 11,872 genes were kept for further 
analysis.  
 
Validation of microarray data by pyrosequencing 
Five genes were selected for validation analysis of microarray results in 8 healthy tissue 
samples by bisulfite/pyrosequencing (Supplementary Figure 7). PCR was performed in 
two reactions. The first PCR used a forward and a reverse primer with one primer 
contained an 11-base tag sequence, 5′-GCCCCCGCCCG-3′. The second PCR 
contained one of the same primer as before and second universal primer was an 11-
base tag sequence, 5′-(biotin)GCCCCCGCCCG-3′, which had been biotin labeled at the 
5′ end and HPLC-purified (Microsynth AG, Switzerland). 
The first PCR was carried out in a volume of 25 μl using the FastStart Taq DNA 
polymerase (Roche Diagnostics,USA). After 6 min of initial denaturation at 95°C, the 
cycling conditions of 35 cycles consisted of denaturation at 95°C for 30 s, annealing at 
 56°C (PYCARD), 58°C (TLE1, RAC2), 59°C (ZBTB9) or 62°C (CHD5) for 30 s and 
elongation at 72°C for 45 s. The amplified fragment was diluted 1000-fold and used as 
template in the second PCR. The second PCR was carried out in a volume of 50 μl,  
which after initial denaturation at 95°C for 5 min comprised 20 cycles with denaturation 
at 95°C for 30 s, annealing at 52°C for 30 s and elongation at 72°C for 45 s. The PCR 
products were purified using NucleoSpin Extract II kit (Macherey-Nagel GmbH, 
Germany) and were stored at 4°C until ready for pyrosequencing. 500ng of PCR 
product was used for pyrosequencing using the PyroMark Q24 Pyrosequencing system  
according to manufacturer’s instructions (Qiagen). The primers used in the PCR runs 
and pyrosequencing reactions are shown in Supplementary Table 2. 
 
Statistical analysis 
Genome-wide methylation analysis: To assess differences in CpG methylation over 
10 years of age, we fitted linear regression models on M-values [2] adjusted for 
important covariates, including aspirin use, use of HRT, BMI and smoking.  By doing 
stratified multivariable regression analyses, we further evaluated potential age-related 
differential methylation modification for aspirin use (user ≥ 2 years vs. non-user), HRT 
(user after age 50 vs. non-user), BMI (high > 25kg/m2 vs. normal ≤ 25kg/m2) and 
smoking status (smoker ≥ 20 years vs. nonsmoker). All above models were also done 
separately for each colonic location. Similarly, stratified multivariable regression 
analyses were done for Aspirin/BMI (non-user/normal BMI, user/normal BMI, non-
user/high BMI, user/high BMI), Aspirin/smoking (non-user/non-smoker, user/non-
smoker, non-user/smoker, user/smoker), HRT/BMI (non-user/normal BMI, user/normal 
BMI, non-user/high BMI, user/high BMI) and HRT/smoking (non-user/non-smoker, 
user/non-smoker, non-user/smoker, user/smoker). All above models were also 
performed on β values and coefficients of multivariable regression models were used to 
determine the rate of DNA methylation change / 10 years in each group.  
An equivalent approach was used to assess differences in CpG methylation 
between 59 tumors tissues (3) versus 178 healthy tissues. We first assessed the 
inherent  
 batch effect between two data sets. We compared these methylation profiles with those 
obtained from 4 CRC samples processed together with the healthy mucosa samples in 
our laboratory. This showed a significant correlation (r2 = 0.95; P < .001), suggesting 
that batch-effect in the data sets are minimal.  
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 Supplementary Table 1. Primers used for ln-qMSP and pyrosequencing 
Primer name Sequences 
Locus normalized quantitative methylation specific PCR (ln-qMSP) primers 
hMLH1-M
†
 F: 5′-CGG GTA AGT CGT TTT GAC GTA GAC-3′ 
  R: 5′-ACG CCA CTA CGA AAC TAA ACA CG-3′ 
hMLH1-U
‡
 F: 5′-GAT GTA GAT GTT TTA TTA GGG TTG TGT-3′ 
  R: 5′-TATCAC CAC CTC ATC ATA ACT ACC CA-3′ 
hMLH1-S
¶
 F: 5′-AGT TTG GAG TGG TAG GTT TTT AGA GG-3′ 
  R: 5′-CAT CCC CAA ATT CTT ACT CCT TCT TTC-3′ 
MGMT-M
†
 F: 5′-AGG CGT CT TCG GTT TGT ATC G-3′ 
  R: 5′-CGC CGA ACC TAA AAC AAT CTA CG-3′ 
MGMT-U
‡
 F: 5′-GGT GGA AGT TGG GAA GGT GTT G-3′ 
  R: 5′-CAA CAC ATA CCC AAT ACA ACA ACA CCA-3′ 
MGMT-S
¶
 F: 5′-GTG TTT GGA GGA AAA GGG GTT-3′ 
  R: 5′-CTA CCC CTC ACT AAA CAA CCA-3′ 
Pyrosequencing primers 
PYCARD F: 5′-GTT ATT TTG GAT GAG TTG GAG AAT TTG AT-3′ 
  R: 5′-GCC CCC GCC CGA CCA TCT CCT ACA AAC CCA TAT C-3′ 
  seq:5′-GAG TTT AAG AAG TTT AAG TTG A-3′ 
TLE1 F: 5′-GCC CCC GCC CGG GGT TTG TGT GGG GTT AG-3′ 
  R: 5′-CCA AAC CAA CTA CTT TTC TTT ACT CTT CTC-3′ 
  seq:5′-CTT TTC TTT ACT CTT CTC C-3′ 
RAC2 F: 5′-GGG GAG AGT AGT TTG AGT AAG TTT-3′ 
  R: 5′-GCC CCC GCC CGC CAC CAC ACA CTT AAT AAC CTA CA-3′ 
  seq:5′-GTT TTA TTA GTT TTT ATA TTT TTT G-3′ 
CHD5 F: 5′-TTA GTT TTG TTT TAG AGG GTT TTG GTT T-3′ 
  R: 5′-GCC CCC GCC CGC CAA AAA ACC CCT CCA AAC T-3′ 
  seq:5′-TTG TTT TGA GAT AGG TGT-3′ 
ZBTB9 F: 5′-AGG ATA TTT TGG GTT TGT GTT TTT TTA TTA-3′  
  R: 5′-GCC CCC GCC CGA CAA TAC CCA CAA AAA TCT ACT CC-3′ 
  seq:5′-GAG TTG TAG AGG TAT TGT AA-3′  
Universal primer 5′-GCC CCC GCC CG-3′ 
†
Methylated primer. 
‡
Unmethylated primer. 
¶
Standard primer. seq: sequencing primer. Sequence 
underlined represents the 11-base tag. 
 
 
 
 
 Supplementary Table 2. Association of hMLH1 promoter methylation and various 
lifestyle factors 
Variables Proximal colon   Distal colon 
  Ratio (95% CI)
¥
 P
ᶴ
   
 
Ratio (95% CI)
¥
 P
ᶴ
  
Age (for every 10 years) 2.06 (1.49-2.85) 0.0002 
 
1.41 (1.02-1.96) 0.08 
Age-aspirin use interaction 
Non-user
c
 1 (ref) - 
 
1 (ref) - 
Short-term user (<2y) 1.06 (0.65-1.74) 0.84 
 
0.73 (0.44-1.20) 0.29 
Long-term user (≥2y) 1.01 (0.64-1.61) 0.97 
 
1.06 (0.66-1.69) 0.84 
Age-HRT interaction 
Non-user
ψ
 1 (ref) - 
 
1 (ref) - 
< age 50 1.25 (0.85-1.83) 0.35 
 
1.33 (0.90-1.96) 0.22 
≥ age 50 1.24 (0.80-1.92) 0.41 
 
0.97 (0.63-1.51) 0.92 
Age-BMI interaction 
Normal (18.5-25)
 ψ
 1 (ref) - 
 
1 (ref) - 
Overweight (26-30) 0.79 (0.56-1.11) 0.25 
 
1.12 (0.79-1.59) 0.59 
Obese (>30) 1.05 (0.65-1.69) 0.88 
 
0.69 (0.43-1.12) 0.20 
Age-smoking interaction 
Non-smoker
ψ
 1 (ref) - 
 
1 (ref) - 
Short-term smoker (<20y) 0.88 (0.57-1.35) 0.62 
 
1.06 (0.68-1.64) 0.84 
Long-term smoker (≥20y) 1.06 (0.71-1.58) 0.82   1.26 (0.84-1.89) 0.34 
¥
 Log-linear regression coefficients from multivariable regression model were back transformed and 
referred as rate ratio (RR) with respect to reference category in each comparison.. In bracket is 95% 
confidence interval. Separate models were done for each location and gene. Explanatory variables of 
primary interest were age, regular aspirin use, cigarette smoking, HRT and BMI. To test whether age-
related increase of methylation is influenced by any of the lifestyle variable, corresponding interaction 
terms were used in the models. 
ᶴ
P derived from multivariable regression model, 
ψ
Reference category. 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 3. Association of MGMT promoter methylation and various 
lifestyle factors 
Variables Proximal colon   Distal colon 
  RR (95% CI)
¥
   P
ᶴ
   
 
RR (95% CI)
¥
      P
ᶴ
  
Age (for every 10 years) 1.03 (0.74-1.43) 0.89 
 
1.08 (0.80-1.46) 0.67 
Age-aspirin use interaction      
Non-user
ψ
 1 (ref) - 
 
1 (ref) - 
Short-term user (<2y) 0.82 (0.50-1.35) 0.51 
 
0.70 (0.44-1.11) 0.21 
Long-term user (≥2y) 0.44 (0.27-0.70) 0.004 
 
0.47 (0.31-0.73) 0.005 
Age-HRT interaction 
    
  
Non-user
ψ
 1 (ref) - 
 
1 (ref) - 
< age 50 1.25 (0.85-1.84) 0.34 
 
1.31 (0.92-1.87) 0.21 
≥ age 50 1.63 (1.05-2.53) 0.07 
 
0.92 (0.61-1.38) 0.73 
Age-BMI interaction 
    
  
Normal (18.5-25)
 ψ
 1 (ref) - 
 
1 (ref) - 
Overweight (26-30) 1.20 (0.84-1.70) 0.39 
 
1.22 (0.89-1.69) 0.30 
Obese (>30) 1.15 (0.71-1.87) 0.63 
 
1.04 (0.67-1.62) 0.89 
Age-smoking interaction 
    
  
Non-smoker
ψ
 1 (ref) - 
 
1 (ref) - 
Short-term smoker (<20y) 1.01 (0.65-1.56) 0.98 
 
1.01 (0.67-1.51) 0.10 
Long-term smoker (≥20y) 1.51 (1.01-2.26) 0.09   1.20 (0.83-1.73) 0.43 
¥
Log-linear regression coefficients from multivariable regression model were back transformed and 
referred as rate ratio (RR) with respect to reference category in each comparison. In bracket is 95% 
confidence interval. Separate models were done for each location and gene. Explanatory variables of 
primary interest were age, regular aspirin use, cigarette smoking, HRT and BMI. To test whether age-
related increase of methylation is influenced by any of the lifestyle variable, corresponding interaction 
terms were used in the models. 
ᶴ
P derived from multivariable regression model, 
ψ
Reference category. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 4. Association of promoter methylation with occurrence of polyps 
 Proximal colon  Distal colon 
 Cases RR
¥
 (95% CI) P
ᶴ 
 Cases RR
¥
 (95% CI) P
ᶴ
 
hMLH1        
No polyps
ψ 
350 1.00   350 1.00  
Any polyp 74 0.92 (0.72-1.17) 0.57  122 1.01 (0.79-1.29) 0.96 
Tubular adenoma 49 0.96 (0.70-1.32) 0.84  41 0.86 (0.62-1.19) 0.45 
Serrated lesion 25 0.91 (0.67-1.22) 0.59  81 1.15 (0.85-1.55) 0.46 
MGMT        
No polyps
ψ 
350 1.00   350 1.00  
Any polyp 74 1.05 (0.82-1.33) 0.77  122 1.30 (1.00-1.69) 0.04 
Tubular adenoma 49 1.34 (0.57-1.21) 0.13  41 1.15 (0.86-1.55) 0.44 
Serrated lesion 25 0.85 (0.27-1.49) 0.37  81 1.48 (1.12-1.95) 0.02 
¥
Log-linear regression coefficients from multivariable regression model were back transformed and 
referred as rate ratio (RR) with respect to reference category in each comparison. In bracket is 95% 
confidence interval. Separate models were done for each location and gene.
 ᶴ
P derived from multivariable 
regression model, 
ψ
Reference category. 
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Supplementary Figure 1. Association of age-specific hMLh1 promoter methylation with 
various lifestyle factors. A) Association between age-dependent hMLH1 promoter 
methylation and lifestyle factors. Each point represents one biopsy. P values for the 
difference are derived from log-linear multivariable regression models (Supplementary 
Table 2). B) Association of MGMT promoter methylation with the occurrence of polyps.   
P values are derived from log-linear multivariable regression (Supplementary Table 4).  
 
 
 
 
  
  
Supplementary Figure 2. Genome-wide association of age-specific DNA methylation 
with various lifestyle factors when stratified by colon location.  Lifestyle modulated age-
associated differentially methylated CpGs when stratified by colon location (A) proximal 
(B) distal. Numbers of samples tested in each category are indicated at the bottom of 
each bar. C) Effect of aspirin and HRT on number of DNA methylation changes in 
individuals with a normal BMI versus a high BMI and non-smokers versus smoker. 
Numbers of samples are indicated at the bottom of each bar. FDR adjusted P < .05 was 
used as cutoff to identify significant differential methylated probes. P values to test 
differences in median rate of methylation change are calculated by Wilcoxon rank sum 
test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Supplementary Figure 3. KEGG cancer reference pathways associated with genes 
showed repressed methylation in aspirin user. Entries mapped to the pathways are 
outlined in bold. Color gradient (yellow to blue) for mapped entries represents degree of 
repressed methylation compared to aspirin non-user. 
 
  
 
Supplementary Figure 4. KEGG cancer reference pathways associated with genes 
showed repressed methylation in HRT user. Entries mapped to the pathways are 
outlined in bold. Color gradient (yellow to blue) for mapped entries represents degree of 
repressed methylation compared to HRT non-users. 
 
  
 
Supplementary Figure 5. KEGG cancer reference pathways associated with genes 
showed hypermethylation in high BMI. Entries mapped to the pathways are outlined in 
bold. Color gradient (yellow to red) for mapped entries represents degree of 
hypermethylation over normal BMI. 
 
  
 
Supplementary Figure 6. KEGG cancer reference pathways associated with genes 
showed hypermethylation in smoker. Entries mapped to the pathways are outlined in 
bold. Color gradient (yellow to red) for mapped entries represents degree of 
hypermethylation over non-smoker. 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 7. Pyrosequencing validation of DNA methylation measured by 
Illumina Infinium HumanMethylation27 BeadChip.  A) Comparion between methylation 
values measured by array and pyrosequencing in 8 healthy tissue samples. r = Pearson 
correlation coefficient. B-F) Average percentage methylation of all CpG sites for each 
pyrosequencing assay. White boxes show the CpG of the pyrosequencing target that 
corresponds to the one that was measured by array.  
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Highlights  
 SHOCA-2 is a newly identified tumor suppressor in colorectal cancer (CRC)  
 SHOCA-2 acts as an novel adaptor protein that binds PP1 to inactivate 
STAT3 
 SHOCA-2 expression is lost in CRC due to genetic and epigenetic silencing 
 Low SHOCA-2 expression alters CRC proliferation and correlates with poor 
prognosis 
 
Summary  
Chromosomal deletions at 8p21.3 have been associated with cancers of various 
tissues, including the colon, but the tumor suppressor function affected has not 
been described. Here, we identify SH2D4A as a suppressor of colorectal cancer 
(CRC) mapping to 8p21.3. SH2D4a encodes SHOCA-2, a SH2 domain-containing 
adapter protein that, upon EGF signaling, interacts with the serine/threonine 
phosphatase PP1 and consequently inhibits STAT3 activity via 
dephosphorylation. Conversely, knock-down of SHOCA-2 stimulates c-Myc, Cyclin 
D1 and Jun B expression and accelerates CRC growth through unopposed STAT3 
activity. Loss of SHOCA-2 expression in CRC correlates with advanced disease 
stages and poor prognosis and is caused by chromosomal rearrangements, point 
mutations and epigenetic changes, Thus, SHOCA-2 functions as an inhibitor of the 
EGFR pathway and its absence impacts on CRC development and progression. 
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Significance 
Colorectal cancer (CRC) yearly claims more than 655,000 lives worldwide and 
represents the third most frequent cause of death in the Western world. Though a 
8p21-23 chromosomal deletion has been linked to CRC development and 
progression, the molecular mechanisms related to this genomic region have not 
been recognized to date. Encoded on 8p21.3, the SH2 domain-containing 
SHOCA-2 protein represents a hitherto unrecognized CRC tumor suppressor that 
limits cell proliferation via a negative feedback loop controlling EGFR signaling. 
Consequently, a loss of SHOCA expression results in the oncogenic activation of 
STAT3, a hallmark of many CRC. Since drugs inhibiting EGFR and STAT3 activity 
offer only limited efficiency, enhancing SHOCA-2 function constitutes a novel 
therapeutic target for the treatment of CRC. 
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Introduction 
Oncogene activation and loss of tumor suppressor activity are responsible for 
cancer initiation and progression (Vogelstein and Kinzler, 2004). Overexpression 
of the epithelial cell growth factor receptor (EGFR) is frequently observed in 
colorectal cancer (CRC), and correlates with a poor clinical outcome (Saif, 2010). 
EGFR is receptor tyrosine-kinase that relays its activation through the signal 
transducer and activator of transcription 3 (STAT3) to the nucleus controlling the 
transcription of genes involved in cell proliferation and survival (Aggarwal et al., 
2009). Constitutive activation of the STAT3 signaling pathway as a consequence 
of genetic mutation is oncogenic, and a hallmark of many CRC (Bromberg et al., 
1999; Klampfer, 2008). 
Genetic and epigenetic alterations in the expression of tumor suppressor genes 
are typical features of neoplastic transformation and contribute to both initiation 
and progression of tumor formation (Weinberg, 1991; Vogelstein and Kinzler, 
2004). The loss of heterozygosity (LOH) across variable parts of chromosome 8p 
has been identified as a frequent abnormality associated with CRC (Emi et al., 
1992) and linked to DNA breakage at fragile sites located at 8p12 and 8p22 
(Birnbaum et al., 2003). Although predicted from chromosome transfer studies 
(Tanaka et al., 1996), specific tumor suppressor genes have to date not been 
identified in this critical chromosomal region. It is thus unknown how genetic 
alterations in 8p contribute to CRC development and progression. 
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Results 
Identification of SHOCA-2 and its loss of expression in colorectal cancer 
cDNA Representational Difference Analysis (cDNA-RDA) comparing epithelial 
cells at two sequential stages of embryonic maturation identified transcripts of a 
previously uncharacterized gene, designated SH2D4B (NCBI gene ID 387694; 
S.Z. and G.H., unpublished data). Homology searches identified SH2D4A as a 
paralogue (NCBI gene ID 63898; Figure 1A). Both genes are evolutionary 
conserved (Figure S1A) and ubiquitously expressed, with SH2D4A being 
significantly more abundant than SH2D4B (Figure S1B). The proteins encoded by 
SH2D4A and SH2D4B display 65% amino acid sequence identity at their C- and 
N-termini and share several structural motifs including three coiled-coil domains in 
the middle of the molecule and a Src homology (SH2) domain at the C-terminal 
end (Figure 1A; Figure S1C). It is for these motifs and the putative function as an 
adaptor that we named this family of proteins SHOCA, an acronym for SH2-
domain containing adaptor protein. 
 
SH2D4A maps to human chromosome 8p21.3 (Figure 1A) and encodes 
SHOCA-2. Because the chromosomal region surrounding SH2D4A (8p21-23) is 
frequently lost in CRC and other epithelial tumors  (Emi et al., 1992), we 
determined by immunohistochemistry the expression of SHOCA-2 in 400 
consecutive, sporadic CRCs (Figure S1D). The revealed significant differences in 
detectable SHOCA-2 protein, correlating with clinical tumor stage (I-IV) (Figures 
1B and 1C; Table S1A and S1B); SHOCA-2 expression was reduced or a lost of 
with advanced CRC pathology. Patients with tumors displaying either low or 
absent SHOCA-2 expression had a poorer outcome (log-rank test p=0.0118; 
Figure 1D; Table S1C) though SHOCA-2 expression, when stratified by disease 
stage, did not serve on its own as an independent predictor of survival. An identical 
conclusion was drawn from a Cox regression analysis (p=0.0134 with HR 
(95%CI)=0.56 (0.35-0.89) and a Wilcoxon test (p=0.0133) (Table S2). Gene 
expression data available in public databases for carcinomas of different origin 
including bladder, breast, head and neck, esophagus, liver and ovary suggested 
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similar correlations between disease stage and SHOCA-2 expression (Figure 
S1E). Finally, further analysis of SHOCA-1 expression (mRNA levels) in CRC 
samples with absent or reduced SHOCA-2 expression revealed a concurrent loss 
of SHOCA-1 in approximately half of the samples whereas SHOCA-1 loss was 
neither observed in healthy mucosa nor in CRC tissues proficient for SHOCA-2 
(Figure S1F).  
 
Genetic and epigenetic alterations of the SH2D4A locus in CRC 
To determine the molecular basis for decreased SHOCA-2 expression, we chose 
from an unselected cohort of 70 CRC patients 27 subjects with SH2D4A alleles 
that could be distinguished by microsatellite markers and SNPs (Figure S1D). In 
17 of these (63%), the primary tumor had lost or diminished SHOCA-2 expression 
whereas only 3 samples (11%) displayed an EGFR gene amplification. A loss of 
the SHOCA-2 gene and a simultaneous amplification of EGFR were, however, 
noted in 2 out of these 3 individuals. This result is in accordance with the 
observation that EGFR over-expression in CRC is rarely caused by EGFR gene 
amplification (Saif, 2010). Using 3 flanking microsatellite markers and 6 gene-
specific SNPs (Figure S2A), we detected LOH at SH2D4A in 7 of the 17 tumors 
(41%). Gene dosage quantification of the short arm of chromosome 8 indicated 
mono- and biallelic deletions in 6 and 1 of these LOH tumors, respectively (Figure 
2A). When normal mucosa was examined, four of the six patients with a 
monoallelic SH2D4A loss in tumor tissue were heterozygous for the intronic SNP 
rs17128221 (c.342-5T>C). This SNP is located in a mRNA splice acceptor site and 
causes non-canonical exon 4 skipping, which in turn causes a translational frame 
shift and premature termination in exon 5 (Figure 2B). Consistent with a 
pathological effect, the cancer tissue of patients heterozygous for the C allele 
uniformly demonstrated a selective loss of the T allele (Chi square p=0.006) 
whereas homozygosity for the C allele was never observed in mucosa tissue 
samples of 83 healthy Caucasian individuals (Figure 2B). 
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Missense mutations and deletions in the SH2 domain of SHOCA-2 were 
observed in three of the 10 SH2D4A biallelic CRC samples characterized by a low 
or absent SHOCA-2 expression. These alterations either produced single amino 
acid changes (p.Arg324Trp and p.Ser430Phe) with predicted structural effects 
(Polyphen-2 score of >0.95, SIFT score<0.02), or caused a translational frame 
shift (p.Ile378fsX15) giving rise to a loss of amino acids 377 to 454 and reduced 
protein expression (Figure 2C).  
 
To determine causes for low or absent SHOCA-2 expression other than LOH 
and gene mutations, we next analyzed primary CRC tissue and surrounding 
healthy mucosa for DNA cytosine methylation in the 5’ untranslated region (5’UTR) 
of SH2D4A (Figure 2D). Pyrosequencing of bisulfite-converted genomic DNA 
(Bettstetter et al., 2007) revealed two specific CpG dinucleotides showing 
increased methylation in cancer tissue when compared to matched normal 
mucosa. One of these CpGs is within a canonical Sp1 transcription factor 
recognition motif and its methylation significantly reduced the Sp1 binding affinity 
(Figure S2B). Epigenetic changes at the DNA level may therefore represent 
another cause for reduced SH2D4A gene expression in CRC. Taken together, in 
15 of 17 CRCs investigated in molecular detail (Figure 2E), distinct genetic and 
epigenetic alterations explaining the loss or reduction in SHOCA-2 expression 
could be identified; chromosomal deletions at 8p21.3, genetic mutations in the 
SH2D4A gene, a mRNA splicing defect associated with a specific SNP, and site-
specific changes in promoter DNA methylation.  
 
SHOCA-2 negatively regulates EGF-induced STAT3 phosphorylation and 
transcriptional activity  
A proteomic analysis of phospho-tyrosine signaling in non-small-cell lung cancer 
cell lines driven by EGFR-activating mutations identified a target peptide with 
sequence homology to SHOCA-2 (Guo et al., 2008). We confirmed that EGFR 
activation triggered tyrosine phosphorylation of SHOCA-2 in HeLa cells (Figure 
3A). To investigating a potential involvement of SHOCA-2 in the activation of the 
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downstream EGFR effectors STAT3, ERK and PI3K-Akt, we stimulated HeLa cells 
with EGF. The ectopic expression of SHOCA-2 in these cells specifically 
decreased the STAT3 phosphorylation at Tyr705 (Figure 3B). The phosphorylation 
of this residue constitutes an important post-translational modification of STAT3 
as it triggers its dimerization, nuclear translocation and DNA binding (Heinrich et 
al., 2003). By contrast, the relative level of Akt phosphorylation was increased 
whereas the MAP kinase pathway remained unaffected in EGF simulated HeLa 
cells (Figure S3A). Although SHOCA-2 had been previously been suggested to be 
associated with the ER alpha/PKC signaling pathway (Li et al., 2009), we were 
unable in several independent attempts to observe in HeLa cells overexpressing 
SHOCA-2 a change in PKC phosphorylation (Figure S3B). 
 
To analyze EGF signaling in cells with reduced SHOCA-2 levels, we generated 
short hairpin RNA (shRNA) expressing HeLa cell clones in which SHOCA-2 
protein was knocked down by 90% (SHOCA-2 KD; Figure 3C). When stimulated 
with EGF, the extent of STAT3 phosphorylation at tyrosine 705 (Tyr705) and serine 
727 (Ser727) was inversely correlated with the SHOCA-2 protein level (Figure 3C). 
In keeping with a significant increase in phosphorylated STAT3, the transcription 
of the c-MYC and Cyclin D1 was enhanced (see below). In contrast, the 
phosphorylation of AKT was decreased while that of ERK 1/2 remained 
unchanged in SHOCA-2 KD cells (Figure S3C). These results further corroborated 
the specific involvement of SHOCA-2 in STAT3-mediated signaling following EGF 
stimulation. 
 
Using a STAT3-driven luciferase reporter assay (Kreis et al., 2007), we next 
examined in HeLa cells whether STAT3 transcriptional activity was altered in the 
presence of decreased or increased SHOCA-2 protein levels. As demonstrated in 
Figure 3D, EGF treatment of HeLa cells with a significant loss of SHOCA-2 
expression (SHOCA-2 KD cells) resulted in a robust transcriptional activity. In 
contrast, the transcription of the luciferase reporter was significantly reduced in 
HeLa cells overexpressing SHOCA-2 and exposed to EGF (Figure 3D; Figure 
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S3D). To investigate the nature of SHOCA-2’s influence on STAT3, we also tested 
porcine aortic endothelial cells (PAE) that lack endogenous EGFR expression and 
mouse embryonic fibroblasts (MEF) rendered deficient for STAT3 expression 
(Huang et al., 2007; Costa-Pereira et al., 2002). In these cells, SHOCA-2 bound 
to STAT3 and EGFR and this interaction was always independent of the missing 
binding partner normally present in wild type cells (Figure 3E, Figure S3E). 
Moreover, the binding of SHOCA-2 to EGFR and STAT3 was unrelated to its SH2 
domain (Figure S3F) and isoform-specific because SHOCA-1 did not physically 
bind to STAT3 (Figure S3G). Taken together, these results suggest that SHOCA-
2 inhibits EGF-induced STAT3 activation through its physical association with both 
EGFR and STAT3 independently of its SH2 domain. 
 
SHOCA paralogues bind PP1  
Using tandem affinity purification (TAP) and reciprocal immunoprecipitation, we 
and others (Ewing et al., 2007) identified the serine/threonine Protein 
Phosphatase-1 beta (PP1) as an interaction partner of SHOCA-1 and SHOCA-2 
(Figure 4A; Figures S4A-C; Table S2). The eukaryotic PP1 protein family is 
composed of the 3 isoforms ,  and , whose functionality relies on the 
association with different regulatory proteins (Ceulemans and Bollen, 2004). Both 
SHOCA paralogues bound PP1 but neither PP1 or PP1, demonstrating an 
isoform-specific interaction (Figure 4B). Confocal immunofluorescence 
microscopy and immunoprecipitation of PP1 from cytoplasmic and nuclear 
protein fractions detected the SHOCA-2-PP1 interaction in both subcellular 
compartments further confirming their physical association (Figure S4D). 
 
The RK-X(0,1)-VI-P-FW] sequence has previously been identified as a 
PP1-interacting motif (Hendrickx et al., 2009). We therefore tested whether the 
KXILF and KXVIQHW sequences located in the N-terminus of SHOCA-1 and -
2 may mediate such binding (Figure 4C left panel; Figure S4E). Site-directed 
mutagenesis was used to alter in the SHOCA isoforms the first motif from KXILF 
to AXALA (designated PP1Mut1) and the second sequence from KXVIQHW to 
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AXAQHA (PP1Mut2; Figure 4C). Overexpression of SHOCA mutant proteins in 
HEK293 cells demonstrated that only the PP1Mut2 proteins failed to interact with 
PP1 identifying the KXVIQHW sequence as the relevant docking site (Figure 
4C, middle and right panels). 
 
STAT3 inhibition by SHOCA-2 requires EGF-induced phosphorylation of 
Tyr131 and the recruitment of PP1 
We next investigated whether EGFR and/or STAT3 could pre-associate with 
SHOCA-2 independently of any EGFR stimulation, or, alternatively, whether these 
interactions required an activation-induced phosphorylation of the individual 
binding partners. Immunoprecipitation experiments showed that SHOCA-2, 
STAT3 and PP1 co-precipitated in serum starved, unstimulated HeLa cells that 
was independent of prior EGF stimulation. To further characterize this interaction, 
unstimulated HeLa cells were transfected with mutant forms of either EGFR or 
STAT3. The EGFR mutant had its Tyr1068 and Tyr1086 replaced by phenylalanine 
(EGFR Y1068/1086F) and hence lost a motif known for classical STAT3 
recruitment (Shao et al., 2003), whereas Tyr705 was replaced in the STAT3 mutant 
to a phenylalanine thus eliminating several essential functions (Heinrich et al., 
2003). Neither the association of mutant EGFR with wild type STAT3 nor the 
interaction of altered STAT3 with EGFR were affected by these changes (Figure 
S4F), thus demonstrating that EGFR’s Tyr1068/Tyr1086 and STAT3’s Tyr705 were not 
critically important for the interaction with each other (Figure S4F). The latter 
finding is in accordance with a pTyr705 independent recruitment of STAT3 to the 
IL-22 receptor, an interaction that however requires the coiled-coil domain of 
STAT3 (Dumoutier et al., 2009). Following EGF activation, the association of 
SHOCA-2, STAT3 and PP1 significantly increased in HeLa cells (Figure 4D) 
demonstrating the formation of additional complexes with a possibly different 
composition of their signaling components. Although STAT3 can be indirectly 
activated through c-SRC (Quesnelle et al., 2007), c-SRC was not associated with 
the SHOCA-2, STAT3 and PP1 complex excluding a role of c-SRC in the 
inhibition of STAT3 by SHOCA-2 (Figure S4G). 
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Because EGF-stimulation resulted in Tyr131 phosphorylation of SHOCA-2 
(Figure 3A and (Guo et al., 2008)), we next examined whether this modification is 
essential for the formation of the SHOCA-2/EGFR/STAT3/PP1 complex and its 
function. Though changing the tyrosine residue to alanine (Y131A) did not disturb 
SHOCA-2’s ability to complex with EGFR, STAT3 and PP1 (Figure S4H), the 
point mutation resulted in a constitutive phosphorylation of other SHOCA-2 
tyrosine residues and an insensitivity to EGFR signal-mediated inhibition of STAT3 
tyrosine phosphorylation (Figure S4I). The regulation of STAT3 activity by EGFR 
is therefore critically dependent on the phosphorylation of SHOCA-2’s Tyr 131. 
 
We next characterized in further detail the conditions under which SHOCA-2 
can bind to its partners. Testing a SHOCA-2 mutant unable to associate with PP1 
(SHOCA-2-PP1Mut2), did not require an association with PP1 SHOCA-2 bind 
to the EGFR/STAT3 complex (Figure S4H). However, the inactivation of STAT3 
was dependent on SHOCA-2’s ability to associate with PP1 as the 
overexpression of SHOCA-2 PP1Mut2 failed to alter STAT3 Tyr705 phosphorylation 
following EGF stimulation (Figure 4E). Consequently, STAT3-dependent 
transcription in a reporter assay was not diminished in HeLa cells overexpressing 
SHOCA-2 PP1Mut2 that had been treated with EGF  (Figure 4F). SHOCA-2 thus 
binds to the EGFR/STAT3 complex independently of PP1, but requires the 
association with the phosphatase to modulate STAT3 activity. 
 
SHOCA-2 requires PP1 to inhibit STAT3-dependent tumor cell growth 
To address the contribution of SHOCA-2 to cellular growth control, we assessed 
the expression of STAT3-controlled cell proliferation genes (Aggarwal et al., 2009; 
Trenerry et al., 2007) in HeLa cells expressing reduced levels of SHOCA-2 
(SHOCA-2 KD). The increase of c-Myc, Cyclin D1 and Jun B transcripts in these 
cells upon EGF stimulation inversely correlated with a robust reduction in SHOCA-
2 expression (Figure 5A, left panel). Consequently, the fraction of cells in G2/M of 
the cell cycle was significantly higher in both unstimulated (8.8% vs. 5% G2/M cells 
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[p<0.0002]) and EGF activated SHOCA-2 KD HeLa cells (21.2% vs. 9.4% G2/M 
cells, [p<0.004]) when compared to wild type controls (Figure 5A, right panel). A 
significantly increased cell proliferation (Ki-67 positivity) and higher levels of c-
Myc, Jun B, and Cyclin D1 transcripts were also detected in tissue sections of 
clinically advanced CRC further confirming an inverse correlation between 
SHOCA-2 expression and STAT3 mediated cellular responses (Figure 5B; Figure 
S5A). A decrease in SHOCA-2 expression therefore promotes the transcription of 
cell proliferation factors that in term drive cell cycle progression. 
 
To determine the molecular mechanism by which SHOCA-2 suppresses cell 
proliferation, we next transfected the colorectal cancer cell line SW480 to over-
express STAT3 alone or in combination with either wild-type or mutant SHOCA-2. 
In a colony formation assay, overexpression of only STAT3 significantly increased 
the number of colony forming units (Figure 5C), a response that correlated with a 
higher degree of STAT3 phosphorylation (Figure 5D). Overexpression of STAT3 
together with wildtype SHOCA-2 significantly reduced the colony forming potential 
of SW480 cells as well as STAT3 phosphorylation. This growth suppressive effect 
was less pronounced when SHOCA-2 mutants deficient in either PP1 interaction 
(SHOCA-2 PP1Mut2) or Tyr131 (Y131A) phosphorylation were co-overexpressed 
instead (Figure 5C). The extent to which the number of colonies could be 
decreased as a consequence of SHOCA-2 PP1Mut2 expression was, however, 
limited by the continued presence of endogenous (i.e. wild type) SHOCA-2 thus 
effecting a competitive condition. Comparable results using the overexpression of 
wild type and mutant SHOCA-2 were obtained in the adenocarcinoma cell line 
H1975 which expresses an EGFR mutation constitutively activating STAT3 (Figure 
S5B) (Lu et al., 2007). Consistent with a role of SHOCA-2 in suppressing STAT3-
mediated cell growth, SW480 cells in which SHOCA-2 expression was knocked 
down by shRNA diminished their proliferation rate upon exposure to 
pharmacological inhibition of STAT3 by S31-201, a chemical probe blocking 
STAT3-STAT3 complex formation and STAT3-DNA binding (Figure S5C). Finally, 
overexpression of SHOCA-2 in a CRC cell line (SW620) with constitutive STAT3 
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phosphorylation (Maa et al., 2007) and spontaneously low endogenous SHOCA-
2 expression (Figure S5D) suppressed anchorage-independent cell growth (Figure 
5E). Taken together, these results demonstrate under different experimental 
conditions that SHOCA-2 acts as a suppressor of STAT3-driven cancer cell 
proliferation. 
 
Downregulation of SHOCA-2 alters the cell phenotype and promotes in vivo 
tumor growth  
The cobble-stone shape of SW480 cells, which usually express high endogenous 
SHOCA-2 levels, changed to a spindle-like morphology following the knock-down 
of SHOCA-2 transcripts (Figure 6A, Figures S5D and S6A). This change in cell 
shape was paralleled by features of epithelial-mesenchymal transition (EMT) 
(Christofori, 2006) such as a reduction in E-cadherin and an increase in N-
cadherin, vimentin, SNAIL and ZEB1 expression (Figure 6B). These alterations 
were, however blocked by the inhibition of EGFR using Tyrphostin (AG1478; 
Figure S6B). Moreover, SHOCA-2 deficient SW480 cells proliferated at a greater 
rate and displayed a higher sensitivity to EGFR inhibition when compared to mock 
transfected controls (Figure 6C). Re-establishing mouse Shoca-2 expression in 
human SHOCA-2 deficient SW480 cells however decreased their proliferation rate 
(Figure 6D), thus demonstrating again that SHOCA-2 controls STAT3-mediated 
tumor growth.  
 
To establish an in vivo role for SHOCA-2 as a tumor suppressor, SW480 cells that 
had their SHOCA-2 expression either knocked-down or left unchanged were 
transplanted into nude mice. Grafts with cells where SHOCA-2 was reduced 
displayed a significant increase both in tumor incidence and size when compared 
to control transplants (Figure 6E). Moreover, significant levels of phosphorylated, 
nuclear STAT3 were detected in tumors that had emerged from grafted cells 
lacking regular SHOCA-2 expression (Figure 6F, upper left panel). Consistent with 
this experimental finding, increased STAT3 phosphorylation at residues Tyr705 and 
Ser727 (Figure 6F, upper right and lower panels) were also detected in the majority 
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of CRC biopsies with low SHOCA-2 expression (H-score <100). Taken together, 
experimental in vivo tumor models using CRC cell lines and the detailed analysis 
of biopsies taken from CRC patients identified the inhibitory role of SHOCA-2 on 
STAT3 activation.  
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Discussion 
Genomic deletions within the 8p21-23 region constitute a characteristic 
cytogenetic feature of CRC (Emi et al., 1992) and have been linked to 
carinogenesis (Macartney-Coxson et al., 2008). How deletions in this 
chromosomal region contribute to CRC development has remained unclear since 
tumor suppressor genes could so far not be allocated to 8p21-23 (Macartney-
Coxson et al., 2008). With the assignment of the SHOCA-2 encoding SH2D4A 
gene to 8p21.3, we have linked genomic instability at this locus with the loss of a 
specific tumor suppressor activity in CRC. We provide experimental evidence and 
clinical data that a loss of SHOCA-2 expression results in unopposed STAT3 
activation following EGFR stimulation and marks in patients with colorectal cancer 
accelerated tumor growth as well as poor prognosis. Our findings of a role for 
SHOCA-2 in the control of tumor growth also extends to malignancies where the 
mechanism of tumor development and progression are still only poorly understood 
(Roessler et al., 2011). 
 
EGFR is an upstream activator of multiple pathways involved in cell proliferation, 
apoptosis and carcinogenesis. Overexpression of EGFR and constitutive 
activation of its major downstream effector, STAT3, have been linked to cancer 
progression, a higher risk for metastasis and reduced survival (Quesnelle et al., 
2007; Klampfer, 2008; Saif, 2010). Since STAT3 regulates cell growth and tissue 
homeostasis (Aggarwal et al., 2009), its activation must be under stringent control. 
We found that SHOCA-2 cooperates with PP1 in modulating the EGFR-induced 
STAT3 activation, thereby limiting cell proliferation. In view of the specific genetic 
and epigenetic alterations of SH2D4A, that particularly emerge in late stage CRCs, 
and given the correlation between poor clinical outcome and the loss of SHOCA-
2 expression, we conclude that SHOCA-2 is a novel tumor suppressor modulating 
the activation of the EGFR signaling pathway (Walther et al., 2009). However, in 
the cohort studied here, the SHOCA-2 status was not a reliable predictor of survival 
in patients stratified by disease stage. This result is not surprising as it is consistent 
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with the predictive potential of other tumor suppressors. For example, p53, APC, 
and DCC also fail to serve as prognostic markers though their loss of expression 
in colorectal cancer is correlated with increased tumor aggressiveness (Roth, 
1999; Walther et al., 2009). 
 
Based on the evidence that SHOCA-2 binds to both EGFR and phosphatase 
PP1 and is itself phosphorylated upon EGF signaling, we propose that SHOCA-
2 controls STAT3 activity through the catalytic activity of PP1. SHOCA-2 and 
PP1 form a complex with STAT3 in that SHOCA-2 acts as an adaptor to bring the 
PP1phosphatase into physical proximity of STAT3, which in term effects the 
dephosphorylation of activated STAT3. Indeed, phosphorylation/dephosphoryla-
tion of Ser727 plays an important role in modulating STAT3’s transcriptional activity 
(Levy and Darnell, 2002; Wen et al., 1995; Shen et al., 2004), though the molecular 
mechanisms underlying Ser727 dephosphorylation have not yet been fully 
delineated. Though the serine/threonine phosphatases PP1 and PP2A have 
already been identified to dephosphorylate Ser727  (Lütticken et al., 1995; 
Woetmann et al., 1999; Togi et al., 2009; Haridas et al., 2009), the regulatory 
subunit that confers selectivity, specificity, and subcellular localization of PP1 
towards STAT3 has so far and contrary to PP2A (Togi et al., 2009) remained 
unidentified. For the EGF pathway, we now demonstrate that Ser727 
phosphorylation of STAT3 decreases on the condition that PP1 associates with 
activated SHOCA-2.  
 
Dephosphorylation of Tyr705 constitutes another critical step in the events 
leading to STAT3 deactivation (Heinrich et al., 2003). One of the phosphatases 
involved in this event is the receptor protein tyrosine phosphatase delta (PTPRD), 
which has been shown to act as a tumor suppressor in both colon cancer and other 
neoplasms (Zhang et al., 2007; Veeriah et al., 2009). Though PP1 constitutes yet 
another phosphatase involved in STAT3 inactivation, it remains unknown whether 
it acts indirectly via a tyrosine-specific phosphatase (e.g. SHP (Neviani et al., 
2005)), or directly through target promiscuity (MacKintosh et al., 1996; Shi, 2009). 
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A dual specificity of PP1 unparalled as a comparable 
mechanism has been described for the protein tyrosine phosphatase SHP-2 which 
catalyzes the dephosphorylation of both Tyr701 and Tyr727 residues in STAT1 (Wu 
et al., 2002). Alternatively, the enhanced physical interaction between PP1 
SHOCA-2 and STAT3 following EGF binding to its receptor may be sufficient to 
inactivate STAT3 secondary to conformational changes independent of any 
catalytic activity (Lee et al., 2009). The precise molecular mechanism by which 
Tyr705 is de-phosphorylated remains to date unidentified. Irrespective of this lack 
of knowledge, inappropriate STAT3 regulation is the noticeable consequence of 
aberrant SHOCA-2 expression and results in an up-regulation of genes involved 
in cell proliferation. 
 
The reduction of SHOCA-2 expression in the CRC cell line SW480 also 
produced phenotypic features characteristic of EMT. Such a transformation has 
been implicated in the conversion of early stage malignancies towards more 
aggressive tumors showing invasive growth and the formation of metastasis 
(Thiery et al., 2009). Consistent with a role in EMT, LOH at SH2D4A was mostly 
detected in patients with a disease stage typically associated with metastasis. It is 
thus conceivable that the loss of SHOCA-2 plays a part in tumor progression not 
only through its impact on tumor cell growth but possibly also via its contribution to 
EMT. 
 
EGFR and STAT3 constitute promising drug targets in the treatment of cancer 
including CRC (Quesnelle et al., 2007). However, therapeutic responses are 
observed in only 10 to 20% of patients treated with EGFR antagonists (Ciardiello 
and Tortora, 2008) and none of the available STAT3 inhibitors can to date be 
considered as viable drug candidates because of their limited efficiency in 
disrupting STAT3 homodimerization (Yue and Turkson, 2009). SHOCA-2 may 
therefore constitute a novel therapeutic target for the design of strategies to 
interfere rationally with a STAT3-mediated activation in cancer cells. 
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Experimental Procedures 
 
A detailed description of the methods used can be found in Supplemental 
Experimental Procedures. 
 
Plasmids, antibodies, cells and reagents. 
Antibodies, expression plasmids, cells and reagents were either gifts from 
investigators or bought commercially, as specified in Extended Experimental 
Procedures. 
 
Bioinformatic analysis. 
The SHOCA-1 (SH2D4B) and SHOCA-2 (SH2D4A) sequences were analyzed 
using NCBI, ENSEMBL (Hubbard et al., 2009), the kinBase database 
(http://www.kinase.com /kinbase/), the TCoffee software (Notredame et al., 2000), 
and Oncomine (Rhodes et al., 2007). 
 
TAP purification and mass spectrometry. 
The TAP purification (Chen and Gingras, 2007) and mass spectrometry (Hess et 
al., 2008) were carried out as previously reported. 
 
Western Blot, immunoprecipitation and cell fractionation. 
Cells lysates were either separated on a 8%-12% SDS-PAGE or 
immunoprecipitated with protein G Plus-Sepharose beads coupled to specified 
antibodies and analyzed by western blotting. Cell fractionation was achieved using 
the CelLytic Nuclear extraction kit (Sigma). 
 
Luciferase reporter gene assays. 
HeLa cells were transfected with a firefly luciferase reporter SIE (sis-inducible 
element) plasmid plus a Renilla luciferase plasmid (both Promega) and plasmids 
that encode either STAT3 or SHOCA-2. Cell extracts were tested using the Dual 
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Luciferase Assay System (Promega) and analyzed using a luminometer. Firefly 
luciferase activity was normalized to Renilla luciferase activity. 
 
Cell cycle analysis. 
Cells were incubated for 15 min with ice-cold hypotonic Propidium Iodide staining 
solution and subsequently analyzed by flow cytometry (FACSCalibur, Becton 
Dickinson) using the FlowJo software (Tree Star, Oregon Corporation). G1, S and 
G2/M phases were defined using the mathematical Watson Pragmatic model. 
 
Colony formation and anchorage-independent growth assays. 
For colony formation assay, SW480 cells co-transfected with a control vector or 
plasmids that encode STAT3, SHOCA-2, SHOCA-2 PP1Mut2 or SHOCA-2 Y131A 
were cultured for 15 days under neomycin selection (G418: 1 mg/ml) and then 
analyzed for colony frequency following fixation and crystal violet staining of the 
cells. SW620 cells transfected with a control vector or plasmids that encode 
SHOCA-2, SHOCA-2 PP1Mut2 or SHOCA-2 Y131A, cultured under neomycin 
selection (G418, 1 mg/ml) in a soft agar (CytoSelect, Cell Biolabs) for 15 days and 
then analyzed for colony frequency. 
 
In vivo analyses of tumor formation. 
SW480 cells (5 × 106) were grafted to the flank of 6 week-old female BALB/c nude 
mice and the size of the tumor was measured weekly. Mice were sacrificed after 5 
weeks and tumors were removed for further analysis. The animal experiments 
were carried out in accordance with the legal requirements of the Swiss veterinary 
authorities. 
 
Human tissues and immunohistochemistry. 
For the genetic and epigenetic study, specimens from 70 CRC patients were 
obtained from the Department of Surgery of the Kantonsspital Aarau, Switzerland 
and from of the Department of Gastroenterology of the Inselspital in Berne, 
Switzerland, with approval of the local medical ethics boards and written consent 
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from patients. Tissues were stored in RNAlater reagent at -70°C. Single-punch 
tumor samples from 501 patients (Institute of Pathology, Stadtspital Triemli, Zürich, 
Switzerland) were analyzed by tissue microarrays as described previously (Zlobec 
et al., 2010). SHOCA-2 expression and STAT3 phosphorylation were quantified 
using the H score (Hirsch et al., 2003). 
 
Mutational screening, loss of heterozygosity and gene dosage analysis. 
The complete coding sequence including flanking intronic regions of the SH2D4A 
gene was analyzed in all cancers lacking SHOCA-2 protein expression and/or that 
were positive for LOH. LOH for the SH2D4A locus was determined using a set of 
3 flanking microsatellite markers and 6 gene-specific single nucleotide 
polymorphisms (SNP) (for details see Extended Experimental Procedures). Gene 
dosage was determined for each cancer using a chromosome 8-specific multiplex 
ligation-dependent probe amplification (MLPA) assay (SALSA P014-1A, MRC 
Holland) and data were processed by the GeneMarker software package 
(Softgenetics).  
 
Methylation analysis. 
Genomic DNA was converted by bisulfite treatment using the EZ DNA Methylation 
KitTM according to the manufacturer´s instructions (Zymo Research). CpG island 
regions were amplified by PCR from bisulfite treated DNA and sequenced with the 
PyroMark Q24 pyrosequencing system (Qiagen) allowing the quantitation of 
methylated CpG sites (PCR conditions and primer sequences are given in 
Extended Experimental Procedures). Bisulfite treated genomic DNA, previously in 
vitro methylated with M.SssI methyltransferase (New England BioLabs), served as 
the positive control. 
 
Statistical analyses. 
Student's t test, Likelihood ratio test, Chi-square test, Gehran-Wilcoxon test, 
Fisher’s Exact test, binomial test for equal proportions, Log-rank test, multivariate 
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Cox regression analysis and Kaplan-Meier method were used for statistical 
analyzes, as indicated.  
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Figure legends  
Figure 1. Reduced SHOCA-2 expression in human colorectal cancers 
correlates with advanced disease stage. 
(A) Left, location of SHOCA-2 on human chromosome (huChr) 8p. Middle, degree 
of conservation between the two human SHOCA sequences with higher degrees 
of conservation specified by darker shades of grey; box, a consensus MyPhoNE 
sequence typically present in myosin homologues (Hendrickx et al., 2009). Right, 
predicted domain organization of SHOCA; the amino acid identity between 
SHOCA-1 and -2 is given for the MyPhoNE and SH2 domains. Of note, SHOCA-2 
protein contains only one coiled-coil domain (CC), namely CC2. 
(B) Immunohistochemical analysis of a single tissue microarray containing 400 
samples from unselected, untreated patients with sporadic CRC. SHOCA-2 
expression was quantified using the H-score that determines the percentage of 
positive tumor cells multiplied by their staining intensity generating individual 
groups with scores of >200 (n=275), defining a strong expression (green); 100-200 
(n=87), identifying a moderate expression (blue); <100 (n=38), characterizing a 
low or absent expression (red).  
(C) Representative immunohistochemical analysis of tumor tissue of distinct CRC 
stages depicting either diffuse (>90% cells stained; left), patchy (<30%; middle) or 
no SHOCA-2 expression (right). T = tumor tissue, N = normal tissue. Scale bar, 
200 m. 
(D) Kaplan-Meier survival analysis of patients with high (green), moderate (blue) 
and low SHOCA-2 expression (red) for which sufficient clinical information was 
available (log-rank test p = 0.0118 when comparing high to low SHOCA-2 
expression).  
 
Figure 2. Genetic and epigenetic silencing of SH2D4A encoding SHOCA-2. 
(A) HuChr8p copy number variation profiles in SHOCA-2-positive and SHOCA-2-
negative CRC. Values <0.75 indicate chromosomal deletions (Del) whereas values 
>1.25 designate chromosomal duplications (Dup). Red dashed lines, threshold. 
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(B) Top, comparison of the SH2D4A c.342-5T>C (rs17128221) SNP frequency 
between 83 unrelated healthy Caucasian controls and 16 CRC patients (Chi 
square p value = 0.006). Bottom, SNP rs17128221 RT-PCR (right) and sequencing 
analysis (left), the diagram depicts exon usage and the arrows indicate the 
annealing sites for the primers.  
(C) i: top, alignment of amino acid sequences for the SH2 domain (AA 320-454) of 
human SHOCA-2 (AAH82982) with homologues of mus musculus (AAI16683), 
rattus norvegicus (NP_001012048), and gallus gallus (XP_420452); bottom, 
sequence analysis of patient tumors. ii: immunoblot analysis of HeLa cells 
transfected to express Flag-fusion proteins of the indicated human SHOCA-2 
mutations.  
(D) DNA methylation analysis of CpG island located in the 5’UTR of SH2D4A 
comparing normal and tumor tissue. 
(E) Summary of all genetic and epigenetic changes detected in a cohort of 27 
informative CRC samples; CNV = copy number variation, SNP = single nucleotide 
polymorphism. Green = normal finding, red = pathological result, n.d. = not done, 
roman numerals = number of alleles affected. 
 
Figure 3. SHOCA-2 is phosphorylated following EGFR activation and inhibits 
STAT3 activity.  
(A) SHOCA-2-Flag expressing, serum-starved HeLa cells were stimulated as 
indicated with EGF (100 ng/ml). Cell lysates were immunoprecipitated with anti-
phosphotyrosine (pTyr) antibody or rabbit IgG and immunoblotted to detect Flag 
and pTyr. 
(B) Serum-starved HeLa cells were transiently transfected with either a control 
vector or a vector encoding the human SHOCA-2-Flag and stimulated as indicated 
with EGF (100 ng/ml); immunoblotting for the detection of the indicated proteins. 
The ratio of phosphoprotein to total protein (designated P/Total) was determined 
by densitometry.  
(C) Serum-starved HeLa cells that express normal (control, 100%) or 10% of 
SHOCA-2 (SHOCA-2 KD) were stimulated for 5, 10 and 15 min with EGF (100 
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ng/ml). The indicated proteins were detected by immunoblotting. Densitometry 
was used to determine the ratio of phosphoprotein to total protein (designated 
P/Total).  
(D) Serum-starved HeLa cells and SHOCA-2 KD HeLa cells transiently co-
transfected with a SIE firefly luciferase reporter, a renilla luciferase plasmid and a 
SHOCA-2 expression plasmid were stimulated for 6 hrs with EGF (100 ng/ml; filled 
bar) or left untreated (open bar). Luciferase assay was performed on lysates. 
Renilla luciferase activity was used to normalize transfection efficiency. Data 
represent the mean ± SD of three independent, triplicate assays (Student's t test, 
**p < 0.01; ***p < 0.005). 
(E) Immunoblotting of HeLa, PAE and MEF lysates immunoprecipitated with anti-
EGFR, anti-SHOCA-2, anti-Flag or mouse IgG antibodies for the detection of 
EGFR, STAT3, SHOCA-2 and Flag. 
 
Figure 4. SHOCA-2 controls STAT3 activity in a PP1-dependent fashion.  
(A) Lysates from HEK293 cells (bottom) and HEK293 cells expressing SHOCA-2-
Flag (top) were immunoprecipitated with anti-PP1 antibody or IgG and 
immunoblotted for PP1, and Flag (top) or SHOCA-2 (bottom). Human SHOCA-2 
is detected as isoforms due to exon 5 skipping. 
(B) Lysates from HEK293 cells expressing CTAP fusion proteins and EGFP-
tagged PP1 isoforms were immunoprecipitated with IgG sepharose beads 
(recognizing CTAP fusion proteins) and immunoblotted for the detection of CTAP 
and EGFP fusion proteins. 
(C) Left, diagram representing wild-type and mutant SHOCA altered PP1 -binding 
sites (boxes) are marked by crosses. Middle, CTAP fusion proteins and PP1 were 
detected in total and immunoprecipitated lysates from transfected HEK293 cells. 
Right, SHOCA-2, Flag and PP1, respectively, were detected in total lysates and 
anti-Flag immunoprecipitates from HEK293 cells expressing wild type or mutant 
SHOCA fusion proteins. 
(D) Left, serum-starved HeLa cell expressing the human SHOCA-2-Flag fusion 
protein were stimulated with EGF (100 ng/ml) for the indicated times. Lysates were 
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analyzed unmanipulated or were immunoprecipitated with anti-EGFR antibody for 
the detection of EGFR, STAT3, Flag and PP1 by immunoblotting. Right, ratio of 
immunoprecipitated protein to total protein (designated IP/Total) as determined by 
densitometry. 
(E) Serum-starved HeLa cell co-expressing the indicated proteins were stimulated 
with EGF (100 ng/ml) for the specified times. Lysates were immunoblotted for the 
detection of phospho-EGFR (Tyr845), phospho-STAT3 (Tyr705/Ser727), STAT3, 
Flag, and GAPDH. 
(F) Serum-starved HeLa cells transiently co-transfected with a SIE firefly luciferase 
reporter, a renilla luciferase plasmid and plasmids encoding either STAT3, the 
human SHOCA-2-Flag fusion protein or a mutant human SHOCA-2-Flag fusion 
protein unable to associate with PP1 (PP1Mut2) were stimulated for 6 hrs with EGF 
(100 ng/ml; filled bar) or left untreated (open bar). Luciferase assay was performed 
on lysates. Renilla luciferase activity was used to normalize transfection efficiency. 
Data represent the mean ± SD of three independent, triplicate assays (Student's t 
test, *p < 0.05; **p < 0.01; ***p < 0.005). 
 
Figure 5. SHOCA-2 and PP1 arrest tumor cell proliferation sustained by 
STAT3. 
(A) Left panel: Serum-starved HeLa cells that expressed wild type (control) or 
reduced (SHOCA-2 KD) SHOCA-2 levels were either left untreated or stimulated 
with EGF (100 ng/ml) for 6 and 12 hrs. Cell lysates were immunoblotted for the 
detection of phospho-STAT3 (Tyr705), STAT3, c-Myc, Jun B, Cyclin D1, SHOCA-
2 and GAPDH. Right panel: After 24 hrs of serum starvation, control and SHOCA-
2 KD HeLa cells were stimulated with EGF (100 ng/ml) for 12 hrs. The cell cycle 
profile was evaluated by flow cytometry using propidium iodide staining (PI). The 
bar graph shows the percentage of cells in the indicated phases of the cell cycle. 
The data is representative of 3 separate experiments, each performed in triplicate 
(*p < 0.05; ***p < 0.005 using Student's t test). 
(B) CRC tissue sections from a cohort of 27 informative CRC patients (see Figure 
2E) were analyzed for the proportion of tumor cells that stained for SHOCA-2 and 
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Ki-67 (Wilcoxon test, *p < 0.05; ***p < 0.005). 
(C) SW480 cells transfected to express the indicated empty (pYN3218, Flag) and 
recombinant vectors were grown for 15 days under neomycin selection and then 
scored for the number (top) and appearance of colonies (bottom). The graph is 
representative of two independent experiments performed in triplicates (Student's 
t test, *p < 0.05; **p < 0.01; ***p < 0.005). 
(D) SW480 cells were transiently transfected with a control vector or recombinant 
vectors as indicated, serum-starved, and then stimulated with EGF (100 ng/ml) for 
10 and 15 min. Lysates were immunoblotted to detect phospho-STAT3 (Tyr705 
and Ser727), STAT3, phospho-Akt (Ser473), Akt, phospho-ERK1/2 
(Thr202/Tyr204), Flag and GAPDH. 
(E) SW620 cells expressing wild-type human SHOCA-2 or a SHOCA-2 mutant 
(PP1Mut2, Y131A) were grown for 15 days under neomycin selection in soft agar 
and then scored for the number (top) and appearance of colonies (bottom). The 
graph is representative of two independent experiments performed in triplicates 
(Student's t test, ***p < 0.005). 
 
Figure 6. SHOCA-2 is required for maintaining epithelial morphology and its 
down-regulation promotes tumorigenesis in vivo  
(A) Phase-contrast images of control SHOCA-2 expressing SW480 cells and 
polyclonal SHOCA-2 knockdown (KD) SW480 cells grown at different densities. 
Scale bar, 100 m. 
(B) Immunoblot analysis of E-cadherin, N-cadherin, Vimentin, ZEB-1, SNAIL, 
SHOCA-2 and GAPDH protein expressions in lysates from SW480 stable 
transfectants (shRNA control, SHOCA-2 KD). 
(C) Proliferation of SW480 cells that have been stably transfected with shRNA for 
the knock-down of SHOCA-2. The cells have been grown in the presence or 
absence of EGFR inhibitor (AG1478). Data represent the mean ± SEM of two 
independent experiments. 
(D) SW480 cells with or without a knock-down of SHOCA-2 were transfected to 
express either a control plasmid (designated Flag) or a murine (m) SHOCA-2-Flag 
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fusion protein that was not targeted by the shRNA used. Transfected cells selected 
with neomycin and scored for the number of colonies detected (top). Cell lysates 
were immunoblotted for SHOCA-2 and GAPDH protein expression (bottom). The 
data are representative of two independent experiments. 
(E) Monitoring tumor incidence and size in nude mice (n=5 mice per group) grafted 
with either SHOCA-2 wild type (shRNA CT) or knock-down SW480 cells (SHOCA-
2 KD). Data represent the mean ± SEM of two independent experiments. 
(F) Immunohistochemistry of grafted SW480 tumor cells either wild type or knock-
down for SHOCA-2 expression (upper left panel; scale bar, 100 m) and of human 
CRC tissues (right; scale bar, 50 m). Left upper panel: Immunohistochemical 
analysis of in vivo grafted SW480 cells for STAT3 phosphorylated at Tyr705; Left 
lower panel:  H-score analysis for Tyr705 and Ser727 STAT3 phosphorylation in CRC 
samples with low to absent SHOCA-2 expression, displayed as a relative 
percentage of the biopsies investigated. Right: analysis of CRC tissues on 
consecutive section for the detection of SHOCA-2 and STAT3 phosphorylated 
either at Tyr705 or Ser727. 
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Figure S1. Related to Figure 1. SHOCA sequence analyses and expression profiling in 
mouse tissue and in tumors. (A) The figure represents an unrooted evolutionary tree analysis of 
SH2D4 paralogues using the Unweighted Pair Group Method with Arithmetic mean (UPGMA) 
method. Concurrent with the development of vertebrates (thick line), two distinct SH2D4 family 
members developed. (B) Tissues from 10 week-old Balb/c mice were analyzed for SH2D4B and 
SH2D4A expression using real time RT-PCR. The results are normalized to 18S rRNA levels. The 
black bars correspond to SH2D4B mRNA levels and the gray bars correspond to SH2D4A mRNA 
levels. (C) The N-terminal amino acid sequences (AA1-51) of human SHOCA-1 and human 
SHOCA-2 are aligned with human myosin homologues: MYO16 (Myosin-XVI), MYPT1 (Myosin 
phosphatase-targeting subunit 1, a.k.a. PPP1R12A), MYPT2 (Myosin phosphatase-targeting 
subunit 2, a.k.a. PPP1R12B), PPP1R12C (Protein phosphatase 1 regulatory subunit 12C), MYPT3 
(Myosin phosphatase-targeting subunit 3, a.k.a. PPP1R16A) and ANKRD4 (Ankyrin repeat 
domain-containing protein 4, a.k.a. PPP1R16B). The box identifies the MyPhone consensus 
sequence typically present in myosin homologues. (D) From a cohort of 571 unselected patients 
with sporadic CRC, paraffin-embedded tissue for tissue microarrays (TMA) was available for 501 
patients. SHOCA-2 expression analysis was carried out on 400 samples with sufficient tumor tissue 
(>50%/biopsy) and documented disease stage. Given an informative immunohistochemical 
analysis and clinical data, survival probability could be calculated for 300 of these patients. LOH 
was investigated on fresh frozen tissues for 70 of the 571 patients, and epigenetic and genetic 
analyses were carried out on 27 cases informative for LOH. (E) SHOCA-2 mRNA levels were 
analyzed by using 9 public gene expression datasets available for meta-analysis (Oncomine)1. n 
designates the number of cases included in the analysis. The Y-axis represents expression units 
that have been normalized as described elsewhere 
(http://www.compendiabio.com/support/normal.htm). Shaded boxes represent the interquartile 
range (i.e. the 25th-75th percentile); whiskers define the 10th-90th percent range; bars indicate the 
median value; and closed circles identify outlayers. The p-value was calculated using Student's t-
test. (F) Tissues from human healthy mucosa (n= 4) and tumors (n=10) were analyzed for SHOCA-
1 expression using real time RT-PCR. The results are normalized to GAPDH levels. The dots 
correspond to the relative SHOCA-1 expression of each sample and the bars represent the group's 
median value. The p-value was calculated using Mann-Whitney test. 
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Table S1. Related to Figure 1. Statistical analyses for association of SHOCA-2 H-score, stage 
and survival time (A) Differences in the stage distribution among each H-score category (binomial 
test for equal proportions). (B) Unadjusted p-values for association of H-scores and stage (Chi-
Square or Fisher’s Exact test). (C) P-values for survival time differences overall and stratified by 
stage using three different statistical tests. 
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Figure S2. Related to Figure 2. Epigenetic and genetic analyses on SH2D4A gene. (A) Loss 
of Heterozygosity (LOH) analysis for SH2D4A. Loss of heterozygosity analysis for the SH2D4A 
locus. Panels i and ii depict 3 flanking and 1 gene-specific microsatellite marker, respectively, that 
cover the region (approximately 7Mb) from 8p21.3 to the telomeric boundary of 8p22. Panel iii 
demonstrate for cancer sample number 17 the analysis of 5 gene-specific SNPs and reveal a 
selective loss of a single SHOCA-2 allele. (B) Left, Sp1 binding affinity differs between methylated 
and unmethylated SH2D4A DNA oligomers. The Sp1 specific gel-shifts were carried out using a 
fluorescein-labeled oligomer binding Sp1 (CT+). CT+ and SW48 nuclear extract were incubated in 
a competitive manner in the absence or presence of increasing concentrations of an unlabeled 
oligomers. This oligomer sequence, which represents part of the genomic SH2D4A sequence, had 
either an unmethylated (Unmeth) or a methylated (Meth) Sp1 binding site. As a negative control 
(designated Oligo), CT+ oligomer was incubated in the absence of nuclear extract. Data from four 
independent experiments are shown and represent the mean and the interquartile range (i.e. the 
25th-75th percentile) of the percentage of the fluorescence signal obtained with experimental 
samples in comparison to control (CT+; *p < 0.05 using Mann-Whitney test). The presence of Sp1 
in the shifted bands was confirmed by western blotting (WB). Right, HeLa cells were transiently 
46 
 
transfected with either a control vector or a vector encoding Sp1; immunoblotting for the detection 
of the indicated proteins. 
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Figure S3. Related to Figure 3. Effect of SHOCA-2 on EGFR-mediated signaling. (A,B) Serum-
starved HeLa cells were transiently transfected with either a control vector or a vector encoding the 
human SHOCA-2-Flag and stimulated as indicated with EGF (100 ng/ml); immunoblotting for the 
detection of the indicated proteins. The ratio of phosphoprotein to total protein (designated P/Total) 
was determined by densitometry. (C) HeLa cells were stably transfected either with a plasmid 
encoding an shRNA specific for SHOCA-2 or with plasmid devoid of an insert. Following serum 
starvation for 24 hrs, the cells were stimulated with EGF (100 ng/ml) as indicated. Western blotting 
for the indicated proteins were performed on aliquots of transfected cell lysates. The efficiency of 
SHOCA-2 silencing is indicated as a percentage of control transfected cells. Densitometry was 
used to determine the ratio of phosphoprotein to total protein signal (designated P/Total). (D) A SIE 
firefly luciferase reporter construct and a renilla luciferase plasmid were transiently transfected 
together with a STAT3 expression vector into unmanipulated HeLa cells. Transfected cells were 
serum-starved for 24 hrs and then either stimulated with EGF (100 ng/ml; filled bar) for 6 hrs or left 
untreated (open bar). The renilla luciferase activity was used to normalize for the transfection 
efficiency. Data are representative of 3 experiments, each performed in triplicate (*p < 0.05; **p < 
0.01; ***p < 0.005 using Student's t test). (E) Immunoblotting of lysates from PAE cells, HeLa, and 
wild type and Stat3 deficient MEFs for the detection of EGFR and Stat3, respectively. (F) HeLa 
cells were transfected to express a Flag-fusion protein of either the wild-type form of human 
SHOCA-2 or a mutant form of human SHOCA-2 that lacks the SH2 domain (designated SHOCA-
2-SH2). Cell lysates were immunoprecipitated with anti-Flag antibodies and subsequently 
analyzed by immunoblotting using antibodies specific for Flag, STAT3 and EGFR (left panel). Total 
lysates were used as loading controls (right panel). (G) HEK293 cells were transfected to express 
STAT3-HA and a C-terminal TAP-tag fusion proteins of SHOCA-1 or EGFP. Cell lysates were 
immunoprecipitated with IgG beads, and immunoblotted with either antibodies specific for HA-tag 
or with Rabbit IgG recognizing the protein A component of the TAP-tag. 
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Figure S4. Related to Figure 4. Interaction of SHOCA-2 with the EGFR/STAT3/PP1 complex. 
(A) Multiple reaction monitoring (MRM) comparison of two selected peptides from SHOCA-1, PP1 
and HSP71, respectively. Red and blue lines represent peptides retrieved from the SHOCA-1-
CTAP and control EGFP-CTAP pull-downs, respectively. The transition signals are labeled with the 
mass (m/z) of the peptides. Peptides derived from non-specific interactions (e.g. heat shock protein 
HSP71) were identified in both eluates whereas SHOCA-1 and PP1 peptides were only found in 
the SHOCA-1-CTAP immunoprecipitation. (B) Cell lysates from HEK293 cells transfected to 
express SHOCA-1-Flag fusion protein were immunoprecipitated either with an antibody specific for 
PP1 or with goat IgG and then immunoblotted with antibodies specific for Flag and PP1. (C) 
HEK293 cells were transfected to express the indicated TAP-tag fusion proteins. The cell lysates 
were immunoprecipitated with IgG beads, and immunoblotted with either antibody specific for PP1 
(loading control) or with Rabbit IgG recognizing the protein A component of the TAP-tag. (D) Top, 
HeLa cells expressing an EGFP-PP1 fusion protein were stained with anti-SHOCA-2 antibody 
and DAPI to detect colocalization by confocal microscopy. Bottom, endogenous SHOCA-2 was 
detected in cytoplasmic (GAPDH+) and nuclear (Histone H1+) HeLa cell lysates 
immunoprecipitated with anti-PP1. (E) HEK293 cells were transfected to express either a wild-
type SHOCA-1-Flag fusion protein or one of two deletion mutants AA1-80 or AA51-94, fused to 
Flag (left panel; the alleged PP1-binding sites are indicated as vertical bars). Lysates from 
transfected cells were immunoprecipitated with anti-Flag antibodies and immunoblotted with 
antibodies directed against Flag or PP1 (right panel). Interaction of wild type and mutant SHOCA-
2 with EGFR and STAT3 (F) Lysates of HeLa cells expressing HA-tagged wild-type (WT) STAT3 
or the Y705F STAT3 mutant and wild-type (WT) EGFR or the Y1068/1086F EGFR mutant were 
immunoprecipitated with an EGFR specific antibody. EGFR and HA were detected by 
immunoblotting. (G) Serum-starved HeLa cell expressing the human SHOCA-2-Flag fusion protein 
were stimulated with EGF (100 ng/ml) for the indicated times. Lysates were immunoprecipitated 
with anti-Flag antibody. EGFR, STAT3, c-SRC, Flag, PP1 was detected by immunoblotting. (H) 
HeLa cells were transfected with an expression plasmid encoding a Flag-fusion protein of either 
the wild-type (WT), the PP1Mut2 or the Y131A mutant form of human SHOCA-2. Cell lysates were 
immunoprecipitated with anti-Flag antibodies and subsequently analysed by immunoblotting using 
antibodies specific for Flag, STAT3, EGFR and PP1 (left panel). Total lysates were used as 
loading controls (right panel). (I) Serum-starved HeLa cells expressing human wild-type SHOCA-
2-Flag or the Y131A mutant were stimulated with EGF (100 ng/ml) for the indicated times. Lysates 
were immunoprecipitated with a phosphotyrosine (pTyr) specific antibody. STAT3, Flag and pTyr 
were detected by immunoblotting. 
  
51 
 
 
 
 
 
Table S2. Related to Figure 4. LC-MS/MS analysis: comparison of peptides eluted following 
SHOCA-1- and EGFP-TAP purification. Proteins were identified using 2 or more unique peptides 
with a MASCOT score above 20. To distinguish between correct and incorrect peptide 
assignments, protein spectra with less than 4 peptides were manually evaluated. Spectral count: 
number of spectra identified for each protein. 
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Figure S5. Related to Figure 5. SHOCA-2 influences cell cycle progression and proliferation 
in STAT3-dependent fashion. (A) mRNA expression of SHOCA-2, Cyclin D1, Jun B, c-Myc, was 
assessed in 32 adenoma and 13 sporadic colorectal cancers by means of Affymetrix GeneChip 
U133 expression arrays. Shaded boxes represent interquartile range (i.e. the 25th-75th percentile); 
whiskers indicate the 10th-90th percent range; bars provide the median value. (B) H1975 cells were 
transfected to express either a vector without insertion (designated Flag) or a vector encoding Flag-
fusion proteins of either wild type SHOCA-2, a SHOCA-2 mutant unable to bind to PP1 (SHOCA-
2-PP1Mut2), or a SHOCA-2 mutant in which the tyrosine at position 131 was exchanged for an 
alanine (SHOCA-2-Y131A), or wild type Shoca-1. The cells were grown for 15 days under 
neomycin selection and then scored for the number (bar graphs) and appearance of colonies 
(microphotographs). The data is representative of two independent experiments performed in 
triplicates (Student's t test, *p < 0.05; **p < 0.01; ***p < 0.005). (C) Proliferation of SW480 cells that 
have been stably transfected with a control (shRNA control) vector or a recombinant vector to 
knock-down SHOCA-2 expression (SHOCA-2 KD). Successfully transduced cells were grown 
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either in the presence or in the absence of the STAT3 inhibitor S3I-201 diluted in DMSO (100M). 
Data represent the mean ± SD of two independent experiments carried out in triplicates. (D) 
SHOCA-2 protein expression in the CRC cell lines SW480 (primary tumor) and SW620 (metastasis 
from the same patient) was assessed using Western-blotting. 
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Figure S6. Related to Figure 6. SHOCA-2 knock-down SW480 cells display features of EMT. 
(A) Low power view of SW480 cells expressing either a control vector (shRNA control, left panel) 
and or a vector to knock-down SHOCA-2 expression (SHOCA-2 KD; right panel). Scale bar, 100 
m. (B) Left, phase-contrast images of Shoca-2 KD SW480 cells grown in the presence or absence 
of EGFR inhibitor AG1478 diluted in DMSO (10M; scale bar: 50 m). Right, immunoblot analysis 
of E-cadherin, Vimentin, Shoca-2 and GAPDH protein expressions in lysates from shRNA control 
and Shoca-2 KD SW480 cells cultured in the in the presence or absence of EGFR inhibitor AG1478 
diluted in DMSO (10M). 
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Supplemental Experimental Procedures 
 
Plasmids, antibodies and reagents 
Mouse and human SHOCA-1 and SHOCA-2 sequences were amplified from 
thymus cDNA libraries by PCR, subcloned into the expression vectors pcDNA-Flag 
3.1, CTAP and NTAP (a kind gift from Dr. A.C. Gingras, Samuel Lunenfeld 
Research Institute at Mount Sinai Hospital, Toronto, Canada) and sequenced. 
Site-directed mutagenesis (Qiagen) was used to introduce specific mutations. The 
human EGFP-PP1, , 1 constructs were generously provided by Dr. L. Trinkle-
Mulcahy (Wellcome Trust Centre for Gene Regulation and Expression, University 
of Dundee, Scotland, UK), the EGFP-CTAP plasmid was a gift from Dr. S. Meloche 
(Institute of Research in Immunology and Cancer, Université de Montréal, 
Canada), the SIE firefly luciferase reporter plasmid was kindly made available by 
Dr. I. Behrmann (Life Sciences Research Unit, University of Luxembourg, 
Luxembourg), the EGFR wild-type and Y1068/1086F mutant constructs were 
generously provided by Dr. S. Sigismund (IFOM, Milano, Italy) and the STAT3 
expression vector was obtained courtesy of Dr. J.Y. Yoo (Pohang University of 
Science and Technology, Pohang, Republic of Korea). Antibodies used were 
directed against PP2A (Upstate); Flag, ERK ½, anti-vimentin (all from Sigma); 
Histone H1, Jun B, c-Myc, cyclin D1, c-SRC and ZEB-1 (all from Santa-Cruz); 
GAPDH, SNAIL and PP1 (all from Abcam); SH2D4A (Abnova); EGF receptor, 
Tyr845-phosphorylated EGFR, Ser660-phosphorylated PKC, phospho-tyrosine 
(designated pTyr), Tyr705/Ser727-phosphorylated STAT3, Akt, Ser473-phospho-
Akt, Thr202/Tyr204-phospho-ERK 1/2 (all from Cell Signaling); GFP (Roche); anti-
N-cadherin (Takara Biomedicals); anti-E-cadherin and STAT3 (both from BD 
Biosciences). EGF was obtained from Peprotech and used at a concentration of 
100 ng/ml. AG1478 was purchased from Axxora and the STAT3 inhibitor (S3I-201) 
was obtained from Merck. 
 
Cell culture and transfection 
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HEK293, HeLa, SW480, SW620 cells (a kind gift from Dr. G. Marra, Institute of 
Molecular Cancer Research, University of Zurich, Switzerland), Murine embryonic 
fibroblasts (MEF) either wild type (fl/fl) or deficient for Stat3 (MEFΔ/Δ), a generous 
gifts of Dr. Valeria Poli, University of Turin, Torino, Italy, were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with Glutamax (4 mM), and 10% 
fetal calf serum (Invitrogen-Gibco). Porcine aortic endothelial (PAE) cells (kindly 
made available by Dr. P. Berger, Paul Scherrer Institut, Villigen, Switzerland) were 
grown in F-12 Nutrient Mixture (Ham) supplemented with Glutamax (4 mM), and 
10% fetal calf serum (Invitrogen-Gibco). Transient transfections were 
accomplished using Lipofectamine 2000 (Invitrogen) for HEK293 and Fugene HD 
(Roche) for HeLa, SW480, SW620 cells according to the manufacturer's 
recommendations. For stable pShoca-1-CTAP or pEGFP-CTAP transfectants, 
HEK293 cells were co-transfected with the puromycin resistance plasmid, pBabe-
puro (Cell Biolabs). Cells were first plated onto 100-mm plates and allowed to grow 
to 80% confluence, then rinsed twice with phosphate-buffered saline (PBS) and 
finally exposed to the plasmids/Lipofectamine-DMEM mixture. After overnight 
incubation, the cells were washed, split into a 150-mm plate and for selection 
grown in DMEM containing puromycin (10.8 g/ml for the first 48 hrs and then 3.6 
g/ml). Several puromycin resistant clones were established. Cells expressing 
comparable amounts of either Shoca-1-CTAP or EGFP-CTAP protein (as 
analyzed by western-blotting) were selected for further analysis. For the stable 
knock-down, HeLa and SW480 cells were transfected using different human 
SHOCA-2 (SH2D4A)-specific shRNA constructs (Origene).  
 
Bioinformatic analysis 
Sequences from SHOCA-1 (SH2D4B) and SHOCA-2 (SH2D4A) were retrieved by 
homology search with ENSEMBL2: C. elegans SHOCA, F13B12.6; Danio rerio 
SHOCA-1, ENSDARG00000015144; Gallus gallus SHOCA-1, 
ENSGALG00000002370; Mus musculus SHOCA-1, ENSMUSG00000037833; H. 
sapiens SHOCA-1, ENSG00000178217; Danio rerio SHOCA-2, 
ENSDARG00000041378; Xenopus laevis SHOCA-2, ENSXETG00000004464; 
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Gallus gallus SHOCA-2, ENSGALG00000010122; Mus musculus SHOCA-2, 
ENSMUSG00000053886; H. sapiens SHOCA-2, ENSG00000104611. The 
common SHOCA precursor (Sh2d4) sequence of Monosiga brevicollis (30425.AA) 
was identified in the KinBase database (http://www.kinase.com/kinbase/). 
Sequences were aligned with the TCoffee software (http://tcoffee.vital-it.ch)3. An 
unrooted evolutionary tree of SHOCA homologues was generated using the 
Unweighted Pair Group Method with Arithmetic mean (UPGMA). The gene 
microarray analysis tool made available by Oncomine1 (Compendia Bioscience, 
Ann Arbor, MI, USA: http://www.oncomine.org) was used to determine SHOCA-2 
mRNA expression in various cancers. 
 
Quantification of SHOCA-2 expression and STAT3 phosphorylation on 
tissue microarrays & whole-tissue sections 
The H score determines the percentage of positive tumor cells multiplied by their 
staining intensity4. Given the size of the cohort of patients analyzed, three ranges 
of scores were considered: >200, identifying strong expression or phosphorylation; 
100-200, classifying moderate expression or phosphorylation; <100 characterizing 
a low or absent expression or phosphorylation. 
 
Statistical analyses 
The likelihood ratio test and binomial test for differences in proportions were used 
to compare H-scores between and among disease stages, respectively5. Survival 
time analysis was performed using three different methods: the non-parametric 
log-rank test, the non-parametric Gehran-Wilcoxon tests and the Cox regression 
analysis which was carried out after verification of the assumption of proportional 
hazards; survival time differences were represented using the Kaplan-Meier 
method6. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained to 
measure effect size with values <1.0 indicating more favorable survival time with 
higher protein expression. P-values were two-sided and considered statistically 
significant when p<0.05. 
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Real-time RT-PCR 
Using TRI reagent (Molecular Research Center), total RNA was prepared from 
various tissues freshly isolated from 10 week-old Balb/c mice. Oligo(dT20) or 
random-N6−primed cDNA was generated with M-MLV Reverse Transcriptase 
(Invitrogen-Gibco) employing standard protocols. For quantitative real-time PCR, 
the SYBR Green-based method was used (Sensimix, Quantace); primers are 
available upon request. PCR specificity was controlled by analyzing the melting 
curves and agarose gel electrophoresis of the PCR products. Amounts of specific 
mRNA were normalized to levels of 18S rRNA transcripts. 
 
Mass spectrometry 
TCA precipitated and acetone washed or Chlorophorm/Methanol treated protein 
pellets were reduced with TCEP (tris(2-carboxyethyl)phosphine), alkylated with 
Jodoacetamide and digested with Trypsin. The generated peptides were analyzed 
by NanoLC-MS/MS on a 4000Q Trap (MDS Sciex) as described7. The proteins 
were identified with Mascot (Matrix Science) searching the Uniprot database8. 
MRM-buddy, a software developed at the Friedrich Miescher Institut (A. di Cara, 
R. Sack and R. Portmann, unpublished results) was used to extract the MRM-
relevant information for the quantification of selected proteins. MRM analysis was 
done as described7. 
 
Western Blot and immunoprecipitation 
Total protein (40g as quantified by the Bradford method; Biorad) was separated 
on a 8%-12% SDS-PAGE and transferred to nitrocellulose membranes (Biorad). 
Membranes were blocked with 5% milk (Migros) in TBS-Tween and subsequently 
incubated overnight with primary antibody using concentrations that have either 
been previously established or used according to the manufacturer’s 
recommendations. After a one hour incubation with a secondary antibody 
conjugated to horseradish peroxidase (Southern Biotech), the reaction was 
visualized by ECL (Pierce). For immunoprecipitation, cell lysates containing equal 
amounts of total protein were precleared for 1 hr with 40 l of 50% (wt/vol) protein 
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G Plus-Sepharose beads (Amersham) and incubated for 2-3 hrs at 4°C with 
primary or control (IgG) antibodies. The beads were added for 1 hr and then 
washed extensively with lysis buffer; bound proteins were fractionated on a 8%-
12% SDS-PAGE, and analyzed by western blotting as detailed above. 
Immunoprecipitations were performed using RIPA buffer with the notable 
exception of analyses shown in Figures 3e and 4d which were carried out using 
the JS lysis buffer (50 mM HEPES at pH 7.5, 1% glycerol, 50 mM NaCl, 1% Triton 
X-100, 1.5 mM MgCl2, 5 mM EGTA). 
 
Confocal microscopy 
HeLa cells grown plated on glass coverslips were transiently transfected to 
express the EGFP-PP1 fusion protein. Twenty-four hours later, cells were 
washed in PBS and fixed for 15 min using 4% paraformaldehyde at room 
temperature (RT). Following three washes with PBS, cells were permeabilized on 
ice for 15 min using cold 0.1% Triton X-100 (v/v) in PBS. All staining reactions were 
performed at RT. To prevent unspecific binding, the cells were exposed for 30 min 
to 5% normal goat serum diluted in PBS. Next, the cells were incubated for 1 hr 
with the primary antibody, then washed three times in PBS and finally exposed for 
30 min to the secondary antibody, an Alexa 555-conjugated goat anti-mouse 
antibody (Invitrogen). Prior to mounting, nuclei were stained with DAPI (4',6-
diamidino-2-phenylindole, diluted 1:10,000 in PBS from a 1 mg/ml stock) and 
washed twice with PBS. Coverslips were mounted with fluorescent mounting 
medium (Dako). Images were acquired using an LSM 510 Meta confocal 
microscope and LSM510 imaging software (Carl Zeiss). 
 
Cell cycle analysis 
HeLa cells stably transfected with shRNA plasmid specific for the knock-down of 
SHOCA-2 or with a control plasmid were serum-starved for 24 hrs prior to a 12 hrs 
stimulation with EGF (100 ng/ml). After trypsinization and centrifugation, 5 x 105 
cells were resuspended in 0.5 ml of cold hypotonic PI (Propidium Iodide) staining 
solution (50 g/ml PI (Sigma), 0.1 mg/ml RNase A, 0.1% Triton X-100, 0.1% 
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sodium citrate). Following vigorous resuspension, the cells were incubated (15 
min) on ice and then analyzed by flow cytometry (FACSCalibur, Becton Dickinson) 
using the FlowJo software (Tree Star, Oregon Corporation). G1, S and G2/M 
phases of cell cycle were defined using the mathematical Watson Pragmatic 
model. 
 
Cell proliferation 
SW480 cells (5 × 104 cells/well) were cultured in 96-well plates in the absence or 
presence of AG1478 (10 μM) or S3I-201 (100M) in 10% serum condition. After 
48 hours of treatment, cell proliferation was analyzed using CellTiter 96 aqueous 
nonradioactive cell proliferation assay kit (Promega, Madison, WI). The cell 
proliferation index was calculated as a percentage of the absorbance in relation to 
the untreated control cells. 
 
Human tissues and DNA extraction 
The tissues from primary colorectal carcinomas and the macroscopically healthy-
appearing neighboring mucosa (7cm proximal of tumor) were resected on the 
occasion of surgical cancer therapy. All the tissue samples were immediately 
submerged into RNAlater® RNA stabilization reagent (Qiagen) and kept at room 
temperature for several hours to guarantee a complete penetration by the reagent. 
The vials were then stored at -80°C until the tissue was further processed. DNA 
from approximate 20 mg of tissue was extracted with the QIAamp DNA Mini Kit 
(Qiagen) according to the manufacturer’s specifications. 
 
LOH and mutational analysis of the SH2D4A gene 
All canonical exons, the flanking intronic sequences as well as 5’ and 3’ UTR 
regions were subjected to PCR amplification (KapaHiFi™ system ; Kapa 
Biosystems, USA) and sequenced (BigDye terminator kit v1.1 on ABI 3130xl; both 
Applied Biosystems, USA) using the set of primers described in the supplementary 
table. Putative mutations were confirmed by bi-directional sequencing of a second 
independent PCR product. In Silico mutation impact prediction scores (SIFT: 
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http://sift.jcvi.org and PolyPhen-2: http://genetics.bwh.harvard.edu/pph2) were 
calculated for all somatic point alterations found. Loss of heterozygosity was 
assessed using 3 flanking microsatellite markers (D8S549, D8S1715 and D8S258 
labeled at 5’ end with 6-Carboxyfluorescein (6-FAM) dye) as well as 6 single 
nucleotide polymorphisms refSNP rs2280444, rs877386, rs1574288, rs17128221, 
rs4921637, rs36092909) located within the SH2D4A gene itself. The relative 
proportions of alleles 1 and 2 in non-tumor and tumor samples corresponds to the 
ratio of the heights of the corresponding peaks. An LOH index was calculated by 
dividing the ratio of allele 2 to allele 1 in the non-tumor DNA by the corresponding 
ratio in the tumor DNA. LOH positivity was defined as an LOH index of <0.5 
(reflecting a substantial loss of allele 1 in the tumor sample) or >1.5 (indicative of 
substantial loss of allele 2).  
 
Identification and characterization of exon 4 skipping variant of the human 
SH2D4A gene by RT-PCR 
First strand cDNA was synthesized from 500ng of total RNA using random-primed 
reverse transcription (Verso cDNA; Thermo Scientific). PCR amplification was next 
carried out on a cDNA template, products were separated on a 2% agarose gel 
and visualized with ethidium bromide. Individual bands were excised from the gel, 
eluted (Quiaquick gel extraction kit; Quiagen, Germany), reamplified and 
sequenced. 
 
Conditions and primers for sequence, LOH and cDNA analyses 
For the SH2D4A sequence analysis the following PCR conditions were used: initial 
denaturation of 2min at 94°C followed by 35 cycles of 10sec at 94°C, of 15sec at 
56°C and of 15sec at 72°C and a final elongation step of 3min at 72°C. When using 
the ABI Prism TrueAllele premix, the initial denaturation step was extended to 
10 minutes.  The following primers were used: 
Mutational Analysis DNA sequence 5’→3’ 
SH2D4A_x1_For CGATTGCGCCCCGCCAGTCA 
SH2D4A_x1_Rev CTCCCATGCACCCATGCAAC 
62 
 
SH2D4A_x2_For GGAACTTTTGCCACAAGTAT 
SH2D4A_x2_Rev CTTGCACCTGCTTTGCTTG 
SH2D4A_x3_For ATTGCTACCTACAGATGTTC 
SH2D4A_x3_Rev AAGTGACTTTTGTGACCCTC 
SH2D4A_x4_For ACGTCTTTACACACCTAGC 
SH2D4A_x4_Rev AAATTCCGCACGTCTACAG 
SH2D4A_x5_For TCACATGCCCGTTGCTGT 
SH2D4A_x5_Rev ATGCCTAGGTATGCAGCCC 
SH2D4A_x6_For AGGAAACTGCTGGATTTGCT 
SH2D4A_x6_Rev ATCAGCTGAGAGCCTGGAAG 
SH2D4A_x7_For ATAAGCAGACAACAAACTG 
SH2D4A_x7_Rev CTCATACAATTCCCCTTTAA 
SH2D4A_x8_For TATATGACTTTTGAGGGC 
SH2D4A_x8_Rev TTCCTGGTAGATTAGCACAG 
SH2D4A_x9_For TGCTCTTATTGTGTCTTATTTAGGC 
SH2D4A_x9_Rev CTCAGAAGGCAAATTAAGTT 
SH2D4A_x10_For GGTCACATGTAGATAAGAAA 
SH2D4A_x10_Rev AAAACAAACTCAGCGATGT 
LOH Analysis  
D8S1715_For CAGGTGATGTCCCAGAGG 
D8S1715_Rev CGAACATGAATTAGAAATCCAGTG 
D8S258_For CTGCCAGGAATCAACTGAG 
D8S258_Rev TTGACAGGGACCCACG 
D8S549_For AAATGAATCTCTGATTAGCCAAC 
D8S549_Rev TGAGAGCCAACCTATTTCTACC 
rs36092909_For ACAAATGCCACTGCAACATT 
rs36092909_Rev TACATCATTAAGGTCATAC 
cDNA Analysis  
SH2D4A_cx2.1_For CAGACCAAAGAAAGAGAATGGCA 
SH2D4A_cx2_Rev ATCTGCCAACATTTGTTGAA 
SH2D4A_cx2.1_Rev CTTTGGATTTTCGCAGAGATG 
 
Multiplex-ligation dependent-probe-amplification (MLPA) 
Chromosome 8 copy-number variation was investigated by multiplex ligation-
dependent probe amplification assay (kit P014-1A, MRC Holland) according to the 
manufacturer’s protocols. Calculations were performed using GeneMarker 
software (SoftGenetics). Gene dosage with relative value of 1 is expected for two 
copies, whereas values of 0.5 and 1.5 indicate loss and gain of one copy, 
respectively. MLPA results indicative of a somatic deletion were independently 
confirmed in at least one additional experiment.  
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Methylation analysis  
Genomic DNA from primary tumor samples and adjacent matched healthy 
appearing mucosa, respectively, was extracted using the QIAamp DNA Mini Kit 
(Qiagen), and bisulfite converted using the EZ DNA Methylation KitTM (Zymo 
Research). Promoter associated CpG-island regions of SH2D4A were amplified by 
PCR and biotin labeled either directly using biotin-labelled reverse primers or 
during a second PCR step using a biotinylated universal primer annealing to a 
sequence introduced by the reverse primer used in the first PCR. PCR conditions 
and primer sequences are provided on supplementary table. Labelled PCR 
products were purified (QIAquick® PCR Purification Kit, Qiagen), bound to 
streptavidin-covered sepharose beads and analyzed by pyrosequencing using the 
PyroMark Q24 pyroseqencing system (Qiagen). Sequencing-assay design as well 
as quantification of methylation was performed with the PyroMark Q24 1.0.10 
software. Peripheral blood DNA treated with M.SssI methyltransferase (New 
England BioLabs) and subsequently bisulfite treated served as positive control. 
 
Conditions and primers for methylation analysis 
PCR Amplification of CpG islands  
1st CpG island forward 5'-GTT TTA TGA ATT AAG AGA 
GGA GAG GAT AAG TTT ATT T-3' 
1st CpG island reverse 5'-GCC CCC GCC CGC CCC CAA 
CAC CTA CCA ATA C-3' 
Biotinylated primer 5'-Bio-GCC CCC GCC CG-3´ 
2nd CpG island forward 5'-AG GTT GTA TGG GTG TAT GGG 
AG-3' 
2nd CpG island biotinylated reverse 5´-Bio-CAA CTC AAA AAA CCT ACA 
AAC TAT AAC TCC TTC-3´ 
PCR conditions: 
 
1st CpG island 1st PCR 
 
 
 
 
 
 
Enzyme activation: 95°C for 2min 
40 cycles of  
Denaturation: 95°C for 30 sec 
Annealing: 61°C for 25 sec 
Extension: 72°C for 30 sec 
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1st CpG island 2nd PCR 
 
 
 
 
 
 
 
2nd CpG island 
 
3.5mM MgCl2, 0.5µM primer 
 
Enzyme activation: 95°C for 2min 
20 cycles of  
Denaturation: 95°C for 30 sec 
Annealing: 61°C for 30 sec 
Extension: 72°C for 30 sec 
 
2.5mM MgCl2, 0.5µM primer 
 
Enzyme activation: 95°C for 4min 
35 cycles of  
Denaturation: 95°C for 30 sec 
Annealing: 61°C for 30 sec 
Extension: 72°C for 55 sec 
 
2.5mM MgCl2, 0.25µM primer 
 
Pyrosequencing primers 
1st CpG island 
 
Primer 1 5'- GGA GGA GAG GAT AAG T -3' 
Primer 2 5'- GTT TTG GAG AGT TTT TAG -3' 
Primer 3 5'- GTT ATA AGA GTT GTT TTG -3' 
Primer 4 5'- GGT TAA GTG GAT GTG -3' 
2nd CpG island  
Primer 1 5'- TAT GGG TGT ATG GGA G -3' 
Primer 2 5'- GGG TTT AGG TG -3' 
Primer 3 5'- GTT GGT TAG GTG AG -3' 
Primer 4 5'- AGG GAG AGG GTT TG -3' 
Primer 5 5'- GGG GAG TGT AGG TTT -3' 
Primer 6 5'- TAT GGA AAT TTT TTA GGA GG 
-3' 
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Primer 7 5'- TGG GGT TTG GGA G -3' 
Primer 8 5'- GGG TTG GTT TAG ATT TAG -3' 
 
Gel-Shift, Shift-Western Blot, and Western Blot 
The gel-shift method employed was adopted from Harrington et al9. A 28 bp long, 
fluorescein-labeled dsDNA probe containing a Sp1 recognition site was incubated 
for 15 min at RT with SW48 nuclear extract in the presence of increasing 
concentrations of an unlabeled 28mer oligomer. The competitor had either a 
methylated or an unmethylated Sp1 recognition site. The mixture was then run in 
a 6% native polyacrylamide gel and fluorescence signals were subsequently 
detected using a biomolecular imager (Typhoon 9400, Amersham Biosciences). 
Fluorescence intensity of shifted bands was normalized against the sum of signals 
provided by both unbound oligomers and shifted bands. Experiments were 
performed in quadruplicates.  
Bands from the polyacrylamide gel were transferred onto a nitrocellulose 
membrane using the wet blotting method and Sp1 was detected via 
chemiluminescence with anti-human Sp1 primary antibody (polyclonal rabbit, 
Millipore) and a HRP-labeled anti-rabbit secondary antibody (GE healthcare). 
 
Sequences of oligomers:  
Positive control: Forward: 5´-ACG TTG CAG CCG GGG CGG GGC TTC TGC A-
3´, Reverse: 5´-TGC AGA AGC CCC GCC CCG GCT GCA ACG T-3´ 
Methylated competitor: Forward: 5´-CCT CAC CCC CGC CTC CAC CCC TTC 
GCG G-3´, Reverse: 5´-F-CCG CGA AGG GCT GGA GGCm GGG GGT GAG G-
3´ 
Unmethylated competitor: Forward: 5´-CCT CAC CCC CGC CTC CAC CCC TTC 
GCG G-3´, Reverse: 5´-F-CCG CGA AGG GCT GGA GGC GGG GGT GAG G-3´ 
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2 
Abstract 
Gene silencing by aberrant DNA methylation is a hallmark of colorectal cancer (CRC). How-
ever, little is known about its precise timing during tumor development. We aimed to identify 
novel targets of aberrant methylation early in colorectal carcinogenesis. In addition to MGMT 
and hMLH1, we determined the methylation in five gene promoters in matched tumor tissue, 
cancer-associated mucosa (CAM) and blood samples from 106 unselected CRC patients, and 
in 62 normal colorectal mucosa (NM) samples from 31 healthy individuals, using locus-nor-
malized quantitative methylation-specific PCR (ln-qMSP). We identified FOXF1, CA4, 
NPY1R, IFITM1 and GREM1 as novel targets of aberrant methylation in CRC. The frequency 
of tumors showing > 99% cancer-specific hypermethylation was 66% for FOXF1, 36% for 
MGMT, 21% for CA4, 19% for NPY1R, 15% for IFITM1, 14% for hMLH1 and 13% for 
GREM1. This seven-marker panel separated CRC from CAM in 82% of all and in 94% of right-
sided tumors with a specificity of 99%. We observed concomitant methylation of CA4, NPY1R 
and GREM1 with hMLH1 in CRC, suggesting them to represent novel CIMP markers. Using 
highly sensitive ln-qMSP and genome-wide methylation profiling, we also found synchronous 
low level methylation in CA4, NPY1R, GREM1 and several validated CIMP markers, but not 
in hMLH1, in virtually all CAM and NM from healthy individuals. Thus, concomitant low-
level methylation of some, but not all CIMP markers is readily detectable in the colorectum of 
healthy individuals, suggesting that part of the CIMP signature reflects a physiological condi-
tion. 
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Introduction 
Gene silencing by DNA hypermethylation in promoter CpG islands (CGIs) is a hallmark 
of colorectal cancer (CRC). Yet, little is known about the underlying causes and the precise 
timing of these epigenetic changes during neoplastic transformation. A key question is whether 
aberrant DNA methylation observed in cancers originates from a random instability in DNA 
methylation and selection during carcinogenesis, or from specific defects in the methylation 
machinery. The identification of a subgroup of CRC displaying widespread hypermethylation 
at gene promoters, a phenomenon referred to as the CGI methylator phenotype (CIMP), argues 
for a specific pathway driving aberrant methylation in CIMP-positive cancers (1). CIMP-
positive cancers indeed present with distinct clinical features, such as proximal location, older 
age at diagnosis and female gender, and they appear to be defined by specific patterns of gene 
promoter hypermethylation (1-6). The cellular and molecular events underlying the formation 
of CIMP-positive as opposed to CIMP-negative CRC, however, have not been identified. 
Some genes undergo progressive methylation in their promoter CGIs in an age-depend-
ent manner in normal colorectal mucosa. The causes and mechanisms underlying age-related 
methylation changes are largely unknown. While many targets displaying hypermethylation in 
CRC are thought to result from aberrant de novo methylation in normal colonic cells during 
aging, others exhibit cancer-specific methylation as observed predominantly in CIMP-positive 
tumors (1). Only few studies, however, investigated normal colorectal mucosa to dissect meth-
ylation changes occurring early in colorectal carcinogenesis. Probably the majority of methyl-
ation changes accumulated during aging and observed in CIMP-positive tumors is not causally 
involved in colorectal carcinogenesis and accompany rather than initiate tumorigenesis. By 
contrast, the pathogenetic consequence of inactivation of the mismatch repair gene hMLH by 
CGI hypermethylation is well established and provides the molecular basis for sporadic mi-
crosatellite (MS) unstable CRC, which occur mainly in the proximal colon of elderly females 
(7, 8). Although hMLH1 is a robust CIMP marker, i.e. cancer-specific, we have recently demon-
strated that methylation in its promoter is detectable at a low level in the normal appearing 
colorectal mucosa of healthy individuals (9, 10). Notably, the epidemiological pattern of spo-
radic MS-unstable CRC was already established in healthy individuals, i.e., the age-related 
methylation increase in hMLH1 was observed in the proximal colon of healthy females. Thus, 
targets formerly being proposed to be cancer-specifically methylated are in fact also methylated 
in an age-dependent manner.  
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In the present study, we aimed to (i) identify gene promoter targets affected by aberrant 
promoter methylation early in colorectal carcinogenesis; (ii) establish cancer-specific methyla-
tion thresholds for these targets (iii) compile a highly cancer-specific marker panel that covers 
the majority of CRC; and (iv) investigate their DNA methylation patterns in normal colorectal 
mucosa from healthy individuals. Towards these aims, we determined methylation levels of 
seven gene promoters in tumor tissue, matched adjacent normal mucosa and blood samples of 
106 unselected CRC patients and in normal colorectal mucosa biopsies of 31 healthy individu-
als using sensitive locus-normalized qMSP (ln-qMSP).  
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Material and Methods 
Recruitment of patients and healthy individuals and tissue sampling 
Tissue and blood samples from 106 unselected colorectal cancer patients undergoing 
surgical therapy at the Department of Surgery of the cantonal hospital of Aarau, Switzerland, 
were collected. Informed consent was received from all patients and the study protocol was 
approved by the local medical ethical committee. From each patient, a tissue sample of the 
primary tumor and of apparently normal mucosa 7 cm proximal to the primary tumor (cancer 
associated mucosa, CAM) were collected in the operating theatre immediately after surgical 
removal of colorectal segment. All samples were submerged in RNAlater and stored at -80°C 
until further processing. All primary tumors were histopathologically confirmed adenocarcino-
mas. Blood samples were drawn from each patient and stored in ethylenediaminetetraacetate 
(EDTA) at -80°C. From 31healthy individuals without colorectal polyps, we obtained biopsies 
of normal mucosa from the cecum and the sigmoid colon at their screening colonoscopy at the 
cantonal hospital of Uri, Switzerland (9). The stage of disease refers to (11). Tumors from the 
cecum to the splenic flexure and from the splenic flexure to the rectum were termed right- and 
left-sided, respectively.  
Selection of gene promoters for methylation analysis 
To identify novel gene promoters affected by aberrant methylation early in colorectal 
carcinogenesis, we explored data of a previously published transcriptome analysis of 32 
matched adenoma and normal colorectal tissue samples (12). Genes fulfilling the following 
criteria were selected for further examination: (i) mRNA expression downregulated (<90%) in 
at least 26 adenomas compared to matched normal tissue, (ii) presence of a promoter CpG island 
(≥200 bp length, GC percentage > 50%, observed/expected CpG ratio > 60%), (iii) not previ-
ously reported as a target of aberrant methylation in CRC, (iv) cancer-specific methylation 
(specificity), and (v) sufficient diagnostic sensitivity in a pilot study performed in matched can-
cer, CAM and blood samples from 20 patients. More detailed information about the reanalysis 
of the mRNA expression chips is given in the supplemental data. 
DNA extraction and bisulfite conversion 
Genomic DNA from colorectal tissue and colorectal cancer cell lines was extracted with 
the QIAamp DNA mini kit (Qiagen, Hilden, Germany). An RNAse A (Qiagen) treatment was 
included in the protocol according to the manufacturer’s protocol. Genomic DNA from blood 
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samples was extracted with the NucleoSpin Blood L Kit (Macherey-Nagel, Dueren, Germany). 
For methylation analysis, we converted 2 µg of purified DNA with sodium bisulfite using the 
EZ DNA Methylation Kit® (Zymo Research, Orange, USA).  
Methylation analysis, locus-normalized quantitative methylation-specific PCR and bisul-
fite sequencing 
Methylation of the selected target promoters was analyzed by locus-normalized quanti-
tative methylation specific PCR (ln-qMSP), which is a modification of the quantitative MSP 
assay developed and validated in our laboratory (9). To achieve accurate locus normalization, 
we introduced standardizer primer pairs for each target, amplifying input DNA after bisulfite 
conversion at the locus examined, thereby minimizing copy number biases. Methylation at tar-
get sequences was then expressed as percentage of methylated alleles (PMA), ranging from 0% 
(unmethylated) to 100% (fully methylated). ln-qMSP results were confirmed by bisulfite se-
quencing. Sequences of primers used for qMSP and bisulfite sequencing, the regions and CpG 
sites examined by both methods as well as detailed information on the assays are given in the 
Supplemental data. 
Genome-wide promoter methylation analysis 
1 µg of genomic DNA was sodium bisulfite converted with the Zymo EZ DNA Meth-
ylation kit (zymo Research,D5002) by following the manufacturer’s protocol with modifica-
tions for the illumina infinium methylation assay. Briefly, after the denaturation step, DNA was 
incubated in a thermocycler for 16 cycles at 95°C for 30 seconds and 50°C for 60 minutes. 
DNA was eluted from the column in 12 µl elution buffer. Concentration of the eluted samples 
were measured using Nanodrop-1000. The methylome state of bisulfite-converted genomic 
DNA was analyzed using illumina’s infinium Human Methylation27 beadchip kit (WG-311-
1202), interrogating 27,578 CpG loci covering more than 14,000 human RefSeq genes at single 
nucleotide resolution. Chip process and data analysis were performed by using the kit reagents 
provided according to the manufacturer’s manual. Raw signals were normalized using back-
ground subtraction in the BeadStudio v3.0 software. Methylation values for each CpG locus are 
expressed as beta (β )- value representing a continuous measurement from 0 (unmethylated) to 
1 (fully methylated). For each CpG site, the β value is calculated by dividing the signal intensity 
of methylation-detection probe (M) by the sum of signals for both methylation-detection probe 
and non-methylation detection probe (U): β = Max(M,0) / [Max(M,0) + Max(U,0) + 100].  
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mRNA expression in CRC and CAM tissue 
Matched CRC and CAM samples from 10 patients with extensively methylated tumors 
were selected to analyze the correlation between FOXF1 methylation and gene expression. 
Simultaneous purification of DNA and RNA from tissue samples was performed with the All-
Prep DNA/RNA/Protein Mini Kit® (Qiagen, Germany). For protocol modifications, cDNA syn-
thesis and qRT-PCR conditions see Supplemental data.  
Promoter derepression by TSA and 5-Aza-cytidine treatment 
To correlate the promoter methylation levels with gene activity, the human colorectal 
cancer cell lines CO115, SW48 and GP5d, showing full methylation in the gene promoters of 
interest, were treated with the demethylating agent 5-Aza-cytidine and/or the histone-deacety-
lase inhibitor Trichostatin A (TSA). After total RNA extraction and cDNA synthesis mRNA 
levels were analyzed by quantitative RT-PCR. For detailed information on the drug treatment, 
the qRT-PCR conditions, and cell culture conditions see Supplemental data. 
Statistical analyses 
To analyze the correlation of FOXF1 gene methylation and RNA expression in patient 
samples, the probability for the number of matched sample pairs which show an RNA expres-
sion higher in the poorly methylated CAM than in the extensively methylated CRC was calcu-
lated by a binomial probability function. For the analysis of concomitant target methylation, 
PMA values of all targets in NM and CAM samples were clustered by means of unsupervised 
hierarchical clustering (Euclidian distance) with the MeV software Version 4.3 
(http://mev.tm4.org/). Methylation levels of all targets were subjected to a repeated measures 
ANOVA analysis for NM (normally distributed), and to a Friedman non-parametric test for 
CAM samples (not normally distributed). Both statistical analyses were followed by a Tukey’s 
multiple comparison test and a Dunn’s multiple comparison test, respectively. Resulting P-val-
ues were considered an inverse measure for concomitant target methylation with P >0.05 or ≤ 
0.05 representing concomitant or independent, respectively. Cancer PMA values were catego-
rized in either “hypermethylated” or “not hypermethylated” according to the target-specific 
threshold established and contingency tables were created for pairs of all targets. The probabil-
ities of the resulting contingency tables were calculated by a Fisher’s exact test.  
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Results 
Identification of methylation targets of early colorectal carcinogenesis 
To identify gene promoters affected by aberrant cytosine methylation early in colorectal 
carcinogenesis, we explored previously published gene expression profiles of matched ade-
noma and normal colorectal tissue samples (15). We screened the data for genes with reduced 
mRNA expression in adenomas that have a CGI in their promoter not previously associated 
with aberrant methylation in CRC. We analyzed five candidate genes in detail for cancer-spe-
cific DNA methylation: Forkhead box F1 (FOXF1), Carbonic anhydrase IV (CA4), Neuropep-
tide Y receptor Y1 (NPY1R), Gremlin 1 (GREM1) and Interferon-induced transmembrane pro-
tein 1 (IFITM1). 
We determined CpG methylation as percentage of methylated alleles (PMA) in the pro-
moters of these five genes along with two known targets of aberrant methylation in CRC, the 
DNA repair genes human MutL Homolog 1 (hMLH1) and O-6-methylguanine-DNA methyl-
transferase (MGMT). We performed these measurements in DNA of matched colorectal cancer 
tissue (CRC), CRC-associated mucosa (CAM) and blood samples from 106 unselected patients 
(Table 1), using a highly sensitive, locus-normalized methylation-specific quantitative PCR as-
say (ln-qMSP). The mean PMA at all targets increased from blood to CAM by approximately 
two-fold and from CAM to tumor tissue by one order of magnitude (Fig. 1A, Supplementary 
Table S1). Comparing the methylation levels in these three tissues allowed us to establish a 
methylation threshold for each target, discriminating cancer from CAM with ≥ 99% specificity. 
These thresholds ranged from 4% methylated alleles for FOXF1 to 7% for IFITM1 (Fig. 1A, 
Table 2). Tumor samples showing methylation levels above this cut-off were classified as hy-
permethylated. Accordingly, the frequency of CRCs hypermethylated in these promoters were 
66% for FOXF1, 36% for MGMT, 21% for CA4, 19% for NPY1R, 15% for IFITM1, 14% for 
hMLH1 and 13% for GREM1 (Fig. 1B, Table2). According to the criterion that one of these 
targets must be methylated above threshold, this seven-marker panel separated cancer from 
CAM in 87 of the 106 unselected CRC cases (82%) with a specificity of 99%. When applied to 
right-sided CRCs, the coverage reached 94% (30/32) at the same level of specificity (Fig. 1C).  
To address the effect of promoter methylation on the expression of the newly identified 
hypermethylation target genes, we measured the respective mRNA levels in matched cancer 
tissue and CAM (FOXF1) or in colorectal cancer cell lines (FOXF1, CA4, NPY1R, IFITM1 and 
GREM1) before and after treatment with the demethylating agents 5’-Aza-Cytidine and/or the 
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histone deacetylase inhibitor Trichostatin A (TSA). Consistent with a gene silencing effect of 
the promoter methylation, FOXF1 expression was significantly reduced in hypermethylated 
cancers (p = 0.04) (Supplementary Fig. S2) and promoter demethylation partly restored RNA 
expression for all genes, except GREM1, in CRC cell lines (Supplementary Fig. S3). 
We then investigated the association of promoter hypermethylation patterns in CRCs 
with clinical parameters (Table 1), including gender, tumor location and stage of disease. Tu-
mors hypermethylated in IFITM1 occurred more frequently in men (20.9% vs. 5.2%, P= 0.046), 
while FOXF1, MGMT, NPY1R, GREM1, and hMLH1 were more frequently hypermethylated 
in women, with the difference for hMLH1 being statistically significant (25.6% vs. 7.5%, P = 
0.018) (Supplementary Table S2, Supplementary Fig. S4A). All targets, except IFITM1, were 
more frequently hypermethylated in proximal than in distal CRC (FOXF1 91% vs. 55%, P = 
0.0003; CA4 59% vs. 4%, P<0.0001; NPY1R 34% vs. 12%, P=0.01; GREM1 31% vs. 5%, P = 
0.0008; hMLH1 34% vs. 5%, P = 0.0003) (Fig. 1B, Supplementary TableS3). MGMT was found 
hypermethylated more frequently at advanced tumor stages (P = 0.049), whereas none of the 
other targets showed an association between tumor stage and hypermethylation (Supplementary 
Table S4, Supplementary Fig. S4B).  
Association of the Newly Identified Methylation Targets with CIMP 
We then asked whether the methylation targets identified in this study acquire aberrant 
methylation as a consequence of an overall methylator phenotype as proposed for CIMP. The 
analysis of all CRC samples according to their methylation status at all promoter targets (hy-
permethylated vs. not hypermethylated), revealed concomitant hypermethylation of CA4, 
NPY1R and GREM1 with the established CIMP marker hMLH1, while MGMT and IFITM1 
appear to be methylated independently (Fig. 3C, Supplementary Table S5), and this was con-
firmed by an unsupervised hierarchical clustering (Fig. 2B). Finally, we performed a genome-
wide promoter methylation analysis in three CIMP-positive and four CIMP-negative cancers, 
classified according to their BRAFV600E mutation status. As controls, eight normal colorectal 
mucosa biopsies and one blood sample from healthy subjects were included in the analysis. The 
clinical characteristics of the cancer patients and healthy probands are shown in Supplementary 
Table S6. We used single CpG site-resolving bead chip technology (Infinium HumanMethyla-
tion27, Illumina), which simultaneously captures the methylation status of 27’578 CpG sites. 
The methylation levels of CA4, GREM1 and the validated CIMP markers CACNA1G, 
NEUROG1 and hMLH1 were significantly higher in CIMP-positive compared to CIMP-
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negative tumors, while the difference was clearly notable but not statistically significant for 
NPY1R (Fig. 4). Hence, our data suggests that CA4 and GREM1 represent novel CIMP markers 
while NPY1R appears to be loosely associated with CIMP as well. Consistently, all CRCs hy-
permethylated in CA4, NPY1R, GREM1 and hMLH1 (n = 8) located exclusively to the right-
sided colon, which is a typical clinical feature of CIMP (P = 0.00003) (Fig 2A). All CIMP-
positive tumors, as defined by hMLH1 hypermethylation, were also hypermethylated in 
FOXF1, suggesting that these cancers represent a subgroup of FOXF1-hypermethylated CRC. 
CIMP Signatures in Non-Cancerous Mucosa and Healthy Individuals 
We reported that methylation at the hMLH1 promoter, a bona fide CIMP marker, are 
detectable in the normal colorectal mucosa of healthy individuals (9). We investigated the meth-
ylation levels of all seven targets in CAM of the 106 CRC patients and, except the two DNA 
repair genes, in normal mucosa of 31 healthy subjects. We designated methylation levels above 
≥ 0.01% (detection limit), but below cancer-specific thresholds as low-level methylation.  
In CAM, the frequency of samples with low-level methylation ranged from 95.9% 
(GREM1) to 100% (FOXF1, CA4, NPY1R and IFITM1) with mean PMA ranging from 0.99% 
(FOXF1) to 2.49% (IFITM1) (Supplementary Table S7). Regarding hMLH1 and MGMT, both 
the frequency of low-level methylation and mean PMA were significantly lower (hMLH1 
36.8%, 0.16%; MGMT 55.6%, 0.28%). Unsupervised hierarchical clustering in CAM revealed 
concomitant methylation of CA4, NPY1R and GREM1, but not with hMLH1 (data not shown), 
which was confirmed by non-parametric repeated measures multiple comparison testing (Fried-
man and Dunn’s test) (Fig. 3B, Supplementary Table S8). Concomitant methylation of these 
three targets was independent of the anatomic location along the colorectum (Fig. 3B).  
In the colorectal mucosa of healthy individuals, the frequency of low-level methylation 
ranged from 90.3% (FOXF1) to 100% (NPY1R, IFITM1) (Supplementary Table S9), which was 
clearly higher than the frequencies measured for hMLH1 (70%) and MGMT (44%) as reported 
previously (9). Unsupervised hierarchical clustering and multiple comparison ANOVA testing 
revealed concordant methylation of CA4, NPY1R and GREM1, again irrespective of the ana-
tomic location (Fig. 3A, Supplementary Table S10). Thus, the only three targets being concord-
antly methylated in cancer tissue, CAM and normal mucosa from healthy individuals were CA4, 
NPY1R and GREM1, as indicated by the gray area in Fig. 3A-C. We investigated each four 
samples of normal mucosa from healthy individuals aged 50 and 75, respectively, for genome-
wide promoter methylation, using the aforementioned technology. The clinical characteristics 
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of the healthy subjects are shown in Supplementary Table S6. This assay showed low-level 
methylation of CA4, NPY1R and GREM1 as well as in the established CIMP markers 
CACNA1G, NEUROG1, IGF2, CDKN2A and hMLH1 in all samples (Fig. 4). Hence, methyla-
tion in validated and in the newly identified CIMP markers is readily detectable at low levels 
in healthy individuals. 
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Discussion 
Our effort was to identify genes that show cancer-specific aberrant promoter methyla-
tion early in colorectal carcinogenesis. We could establish ≥99% cancer-specific methylation 
thresholds for seven gene promoters and identified FOXF1, IFITM1, CA4, NPY1R and GREM1 
as novel potent targets of aberrant methylation in CRC, the later three targets representing novel 
CIMP markers. Though all investigated targets displayed highly cancer-specific methylation 
thresholds, they showed marked methylation differences in CAM and healthy individuals, sug-
gesting different functional roles early in colorectal carcinogenesis. 
Detection of aberrant DNA methylation in normal mucosa of healthy individuals may 
serve as a biomarker for CRC risk. Particularly, monitoring increasing methylation levels of 
targets with cancer-specific methylation thresholds might identify individuals at risk to develop 
CRC. For optimal sensitivity, there is a need for specific markers that cover the multiple path-
ways leading to CRC. The identification of a highly cancer-specific marker panel, which has a 
sensitivity of 83% for all and 94% for right-sided CRC, offers the possibility to monitor early 
methylation patterns in the colorectal carcinogenesis. The single most sensitive marker FOXF1 
was hypermethylated in 66% of all and in 91% of proximal tumors, a clearly higher frequency 
compared to other targets that are hypermethylated in CRC (12). FOXF1 has previously been 
described as a target of aberrant methylation in the SW48 colorectal cancer cell line, but was 
not systematically investigated in CRC (13). 
Several lines of evidence demonstrate that the genes investigated here become differen-
tially methylated early in colorectal carcinogenesis. In CAM, both the frequency and levels of 
low-level methylation were higher in the newly identified targets compared to hMLH1 and 
MGMT. This difference is also reflected by two different patterns of methylation distribution 
observed in CAM, i.e., a narrow and discontinuous distribution of the novel targets and a more 
wide and continuous pattern in the two DNA repair genes (Fig. 1A). Similarly in normal mucosa 
of healthy individuals, low-level methylation of FOXF1, CA4, NPY1R, IFITM1, and GREM1 
was detected in > 90% of samples compared to 70% of hMLH1 and 44% of MGMT, as reported 
in our previous study (9). These data suggest low-level methylation in the newly identified 
targets to be constitutive and their cancer-specific methylation to be characterized not by the 
presence or absence of methylation itself, but rather by levels. Cancer-specific methylation in 
these promoters might therefore derive from clonal expansion of cells harboring physiological 
low-level methylation in these targets. Hence, methylation of FOXF1, CA4, NPY1R, IFITM1, 
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and GREM1 is rather consequence than cause of neoplastic transformation in CRC development 
(constitutive type methylation markers). By contrast, any methylation in hMLH1 and MGMT in 
normal mucosa probably occurs de novo in aging mucosa and is of pathologic functional con-
sequence (oncogenic type methylation markers). 
We addressed the question of whether the newly identified targets represent markers of 
CIMP, designating a subgroup of tumors with widespread CpG islands methylation. Our anal-
yses, including a genome-wide promoter methylation assay, showed concordant methylation of 
CA4, NPY1R and GREM1 with hMLH1 and other validated CIMP markers (e.g. CACNA1G, 
NEUROG1) in cancer tissue and we propose that these genes represent newly identified CIMP 
targets. In addition to the molecular data, tumors hypermethylated in CA4, NPY1R and GREM1 
showed the typical right-sided location of CIMP-positive tumors. Notably, not all CIMP loci 
become simultaneously aberrantly methylated during the neoplastic process. We observed con-
comitant methylation of hMLH1 with CA4, NPY1R and GREM1 in tumor tissue, while the later 
three targets were not methylated together with the DNA repair gene in CAM and normal mu-
cosa of healthy individuals. By contrast, CA4, NPY1R and GREM1 also showed concomitant 
methylation in CAM and healthy individuals (Fig 3). Our genome-wide analysis revealed meth-
ylation not only in our newly identified targets, but also in several established CIMP markers 
in all samples of normal mucosa from healthy individuals. Hence, low-level methylation of 
CIMP markers is not rare, but readily detectable in healthy individuals (14). These data there-
fore support our previous finding that targets being proposed to be cancer-specifically methyl-
ated are in fact also methylated in healthy individuals. However, methylation changes in CIMP 
markers develop not uniformly in early colorectal carcinogenesis, although these markers ulti-
mately display concomitant hypermethylation in a specific CRC group. 
CIMP-positive cancers present mainly in the proximal colon, however, concomitant 
methylation of CA4, NPY1R and GREM1 occurred independently of the anatomic location 
along the colorectum in CAM and normal mucosa of healthy individuals (Fig 3). This suggests 
that low-level methylation in these promoters derives from the same cell population in the dif-
ferentiated colonic epithelium along the colorectum. Hence, the mechanism underlying the sim-
ultaneous methylation of CA4, NPY1R and GREM1 is not carcinogenic per se and not initiated 
during cancer initiation, but rather reflects a physiological condition in healthy individuals. A 
location-specific trigger might drive the aberrant proliferation of the cell population in the right-
sided colon, thereby increasing methylation above cancer-specific thresholds and establish the 
CIMP phenotype. 
14 
Sporadic MS-unstable CRC develops mainly in the right-sided colon of elderly females, 
indicating that that epigenetic instability in hMLH1 is both location- and gender-specific. In our 
previous study we showed that the age-related increase of hMLH1 methylation is most pro-
nounced in the proximal colon of elderly females. Thus, the methylation signature underlying 
sporadic MS-unstable CRC is yet recognizable in the normal mucosa of healthy individuals. 
Integrating our results, we propose the following model for the development of CIMP-positive 
cancer (Fig. 5): a cell type in the normal mucosa along the colorectum of aging individuals 
harbors constitutive methylation in a group of gene promoters, including our novel and several 
established CIMP markers, but not in hMLH1. Critical genetic and/or epigenetic events, such 
as activating BRAFV600E mutation and/or aberrant hMLH1 methylation, might occur in this cell 
population, thereby transforming them into a CIMP cancer stem cell. Clonal expansion of this 
cell type is associated with progressive methylation at selected genes and results in the estab-
lishment of the CIMP-positive phenotype. hMLH1 therefore not only represent a genetic, but 
also an epigenetic gatekeeper.  
Taken together, the methylation patterns of genes displaying highly cancer-specific 
thresholds are not uniform in healthy individuals. The occurrence of aberrant methylation in 
CIMP markers is not homogeneous early in colorectal carcinogenesis and parts of the CIMP 
methylation signature, characterizing a distinct cancer phenotype, are already established in the 
normal mucosa of healthy individuals. Our data indicate that only some genes initiate neoplastic 
transformation, while others achieve cancer-specific methylation and accompany the CIMP 
phenotype by clonal expansion of cells harboring constitutive methylation at various loci. 
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Tables 
Table 1. Clinical characteristics of the study cohorts  
A) Colorectal cancer patients  
Patients All Female Male 
Number 106 (100%) 39 (36.8%) 67 (63.2%) 
Age (y)    
Median 69.5 66 71 
Mean 68.3 64.6 70.4 
Standard deviation 12.4 14.5 10.5 
Normal distribution Yes1/Yes2/No3 Yes1/Yes2/Yes3 No1/Yes2/Yes3 
Tumor location    
Right 32 (30.2%) 10 (9.4%) 22 (20.8%) 
Left 74 (69.8%) 29 (27.4%) 45 (42.5%) 
Stage of disease (UICC/AJCC)    
I 22 (20.8%) 10 (9.4%) 12 (11.3%) 
II 24 (22.6%) 8 (7.5%) 16 (15.1%) 
III 32 (30.2%) 13 (12.3%) 19 (17.9%) 
IV 28 (26.4%) 8 (7.5%) 20 (18.9%) 
1 Kolmogorov-Smirnov normality test; 2 D'Agostino & Pearson omnibus normality test; 3 
Shapiro-Wilk normality test. 
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B) Healthy individuals  
Subjects All Female Male  
Number 31 16 15  
Age (y)     
Median 62 63.5 60  
Mean 63.6 64.8 62.4 P = 0.4231 
Standard deviation 8.23 8.89 7.56  
Distribution Normal Normal Normal  
Distribution was assessed with the Kolmogorov-Smirnov normality test, D'Agostino & Pearson 
omnibus normality test and Shapiro-Wilk normality test. 1 Unpaired t test.  
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Table 2. Methylation cut-off, cancer sensitivity and specificity 
Target 
Cut-off 
PMA (%) 
Cancer Sensitivity 
(%) 
Cancer Specificity 
(%) 
FOXF1 4 66 99.1 
MGMT 5 35.8 100 
CA4 5 20.8 100 
NPY1R 5 18.9 100 
IFITM1 7 15.1 100 
hMLH1 6 14.2 100 
GREM1 6.5 13.2 100 
Cut-off values (percentage of methylated alleles, PMA) were established 
for each gene promoter to discriminate cancer tissue from cancer-associ-
ated mucosa with ≥ 99% specificity. Tumors with a PMA value above this 
cut-off are considered hypermethylated. Cancer sensitivity represents the 
frequency of hypermethylated tumors. 
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Figure legends 
Figure 1 
Cancer-specific Methylation of the Investigated Gene Promoters. A, Cancer-specific methyla-
tion levels: Scatter plot showing the percentage of methylated alleles (PMA) for each gene in 
matched CRC, CAM and blood samples (n = 106). The gray bar indicates the ≥ 99% cancer-
specific methylation threshold, ranging from 4% (FOXF1) to 7% (IFITM1). B, Frequency of 
hypermethylated CRCs. Tumors showing methylation levels above the ≥ 99% cancer-specific 
threshold are classified as hypermethylated in a particular target. Shown is the frequency of 
hypermethylated cancers according to location. *: P < 0.05. C, CRC coverage by the seven 
marker panel. Methylation above the > 99% cancer-specific threshold in either of the seven 
gene promoter panel discriminates 82% of all tumors and 94% of right-sided tumors from 
CAM. 
Figure 2 
Clustering of Target Methylation in Colorectal Cancer. A, Distribution of Hypermethylated 
tumors according to Gender and Location. Hypermethylated tumors in a particular target are 
represented by a grey box. B, Heat Map of unsupervised hierarchical clustering. Methylation 
levels are represented by different colors with red indicating the highest and black the lowest 
values.  
Figure 3 
Methylation clustering in cancer patients and healthy individuals. Concomitant methylation be-
tween the investigated targets is shown for normal mucosa from healthy individuals (A), can-
cer-associated mucosa from patients (B), and tumor tissue (C). Red lines indicate concomitant 
methylation as assessed by Fisher’s exact test of contingency tables for all target pairs or re-
peated measures non-parametric and parametric (ANOVA) tests. Accordingly, thin black lines 
indicate absent concomitant methylation. The gray area illustrates the concordant methylation 
of the newly described CIMP targets CA4, NPY1R and GREM1 preserved in all three tissues. 
Figure 4 
Methylation levels of newly defined and classical CIMP targets in cancer patients and healthy 
individuals. Shown are median methylation beta values of genome-wide promoter methylation 
analyses in CIMP-positive (CIMP+ PT) and CIMP–negative (CIMP- PT) cancers as well as 
normal colorectal tissue and one blood sample from healthy individuals (NM). P-values for the 
21 
difference in beta values between normal tissues from individuals aged 75 years and CIMP-
positive cancers are indicated. NM Age 50/75: Normal mucosa from healthy individuals aged 
50 and 75 years. 
Figure 5 
Model for the pathogenesis of CIMP-positive colorectal cancers (serrated pathway). A differ-
entiated epithelial cell population along the colorectum is constitutively low-level methylated 
in FOXF1, CA4, NPY1R and GREM1 (constitutive methylation markers). Critical (epi)genetic 
events in these cells, e.g. activating BRAFV600E mutation and/or aberrant methylation of hMLH1 
(oncogenic type marker) contribute to malignant transformation. Clonal expansion of this cell 
population, occurring typically in the proximal colon, leads to cancer-specific methylation of 
various targets and the establishment of the CIMP phenotype. met: methylated; unmet: un-
methylated. 
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Supplemental data 
Supplementary Materials and Methods 
Reanalysis of the transcriptome of 32 colorectal adenomas and matched mucosa tissues 
Transcriptome analysis of 32 colorectal adenomas and matched mucosa tissues was performed 
by Sabates-Bellver et al. (1) as previously described. Briefly, the polyp sample and three biop-
sies of normal mucosa from the same colon segment were immersed in RNAlater (Ambion). 
Total RNA was extracted (RNeasy Mini kit, Qiagen) from homogenized tissue samples (5-15 
mg), and its integrity was verified by capillary gel electrophoresis (Bio Analyzer, Agilent Tech-
nologies). Complementary RNA (15 µg/sample), synthesized and labeled as previously de-
scribed, was hybridized with the Affymetrix U133 Plus 2.0 array, which contains in situ syn-
thesized oligonucleotides representing the entire human genome (54,675 probes). We imported 
the raw gene expression data generated by GeneChip Operating Software (Affymetrix) (GEO 
record GSE8671) into ROCHE Affymetrix Chip Experiment Analysis (RACE-A) Software (2) 
and normalized per chip (i.e., to the median of all values on a given array) and per gene (i.e., to 
the median expression level of the given gene across all samples).  
Cell lines 
CO115, SW48 (both microsatellite instable) and GP5d human colorectal cancer cell lines were 
grown according to a routine protocol. Briefly, they were incubated in Dulbeco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% (V/V) Penicil-
line/Streptomycin and 2 mM L-Glutamine. The cells were kept at 37°C in an atmosphere con-
taining 4% CO2 and were harvested in an exponential growth phase. 
Methylation analysis, locus-normalized quantitative methylation-specific PCR and bisul-
fite sequencing 
Methylation of the CpG-rich promoter regions of FOXF1, CA4, NPY1R, GREM1, hMLH1, 
MGMT and IFITM1 was analyzed by quantitative methylation specific PCR (qMSP). Strand-
specific primers complementary to the methylated or unmethylated (M- and U-primers) pro-
moter sequence were used. All qMSP primer sequences are listed in Supplementary Table S11. 
Additionally, we used methylation insensitive S-primers to standardize for the DNA input after 
sodium bisulfite treatment. The S-primer amplicon did not contain any CpG dinucleotides and 
was chosen in the close proximity to the interrogated promoter to standardize for its locus, 
thereby eliminating ploidy aberration bias. We therefore termed this assay locus-normalized 
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qMSP (ln-qMSP). qMSP reactions were performed with the Rotor-Gene 3000 real time thermal 
cycler (Corbett Life Science, Sydney, Australia) and the QuantiTect SYBR Green Kit (Qiagen). 
Each reaction was performed in a volume of 15 µl and contained 0.5 µM of each primer and 
1.5 µl of bisulfite converted DNA. Real time PCR conditions were as followed: activation of 
polymerase at 95°C for 15 minutes followed by 50 cycles with denaturation at 94°C for 10 
seconds; primer annealing at 57°C (FOXF1), 58°C (hMLH1, MGMT), 59°C (GREM1, NPY1R), 
61°C (CA4) or 52°C (IFITM1) for 25 seconds and extension at 62°C for 20 seconds or at 60°C 
for 30 seconds (IFITM1). In order to ensure product specificity, a melting point analysis was 
performed after every run. The correct size of PCR products was verified by agarose gel elec-
trophoresis. 
For methylation quantification standard curves were generated by real time amplification of 
serial 1:10-dilutions (from 100 to 0.1%) of M.sssI methylase and sodium bisulfite treated blood 
DNA with M- and S-primers (Supplementary Fig. S5A). The quality of positive control DNA 
was proven by unsuccessful amplification with U-primers under optimized conditions. The 
tester DNA was amplified by two separate real-time PCR runs with the M- and the S-primer set 
in technical duplicates each. The percentage of methylated alleles (PMA) was calculated by the 
ratio between the values of the amplification with the M- and the S-primer set (for a calculation 
example see Supplementary Fig. S5B). The percentage of unmethylated alleles (PUA) was de-
termined analogously using the U- and S-primer sets. Here, peripheral blood DNA served as a 
methylation negative control to establish the standard curves. Real time amplification profiles, 
melting and standard curves for all newly established targets are shown in Supplementary Fig. 
S5A, C-F. 
Complementarity experiments using locus-normalized qMSP showed that the sum of the values 
obtained by amplifications of defined mixtures of methylated (99, 90, 10, and 1%) and un-
methylated DNA with the M- and U-primers was close to 100% (from 90 to 105%) for the 
validation experiments indicating an accurate measurement of methylated alleles. In conse-
quence, quantitative methylation results in 106 tumor samples did not yield values of more than 
100% methylation. Values greater than 100% may result from cancer-associated phenomena 
like loss of heterozygosity (LOH) or chromosomal abnormalities (aneuploidies), and are fre-
quently seen when using other techniques, which do not normalize for the locus under investi-
gation.  
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To validate our ln-qMSP results we analyzed FOXF1, CA4, NPY1R, GREM1 and IFITM1 pro-
moter methylation in two primary tumors and one cancer-associated mucosa sample (the latter 
only for FOXF1) by bisulfite sequencing (Supplementary Fig. S6, primer sequences are given 
in Supplementary Table S12). After bisulfite conversion of genomic DNA CpG-rich promoter 
regions were PCR amplified with True Start Taq Polymerase (Fermentas; Burlington, Canada). 
PCR conditions were as followed: Polymerase activation at 95°C for 2 minutes followed by 40 
cycles of denaturation at 95°C for 20 seconds, primer annealing at 51°C (GREM1 distal, 2.5 
mM MgCl2, 1 µM each primer), 53°C (GREM1 proximal, 1.5 mM, 0.5 µM), 57°C (FOXF1 
proximal, NPY1R, IFITM1, all 2.5 mM, 0.5 µM), 62°C (CA4, 2.5 mM, 0.5 µM) or 63°C 
(FOXF1 distal, 2.5 mM, 0.5 µM) for 25 seconds and primer extension at 72°C for 50 seconds. 
PCR was completed by a final extension at 72°C for 15 minutes. To avoid an amplification bias 
towards more unmethylated sequences the primers each covered one CpG site at the very 5´-
end and were designed complementary to the methylated sequence (3) (Supplementary Table 
S12). The amplification efficiencies were equalized by adjusting the PCR conditions in real 
time PCR reactions (standardized with the S-primer sets from the qMSP assay) visualized with 
EvaGreen (Biotium, USA).  
The correct, unbiasedly amplified PCR products were purified by gel extraction (QIAEX Gel 
Extraction Kit, Qiagen) and subsequently incubated with true Start Taq Polymerase and 0.2 
mM ATP to re-establish 3´-A overhangs usually introduced by Taq polymerases and lost to a 
certain extent during gel extraction. Purified PCR products were cloned into the pCR®4-TOPO® 
vector provided with the TOPO TA Cloning Kit for Sequencing (Invitrogen; Carlsbad, USA). 
Chemically competent E.coli cells (also provided in the Kit) were transformed and grown on 
Ampicillin (0.1 mg/ml) containing LB-agar plates. Inserts were checked by Colony PCR and 
plasmid DNA of positive clones was purified with the peqGOLD Plasmid Miniprep Kit I 
(Peqlab; Erlangen, Germany). Inserts were sequenced using the Big Dye Terminator Sequenc-
ing Kit (Applied Biosystems; Foster City, USA).  
DNA methylation and mRNA expression in colorectal tissue 
Simultaneous purification of DNA and RNA from 10 pairs of matched CRC and CAM samples 
was performed with the AllPrep DNA/RNA/Protein Mini Kit® (Qiagen, Hilden, Germany). Up 
to 30 mg of tissue were disrupted in 600 µl Buffer RLT and 300 µl Zirkonia beads using the 
FastPrep® cell disrupter (Qbiogene, Carlsbad, USA). The quantity of the purified DNA and 
RNA was determined spectrophotometrically. DNA methylation and RNA expression were an-
alyzed by ln-qMSP and quantitative RT-PCR, respectively (see there). 
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Quantitative Reverse Transcriptase-PCR 
Complementary DNA (cDNA) was synthesized from total RNA using the RevertAid® H Minus 
First Strand cDNA Synthesis Kit (Fermentas) and random hexamer primers (0.5 µM). Synthe-
sized cDNA was diluted 200 times and subjected to qRT-PCR reaction on the Rotor-Gene 3000 
real time thermal cycler (Corbett Life Science) using the QuantiTect SYBR Green Kit (Qiagen). 
The following PCR cycling conditions were used: Hot Start Taq polymerase activation at 95°C 
for 15 minutes followed by 50 cycles of denaturation at 94°C for 10seconds, primer annealing 
at 59°C (CA4, IFITM1, FOXF1, ACTB, GAPDH,GREM1) or 60°C (NPY1R) for 25 seconds and 
extension at 62°C for 20 seconds (primers are listed in Supplementary Table S13). CAM from 
patient 69, which showed expression for all target genes, served as a positive control and for 
the establishment of the standard curves. Tester cell line cDNA was analyzed in technical trip-
licates. Amplification signals of the target genes were normalized to the average signal of the 
housekeeping genes β-Actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Transcription levels were normalized to the expression of the housekeeper genes 
and to the target gene expression of CAM from patient 31.  
Reexpression experiments 
To correlate the promoter methylation levels of the newly established target genes CA4, NPY1R, 
FOXF1, IFITM1 and GREM1 with their expression we analyzed mRNA levels in human CRC 
cell lines (CO115, SW48 and GP5d) before and after treatment with 5-Aza-cytidine (DNA me-
thyltransferase inhibitor) and/or Trichostatin A (Histone deacetylase inhibitor). After 24 h of 
culture in Dulbecco´s Modified Eagle Medium (Sigma; Hamburg, Germany) supplemented 
with 10% fetal calf serum, 2 mM L-Glutamine (Sigma), 60U/ml Penicillin (Sigma) and 10µg/ml 
Streptomycin (Sigma) the medium was replaced with medium containing 1 µM 5´-Aza-C or 
0.5 µM TSA and incubated for five and two days, respectively. The medium was renewed every 
24 h. For the double treatment, cells were initially treated with 5-Aza-cytidine followed by 
Trichostatin A treatment. The cells were harvested and the genomic DNA and total RNA were 
extracted with TRI REAGENT (Sigma). Promoter methylation and mRNA expression were 
analyzed by ln-qMSP and quantitative RT-PCR, respectively (see there).  
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Supplementary figure legends 
Supplementary Figure 1. Methylation levels in tumor tissue (CRC), cancer-associated mu-
cosa (CAM) and blood. 
Bars and whiskers indicate mean PMA (Percentage of methylated alleles) values with standard 
deviations. *: The methylation level for hMLH1in blood is lower than 0.001% and therefore is 
not depicted. 
Supplementary Figure 2. DNA methylation and gene expression of FOXF1 in colorectal 
cancer and cancer-associated mucosa. 
DNA methylation and gene expression of FOXF1 were measured in matched cancer tissue 
(CRC) and cancer-associated colorectal mucosa (CAM) from 10 patients. The mRNA expres-
sion of the investigated samples is indicated as multiples of the mRNA expression in CAM 
from patient 31 (mRNA expression of patient 31 = 1). The P-value for the inverse correlation 
of DNA methylation and gene expression is given. PMA: Percentage of methylated alleles. 
Supplementary Figure 3. Promoter demethylation and gene reexpression in cell lines.  
Three cell lines (CO115, SW48 and GP-5d) were treated with either 5-Azacytidine (5AzaC), 
Trichostatin A (TSA) or both. GP-5d was not methylated in CA4, NPY1R, IFITM1, and 
GREM1. mRNA expression is relative to the cancer-associated mucosa (CAM) from patient 69 
(see Supplementary Fig. S2). 
Supplementary Figure 4. Relation of Hypermethylated Tumors to Clinical Characteris-
tics.  
Frequencies of hypermethylated CRC in relation to gender (A) and tumor stage (B). *: P < 0.05. 
Supplementary Figure 5. Locus-normalized quantitative Methylation Specific PCR (ln-
qMSP) for CA4 (a), NPY1R (c), IFITM1 (d), FOXF1 (e) and GREM1 (f). 
Amplification (I), melting (II) and standard curves (III) for the real time PCR assays with the 
M- (methylation specific) and S-primers (standardization, methylation insensitive) are shown 
(a, c-f). M. sssI methylase and sodium bisulfite treated blood DNA was used as positive control, 
which was serially diluted 1:10 up to 1:1’000. A negative control (sodium bisulfite treated pe-
ripheral blood DNA) and a no template control (NTC) were included in the assay. Melting curve 
analyses verified the specificity of the PCR reactions (absence of primer dimers and unspecific 
PCR products). b) The Ct (threshold cycle) values of the amplifications of a tester DNA with 
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the M- and S-primer sets were compared with the pre-established standard curves and the rela-
tive level of both amplicons (%) determined. The percentage of methylated alleles (PMA) in 
the tester DNA was then calculated by the ratio between the levels of the M- and the S-ampli-
cons. qMSP assay data for hMLH1 and MGMT was already shown in (4). 
Supplementary Figure 6. Bisulfite sequencing of the newly established targets. 
FOXF1, CA4, NPY1R, IFITM1 and GREM1 promoter regions were bisulfite sequenced in two 
cancer tissues (CRC) each. Additionally, FOXF1 methylation was assessed in one cancer-asso-
ciated colorectal mucosa (CAM). Distances from transcription start site (TSS) are indicated at 
the left border. Each circle represents a CpG site with an empty circle ( ) symbolizing an 
unmethylated and a filled circle ( ) a methylated state. : Transcription start site; : ln-
qMSP primer location. 
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Supplementary Tables 
Supplementary table 1. Mean methylation levels in matched cancers, cancer-associated mu-
cosa and blood 
Target 
Mean PMA (%) 
CRC CAM Blood 
FOXF1 21.09 ± 22.63 0.99 ± 0.97 0.01 ± 0.02 
MGMT 11.51 ± 20.83 0.28 ± 0.66 0.02 ± 0.01 
CA4 6.52 ± 13.55 1.09 ± 0.93 0.16 ± 0.16 
NPY1R 6.94 ± 17.54 1.28 ± 0.96 0.12 ± 0.12 
IFITM1 5.00 ± 11.58 2.49 ± 1.18 0.002 ± 0.004 
hMLH1 5.38 ± 15.30 0.16 ± 0.59 0.0003 ± 0.0006 
GREM1 6.21 ± 17.29 1.56 ± 1.27 0.04 ± 0.09 
Values are means with standard deviations. CRC: Colorectal cancer; CAM: Cancer associ-
ated mucosa; PMA: Percentage of methylated alleles. 
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Supplementary table 2. Association of CRC hypermethylation with gender. 
 Female (n = 39) Male (n = 67)  
    
FOXF1    
Hypermethylated (≥ 4%) 74.4% (29) 61.2% (41)  
Not hypermethylated (<4%) 25.6% (10) 38.8% (26) P=0.205 
    
MGMT    
Hypermethylated (≥5%) 46.2% (18) 29.9% (20)  
Not hypermethylated (<5%) 53.8% (21) 70.1% (47) P=0.0988 
    
CA4    
Hypermethylated (≥5%) 20.5% (8) 20.9% (14)  
Not hypermethylated (<5%) 79.5% (31) 79.1% (53) P=1.000 
    
NPY1R    
Hypermethylated (≥5%) 28.2% (11) 13.4% (9)  
Not hypermethylated (<5%) 71.8% (28) 86.6% (58) P=0.0744 
    
IFITM1    
Hypermethylated (≥7%) 5.2% (2) 20.9% (14)  
Not hypermethylated (<7%) 94.8% (37) 79.1% (53) P=0.0461 
    
GREM1    
Hypermethylated (≥6.5%) 17.9% (7) 10.4% (7)  
Not hypermethylated (<6.5%) 82.1% (32) 89.6% (60) P=0.3729 
    
hMLH1    
Hypermethylated (≥6%) 25.6% (10) 7.5% (5)  
Not hypermethylated (<6%) 74.4% (29) 92.5% (62) P=0.0182 
    
Panel    
Hypermethylated in ≥1 marker 84.6% (33) 80.6% (54)  
No hypermethylated marker 15.4% (6) 19.4% (13) P=0.79 
    
Age    
Median (y) 66 71  
Mean (y) 64.59 70.43 P=0.01811 
Standard deviation 14.46 10.46  
Standard error of the mean 2.316 1.277  
Normally distributed Yes4/Yes5/Yes6 No4/Yes5/Yes6  
    
Location of tumor    
Right side 25.6% (10) 32.8% (22)  
Left side 74.4% (29) 67.2% (45) P=0.51382 
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Stage    
I 10 12  
II 8 16  
III 13 19  
IV 8 20 P=0.60433 
    
Statistic test applied is two-sided Fisher’s exact test where not differently indicated. 1 two 
sided unpaired t-test; 2 two-sided Fisher’s exact test; 3 Chi square test, 4 Kolmogorov-Smirnov 
normality test; 5 D'Agostino & Pearson omnibus normality test; 6 Shapiro-Wilk normality test. 
Values in brackets are absolute numbers. 
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Supplementary table 3. Association of CRC hypermethylation with tumor location 
 Right side (n = 32) Left side (n = 74)  
    
FOXF1    
Hypermethylated (≥ 4%) 90.6% (29) 55.4% (41)  
Not hypermethylated (< 4%) 9.4% (3) 44.6% (33) P=0.0003 
    
MGMT    
Hypermethylated (≥ 5%) 40.6% (13) 33.8% (25)  
Not hypermethylated (< 5%) 59.4% (19) 66.2% (49) P=0.5157 
    
CA4    
Hypermethylated (≥ 5%) 59.4% (19) 4.1% (3)  
Not hypermethylated (< 5%) 40.6% (13) 95.9% (71) P<0.0001 
    
NPY1R    
Hypermethylated (≥ 5%) 34.4% (11) 12.2% (9)  
Not hypermethylated (< 5%) 65.6% (21) 87.8% (65) P=0.0133 
    
IFITM1    
Hypermethylated (≥ 7%) 9.4% (3) 17.6% (13)  
Not hypermethylated (< 7%) 90.6% (29) 82.4% (61) P=0.3812 
    
GREM1    
Hypermethylated (≥ 6.5%) 31.3% (10) 5.4% (4)  
Not hypermethylated (< 6.5%) 68.7% (22) 94.6% (70) P=0.0008 
    
hMLH1    
Hypermethylated (≥ 6%) 34.4% (11) 5.4% (4)  
Not hypermethylated (< 6%) 65.6% (21) 94.6% (70) P=0.0003 
    
Panel    
Hypermethylated in ≥ 1 marker 93.8% (30) 77% (57)  
No hypermethylated marker 6.2% (2) 23% (17) P=0.053 
    
Age    
Median (y) 75 67  
Mean (y) 70.88 67.16 P=0.15621 
Normally distributed Yes2, 3 Yes2, 3  
Standard deviation 14.21 11.37  
    
Gender    
Female 10 29  
Male 22 45 P=0.5138 
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Stage    
I 6 16  
II 8 16  
III 9 23  
IV 9 19 P=0.95684 
Right sided tumors derived from the cecum to the splenic flexure and left sided from the splenic 
flexure to the rectum. Statistic test applied is two-sided Fisher’s exact test where not differently 
indicated. 1 two sided unpaired t-test; 2 Kolmogorov-Smirnov normality test; 3 D'Agostino & 
Pearson omnibus normality test, 4 Chi square test. Values in brackets are absolute numbers. 
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Supplementary table 6. Clinical data on samples used for methylome analysis  
Sample type Sample ID Age (years) Gender Location 
Blood (Healthy subject) 1 30 F na 
Normal mucosa (Healthy 
aged 50) 
1 
50 
F 
R 
2 F 
3 M 
4 M 
Normal mucosa (Healthy 
aged 75) 
1 
75 
F 
R 
2 F 
3 M 
4 M 
CIMP+ Cancer (BRAF 
V600E) 
1 78 F 
R 2 82 F 
3 73 M 
CIMP- Cancer (BRAF 
wt) 
1 63 
F R 
2 70 
3 84 
4 85 
F: Female; M: Male; R: Right-sided; Left-sided; wt: wildtype; na: not applicable. 
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